nct_id,title,condition,eligibility_text,age_min,age_max,gender,status,keywords
NCT06624267,Test of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion,Microvascular Disease,"Inclusion Criteria:

* Age \&gt; 60 years
* No diagnosis of T2D according to WHO\&#39;s criteria.
* Speaks and understands Danish (required for reliable cognitive testing)
* Able to provide informed and written consent

Exclusion Criteria:

* Moderate to high intensity training \&gt;2 times/week.
* Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \&lt;45%), asthma.
* Previous stroke or significant neurological disease including cognitive dysfunction.
* Ongoing depression.
* Hypothyroidism
* Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.",18,100,ALL,NOT_YET_RECRUITING,"['fibrillation', '60 years', '* previous stroke', 'times', 'intensity', 'atrial fibrillation', 'valve', 'consent', 'no diagnosis', 'who\\&#39;s criteria', 'week', 'cognitive dysfunction', 'arthrosis', 'reliable cognitive testing', 'disease', '* ongoing depression', 'training', 'lung', 'significant cardiac valve disease', 'depression', 't2d', 'lvef \\&lt;45', 'dysfunction', 'inclusion', 'stroke', 'inclusion criteria', 'hypothyroidism', 'high intensity training', 'injury', 'diagnosis', '* age \\&gt', 'years', 'criteria', 'significant neurological disease', 'hfref', 'asthma', 'danish', 'previous ami', '%', 'testing', '\\&gt', 'exclusion']"
NCT06299800,Phenotyping Patients With Type 2 Diabetes Mellitus and Cancer,"Diabetes Mellitus, Type 2","Inclusion Criteria:

* Legal age
* Diagnosis of type 2 diabetes mellitus

Exclusion Criteria:

* Diagnosis of cancer before diagnosis of type 2 diabetes
* Diagnosis of diabetes secondary to other diseases
* Diagnosis of diabetes secondary to other drugs
* Diagnosis of diabetes following surgery",18,100,ALL,RECRUITING,"['exclusion', 'drugs', 'surgery', 'diabetes', 'other drugs\n* diagnosis', 'diseases', 'diagnosis', 'inclusion', 'type', 'criteria', 'cancer', 'inclusion criteria', 'other diseases']"
NCT04412200,Efficacy of Hyperbaric Oxygen Therapy (HBOT) in New-onset Type-1 Diabetes Mellitus,T1DM,"Inclusion Criteria:

* Parent/guardian willing and able to sign an informed consent
* Participant willing and able to sign an assent
* Diagnosed with type 1 diabetes within 12 weeks prior to randomization
* Treated with insulin by basal-bolus regimen (injections or pump)
* Peak C-peptide ≥ 0.2 pmol/ml
* At least 1 positive diabetes auto-antibody
* No significant abnormalities in hematology and serum chemistry according to the investigator's judgment, taking into consideration the potential effects of the diabetic illness
* No significant abnormalities in urinalysis, taking into considerations the potential effects of the diabetic illness
* For females of child bearing potential: whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator

Exclusion Criteria:

* Planned major surgery within the study period
* Clinically significant inter-current illnesses, including (but not limited to): lung, cardiac, hepatic, renal, eye, neuro",18,100,ALL,RECRUITING,"['the potential effects', 'hematology', 'illness', 'the investigator\n\nexclusion criteria', 'neuro', 'potential', 'assent', ""the investigator's judgment"", 'illnesses', 'consent', 'females', 'type', 'who', 'ml', 'bolus', '* peak', 'judgment', 'peptide', 'eye', 'methods', 'lung', 'basal', 'serum', 'pregnancy', 'the study period', 'pmol', 'period', 'abnormalities', 'parent', 'contraceptive methods', 'inclusion criteria', 'peak', 'the diabetic illness', 'an assent', 'investigator', 'effects', 'weeks', 'study', '* planned major surgery', 'regimen', '0.2 pmol', 'urinalysis', 'child bearing potential', 'injections', 'antibody', 'basal-bolus regimen', 'type 1 diabetes', 'diabetes', 'auto', '12 weeks', 'chemistry', 'child', 'considerations', 'criteria', 'clinically significant inter-current illnesses', 'randomization', 'surgery', 'no significant abnormalities', 'insulin', 'consideration', 'test', 'c-peptide ≥', 'inclusion', 'hematology and serum chemistry', 'pregnancy test', 'exclusion']"
NCT07295600,"Postprandial Effect of Isocaloric Challenge Meals Enriched With Indigenous Fruits and Vegetables on Glucose Metabolism in Individuals With Type 2 Diabetes in Wakiso District, Uganda",Type 2 Diabetes,"Inclusion Criteria:

* Fasting blood sugar \>= \[7 mmol/L\](based on medical records)
* Diabetic regimen for at least 6 months
* Type 2 diabetes
* Plans to continue staying in the same location for the next 6 months

Exclusion Criteria:

* Taking dietary supplements
* Type 1 diabetes
* Tuberculosis co-infection
* Renal failure
* Liver cirrhosis
* Chronic pancreatitis
* Pregnancy and Lactation
* Regular sports activity
* Parallel participation in another clinical trial
* On treatment for dyslipidaemia,
* On treatment for hypertension
* Very low blood pressure (\< 90/50 mmHg)
* Allergic reactions to test products",18,100,ALL,NOT_YET_RECRUITING,"['sugar', 'supplements', '(\\< 90/50 mmhg', 'type', 'tuberculosis', 'trial', 'reactions', 'treatment', '2 diabetes', 'chronic pancreatitis', 'cirrhosis', 'pregnancy', 'dietary supplements', 'co', 'infection', 'mmhg', 'sports', 'pancreatitis', 'plans', 'months', 'liver', 'lactation', 'hypertension', 'regimen', 'dyslipidaemia', 'diabetes', 'failure', 'participation', 'at least 6 months', 'very low blood pressure', 'pressure', 'medical records', '-', 'products', 'criteria', '* diabetic regimen', 'blood', '* allergic reactions', 'the same location', 'blood sugar \\>=', 'another clinical trial', 'location', 'inclusion', 'records', 'exclusion', 'activity']"
NCT06826339,"Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.",Venous Leg Ulcer,"Inclusion Criteria:(DFU)

* Subjects The potential subject must be at least 21 years of age or older.
* The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus.
* At enrollment, the potential subject must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement.
* The potential subject must have a target ulcer that has been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit.
* The potential subject must have a target ulcer located on the foot with at least 50% of the ulcer below the malleolus.
* The potential subject must have a target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus.
* The potential subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following ",21,100,ALL,RECRUITING,"['visit', 'target', '* subjects', 'diabetes mellitus', 'maximum', 'vascular assessment', 'age', 'a target ulcer', 'the ulcer', 'mellitus', 'ulcer', 'the potential subject', 'standard', 'screening', 'aspect', 'subject', 'following', 'type', 'that', 'wagner', 'the foot', 'the muscle', 'the initial screening visit', 'enrollment', 'any', 'surface', '1.0 cm2', 'debridement', 'limb', 'vascular', 'the malleolus', 'the following', '4 weeks', 'subjects', 'it', 'weeks', 'a minimum', 'inclusion criteria:(dfu', 'assessment', 'at least 21 years', 'a maximum surface area', 'dermis', 'diabetes', 'area', 'care', 'diagnosis', 'minimum', 'years', 'a minimum surface area', 'at least 50%', 'a diagnosis', 'muscle', 'perfusion', 'tissue', '52 weeks', 'post', 'foot', 'grade', 'a maximum', 'the medial aspect', 'adequate perfusion', 'malleolus']"
NCT06752577,Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD),Chronic Kidney Diseases,"Inclusion Criteria

* Age \>18 years
* Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2
* Hemoglobin A1c ≤9%, if diabetes mellitus present
* If kidney transplant recipient, must have eGFR\<60 mL/min/1.73m2 and evidence of progressive kidney function loss over ≥6 months
* Ability to give informed consent

Exclusion Criteria

* Anemia (hemoglobin \<8.5 g/dL)
* Body weight \>150 kg or BMI \>50
* Uncontrolled hypertension: sustained systolic blood pressure (SBP) \>160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg despite maximal doses of at least 2 different classes of anti-hypertensive medications
* Chronic hypotension history: sustained SBP \<85 mmHg
* Kidney failure requiring ongoing kidney replacement therapy including hemodialysis or peritoneal dialysis
* Active, high-dose immunosuppression therapy (e.g. chronic prednisone ≥20 mg daily)
* Solid organ transplantation history; excluding kidney transplant
* Active treatment for acute cellular rejection, in kidney transpl",18,100,ALL,RECRUITING,"['acute cellular rejection', 'weight', 'doses', 'mellitus', 'history', 'kidney', 'dose', 'consent', 'kidney transpl', 'chronic prednisone', 'hemodialysis', 'sbp', 'function', 'maximal doses', 'organ', 'transplantation', 'ml/min/1.73m2', 'egfr', 'ongoing kidney replacement therapy', 'treatment', 'dialysis', 'kidney transplant recipient', 'body', 'ability', 'mmhg', 'transplant', 'rejection', '\\>160', 'immunosuppression', 'rate', '\\<60', 'kidney failure', 'medications', 'therapy', 'recipient', 'months', 'filtration', '* ability', 'hypertension', 'loss', 'sustained systolic blood pressure', 'min/1.73m2', 'failure', 'replacement', 'informed consent\n\nexclusion criteria', '(hemoglobin \\<8.5', 'solid organ transplantation history', 'pressure', 'classes', 'years', 'criteria', 'sustained sbp \\<85 mmhg', '\\>18', 'blood', 'age \\>18 years', 'hypotension', 'uncontrolled hypertension', '≥6 months', 'progressive kidney function loss', 'dbp', 'evidence', 'anemia', 'transpl', 'a1c ≤9', 'inclusion', 'hemoglobin', '≥100', 'exclusion']"
NCT07316075,Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas and Paragangliomas,Cardiovascular Abnormalities,"Inclusion Criteria:

* All PHEOs/PGLs patients should be asymptomatic, with confirmed histopathological analysis for those who had surgery or with positive specific imaging functional studies (MIBG, 68Ga DOTATATE, Octreoscan, Tektrotyde)
* Data about the plasma or urine levels of catecholamines, normetanephrines, metanephrines and methoxytyramine (for PGL) levels should be available for every patient and should be lower than the upper normal values measured with LC-MS (supplementary data about CgA, NSE levels can be also included)
* Available data for the ""required"" cardiovascular paraclinical or metabolic parameters should be available pre-surgery or at the time of diagnosis or at follow-up for the ""not operable"" tumors as well as post any treatment

Exclusion Criteria:

* Patients with ambiguous diagnosis of PHEOs/PGLs (absence of histological report and non-specific imaging findings)
* Catecholamines, normetanephrines and metanephrines (and methoxytyramine levels for PGL) levels hig",18,100,ALL,ENROLLING_BY_INVITATION,"['pgl', 'metanephrines', 'values', 'hig', 'normetanephrines', 'analysis', 'mibg', 'patients', 'studies', 'who', 'the upper normal values', 'follow', 'the time', 'dotatate', 'treatment', 'levels', 'catecholamines', 'absence', 'imaging', 'urine', 'any treatment\n\nexclusion criteria', 'plasma', 'confirmed histopathological analysis', 'follow-up', 'methoxytyramine', 'parameters', 'tumors', 'the plasma', 'those', 'data', 'patient', '* available data', 'diagnosis', 'metabolic', 'nse levels', 'time', 'criteria', 'findings', 'surgery', 'pheos/pgls (absence', 'urine levels', 'pgl) levels', 'ambiguous diagnosis', 'report', 'cga', 'every patient', 'non-specific imaging findings', 'inclusion', 'lc-ms (supplementary data', 'exclusion', 'histological report', 'all pheos/pgls patients', 'the ""not operable"" tumors']"
NCT07099482,"""Ultrasound-Enhanced Propolis Therapy for Healing Diabetic Foot Wounds""",Diabetic Foot Ulcer t,"Inclusion Criteria:

Adults aged 18 to 75 years

Diagnosed with type 1 or type 2 diabetes mellitus

Presence of a diabetic foot ulcer classified as Grade 1 or 2 (Wagner classification)

Ulcer size between 1 cm² and 5 cm²

Able and willing to provide informed consent

Exclusion Criteria:

Severe infection or presence of osteomyelitis at the ulcer site

Use of systemic immunosuppressants or corticosteroids

Known allergy or hypersensitivity to propolis

Pregnant or breastfeeding women

Participation in another clinical trial within the past 30 days",18,75,ALL,NOT_YET_RECRUITING,"['presence', 'a diabetic foot ulcer', 'ulcer', 'days', 'consent', 'type', 'wagner', 'allergy', 'classification', 'the ulcer site\n\nuse', 'osteomyelitis', 'adults', 'trial', 'women\n\nparticipation', 'the past 30 days', 'women', 'known allergy', 'site', 'systemic immunosuppressants', 'infection', 'severe infection', 'inclusion criteria', '5 cm²', 'immunosuppressants', 'diabetes', 'participation', '18 to 75 years', 'informed consent\n\nexclusion criteria', 'size', 'years', 'criteria', 'hypersensitivity', '2 diabetes mellitus\n\npresence', 'another clinical trial', 'foot', 'grade', 'inclusion', '1 cm²', 'exclusion', 'corticosteroids']"
NCT06437782,Exploration of Health Literacy in Diabetes in Reunion Island and France,Diabetes type1,"Inclusion Criteria:

Patient with type 1, 2 or gestational diabetes taken care in hospital

Exclusion Criteria:

* Patient unable to understand and respect study procedures
* Patient with cognitive disorder
* Patient with serious acute complication due to diabetes within 15 days before inclusion
* Stroke history with neurologic consequences
* Other specific types of diabetes : chronic calcific pancreatitis, iatrogenic, other secondary diabetes, rare monogenic or genetic diabetes due to insulin resistance",18,100,ALL,RECRUITING,"['history', 'resistance', 'days', '* patient', 'type', 'hospital\n\nexclusion criteria', 'neurologic consequences', 'genetic diabetes', 'chronic calcific pancreatitis', 'stroke', 'inclusion criteria', 'pancreatitis', 'types', 'calcific', 'study', '15 days', 'procedures', 'cognitive disorder\n* patient', 'patient', 'stroke history', 'rare monogenic', 'diabetes', 'consequences', 'care', 'other specific types', 'study procedures', 'criteria', 'complication', 'due to insulin resistance', 'monogenic', 'other secondary diabetes', 'hospital', 'insulin', 'disorder', 'serious acute complication', 'inclusion', 'exclusion']"
NCT07082933,Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes,Pulmonary Arterial Hypertension (PAH),"Inclusion Criteria:

* Individuals aged 18 to 80 years with full capacity for civil conduct.
* Patients diagnosed with pulmonary hypertension by community-level and/or higher-level medical institutions.

Exclusion Criteria:

* Patients with malignant tumors.
* Other physical conditions judged by the researchers as making the patients ineligible to participate in the clinical study.",18,80,ALL,NOT_YET_RECRUITING,"['civil conduct', 'capacity', 'conditions', 'level', 'researchers', 'patients', '* individuals', '* patients', '* other physical conditions', 'community', 'exclusion criteria', 'malignant tumors', 'inclusion criteria', 'institutions', 'tumors', 'study', 'hypertension', 'the patients', 'the researchers', 'years', 'criteria', 'individuals', 'the clinical study', 'pulmonary hypertension', 'inclusion', 'conduct', 'exclusion', 'full capacity']"
NCT01399385,New Heart Imaging Techniques to Evaluate Possible Heart Disease,Healthy,"* INCLUSION:

  1. Subjects with or without history of cardiovascular diseases and with various degrees of cardiovascular risk factor. Subjects with known or suspected atherosclerotic disease based on clinical findings or documented by angiography (conventional, CTA or MRA), or Doppler ultrasound. And, healthy volunteers and subjects with known or suspected diseases affecting the thoracic organs, abdominal organs, and other organs affected by metabolic diseases such as body fat and muscles. Subjects at risk for atherosclerosis including: smoking, obesity, hyperlipidemia, low levels of high density lipoproteins (\<50 mg/dl for women and \<40 mg/dl for men), hypertension, family history (early onset atherosclerosis \<55 year old in male and \< 65 year old in female who is first degree relative), and diabetes mellitus or metabolic syndrome.
  2. Subject must be willing to participate in the protocol.
  3. Subject age greater than 18 years old.
  4. Subject must be able to provide informed",18,100,ALL,RECRUITING,"['/', 'lipoproteins', 'thoracic', 'history', 'mellitus', 'diseases', 'doppler ultrasound', 'dl', 'volunteers', 'subject', 'known or suspected diseases', 'muscles', 'who', 'high density lipoproteins', 'disease', 'year', '\\<50', 'doppler', 'onset', 'women', 'obesity', 'levels', 'other organs', 'body', 'various degrees', 'hyperlipidemia', 'metabolic diseases', 'metabolic syndrome', '4. subject', 'smoking', 'subjects', 'degrees', 'density', '\\<40 mg', 'ultrasound', 'hypertension', 'degree', 'atherosclerosis', 'syndrome', 'low levels', 'the thoracic organs', 'family', 'protocol', 'metabolic', 'findings', '2. subject', 'men', 'years', '* inclusion', 'angiography', 'family history', 'factor', 'organs', 'the protocol', 'and, healthy volunteers', 'cardiovascular diseases', 'clinical findings', 'male', '3. subject age', 'risk', 'inclusion', 'cardiovascular risk factor', 'body fat', 'female', 'abdominal organs']"
NCT07212218,Health Promotion Model-Based Education and Motivational Interviewing for Parents of Children With Type 1 Diabetes,Type 1 Diabetes Mellitus,"Inclusion Criteria:

\- Children aged 8-12 years with type 1 diabetes diagnosed for ≥ 1 year HbA1c ≥ 7% Using insulin pen for treatment Able to read and write Living in Istanbul No intellectual disability No other chronic disease Parent able to communicate by phone and use social media apps (e.g., WhatsApp, Zoom) Both child and parent willing to participate

Exclusion Criteria:

* sychiatric disorder diagnosis Type 1 diabetes diagnosis \< 1 year Using insulin pump or other treatment methods Having another type of diabetes Not in the 8-12 age range Illiteracy (child or parent) Presence of another chronic disease Parent unable to use phone or social media apps Child and/or parent unwilling to participate",8,12,ALL,NOT_YET_RECRUITING,"['presence', 'insulin pen', 'disability', 'istanbul', 'type', 'range', 'year', '\\- children', 'disease', 'methods', 'treatment', 'apps', 'pump', 'inclusion', 'another type', 'exclusion criteria', 'parent', 'both child', 'inclusion criteria', '7%', 'media', 'social media apps', 'phone', 'type 1 diabetes', 'diabetes', 'other treatment methods', 'diagnosis', 'no intellectual disability', 'child', 'years', 'criteria', 'illiteracy', 'children', '≥', 'another chronic disease parent', 'insulin', 'disorder', 'hba1c ≥', 'exclusion', 'insulin pump']"
NCT07251426,Cold atmOspheric plaSMa Therapy Versus standArd Wound Care in Diabetic Foot and Venous Leg ulcerS,Diabetic Foot Ulcer,"Inclusion Criteria:

* 1\. is referred to one of the participating hospitals for treatment of a diabetic foot ulcer (DFU) or venous leg ulcer (VLU) with healing stagnation and

  a. For VLU: i. An ulcer on the lower leg resulting from malfunctioning venous valves in the leg veins.

  b. For DFU: i. An ulcer on the foot or lower leg in person with currently or previously diagnosed diabetes mellitus and usually accompanied by neuropathy and/or peripheral artery disease (PAD) in the lower extremity Note: In patients with both diabetes and chronic venous insufficiency, ulcers will be categorized as DFU in case of symptoms of diabetic neuropathy or loss of protective sensation, and otherwise categorized as VLU.

  2\. has a wound with a minimum wound surface area of 0.5 cm2 and a maximum diameter of 6 cm (\~28 cm2 wound surface area for circular wounds; measured after debridement),

  3\. has a minimum age of 18 years old.

Exclusion Criteria:

* 1\. the participant has one or more of the f",18,100,ALL,NOT_YET_RECRUITING,"['person', 'diabetic neuropathy', 'the f', 'venous valves', 'the lower leg', 'the lower extremity note', 'lower leg', 'mellitus', 'a diabetic foot ulcer', 'ulcer', 'stagnation', 'patients', 'a.', 'participant', 'the foot', 'circular wounds', 'neuropathy', 'wound', 'dfu', 'disease', 'veins', 'artery', 'both diabetes', 'treatment', 'diameter', 'surface', 'debridement', 'a wound', 'healing stagnation', 'insufficiency', 'hospitals', 'the leg veins', 'a minimum age', 'exclusion criteria', 'inclusion criteria', 'symptoms', '6 cm', 'i.', 'valves', 'wounds', 'chronic venous insufficiency', 'sensation', 'pad', 'loss', '0.5 cm2', 'diabetes', 'area', 'extremity', 'the participating hospitals', ': i.', 'venous leg ulcer', 'years', 'criteria', 'a maximum diameter', 'vlu', 'ulcers', 'note', 'protective sensation', 'foot', 'the participant', 'an ulcer', 'inclusion', 'b.', 'exclusion', 'case']"
NCT07378891,Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI),Diabetes (DM),"Inclusion Criteria:

* Voluntary adults
* Aged between 18 and 80 years
* Understanding of the study explanations and instructions
* Prediabetes (defined by elevated fasting glucose 100-125 mg/dL and/or 2-hour glucose in the oral glucose tolerance test of 140-199 mg/dL and/or HbA1c of 5.7-6.4%)
* manifest diabetes (all types of diabetes according to Ahlqvist)

Exclusion Criteria:

* participants unable to give consent
* Those who do not agree to be informed about incidentally detected pathological findings
* Uncontrolled arterial hypertension (Stage III) despite multiple antihypertensive medications
* Eye diseases that impair the interpretability of the fundus examination",18,80,ALL,ENROLLING_BY_INVITATION,"['fundus', 'participants', '* eye diseases', 'the interpretability', 'diseases', 'stage', 'consent', '* voluntary adults', 'that', 'who', 'hour', 'adults', 'glucose', '5.7-6.4%', '* participants', 'examination', 'the fundus examination', 'prediabetes', '18 and 80 years', 'instructions', 'ahlqvist', 'inclusion criteria', 'incidentally detected pathological findings', 'multiple antihypertensive medications', 'explanations', 'understanding', 'types', 'medications', 'study', 'hypertension', 'those', 'diabetes', 'uncontrolled arterial hypertension', 'findings', 'all types', 'elevated fasting glucose', 'criteria', 'years', ')\n* manifest diabetes', 'interpretability', '* understanding', 'test', 'tolerance', 'the study explanations', 'inclusion', 'exclusion', 'stage iii']"
NCT06989502,Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries,Hypertension,"Inclusion Criteria for PHC users with diabetes, hypertension, and/or NTDs:

* Males or females aged 18 years and over, from the selected sites
* Having used the health services in the previous three months
* Diagnosis (or estimated risk) of diabetes mellitus type 2, hypertension, or neurocysticercosis
* Must be able to listen to radio programs, or other audio material

Inclusion Criteria for PHC users without diabetes, hypertension, and/or NTDs:

* Males or females aged 18 years and over, from the selected sites
* Having used the health services in the previous three months
* Must be able to listen to radio programs, or other audio material

Exclusion Criteria for PHC users without diabetes, hypertension, and/or NTDs:

\- Diagnosis (or estimated risk) of diabetes mellitus type 2, hypertension, or neurocysticercosis

The criteria mentioned above refer solely to the quantitative evaluation. For the other types of evaluation, some different populations will be included (such as healthcare",18,100,ALL,NOT_YET_RECRUITING,"['radio', '* males', 'populations', 'some different populations', 'females', 'radio programs', '*', 'the other types', 'material', 'phc users', 'ntds', 'inclusion criteria', 'the health services', 'types', 'the selected sites', 'males', 'months', 'hypertension', 'estimated risk', 'evaluation', 'diabetes', 'health', 'diagnosis', 'users', 'years', 'criteria', 'neurocysticercosis', 'the quantitative evaluation', 'services', 'healthcare', 'the previous three months', 'risk', 'programs', 'sites', 'inclusion', 'the criteria', 'exclusion']"
NCT03527537,Gestational Diabetes and Pharmacotherapy (GAP),Gestational Diabetes,"Inclusion Criteria:

* Viable singleton pregnancy
* Age \>= 18 years old
* Diagnosed with gestational diabetes mellitus
* Able to communicate in English

Exclusion Criteria:

* Pre-gestational diabetes
* Significantly abnormal GDM testing, suggestive of the presence of pre-gestational diabetes, either with fasting values \>=126 mg/dL or 2-hour post-prandial levels \>=200 mg/dL
* Patients who check blood sugars on average less than 2 times per day after appropriate counseling
* Already started pharmacotherapy prior to referral to the study",18,100,FEMALE,RECRUITING,"['mg', 'presence', 'pharmacotherapy', 'times', 'suggestive', 'mellitus', 'fasting values', 'patients', 'who', 'counseling', 'dl\n* patients', 'hour', 'singleton', 'the presence', 'gestational diabetes', 'pre-gestational diabetes', 'appropriate counseling', 'levels', 'the study', 'pregnancy', 'inclusion criteria', 'study', 'english\n\nexclusion criteria', 'testing', 'diabetes', 'day', 'years', 'criteria', 'blood sugars', 'blood', 'sugars', 'referral', 'inclusion', 'exclusion', 'values']"
NCT05156736,Pakistan Study of Premature Coronary Atherosclerosis in Young Adults,Atherosclerotic Plaque,"Inclusion Criteria:

* Native Pakistani
* Men aged 35-60 years \& women aged 35-65 years
* Willing to consent to participation

Exclusion Criteria:

eGFR \< 60 ml/min/1.73m2

Pregnant women

History of stroke or MI (CABG or PCI)

History of Peripheral arterial disease

Weight more than 102 Kg

Any active malignancy

Known contraindication from contrast used in cardiac CTA

Expected migration from residential area within 5 years",35,60,ALL,RECRUITING,"['malignancy', 'peripheral arterial disease\n\nweight', 'history', 'weight', 'migration', 'pakistani', 'disease', 'egfr', 'women', 'contrast', 'more than 102 kg', 'stroke', 'exclusion criteria', 'inclusion criteria', '5 years', 'area', 'cardiac cta\n\nexpected migration', 'years', 'criteria', 'mi', 'pregnant women', 'residential area', 'inclusion', 'exclusion', 'contraindication']"
NCT05074732,Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.,Schizophrenia,"Inclusion Criteria:

* Admitted to the National Forensic Mental Health Service (NFMHS) Ireland after 1st December 2019 until 7 years after the transfer of the National Service to the newly developed complete National Forensic Service at Portrane, North Dublin, Ireland.

Exclusion Criteria:

* This study comprises a complete cohort of admissions to the NFMHS. All adult patients admitted during the time period will be included in the study, regardless of their length of stay.",18,100,ALL,RECRUITING,"['(nfmhs) ireland', 'patients', 'all adult patients', 'north dublin', 'service', 'length', 'the time period', 'ireland', '7 years', 'admissions', 'the study', 'nfmhs', 'period', 'exclusion criteria', 'inclusion criteria', 'a complete cohort', 'transfer', 'the national service', 'study', 'the transfer', 'health', 'time', 'years', 'criteria', 'this study', 'the nfmhs', '1st december', 'their length', 'cohort', 'stay', 'inclusion', 'adult', 'exclusion']"
NCT06804187,Sweet Sensing in Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

* General Eligibility Criteria

  * For T2D: Confirmed Type 2 Diabetes Mellitus (HbA1c\>48 mmol/mol (6.5%) and managed by the anti-diabetic drug metformin alone diagnosed within the last 10 years
  * For Prediabetes: HbA1c 42-48 mmol/mol and no less than 3 years since diagnosis
  * Non-diabetes who had HbA1c screened at their GP in the last 12 months: HbA1c≤42mmol/mol

Phase 1

Inclusion criteria:

Adults aged between 18 -60 years with type 2 diabetes or healthy individuals who had HbA1c checked within the last 12 months. Healthy volunteers who did not have HbA1c screened at their GP will be offered an opportunistic screening blood test.

Phase 2 and 3:

Inclusion criteria:

right-handed adults between 18- 60 years with type 2 diabetes, pre-diabetes and healthy individuals who had HbA1c checked within the last 12 months. Healthy volunteers who did not have HbA1c screened at their GP will be offered an opportunistic screening blood test.

Exclusion Criteria:

* Phas",18,60,ALL,ENROLLING_BY_INVITATION,"['the anti-diabetic drug metformin', 'right-handed adults', 'diagnosis\n  * non', 'phase', 'mellitus', 'screening', 'hba1c≤42mmol', 'their gp', 'volunteers', 'phas', 'type', '* phas', 'who', 'hba1c\\>48 mmol/mol', 'adults', 'hba1c 42-48 mmol/mol', 'type 2 diabetes', '18- 60 years', 'prediabetes', 'the last 10 years', 'the last 12 months', 'exclusion criteria', 'inclusion criteria', '18 -60 years', '* general eligibility criteria', 'months', '6.5%', 'diabetes', 'healthy individuals', 'diagnosis', '1\n\ninclusion criteria', 'years', 'hba1c', 'criteria', 'blood', 'individuals', 'eligibility', 'drug', 'confirmed type 2 diabetes', 'healthy volunteers', 'metformin', 'mol\n\nphase', 'test', 'inclusion', 'exclusion']"
NCT07385547,Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency,Type II Diabetes Mellitus,"Inclusion Criteria:

1. Participant is willing and able to sign a written or electronic informed consent.
2. Participant is an adult male or female, aged between 18 and 80 years of age, inclusive, at the time of screening.
3. Participant has eGFR as defined by CKD-EPI equation and converted to the unit of mL/min according to the following ranges:

   * eGFR ≥ 90 mL/min;
   * eGFR ≥ 30-59 mL/min;
   * eGFR \< 30 mL/min, not on dialysis;
   * eGFR \< 30 mL/min, on intermittent hemodialysis.
4. Participant has a body mass index ≥ 18 kg/m2 and ≤ 42 kg/m2 at the Screening visit.
5. Contraception requirements:

   Female participants must:

   If of reproductive age and sexually active, be willing and able to use a medically highly effective form of birth control 4 weeks prior to and for 30 days following the dose of trial medication. Examples of medically highly effective forms of birth control are:
   1. Confirmed infertility due to surgical procedure or post-menopausal (cessation of mense",18,80,ALL,NOT_YET_RECRUITING,"['visit', 'participants', 'the screening visit', 'reproductive age', 'age', 'screening', '90 ml', 'birth', 'days', 'dose', 'consent', 'female participants', 'participant', 'ml', 'hemodialysis', 'trial', 'medically highly effective forms', 'ranges', 'the unit', 'egfr', 'medication', 'the time', 'cessation', 'dialysis', 'intermittent hemodialysis', '18 kg/m2', 'body', 'surgical procedure', '18 and 80 years', '4. participant', '≤', 'the dose', 'weeks', 'requirements', 'trial medication', '30 ml', 'an adult male', '42 kg/m2', '30 days', 'contraception', 'forms', 'birth control', 'control', 'time', 'min', '2. participant', 'a body mass index', 'criteria', 'the following ranges', 'years', 'unit', '3. participant', 'examples', '1. participant', 'index', '≥', 'confirmed infertility', 'form', 'menopausal (cessation', 'mense', 'male', 'procedure', '5. contraception requirements', 'inclusion', 'adult', 'epi', 'infertility', 'equation', 'female']"
NCT03455868,Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes,Bariatric Surgery,"Inclusion Criteria:

* bariatric groups: men and women; 18 to 60 years old; with a BMI \>=35 kg/m2; with type 2 diabetes: use of oral hypoglycemic agents or insulin OR 2 of the following tests confirming type 2 diabetes: HbA1c \>=6.5%; fasting glucose \>=7.0 mM; 2-h glucose post 75g oral glucose tolerance test (OGTT) \>=11.1 mM) (guidelines.diabetes.ca);) or without diabetes: HbA1c \<6.5% AND fasting glucose \<7.0 mM; who are awaiting bariatric surgery. Control group: BMI 25.0 to 29.9 kg/m2 (overweight group); without diabetes or prediabetes: HbA1c \<6.0% AND fasting glucose \<6.1 mM (Diabetes Canada criteria), with a stable weight for the last 3 months.

Exclusion Criteria:

* bariatric groups: type 1 diabetes; disease (e.g. uncontrolled thyroid disease, malabsorptive or overt inflammatory disorder, metabolic bone disease, creatinine clearance \<60 ml/min) or medication (e.g. glucocorticoids, anti-epileptic drugs, osteoporosis therapy and thiazolidinediones) affecting bone metabolism;",18,60,ALL,RECRUITING,"['metabolism', '\\>=11.1 mm', 'weight', 'bariatric surgery', 'thiazolidinediones', '\\>=11.1', 'creatinine', 'type', 'who', '\\<6.5%', 'disease', 'medication', 'glucose', 'women', 'control group', 'creatinine clearance \\<60 ml/min', 'osteoporosis therapy', 'prediabetes', 'group', 'oral hypoglycemic agents', 'clearance', 'a bmi \\>=35 kg/m2', 'hba1c \\<6.0%', 'exclusion criteria', 'inclusion criteria', 'glucose \\<7.0 mm', 'therapy', 'glucocorticoids', 'the last 3 months', 'months', 'bariatric groups', '* bariatric groups', 'osteoporosis', 'metabolic bone disease', 'diabetes', 'fasting glucose \\>=7.0 mm', '(overweight group', 'hba1c \\>=6.5%', 'tests', 'guidelines.diabetes.ca', 'agents', 'groups', 'the following tests', 'metabolic', 'years', 'hba1c', 'men', 'bone metabolism', 'criteria', 'ogtt', 'surgery', '25.0 to 29.9 kg/m2', 'thyroid', 'fasting glucose \\<6.1 mm', 'a stable weight', '\\<6.1', 'drugs', 'insulin', '\\<6.0', '1 diabetes', 'test', 'e.g. glucocorticoids', 'post', 'tolerance', 'disorder', 'anti-epileptic drugs', '2-h glucose post', 'inclusion', 'bone', 'exclusion', 'thyroid disease']"
NCT06965543,G-POEM for Glycemic Control in Diabetic Gastroparesis,Gastroparesis,"Inclusion Criteria:

* Aged 18 to 90 years;
* Diagnosed with diabetes for at least 5 years and be treated with optimized insulin therapy;
* Severe gastroparesis with gastric retention \>20% at 4h (confirmed by scintigraphy);
* Failure of conventional gastroparesis treatment;
* Continuous glucose monitoring (CGM) in use or willingness to use during study
* Time in range (70-180 mg/dL) \<70%

Exclusion Criteria:

* Are treated with an automated insulin therapy system (closed-loop);
* Have previously undergone gastric neurostimulation therapy with Enterra (Medtronic ©);
* Have been treated with erythromycin in the past three months;
* Do not provide informed consent;
* Are pregnant or breastfeeding during the study period;
* Are under legal guardianship;
* Have contraindications to the POEM procedure, including contraindications to anesthesia and/or active anticoagulation that cannot be paused;
* Have severe chronic constipation, defined by a Cleveland score \>15 (Agachan et al., Dis Colo",18,90,ALL,NOT_YET_RECRUITING,"['loop', 'retention', 'constipation', 'consent', 'study\n* time', 'range', 'at least 5 years', '%\n\nexclusion criteria', 'conventional gastroparesis treatment', 'that', '*', 'enterra', 'severe chronic constipation', 'glucose', 'treatment', 'informed consent', 'the past three months', 'agachan', 'neurostimulation', 'al', 'the poem procedure', 'the study period', 'anesthesia', 'closed-loop', 'gastric retention', 'period', 'gastroparesis', 'inclusion criteria', 'system', 'continuous glucose monitoring', 'scintigraphy', 'therapy', 'months', 'cgm', 'study', '* severe gastroparesis', 'a cleveland score \\>15', 'diabetes', 'legal guardianship', 'failure', 'optimized insulin therapy', 'use', 'gastric neurostimulation therapy', 'medtronic ©', 'time', 'contraindications', 'criteria', 'years', 'monitoring', 'willingness', 'guardianship', 'insulin', '* failure', 'procedure', 'dis colo', 'inclusion', 'anticoagulation', '%', 'exclusion', 'active anticoagulation', 'erythromycin']"
NCT07111416,Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis,Type 2 Diabetes,"Inclusion Criteria:

* Age 65 years of age or older
* A1c 5.3% - 7.4% without a diagnosis on the problem list and/or current or prior treatment for diabetes
* Evidence of A1c discordance by meeting one of two criteria developed by an EHR based algorithm
* At least five (5) HbA1c values and three (3) CBC values available in the EHR in the previous 10 years
* Willingness to wear an Abbott Freestyle Libre 3 System Sensor for up to 48 days
* Willingness to consent to data collection using the electronic health record and sign a medical release to obtain future medical records from other health care facilities

Exclusion Criteria:

* Known or suspected diabetes of other causes (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.)
* Clinically significant anemia based on most recent hematocrit (M = \<38%, F \<33%) and/or hemoglobin (M = \<12 g/dL, F = \<10 g/dL) within the last 12 months
* Condition with short life expectancy
* Blood (hematologic) malignancy
* rtCGM-interferen",18,100,ALL,NOT_YET_RECRUITING,"['cbc values', 'a medical release', 'age', 'the problem list', '* blood (hematologic) malignancy', 'discordance', '\\<38', '* age', 'g', 'diabetes', 'health', 'diagnosis', 'future medical records', 'years', 'willingness', 'list', '= \\<12', 'anemia', 'inclusion', 'records', 'values', '65 years', '* willingness', 'monogenic diabetes', 'malignancy', '* clinically significant anemia', '- 7.4%', 'a1c discordance', 'the previous 10 years', 'f \\<33%', 'system', 'pancreatogenic diabetes', 'data collection', 'life', 'up to 48 days', 'care', 'hematocrit', 'problem', 'release', 'hemoglobin', '%', 'exclusion', 'pancreatogenic', 'expectancy', 'condition', 'dl', 'collection', 'm', '=', 'treatment', 'rtcgm-interferen', 'the electronic health record', 'inclusion criteria', 'current or prior treatment', 'record', 'criteria', 'freestyle', 'blood', 'sensor', 'hematologic', 'a1c 5.3%', '* condition', 'f = \\<10', 'days', 'short life expectancy', 'interferen', 'other causes', 'type', 'an ehr', 'the last 12 months', 'months', 'data', 'type 1 diabetes', 'facilities', 'causes', 'a diagnosis', 'evidence', 'most recent hematocrit', 'two criteria', 'the ehr']"
NCT05819138,Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes,"Diabetes Mellitus, Type 1","Inclusion Criteria:

* Age 18-49 years
* 1\) T1D diagnosis defined as positive T1D-associated antibody(ies) or 2) a clinical diagnosis of T1D plus insulin requirement since diagnosis
* Insulin pump or automated insulin delivery systems
* Estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73m2
* Stable doses of drugs altering cardiovascular and renal function (e.g., Angiotensin-Converting Enzyme Inhibitor (ACEi), Angiotensin Receptor Blocker (ARB), statins, diuretics)
* BMI 20-45 kg/m2
* Adequate contraceptive method for females

Exclusion Criteria:

* HbA1c \>9%, recent diabetic ketoacidosis (DKA) or hospitalization
* Major congenital heart disease, anemia, severe non-proliferative retinopathy, proliferative retinopathy
* History/family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN2), pancreatitis
* Current/planned pregnancy or nursing
* Uncontrolled thyroid disease or hypertension (HTN) (≥ 160/100 mm Hg despite optimal therapy)
* Use of other ",18,49,ALL,RECRUITING,"['carcinoma', 'angiotensin-converting enzyme inhibitor', 'positive t1d-associated antibody(ies', 'doses', 'age', 'delivery', 'history', 'females\n\nexclusion criteria', 'cardiovascular and renal function', 'antibody(ies', 'females', 't1d diagnosis', 'blocker', 'type', 'inhibitor', 'hospitalization', 'dka', 'function', 'disease', 'egfr', 'nursing', 'current', 'pregnancy', 'pump', 'acei', 'estimated glomerular filtration rate', '\\>9%', 'automated insulin delivery systems', 'inclusion criteria', 'optimal therapy', 'rate', 'enzyme', 'endocrine', 'angiotensin', 'pancreatitis', 'therapy', 'filtration', 'hypertension', 'diuretics', 'heart', 'family', 'diagnosis', 'htn', 'years', 'hba1c', 'criteria', 'medullary thyroid carcinoma', 'method', '18-49 years', 'angiotensin receptor blocker', 'drugs', 'thyroid', '≥', 't1d plus insulin requirement', 'statins', 'diagnosis\n* insulin pump', 'receptor', 'ketoacidosis', 'insulin', 'men2', 'anemia', '/min/1.73m2', 'arb', 'a clinical diagnosis', 'inclusion', 'systems', 'requirement', 'exclusion']"
NCT06961643,Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function,Diabetes Mellitus,"Inclusion Criteria:

1. Ability to understand the study procedures and methods, participate voluntarily and be able to complete the study according to the protocol requirements, and sign the informed consent form (ICF) in writing.
2. Aged 18-70 years old on the date of signing the ICF (including the threshold), both male and female.
3. At the time of screening, male subjects weighing no less than 50 kg and female subjects weighing no less than 45 kg; body mass index (BMI): 18\~32 kg/m2 (including the threshold).

Exclusion Criteria:

1. In the judgment of the investigator, may be allergic to the study drug or its components.
2. Smoking an average of more than 10 cigarettes per day within 3 months prior to screening.
3. Alcoholics of within 3 months prior to screening, who consume more than 14 units of alcohol per week (1 unit=beer)360 mL of alcohol, or 45 mL of strong liquor with an alcohol content of 40%, or 150 mL of wine.
4. History of drug or substance abuse, or a positive urine dr",18,70,ALL,RECRUITING,"['abuse', 'screening', 'consent', 'an average', 'more than 14 units', 'drug or substance abuse', 'the time', 'body', 'the study', 'ability', 'wine', 'components', 'an alcohol content', 'strong liquor', 'exclusion criteria', 'urine', 'the informed consent form', 'procedures', 'the threshold', '40%', '4. history', 'years', 'icf', 'cigarettes', 'content', 'a positive urine', 'inclusion', 'units', 'history', 'the investigator', 'ml', 'substance', 'dr', 'methods', 'bmi', 'time', 'unit', 'index', 'form', '150 ml', 'exclusion', 'female', 'threshold', 'who', '18\\~32 kg/m2', 'more than 10 cigarettes', '=', 'the study drug', '3 months', 'the study procedures', 'inclusion criteria', 'alcoholics', 'subjects', 'study', 'requirements', 'female subjects', 'the protocol requirements', 'the judgment', 'day', 'protocol', '(1 unit', 'criteria', 'mass', 'the icf', 'drug', 'liquor', 'date', 'body mass index', 'writing', 'alcohol', 'week', '3. alcoholics', 'judgment', 'its components', 'months', 'average', 'the date', 'investigator', 'both male', 'male', '45 ml']"
NCT06439758,Effects of First-Line Oral Hypoglycemics in Bone Markers of Treatment Naïve Saudi Adults With Type 2 Diabetes,Diabetes Type 2,"Inclusion Criteria:

* Consenting Saudi adults, males, and females, aged 25-65 years with newly diagnosed T2DM will be included.
* T2DM diagnosis will be done by collaborating primary care physicians following the American Diabetes Association (ADA) and World Health Organization (WHO) criteria (ADA, 2022):
* Fasting plasma glucose ≥7.0mmol/l or ≥126mg/dl. Fasting is defined as no caloric intake for at least 8 hours OR
* 2-h PG ≥200 mg/dl (11.1 mmol/L) during OGTT. The test should be performed as described by WHO, using a glucose load containing the equivalent of 75g anhydrous glucose dissolved in water.

OR •Hba1c ≥6.5% (48 mmol/mol). The test should be performed in a laboratory using a method that is National Glycohemoglobin Standardization Program (NGSP) certified and standardized to the Diabetes Control and Complications (Trial) DCCT assay.

OR

•In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dl (11.1 mmol/L).

Exclusion ",25,65,ALL,NOT_YET_RECRUITING,"['mg', 'a glucose load', 'a random plasma glucose', 'a laboratory', 'program', 'who) criteria', 'equivalent', 'primary care physicians', 'dl', ') dcct assay', 'no caloric intake', 'females', 'a patient', 'that', 'who', '≥200', 'the test', 'trial', 'the diabetes control', 'adults', 'dcct', 'assay', 'glucose', 'ada', 'caloric', 'saudi adults', '48 mmol/mol', 'water', 'the american diabetes association', 'hyperglycemia', 'laboratory', 'world', 'inclusion criteria', 'plasma', 'symptoms', 'males', 'plasma glucose', '•hba1c', 't2dm diagnosis', 'hyperglycemic crisis', 'patient', 'diabetes', 'intake', '75g anhydrous glucose', 'national glycohemoglobin standardization program', 'care', 'health', 'hours', 'diagnosis', '≥126mg', 'control', 'fasting', 'years', 'criteria', 'load', 'crisis', 'ogtt', 'method', 'classic symptoms', 'world health organization', '≥7.0mmol/l', 'a method', '(11.1 mmol/l', 'test', 'at least 8 hours', 'complications', 'organization', 'inclusion', 'physicians', '%', 'newly diagnosed t2dm', 'the equivalent', 'exclusion']"
NCT06838416,Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease,Type 2 Diabetes Mellitus,"Inclusion Criteria:

* Diagnosed with Type 2 diabetes according to the 1999 WHO criteria
* Aged ≥18 years
* UACR ≥30 mg/g and eGFR ≥30 ml/min/1.73 m² sustained for over 3 months
* Stable ARB/ACEI treatment for ≥4 weeks prior to enrollment
* Willing to sign a written informed consent and comply with the study protocol

Exclusion Criteria:

* Chronic kidney disease diagnosed before Type 2 diabetes
* Serum potassium \>4.8 mmol/L
* Ineffective blood pressure control at screening (systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg, average of three measurements in the supine position)
* HbA1c \>9%
* Acute urinary tract infection or conditions affecting urine tests
* Primary or secondary adrenal insufficiency
* Use of mineralocorticoid receptor antagonists
* Use of medications with clear effects on urine protein and eGFR within 4 weeks (except kininogenase)
* Use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin, ",18,100,ALL,RECRUITING,"['aged ≥18 years', 'the supine position', 'clarithromycin', 'clear effects', 'kidney', 'conditions', 'consent', 'itraconazole', 'type', 'who', 'inhibitors', 'three measurements', 'tract', '* chronic kidney disease', 'serum potassium', 'disease', 'enrollment', 'egfr', 'treatment', '* use', 'serum', 'cobicistat', 'urine tests', 'a written informed consent', 'antagonists', 'insufficiency', 'acei', 'protein', 'infection', '* stable arb/acei treatment', 'effects', 'measurements', 'over 3 months', 'inclusion criteria', '4 weeks', '≥30 mg', 'medications', 'potassium', 'position', 'urine', 'months', 'average', 'ketoconazole', 'weeks', 'g', 'egfr ≥30 ml/min/1.73 m²', 'study', 'diabetes', 'tests', 'urine protein', 'telithromycin', 'protocol', 'kininogenase', 'pressure', 'years', 'hba1c', 'criteria', 'nelfinavir', 'blood', 'control', 'receptor', '≥4 weeks', 'strong cyp3a4 inhibitors', 'uacr', 'ritonavir', 'inclusion', 'exclusion', 'mineralocorticoid receptor antagonists']"
NCT07270133,Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes,Diabetic Retinal Disease,"Key Inclusion Criteria:

* Age ≥ 18 years
* Diagnosed with Type 1 or Type 2 diabetes or non-diabetic control patients
* Best corrected visual acuity 20/32 or better (Snellen) (≥74 ETDRS letters)
* Meets criteria for one of the defined observational groups below
* Able and willing to provide informed consent

Key Exclusion Criteria:

* Ocular or systemic condition, aside from diabetes mellitus (DM), that is likely to affect the assessment of DRSS, DME, or the functioning of the neural retina
* Previous treatment of any kind for diabetic retinopathy or DME
* Any condition that may preclude adequate imaging of the macula (e.g. dense cataract or other media opacity, ptosis)
* History of rhegmatogenous retinal detachment or macular hole
* History of vitrectomy
* Intraocular surgery (including cataract surgery) within 4 months prior to enrollment or anticipated within the next 6 months
* Requiring treatment for DR/DME in the next 6 months",18,100,ALL,NOT_YET_RECRUITING,"['the macula', 'the defined observational groups', 'condition', 'assessment', 'history', 'age', 'mellitus', 'vitrectomy\n* intraocular surgery', 'the next 6 months', 'diabetic retinopathy', 'consent', 'functioning', 'patients', 'type', 'that', 'dr/dme', 'kind', 'e.g. dense cataract', 'macula', 'the assessment', 'enrollment', 'treatment', '18 years', 'other media opacity', 'cataract surgery', '* history', 'imaging', 'adequate imaging', '(≥74 etdrs letters', 'rhegmatogenous retinal detachment', 'retinopathy', 'media', '(snellen', 'key inclusion criteria', 'dme', '4 months', 'cataract', 'months', 'any condition', 'acuity', 'diabetes', 'any kind', 'ptosis', 'groups', 'control', 'years', 'criteria', 'detachment', 'drss', 'dm', 'surgery', '≥', 'hole', 'macular hole', 'vitrectomy', 'opacity', 'inclusion', 'previous treatment', 'the functioning', 'the neural retina', 'letters', 'exclusion']"
NCT07257952,APOs Associated With Respiratory Viral Infections Before and During Early Pregnancy,Respiratory Viral Infections,"Inclusion Criteria:

* Female;
* Age 20 to 45 years old;
* Physician-diagnosed acute respiratory viral infection occurring within 6 months before pregnancy and/or at \<24 weeks of gestation.

Exclusion Criteria:

* Pregestational T1D or T2D;
* Long-term use of immunosuppressants or glucocorticoids;
* Diseases that severely affect immune or metabolic function (e.g., HIV, SLE, rheumatoid arthritis);
* Severe mental illness or cognitive impairment;
* Women whose electronic medical records lack GDM screening and delivery records.",20,45,FEMALE,NOT_YET_RECRUITING,"['illness', '* female', 'age', 'screening', 'delivery', 'diseases', 'cognitive impairment', 'that', 'function', 'arthritis', 'women', 'whose electronic medical records', 'pregnancy', 'infection', 'term', 'exclusion criteria', 'inclusion criteria', 'glucocorticoids', 'months', 'weeks', 'immunosuppressants', '\\<24 weeks', 'physician', 'impairment', 'metabolic', 'years', 'criteria', 'immune or metabolic function', 'rheumatoid arthritis', 'gestation', '* long-term use', '* diseases', 'sle', '* severe mental illness', 'inclusion', 'records', 'exclusion', '6 months', 'female', 'pregestational t1d']"
NCT06772168,Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia,Dyslipidemia,"Screening (Visit 1) Inclusion Criteria

1. A male or female adult aged between 19 and 80 in South Korea
2. An individual with type II diabetes and dyslipidemia
3. An individual meeting any of the followings at the time of the screening

   1. Metformin monotherapy: An individual who was on a stable dose of metformin ≥1,000 mg/day as monotherapy for at least 6 weeks prior to screening (for a patient who took a dyslipidemia treatment within 4 weeks from the screening, the patient had to be on a stable dose of metformin ≥1,000 mg/day as monotherapy for at least 2 weeks prior to the screening)
   2. Dual combination therapy: An individual who was on a stable dose of metformin ≥1,000 mg/day for at least 1 week prior to the screening in combination with additional oral diabetes treatment (DPP-4i, TZD, SU)
4. An individual meeting the following criteria for HbA1c at the time of the screening

   1. Metformin monotherapy: An individual with 7.0% ≤ HbA1c ≤ 10.5% whose blood sugar level is not a",2,100,ALL,RECRUITING,"['mg', 'sugar', 'meeting', '/', 'the screening', 'screening', 'a stable dose', 'an individual meeting', 'dose', 'combination', 'level', 'dpp-4i', 'a patient', 'individual', 'who', 'week', 'any', 'the time', 'treatment', 'whose blood sugar level', '10.5%', 'metformin ≥1,000', '4 weeks', 'inclusion criteria', 'an individual', 'therapy', 'weeks', 'patient', 'diabetes', 'day', 'additional oral diabetes treatment', 'the following criteria', 'time', 'a dyslipidemia treatment', 'dual combination therapy', 'hba1c', 'criteria', 'followings', 'blood', 'type ii diabetes', 'metformin monotherapy', 'metformin', 'su', 'dyslipidemia', 'south korea', 'the followings', '7.0% ≤ hba1c ≤', 'tzd', 'inclusion', 'adult', 'a', 'monotherapy', 'the patient']"
NCT06706791,Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II,Chronic Heart Failure,"Inclusion Criteria:

1. Age 40-70 years at time of screening.
2. Both Men and women are included in study.
3. Patients with chronic heart failure and currently categorized in class II-IV heart failure as per NHYA classification having ejection fraction less than 40%.
4. Patients having NT- proBNP levels greater than 25pg/ml.
5. Diabetic patient diagnosed (HbA1c \> 6.5mg/dl) and currently taking antidiabetic medicine.

Exclusion Criteria:

1. Pregnant female.
2. Patient with end stage renal disease (ESRD).
3. Patient with acute decompensated heart failure.
4. Acute coronary syndrome patients.",40,70,ALL,RECRUITING,"['pregnant female', 'age', 'screening', 'stage', 'patients', '25pg', 'ml', '40-70 years', 'chronic heart failure', '6.5mg/dl', 'classification', 'acute decompensated heart failure', 'diabetic patient', 'women', 'nhya', 'levels', 'nt- probnp levels', '4. patients', 'fraction', 'exclusion criteria', 'ejection', 'inclusion criteria', 'ejection fraction', 'study', 'syndrome', 'esrd', 'patient', '3. patients', 'failure', 'heart', 'less than 40%', 'time', 'antidiabetic medicine', 'criteria', 'years', 'medicine', 'both men', 'end stage renal disease', 'class ii-iv heart failure', 'inclusion', 'nhya classification', '3. patient', 'female', 'exclusion']"
NCT06575478,Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2","Inclusion Criteria:

1. Age 18-75 years (inclusive), male or female;
2. Patients diagnosed with T2DM ≥ 8 weeks according to the 2020 WHO diagnostic criteria and classification;
3. Have controlled blood sugar through diet and exercise for 3 months before screening and did not receive any hypoglycemic drugs, or used hypoglycemic drugs for no more than 2 weeks within 3 months before screening and did not use hypoglycemic drugs within 1 month before screening;
4. Body mass index (BMI) ≥ 19 kg/m2;
5. Glycated hemoglobin (HbA1c) ≥ 7.0% and \< 10.5% at screening;
6. Fasting plasma glucose (FPG) \< 13.9 mmol/L at screening;
7. Able to understand the procedures and methods of this study, willing to strictly abide by the clinical research protocol to complete this study, and voluntarily sign the ICF

Exclusion Criteria:

1. Non-type 2 diabetes: type 1 diabetes, gestational diabetes, special types of diabetes;
2. History of acute complications of diabetes within 6 months before screening (diabeti",18,75,ALL,RECRUITING,"['acute complications', 'sugar', 't2dm ≥', 'history', 'age', 'screening', 'research', '19 kg/m2', 'any hypoglycemic drugs', 'glycated hemoglobin', 'patients', 'type', 'who', 'classification', 'blood sugar', '7.0%', 'gestational diabetes', 'glucose', 'methods', 'diet', ') \\< 13.9 mmol/l', '18-75 years', '3 months', 'body', 'fpg', '10.5%', 'inclusion', '2. history', '1 month', 'inclusion criteria', 'plasma', 'types', 'the procedures', 'bmi', 'weeks', 'the icf\n\nexclusion criteria', 'months', 'procedures', 'study', 'diabetes', 'type 1 diabetes', 'month', 'the clinical research protocol', 'protocol', 'diabeti', 'years', 'hba1c', 'criteria', 'blood', 'this study', 'index', 'drugs', '≥', '4. body mass index', 'non-type 2 diabetes', 'hypoglycemic drugs', 'special types', 'complications', '6. fasting plasma glucose', 'hemoglobin', 'exclusion', '6 months']"
NCT06402760,Comprehensive Intervention of Diabetes and Psoriasis Comorbidity Prevention and Control,Psoriasis,"Inclusion Criteria:

1. Meet the Western medicine diagnostic criteria for vulgaris psoriasis and the Traditional Chinese Medicine diagnostic criteria for blood stasis syndrome in psoriasis.
2. Newly diagnosed or previously diagnosed with psoriasis; if previously diagnosed, prior treatment methods are not restricted.
3. Identified as high risk for comorbid diabetes based on a risk model calculation.
4. Age between 18 and 80 years old, any gender.
5. Willing to participate in this study and provide informed consent.

Exclusion Criteria:

1. Patients already diagnosed with diabetes.
2. Presence of other active skin diseases that may affect the assessment of the condition.
3. In severe, difficult-to-control acute or chronic infection locally or systemically.
4. Severe systemic diseases; or patients with clinical laboratory indicators falling into any of the following conditions:

   ① Hematology: Hemoglobin (HGB) \< 90g/L; Platelet count (PLT) \< 10010\^9/L; White blood cell count (WBC) \<",18,80,ALL,NOT_YET_RECRUITING,"['high risk', 'hematology', 'presence', 'blood stasis syndrome', 'hgb', 'skin', 'assessment', 'condition', 'count', 'other active skin diseases', 'platelet count', 'diseases', 'conditions', 'consent', 'patients', ':\n\n   ① hematology', 'that', ') \\', 'white blood cell count', 'the condition', 'clinical laboratory indicators', 'indicators', 'the assessment', 'any', 'methods', 'treatment', 'informed consent', 'gender', 'vulgaris psoriasis', 'stasis', 'infection', 'laboratory', 'exclusion criteria', 'a risk model calculation', 'inclusion criteria', 'model', 'psoriasis', 'study', 'syndrome', '4. age', 'diabetes', 'cell', 'comorbid diabetes', 'years', 'criteria', 'blood', 'this study', '2. presence', 'vulgaris', '\\< 10010\\^9/l', 'medicine', 'any gender', 'calculation', 'the following conditions', 'risk', 'plt', 'wbc', 'inclusion', 'hemoglobin', '90g/l', 'prior treatment methods', 'exclusion']"
NCT06296550,Enhancing Digitally Delivered Diabetes Education With Real-Time CGM,Diabetes Type 2,"Inclusion Criteria:

* Diagnosed with type 2 diabetes
* Are not currently using a CGM
* Are not using insulin therapies
* Speak English, Spanish or Arabic
* Have A1c between 7.5% and 12.0% in last 90 days
* Have a cellphone that can receive/send text messages and counts steps

Exclusion Criteria:

* Are using insulin therapies
* Are pregnant
* Are currently using a CGM
* Are currently participating in another diabetes-related study",18,100,ALL,RECRUITING,"['messages', 'cellphone', 'days', 'text', 'insulin therapies', 'type', 'that', 'a cellphone', '*', 'last 90 days', 'therapies', 'between 7.5% and 12.0%', 'pregnant\n*', 'inclusion criteria', 'study', 'diabetes', 'criteria', 'a cgm\n*', 'insulin', 'a1c', 'steps\n\nexclusion criteria', 'another diabetes-related study', 'text messages', 'inclusion', 'exclusion', 'steps']"
NCT06668623,Effect of Reiki on Neuropathic Pain Severity and Sleep Quality in Patients With Diabetic Neuropathy,Diabetic Neuropathy,"Inclusion Criteria:

* Over 18 years of age
* No communication problems
* Communicating in Turkish
* No diagnosis of mental illness
* Willingness to participate in the study
* Being competent enough to answer forms and surveys
* VAS pain intensity 3 and above
* 4 Question Neuropathic Pain score 4 and above
* Not having received Reiki treatment

Exclusion Criteria:

* Receiving a different illness and treatment during the therapy process
* Leaving Reiki practice
* Psychiatric illness
* Becoming a Reiki practitioner or instructor
* Cerebrovascular disease
* Receiving Reiki practice",18,100,ALL,RECRUITING,"['illness', 'reiki', 'pain', 'the therapy process', 'age', 'intensity', 'a different illness', 'reiki practice', 'practice', 'problems', 'no diagnosis', 'disease', 'mental illness', 'treatment', 'no communication problems', 'surveys', 'the study', 'inclusion criteria', 'over 18 years', 'practitioner', 'communication', 'therapy', 'reiki treatment\n\nexclusion criteria', 'study', 'a reiki practitioner', 'question', 'forms', 'process', 'vas pain intensity', 'diagnosis', 'score', '* cerebrovascular disease', 'criteria', 'years', 'willingness', 'instructor', 'inclusion', 'exclusion', '* willingness']"
NCT07379333,A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin,Type 2 Diabetes,"Inclusion Criteria:

* 1\. Adults aged 19 years or older
* 2\. Diagnosed with type 2 diabetes
* 3\. HbA1c level 7.0% ≤ HbA1c ≤ 10.0%
* 4\. Stable administration of metformin (≥1,000 mg/day) and dapagliflozin (10 mg/day) without any change in dosage or formulation for at least 8 weeks prior to Visit 1
* 5\. 20 kg/m2 ≤ BMI ≤ 45 kg/m2
* 6\. Agree to the recommended exercise and diet regimen during this clinical trial

Exclusion Criteria:

* 1\. Patients with a history of allergy or resistance to the investigational drug or background therapy
* 2\. Patients diagnosed with a type of diabetes other than type 2 diabetes
* 3\. Patients with uncontrolled severe diabetic complications
* 4\. Patients with a history of acute or chronic metabolic acidosis, including lactic acidosis or diabetic ketoacidosis.
* 5\. Patients with a history of diabetic coma or precoma
* 6\. Those with a history of severe hypoglycemia
* 7\. Those whose weight change \> 5 kg
* 8\. History of gastrointestinal disease or s",18,100,ALL,NOT_YET_RECRUITING,"['dosage', 'mg', '3\\. patients', 'lactic acidosis', 'diabetic ketoacidosis', '8\\. history', 'weight', 'resistance', 'history', 'administration', 'hba1c level', 'severe hypoglycemia', 'level', 'patients', 'type', 'the recommended exercise', 'allergy', '* 2\\. patients', 'hypoglycemia', 'formulation', 'a history', 'trial', 'adults', 'disease', '2 diabetes', 'diet', 'background', 'inclusion', 'dapagliflozin', '* 6\\.', 'inclusion criteria', '* 4\\. stable administration', '5\\. patients', 's', 'exercise', 'therapy', 'coma', 'a type', 'weeks', '7.0% ≤', 'regimen', 'those', '* 1\\. patients', 'diabetes', '* 1\\. adults', 'day', '5 kg', 'gastrointestinal disease', '≥1,000', 'metabolic', 'change', 'years', '* 4\\. patients', 'criteria', 'the investigational drug', 'diet regimen', 'drug', 'metformin', 'whose weight', 'ketoacidosis', 'background therapy', '10.0%', '10 mg', 'any change', 'diabetic coma', 'complications', 'acidosis', '45 kg/m2', 'uncontrolled severe diabetic complications', 'exclusion']"
NCT05492448,Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease,Type 2 Diabetes,"Inclusion Criteria:

* Subjects are between 50-85 years old, and clinical diagnosis of T2DM (HbA1c ≥ 6.5% or fasting plasma glucose ≥ 126 mg/dL or oral glucose tolerance test 2-hour plasma glucose ≥ 200 mg/dL).
* Patients with stable pulmonary obstruction (pulmonary function FEV1/FVC \<0.7) with symptoms of pulmonary obstruction.
* Subjects can cooperate with the collection of experimental specimens and return for regular visits.
* The patient or family members have signed the informed consent form.
* The patient must receive adjuvant treatment with probiotic for 12 weeks.

Exclusion Criteria:

* The patient or caregiver is unable to follow the physician's instructions for the trial, including the completed symptom assessment form and compliance with medication.
* The patient has a history of related allergic reactions, or the use of other highly sensitive or contraindicated drugs (Allergy to antibiotics or antipyretics).
* The patient have taken oral immunosuppressive drugs, intraveno",50,85,ALL,RECRUITING,"['t2dm', 'antibiotics', '* subjects', 'assessment', 'history', 'related allergic reactions', ""the physician's instructions"", 'dl', '(pulmonary function', 'collection', 'consent', 'patients', 'allergy', 'obstruction', 'a history', 'hour', 'oral immunosuppressive drugs', 'function', '* patients', 'members', 'medication', 'glucose', 'trial', 'reactions', 'compliance', 'treatment', 'regular visits', 'instructions', '/fvc', 'clinical diagnosis', 'experimental specimens', 'symptoms', 'the informed consent form', 'subjects', 'the trial', 'plasma', 'plasma glucose', 'weeks', 'patient', '6.5%', 'caregiver', 'physician', '12 weeks', 'family', 'stable pulmonary obstruction', 'diagnosis', 'specimens', 'years', 'hba1c', 'criteria', 'pulmonary obstruction', 'drugs', '≥', 'the use', 'form', 'symptom', 'test', 'tolerance', 'adjuvant treatment', 'visits', 'the collection', 'inclusion', '\\<0.7', 'antipyretics', 'exclusion', 'the patient']"
NCT06295874,"The Effect of Aromatherapy Massage on Pain, Anxiety and Comfort",Respiratory Insufficiency,"Inclusion Criteria:

* 18 years of age and over,
* Conscious patients,
* Staying in intensive care for 24 hours or more,
* Those with stable hemodynamic status,
* Receiving O2 therapy,
* Intubated patients, patients who have passed 24 hours after being extubated,
* Those whose saturation level is 85 and above

Exclusion Criteria:

* Patients with peripheral neuropathy or quadriplegia,
* Patients with open wounds on their body,
* Patients receiving analgesia and sedation infusion,
* Patients who are sedated,
* Patients in delirium,
* Patients with an allergy detected before starting the application,
* Patients with a GKS (Glasgow Coma Scale) score of 3 and below",18,100,ALL,RECRUITING,"['24 hours', 'peripheral neuropathy', 'o2 therapy', 'age', 'the application', 'an allergy', 'level', 'patients', 'allergy', 'who', 'neuropathy', 'status', '* patients', '* 18 years', 'saturation', 'intubated patients', 'delirium', 'body', '* conscious patients', 'open wounds', 'stable hemodynamic status', 'inclusion criteria', 'coma', 'therapy', 'wounds', 'those', 'whose saturation level', 'hours', 'care', 'quadriplegia', 'score', 'their body', 'criteria', 'years', 'sedation', 'glasgow', ',\n* patients', 'infusion', 'analgesia and sedation infusion', 'application', 'inclusion', 'scale', 'exclusion', 'intensive care', 'glasgow coma scale']"
NCT06411210,Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment,Diabetes type1,"Inclusion Criteria:

* Age 18-30 years with T1D whose BMI meets FDA approval criteria for anti-obesity pharmacotherapy (BMI ≥30 kg/m2 alone or BMI ≥27 kg/m2 with a weight-related comorbidity)
* Clinical diagnosis of T1D
* Diabetes duration diagnosed ≥ 12 months ago
* HbA1c ≤10% at screening and within the past 90 days
* Stable reported insulin dosing in the past 90 days (within 15%)
* Stable reported BMI in the past 90 days (within 5%)
* Ability to provide written informed consent before any trial-related activities
* Use of real-time continuous glucose monitoring and planned continued use
* Females and males of childbearing potential willing to use highly effective methods of contraception for at least 1 month prior to randomization and agreement to use such a method during study participation and for 2 months after the last dose of study medication administration: Combined estrogen-progestogen contraception including: oral, intravaginal, transdermal (patch), Progestogen-only contrace",18,30,ALL,RECRUITING,"['progestogen', 'pharmacotherapy', 'weight', 'age', 'screening', '2 months', 'agreement', 'administration', 'days', 'study participation', '5%', 'dose', 'consent', 'females', 'fda approval criteria', 'oral, intravaginal, transdermal (patch', 'trial', 'medication', 'glucose', 'methods', 'duration', '* use', 'activities', '18-30 years', 'the past 90 days', 'ability', 'written informed consent', 'anti-obesity pharmacotherapy', 'continued use\n* females', 'inclusion criteria', 'the last dose', 'bmi', 'males', 'months', 'any trial-related activities', '* ability', 'real-time continuous glucose monitoring', 'study', 't1d\n* diabetes duration', '15%', 'diabetes', 'whose bmi', 'participation', 'month', 'contraception', 'diagnosis', 'time', 'years', 'hba1c', 'criteria', 'approval', 'randomization', '≥27 kg/m2', 'monitoring', 'method', 'contrace', 'such a method', 'highly effective methods', 'dosing', 'comorbidity', 'insulin', 'study medication administration', 'a weight-related comorbidity', 'inclusion', 'patch', '(bmi ≥30 kg/m2', '%']"
NCT07004335,"Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study",PD-(L)1,"Inclusion Criteria:

Participants must meet all of the following criteria for enrollment:

1. Age ≥18 years;
2. Histologically-confirmed unresectable Stage III or IV melanoma, unsuitable for local therapy;
3. Confirmed PD according to iRECIST within 12 weeks after receiving the last dose of anti-PD-(L)1 monotherapy or in combination with other treatments (including anti-CTLA-4) for at least two doses. (Up to 25% of participants may have received both anti-CTLA-4 and anti-PD-(L)1 treatment);
4. Participants with BRAF/CKIT/NRAS gene mutations must have progressed after targeted therapy;
5. Intolerant to chemotherapy or refused standard therapy;
6. Toxicity from the most recent treatment recovered to grade 1 or below (except alopecia); if participants underwent major surgery or radiotherapy \>30 Gy, they must have recovered from treatment-related toxicities/complications;
7. Life expectancy of at least 3 months;
8. Eastern Cooperative Oncology Group (ECOG) score: 0-1;
9. At least one meas",18,100,ALL,NOT_YET_RECRUITING,"['participants', 'radiotherapy', 'confirmed pd', 'doses', 'anti-pd-(l)1 monotherapy', 'major surgery', '7. life expectancy', 'all', 'stage', 'dose', 'combination', 'toxicities', 'monotherapy', 'up to 25%', 'enrollment', 'mutations', 'meas', 'treatment', 'braf/ckit/nras gene mutations', 'group', 'oncology', 'inclusion', 'gene', 'the last dose', 'inclusion criteria', 'alopecia', 'therapy', 'other treatments', 'at least 3 months', 'weeks', 'months', 'the most recent treatment', 'life', 'age ≥18 years', '4. participants', 'at least one meas', '12 weeks', 'anti-pd-(l)1 treatment', 'the following criteria', 'targeted therapy', 'they', '-', 'ecog', 'criteria', 'years', 'treatments', 'ckit', 'local therapy', 'radiotherapy \\>30 gy', 'surgery', 'at least two doses', 'standard therapy', 'melanoma', 'braf', 'toxicity', 'complications', 'iv melanoma', 'irecist', 'score', 'expectancy', 'treatment-related toxicities/complications']"
NCT07062224,Effect of a Probiotic Supplement on Gut Microbiota and Glycemic Control in Patients With Type 1 Diabetes (PRODIAB),Diabete Type 1,"Inclusion Criteria:

* Age between 18 and 65 years.
* Ability to understand and sign the informed consent form.
* For the patient group: diagnosis of type 1 diabetes with at least 1 year of disease progression.
* For the control group: healthy individuals without a diagnosis of diabetes or other metabolic disorders.
* No use of antibiotics, probiotics, or prebiotics during the 4 weeks prior to the study start.
* Willingness to comply with the study protocol and attend scheduled visits.

Exclusion Criteria:

* Current use of probiotics, prebiotics, or antibiotics.
* Chronic gastrointestinal diseases (e.g., inflammatory bowel disease, irritable bowel syndrome).
* Pregnancy or breastfeeding.
* Participation in another clinical trial within the past 3 months.
* Immunosuppressive diseases, active cancer, or treatment with immunosuppressants.
* Known allergy or intolerance to any component of the supplement or placebo.
* Excessive alcohol or drug use.",18,65,ALL,NOT_YET_RECRUITING,"['irritable bowel syndrome', 'antibiotics', '* chronic gastrointestinal diseases', 'the past 3 months', 'component', 'placebo', 'diseases', '* known allergy', 'other metabolic disorders', 'supplement', 'consent', 'the supplement', 'alcohol', 'type', 'allergy', 'disease progression', 'the study start', 'trial', 'year', 'disease', '* current use', '* immunosuppressive diseases', 'the patient group', '18 and 65 years', 'treatment', 'progression', 'ability', 'group', 'pregnancy', '* age', 'inclusion', 'exclusion criteria', 'the 4 weeks', 'inclusion criteria', '* participation', 'cancer', 'the informed consent form', 'weeks', 'the study protocol', 'study', '* ability', 'immunosuppressants', 'bowel', 'months', 'intolerance', 'diabetes', 'any component', 'participation', 'healthy individuals', 'diagnosis', 'active cancer', 'control', 'metabolic', 'years', 'prebiotics', 'criteria', 'protocol', 'willingness', 'individuals', 'scheduled visits', 'disorders', 'drug', 'a diagnosis', 'no use', '* pregnancy', 'form', 'at least 1 year', 'another clinical trial', 'probiotics', 'start', 'visits', 'the control group', 'e.g., inflammatory bowel disease', 'exclusion', '* willingness']"
NCT06315725,Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients with Type 1 Diabetes (T1D),Type 1 Diabetes (T1D),"Inclusion Criteria:

* Participants with a diagnosis of T1D
* HbA1C ≤ 8 %
* Insulin pump therapy
* Adults of any gender or biological sex aged 18-45 years old,
* Body Mass Index (BMI) between 18.5-29.9 kg/m,
* Non-smokers,
* English or French speaker. ●. Who can consume chicken and fish

Exclusion Criteria:

* A major medical diagnosis that could potentially influence metabolic dysfunction
* A major medical diagnosis other than T1D,
* Alcohol or substance use disorder,
* Eating disorder or history of malabsorptive syndrome,
* Inflammatory bowel disease,
* Self-reported impairment in taste or smell,
* A known taste or smell dysfunction (e.g., anosmia),
* Active pregnancy and/or lactation,
* Food allergies or intolerances,
* Dislike of the test beverages,
* History of bariatric surgery at any point in the past ●. Regular consumer of Gymnema sylvestre",18,45,ALL,RECRUITING,"['a major medical diagnosis', '* insulin pump therapy', 'food', 'disease', 'consumer', 'body', 'dysfunction', '* self-reported impairment', 'sylvestre', 'lactation', 'diagnosis', 'years', 'food allergies', 'anosmia', 'the test beverages', 'any gender', 'insulin', 'gymnema', '8 %', 'self', '18.5-29.9 kg', 'inclusion', 'intolerances', 'allergies', 'history', 'bariatric surgery', 'that', 'substance', '●', 'biological sex', 'metabolic dysfunction', 'bmi', 'bowel', '* adults', 'impairment', '-', 'index', 'beverages', 'english or french speaker', 'taste', 'test', 'exclusion', 'participants', 'who', 'm', '* body mass index', 'dislike', 'gender', 'pregnancy', 't1d\n* hba1c ≤', 'inclusion criteria', 'gymnema sylvestre', 'therapy', 'syndrome', 'criteria', 'smell', 'mass', 'surgery', 'disorder', 'any point', 'alcohol', 'a known taste', 'regular consumer', 'non', 'adults', 'point', '* participants', '* dislike', 'pump', 'smokers', 'malabsorptive syndrome', 'inflammatory bowel disease', 'speaker', 'active pregnancy', 'a diagnosis', 'the past ●', 'chicken']"
NCT07270068,Remission of Diabetes With Lifestyle Intervention for Malaysian Patients,Type 2 Diabetes,"Inclusion Criteria:

1. Diagnosed diabetes for a duration of \< 3 years (diagnosis based on 2 recorded diagnostic-level tests, HbA1C and/or blood glucose)
2. Body mass index (BMI) \> 25 kg/m2
3. HbA1C level above \> 6.5% to 9% as per the last routine clinical check within 6 months
4. Currently being treated with one or more oral glucose lowering drugs

Exclusion Criteria:

1. Type 1 DM
2. Type 2 DM on basal or multiple insulin injections
3. Recent routine HbA1C of \> 9%
4. Patients who in the past 6 months have weight loss exceeding 5 kg (such individuals may have difficulty losing additional weight)
5. Recent (last 12 weeks) or current use of medications/meal replacements for weight loss
6. Alcoholism or any substance abuse
7. History of bariatric surgery, small bowel resection, or extensive bowel resection
8. Chronic treatment with systemic corticosteroids. Use of hormone replacement therapy or oral contraceptives will not lead to exclusion
9. Severe hypertension on multiple drugs tr",18,100,ALL,NOT_YET_RECRUITING,"['abuse', 'weight', 'oral contraceptives', 'hba1c level', 'multiple drugs', 'duration', 'body', 'recent (last 12 weeks', '\\', 'multiple insulin injections', 'bmi) \\> 25 kg/m2', 'injections', 'diabetes', 'replacement', 'use', 'diagnosis', 'years', 'insulin', 'extensive bowel resection', 'inclusion', '6 months', 'corticosteroids', '1. diagnosed diabetes', 'history', 'bariatric surgery', 'level', 'severe hypertension', 'substance', '2 dm', 'weeks', 'bowel', 'hypertension', 'tests', 'hormone replacement therapy', '5 kg', 'such individuals', 'individuals', 'index', 'exclusion', 'meal', 'weight loss', 'systemic corticosteroids', 'contraceptives', 'who', 'check', '9%', 'treatment', '3 years', 'difficulty', 'small bowel resection', 'resection', 'inclusion criteria', 'medications', 'therapy', 'alcoholism', 'criteria', 'surgery', 'any substance abuse', 'drugs\n\nexclusion criteria', 'basal', 'medications/meal replacements', 'additional weight', 'recent routine hba1c', 'hba1c and/or blood glucose', 'patients', 'type', '(diagnosis', 'chronic treatment', 'replacements', 'glucose', '2. body mass index', 'months', 'loss', '2 recorded diagnostic-level tests', 'the past 6 months', 'drugs', 'a duration', 'current use', 'hormone']"
NCT06578689,Factors and Consequences Associated With Diabetic Foot Problems Among Diabetic Patients in Jordan,Diabetic Foot,"Inclusion Criteria:

* Adults DM (1 year)

Have a mobile phone

Exclusion Criteria:

* Cognitive impairment",18,100,ALL,RECRUITING,"['1 year', 'adults', 'year', '* adults', 'phone', 'impairment', 'inclusion', 'criteria', '* cognitive impairment', 'inclusion criteria', 'exclusion']"
NCT07149610,Connected Care for Type 2 Diabetes Self-Management,Diabetes Type 2,"Inclusion Criteria:

* patients with T2DM (as confirmed by the physician's diagnosis);
* belonging to one of the 13 Diabetes Centres (CADs) of the Marche region in Italy (Pesaro, Urbino, Fano, Senigallia, Jesi, Fabriano, IRCCS-INRCA, Azienda Ospedaliera Universitaria delle Marche, Civitanova Marche, Macerata, Fermo, San Benedetto del Tronto e Ascoli Piceno);
* age \> = 18;
* resident in the Marche region;
* HbA1c \> 7 on most recent laboratory report within the last 3 months;
* no changes in diabetes medication in the previous 6 months;
* no prescription for any hypoglycaemic agent within the previous 4 weeks or taking a consistent dose of one or more oral hypoglycaemic agents for more than 12 weeks;
* owning smartphone/mobile phone with an internet connection;
* capable to consent;
* fulfilling and signing the informed consent;
* with self-reported competencies of communicating verbally in local language (corresponding to a level of Italian language knowledge =\>A2 of the CEFR levels)",18,100,ALL,RECRUITING,"['t2dm', 'self-reported competencies', 'more than 12 weeks', 'age', 'agent', 'italian language knowledge', 'prescription', 'fermo', 'competencies', 'the marche region', 'senigallia', 'dose', 'consent', 'level', 'patients', 'internet', 'piceno', 'region', 'any hypoglycaemic agent', 'civitanova marche', '* patients', 'an internet connection', 'resident', 'medication', 'no changes', 'cefr', 'pesaro', 'no prescription', 'changes', 'connection', 'language', 'levels', 'irccs', 'laboratory', 'mobile', 'the 13 diabetes centres', 'inclusion criteria', 'the last 3 months', 'the previous 4 weeks', 'a level', 'the cefr levels', 'months', 'weeks', 'macerata', 'smartphone/mobile phone', ""the physician's diagnosis"", 'physician', 'most recent laboratory report', 'diabetes', 'phone', 'a consistent dose', 'agents', 'diagnosis', 'centres', 'inrca', 'criteria', 'fabriano', 'local language', 'diabetes medication', 'knowledge', 'the informed consent', 'report', 'italy', 'cads', 'jesi', 'self', 'irccs-inrca', 'the previous 6 months', 'inclusion', 'ospedaliera', 'smartphone', 'fano']"
NCT06269120,"SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary",Type 2 Diabetes,"Inclusion Criteria:

* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
* The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/LAR and the treating physician based on local label before and independently from the decision to include the patient in this study.
* Male or female, adults above or equal to 18 years of age at the time of signing informed consent.
* Diagnosed with type 2 diabetes mellitus.
* Patient on metformin (Met) with or without modern oral antidiabetic (MOAD, that is Dipeptidyl Peptidase-4 Inhibitor \[DPP4i\] or/and Sodium-glucose cotransporter-2 Inhibitor \[SGLT2i\]) with or without insulin therapy.
* Available HbA1c value \> 7.0% within 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation vi",18,100,ALL,RECRUITING,"['visit', 'the treating physician', 'age', 'mellitus', 'relation', 'days', 'initiation', 'dipeptidyl peptidase-4 inhibitor \\[dpp4i\\', 'sodium', 'consent', '\\[sglt2i\\', 'type', 'that', 'inhibitor', 'recording', 'the patient/lar', '* available hba1c value', 'adults', 'cotransporter-2 inhibitor', '7.0%', 'glucose', 'commercially available oral semaglutide', 'treatment', 'the time', 'informed consent', 'activities', '18 years', '90 days', '* the decision', '* signed consent', 'any procedure', 'inclusion criteria', 'any study-related activities', 'therapy', 'study', 'data', 'patient', 'diabetes', 'physician', 'measurement', 'protocol', 'time', 'years', 'the decision', 'modern oral antidiabetic', 'sodium-glucose', 'this study', '(v1', 'criteria', 'study-related activities', 'the protocol', 'label', 'antidiabetic', 'local label', 'metformin', 'insulin therapy', 'hba1c measurement', 'insulin', 'semaglutide', 'procedure', 'inclusion', 'decision', 'value', 'moad', 'the patient']"
NCT06273631,Effect of Changes in Carbohydrate Intake Patterns on Glucose Control in Patients with Type 1 Diabetes,Type 1 Diabetes,"Inclusion Criteria:

1. Those who agree to participate in the study and sign informed consent;
2. Diagnosis of type 1 diabetes mellitus (ADA2024);
3. Age of 18\~70 years;
4. Dependent on exogenous insulin therapy, the treatment plan remains unchanged within 2 months (the type of insulin cannot be changed, and the dose can be adjusted according to plasma glucose);
5. Body mass index (BMI) of 18\~25kg/m2;
6. HbA1c ≤11%;

Exclusion Criteria:

1. Honeymooners with type 1 diabetes mellitus;
2. Women who are pregnant or plan to become pregnant;
3. Patients who are vegetarians or are undergoing weight loss;
4. Patients who are users of oral hypoglycemic drugs (alpha-glucosidase inhibitors, DPP-IV inhibitors, etc.);
5. Patients who are users of glucocorticoids within 30 days;
6. History of severe food allergy;
7. Patients with acute complications such as DKA or HHS within six months;
8. Patients with gastroparesis, inflammatory bowel disease and other complications;
9. Patients with large albu",18,100,ALL,RECRUITING,"['acute complications', 'weight loss', 'food', 'the type', '(ada2024', 'weight', 'history', 'mellitus', 'age', '2 months', 'hba1c ≤11%', 'days', 'dose', 'consent', 'glucosidase', 'dpp-iv inhibitors', 'patients', 'type', 'allergy', 'who', 'albu', 'inhibitors', 'dka', 'large albu', 'disease', 'other complications', 'glucose', 'honeymooners', 'women', 'informed consent', 'treatment', '18\\~70 years', 'the treatment plan', 'the study', 'body', '1. honeymooners', 'hhs', 'alpha', 'gastroparesis', 'inclusion criteria', 'alpha-glucosidase inhibitors', 'therapy', 'glucocorticoids', 'the dose', '5. body mass index', 'plasma glucose', 'bmi', 'study', 'months', 'bowel', 'loss', 'vegetarians', 'diabetes', 'plan', '30 days', 'inflammatory bowel disease', 'diagnosis', 'users', 'years', 'criteria', 'hba1c', 'exogenous insulin therapy', 'severe food allergy', 'index', 'drugs', 'insulin', 'type 1 diabetes mellitus', '18\\~25kg/m2', 'complications', 'inclusion', ';\n\nexclusion criteria', 'exclusion', 'six months', 'oral hypoglycemic drugs']"
NCT06426277,Effectiveness of the Brazilian Diabetes Prevention Program,Prediabetic State,"Inclusion Criteria

* Be 18 years or older (no maximum age for being eligible)
* Have a body mass index (BMI) between 25 and 34,9kg/m²
* Have, at least, one electronic device (includes any of the following devices):

  * Computer
  * Laptop/notebook
  * Tablet
  * Smartphone
* Have access to internet (broadband, 3G, 4G, 5G, among others) Without previous nutritional counseling (within the 6 months prior to recruitment/randomization/intervention) Without supervision by a Physical Education Professional (Personal Trainer) in the past 6 months
* Living near the research center (at maximum 60 minutes)
* Had a blood test result in the prediabetes range within the last three months prior to the recruitment/randomization/intervention (includes any of these tests and results):

  * Hemoglobin levels (HbA1c): 5.7-6.4%
  * Blood glucose 2 hours after an oral glucose tolerance: 140-199 mg/dL

Exclusion Criteria:

* Diagnosis of Diabetes Mellitus
* Underlying disease likely to limit life expectanc",18,100,ALL,RECRUITING,"['devices', 'device', 'mellitus', 'internet', 'an oral glucose tolerance', 'disease', 'expectanc', 'tablet', '140-199 mg/dl\n\nexclusion criteria', 'body', 'prediabetes', 'recruitment/randomization/intervention', 'blood glucose', 'the research center', 'g', 'diabetes', 'diagnosis', 'years', 'randomization', 'tolerance', 'inclusion', '34,9kg/m²', 'smartphone', 'intervention', 'center', 'computer', 'these tests', 'broadband', 'counseling', 'previous nutritional counseling', 'trainer', '18 years', 'bmi', 'a blood test result', 'life', 'tests', 'a body mass index', 'index', 'test', 'hemoglobin', 'exclusion', 'recruitment', 'notebook', '60 minutes', '*', '5.7-6.4%', 'the following devices', 'education', 'inclusion criteria', '(broadband', 'laptop', '* hemoglobin levels', 'criteria', 'mass', 'blood', '5g', '(no maximum age', 'result', 'the last three months', 'research', 'the prediabetes', 'life expectanc', 'glucose', 'any', 'levels', 'months', 'results', '3g', 'hours', 'the past 6 months', 'supervision', 'hba1c', 'the recruitment/randomization/intervention', 'access', 'the 6 months', 'minutes', 'one electronic device', 'others']"
NCT06488469,Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus,Type 1 Diabetes,"Inclusion Criteria:

* Children should be between 6-16 years of age.
* Children must be having Hypoglycemia Unawareness as documented by Continuous Glucose Monitoring. (Blood sugar \<70 mg/dl without symptoms)
* Children must be on treatment with Insulin for a minimum period of 6 months
* The care giver/parent must give written informed consent for the child and himself/herself and the child should give assent.

Exclusion Criteria:

* Children with known psychiatric disorders.
* Children who are on steroids and
* Children with documented Learning Disability from a certified psychologist.",6,16,ALL,NOT_YET_RECRUITING,"['mg', 'sugar', '/', '\\<70', 'age', 'disability', 'a certified psychologist', 'dl', 'assent', 'steroids', 'consent', 'who', 'hypoglycemia', 'between 6-16 years', 'known psychiatric disorders', 'the child', 'glucose', 'treatment', 'informed consent', 'psychologist', 'learning', 'period', 'hypoglycemia unawareness', 'exclusion criteria', 'inclusion criteria', 'parent', 'the care giver/parent', 'continuous glucose monitoring', 'symptoms', 'a minimum period', 'months', '* children', 'unawareness', 'herself', 'care', 'child', 'years', 'criteria', 'monitoring', 'blood sugar \\<70', 'documented learning disability', 'himself', 'blood', 'children', 'disorders', 'insulin', 'inclusion', 'exclusion', '6 months']"
NCT04257565,Wheeling to Healing: A Novel Method for Improving Healing of Diabetic Foot Ulceration,Diabetes Mellitus,"Inclusion Criteria:

* ≥ 18 years old
* currently under physician care for a DFU of one foot
* willing and able to sign informed consent
* cognitively functional
* have access to a telephone
* weigh no more than 300lbs as this is the weight limitation of the wheeled knee walker
* have at least one palpable foot pulse
* have a neuropathic plantar DFU corresponding to grade 1A (superficial, not extending to tendon, capsule, or bone) using the University of Texas Diabetic Foot Wound Classification System

Exclusion Criteria:

* coronary or cerebrovascular disease events within the past six months
* uncontrolled, severe medical conditions that place the subject at high risk for adverse events, including but not limited to severe congestive heart failure, angina pectoris, obstructive pulmonary disease
* uncontrolled neurologic or psychiatric disorders
* active infection
* significant ulcers or infections of both lower limbs
* those who have been wheelchair dependent prior to ulcer formation",18,100,ALL,RECRUITING,"['high risk', 'the weight limitation', 'limbs', 'a neuropathic plantar dfu', 'formation', 'weight', 'a dfu', 'a telephone', 'physician care', 'conditions', 'subject', 'consent', 'that', 'who', 'classification', 'severe congestive heart failure', '*', 'disease', 'obstructive pulmonary disease', 'both lower limbs', 'plantar', 'limitation', 'informed consent', 'the wheeled knee walker', 'cognitively functional\n*', 'events', 'infection', 'inclusion', 'inclusion criteria', 'system', 'months', 'telephone', 'those', 'the past six months', 'knee', 'texas diabetic foot', 'one foot', 'physician', 'failure', 'care', 'the subject', 'heart', 'wheelchair', 'years', 'adverse events', 'the university', 'criteria', 'pulse', 'infections', 'access', 'this', 'disorders', '≥', '1a', 'walker', 'ulcers', 'risk', 'foot', 'angina pectoris', 'bone', 'exclusion', 'to ulcer formation']"
NCT06856954,The Skin Barrier in Users of Diabetes Devices,Type 1 Diabetes Mellitus,"Inclusion Criteria:

* diagnosed with type 1 diabetes
* using diabetes device attached to the skin (insulin pump or CGM)

Exclusion Criteria:

* Do not use diabetes device attached to the skin.
* Those unable to read and understand Swedish or English
* impaired cognitive development that may interfere with the ability to answer questionnaires in Swedish/English and/or be reached by phone.",18,100,ALL,RECRUITING,"['the skin', 'skin', 'development', 'device', 'type', 'that', 'swedish/english', 'questionnaires', 'ability', 'pump', 'diabetes device', 'inclusion criteria', 'cgm', 'those', 'diabetes', 'phone', 'criteria', 'insulin', 'english', 'inclusion', 'the ability', 'exclusion', 'insulin pump']"
NCT06598345,Impact of Integrated Pet Care on Glycemic Control and Diabetes Responsibility,Type 1 Diabetes Mellitis,"Inclusion Criteria:

* age 10-13 years (inclusive)
* diagnosis of T1DM for at least one year
* fluency in English or Spanish, (d) recent HbA1c value 7.5% - 14%
* utilization of a CGM or glucometer that links with software to enable viewing and documentation in daily report including a section to enter ""notes"" (i.e. CGM/software, Dexcom/Clarity; Freestyle Libre/LibreView; AccuChek,OneTouch (glucometers)/MySugr)
* current pet fish at home or willingness to obtain a pet fish if randomized to that intervention.

Exclusion Criteria:

* clinical or laboratory characteristics suggestive of type 2 DM
* involvement in foster care
* dual-home living situation
* severe psychiatric disorders
* developmental delay or cognitive impairment that make it difficult to establish consistent diabetes and pet care behaviors
* current participation in another study that may impact glycemic control
* HbA1c \>14% (because these individuals may need a more intensive intervention than this is intended to provide",10,13,ALL,ENROLLING_BY_INVITATION,"['glucometers)/mysugr', 'age', '2 dm\n* involvement', 'daily report', '""notes', 'dexcom', 'exclusion criteria', 'pet care behaviors', '14%', '(i.e. cgm/software, dexcom/clarity', 'diabetes', 'diagnosis', 'delay', 'years', 'glucometer', 'willingness', 'libre', 'onetouch', 'report', '(d) recent hba1c value', 'inclusion', 'current participation', 'intervention', 'a section', 'another study', 'that', 'that intervention', 'clarity', 'software', 'home', 'libreview', '* severe psychiatric disorders', 'impairment', 'care', 'glycemic control', 'individuals', 'these individuals', 'accuchek', 'value', 'exclusion', 'situation', 'suggestive', 'developmental delay', '* utilization', '* diagnosis', 'cognitive impairment', 'consistent diabetes', 'inclusion criteria', 'it', 'study', 'a pet fish', 'participation', 'criteria', 'freestyle', 'involvement', 'disorders', 'this', 'living', 'english', 'a more intensive intervention', 'freestyle libre/libreview', 'section', 'notes', 'type', 'a cgm', 'year', 'laboratory', '10-13 years', 'behaviors', 't1dm', 'control', 'hba1c', 'fish', 'fluency', 'characteristics', 'utilization', 'documentation']"
NCT06865456,Predictors of Survival of DKD Patients in Assiut University Hospital,Chronic Kidney Disease(CKD),"Inclusion Criteria:

* ● Patients age \> 18 years old

  * Both sex
  * diabetic patients with HbA1c level \>6.5( Type 1 and 2)
  * Diabetic patients with CKD 4, 5 )
  * HD Pt

Exclusion Criteria:

* ● Chronic kidney diseases stage 1,2, and 3.

  * Acute kidney injury.
  * Patients with any other causes of CKD autoimmune disease",18,100,ALL,NOT_YET_RECRUITING,"['* acute kidney injury', 'diabetic patients', 'diseases', 'kidney', 'level', 'patients', 'type', 'disease', '* patients', 'any other causes', 'ckd', 'autoimmune disease', 'inclusion criteria', '\\', 'injury', '● patients', 'years', 'criteria', 'causes', 'inclusion', '\\>6.5', 'exclusion']"
NCT07172672,The TiMeD-T1D Project,Postprandial Lipid Metabolism,"Inclusion Criteria:

* Type 1 diabetes duration \> 3 years or c-peptide negative
* Written and informed consent

Exclusion Criteria:

* Medicine with an impact on blood glucose or blood pressure
* Affected screening blood sample as evaluated by the clinical responsible investigator.
* Alcohol or substance abuse
* BMI \> 35 kg/m2 or \< 18.5 kg/m2
* Participation in other clinical trials involving ionized radiation within the last 6 months
* Lactose intolerance
* Doesn't speak and understand Danish.
* Severe claustrophobia.
* Commitment to special diets",18,100,ALL,NOT_YET_RECRUITING,"['impact', 'abuse', 'an impact', 'consent', 'alcohol', 'type', '* commitment', '*', 'substance', 'peptide', 'trials', 'glucose', '* medicine', 'duration', 'diets', 'other clinical trials', 'blood pressure', 'blood glucose', 'inclusion criteria', 'the last 6 months', 'radiation', 'bmi', 'special diets', 'months', 'investigator', 'lactose', 'intolerance', 'participation', 'sample', 'pressure', 'commitment', 'years', 'criteria', 'blood', '* severe claustrophobia', 'ionized radiation', '35 kg', '/m2', 'medicine', '* lactose intolerance', 'danish', 'inclusion', 'the clinical responsible investigator', 'exclusion']"
NCT07278531,Adaptive Dietary Intervention (ADI) for Asian Americans With Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

* Eligible participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans)
* Community-dwelling adults aged ≥ 18 with independent living;
* Diagnosed with T2D;
* Hb1Ac\>7.0%
* Self-identified as first- or second-generation Chinese or Vietnamese immigrants;
* Able to communicate in English, Chinese, or Vietnamese. We will focus on Mandarin-, Cantonese- or English-speaking Chinese Americans because the two best-known and most-spoken variants of Chinese are Mandarin and Cantonese, who use the same writing system;
* Have a smartphone, iPad, tablet, or Apple watch

Exclusion Criteria:

* Taking hypoglycemia agents (e.g., insulin and sulfonylureas) with the major side effect of hypoglycemia that need close monitoring the occurrence of hypoglycemia to adjust/reduce medications to avoid future hypoglycemia.
* Taking medications that impede weight loss (e.g., prednisone) within the last 3 months.
* Currently pregnant, breastfeeding, or contemplating pregnancy within ",18,100,ALL,NOT_YET_RECRUITING,"['writing', 'participants', 'weight loss', '60 chinese americans', 'apple', 'generation', 'weight', 'a smartphone, ipad', '60 vietnamese americans', 'sulfonylureas', 'that', 'who', 'hypoglycemia', 'adults', '(e.g., insulin', 'the occurrence', 'tablet', 'the same writing system', '* community-dwelling adults', 'chinese', 'pregnancy', 'side', 'we', 'inclusion', 'community', 'variants', 'immigrants', 'the major side effect', 'inclusion criteria', 'system', 'ipad', 'medications', 'the last 3 months', 'months', 'loss', 'effect', 'eligible participants', 'future hypoglycemia', 'hypoglycemia agents', 'agents', 'cantonese-', 'criteria', 'n=120', 'english-speaking chinese americans', 'insulin', 'living', 'self', 'english', 'independent living', 'apple watch\n\nexclusion criteria', ', prednisone', 'occurrence', 'exclusion']"
NCT06918977,Improving Glycemic Control With Telemedicine and Smart Insulin Pens,Diabetes Mellitus,"Inclusion Criteria:

* ≥18 years of age
* MDI insulin treated (receiving MDI for at least 3 months prior to the study)

Exclusion Criteria:

* DM patients not treated with MDI for at least 3 months (i.e diet only, any combination of non-insulin antidiabetic drugs only, basal insulin only or bolus/short acting insulin only)
* Patients with DM at the time of screening on insulin pumps
* Pregnant patients
* Patients with extensive skin disease or allergies that preclude wearing the CGM sensor
* Patients who have end-stage renal disease requiring dialysis
* Patients with significant psychiatric illness or any other condition rendering the subject incapable of understanding the objectives and potential consequences of the study
* Patients who receive hydroxyurea or who are on long (chronic) treatment with acetaminophen
* Patients who were started on non-insulin DM medications or had a dose change within 60 days or less prior to study participation
* Patient does not have or not able to gain",18,100,ALL,RECRUITING,"['non-insulin dm medications', 'mdi insulin', 'allergies', 'illness', 'skin', 'condition', 'age', 'screening', 'mdi', 'days', 'stage', 'subject', 'combination', 'dose', 'patients', '≥18 years', 'that', 'who', 'bolus', 'pumps', 'participation\n* patient', 'disease', '* patients', 'significant psychiatric illness', 'the time', 'treatment', 'diet', 'hydroxyurea', 'any other condition', 'dialysis', 'the study', 'end-stage renal disease', 'inclusion', 'a dose change', 'potential consequences', 'inclusion criteria', '60 days', 'medications', 'at least 3 months', 'the objectives', 'months', 'study', 'non-insulin antidiabetic drugs', 'patient', 'consequences', 'participation', 'any combination', 'the subject', 'pregnant patients', 'the study\n* patients', 'dm patients', 'acetaminophen\n* patients', 'years', 'dialysis\n* patients', 'criteria', 'time', 'objectives', 'dm', ')\n\nexclusion criteria', 'change', 'basal insulin', 'drugs', 'insulin', 'sensor', 'the cgm sensor', 'long (chronic) treatment', 'extensive skin disease', 'basal', 'exclusion', 'insulin pumps']"
NCT04934228,Mitigating the Pro-inflammatory Phenotype of Obesity,Blood Pressure,"Inclusion Criteria:

* Male or Female, age 18-79
* Obese: BMI \> 30 m/kg2
* Hypertensive: blood pressure \>130/80
* Elevated insulin resistance (HOMA-IR \> 2.5)
* Waist circ: \>102 cm (men) and \>88 cm (women)
* Fasting glucose \< 126 mg/dL
* Fasting triglycerides \< 250 mg/dL
* HbA1c \< 6.5%
* Willing to visit research lab (Fairway CTSU)
* Willing to undergo a blood draw
* Able to provide written informed consent

Exclusion Criteria:

* Current use of clonidine or beta-blockers
* Current smoker or History of smoking in the past 3 months.
* Hyperlipidemia: Fasting triglycerides \> 250 mg/dL
* Currently taking hypertension medication
* History of heart disease (e.g., myocardial infarction, stent, byass, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)
* History of neurological disorders
* History of transplant
* Actively participating in other studies, except for a registry study.",18,79,ALL,RECRUITING,"['infarction', 'the past 3 months', 'beta-blockers', 'history', 'age', 'resistance', 'research', 'dl', '\\>130/80', 'waist', 'stent', 'consent', 'studies', 'registry', '\\>88 cm', 'hypertensive', 'neurological disorders', 'homa', 'disease', '* current use', 'glucose', 'medication', 'women', 'blockers', 'hypertension medication', 'hyperlipidemia', '* history', 'transplant', 'stroke', 'kg2', '\\', 'inclusion criteria', 'months', 'study', 'hypertension', '6.5%', 'failure', 'triglycerides', 'heart', 'beta', 'heart disease', 'pressure', 'other studies', 'men', '* hyperlipidemia', 'clonidine', 'criteria', '-79\n* obese', 'research lab', 'blood', 'disorders', 'elevated insulin resistance', 'a registry study', 'smoker', 'insulin', '\\>102 cm', 'current smoker', 'attack', 'byass', 'inclusion', 'smoking', 'exclusion', '* waist circ']"
NCT05501483,Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

* Signed informed consent
* BMI 25 kg/m2 or higher
* HbA1c 42 mmol/mol or higher
* For fertile women, effective contraception

Exclusion Criteria:

* HbA1c 65 mmol/mol or higher
* Established cardiovascular disease and/or heart failure
* Severe psychiatric condition
* Active alcoholism
* Insulin treatment
* Anticoagulant therapy (vitamin K antagonists or equivalent)
* Pregnancy, lactation
* Positive GAD or IA2 antibodies
* Low C-peptide/glucose ratio (less than 2 measured as pmol/mg per dL)
* NT-proBNP above the upper normal reference value
* Kidney disease
* Liver disease or hepatic values over twice the upper reference value
* Severe concomitant disease including ongoing cancer",18,100,ALL,RECRUITING,"['anticoagulant', 'hepatic values', 'condition', 'effective contraception\n\nexclusion criteria', 'ratio', 'kidney', 'consent', '25 kg/m2', 'disease', 'peptide', '* severe concomitant disease', 'glucose', 'women', 'treatment', 'ia2 antibodies', 'antagonists', '* severe psychiatric condition', 'vitamin k antagonists', 'pregnancy', 'probnp', 'peptide/glucose', 'inclusion', 'ongoing cancer', 'cancer', 'inclusion criteria', 'vitamin', 'therapy', '* positive gad', 'liver', 'lactation', 'alcoholism', 'failure', 'reference', 'heart', 'contraception', 'hba1c', 'criteria', 'the upper reference value', '* pregnancy', 'nt-probnp', 'fertile women', 'insulin', 'informed consent\n* bmi', '65 mmol/mol', '* anticoagulant therapy', 'antibodies', 'pmol/mg', 'value', 'exclusion', 'values']"
NCT06519942,Muscle and Bone in Patients with Diabetes Mellitus and Neuropathy,"Diabetes Mellitus, Type 2","Inclusion Criteria:

All participants:

* Between 40-70 years of age
* BMI between 18,5 - 35 kg/m2

Persons with T2DM:

* More than 10-year clinical diagnosis of T2DM

Exclusion Criteria:

All participants:

* Possible other causes of nerve impairment (vitamin B12 deficiency, excessive alcohol consumption, chemotherapy)
* Immobilisation (1) \> 3 months in past history or (2) \> 4 weeks in past 6 months
* Chronic conditions affecting the vital organs (New York Heart Association (NYHA) 3/4, Global Initiative for Obstructive Lung Disease (GOLD) 3/4, cystic fibrosis)
* Hypogonadism
* Inflammatory joint or intestinal diseases
* Chronic muscle diseases
* Active malignancy
* Malnutrition disease, eating disorder or bariatric surgery
* Medication use (anticoagulants, glucocorticoids, anti-androgen or anti-estrogen treatment) persons with T2DM:
* Insufficient control of diabetes (HbA1c \>9%)

Healthy controls:

* Fasting glucose \> 100 mg/dl
* HbA1c \> 5.7 %",40,70,ALL,RECRUITING,"['participants', 'age\n* bmi', 'immobilisation', 'fibrosis', 'malignancy', 'deficiency', 't2dm\n\nexclusion criteria', 'history', 'nerve', 'insufficient control', 'diseases', 'vitamin b12 deficiency', 'dl', 'conditions', 'cystic fibrosis', 'alcohol', 'chronic conditions', '> 5.7 %', 'malnutrition', 'chemotherapy', 'year', 'disease', 'controls', 'medication', 'glucose', 'lung', 'consumption', 'treatment', '3 months', 'gold', '\\>9%', '100 mg', 'anticoagulants', 'hypogonadism', 'inclusion criteria', 'obstructive lung disease', 'vitamin', 'initiative', 'glucocorticoids', 'months', 'weeks', '* chronic muscle diseases', 'the vital organs', 'past history', 'diabetes', 'all participants', 'impairment', 'persons', 'glucose \\', 'diagnosis', 'new york heart association', 'nerve impairment', 'control', 'years', 'hba1c', 'criteria', 'organs', 'dm', 'surgery', 'nyha', 'causes', 'muscle', 'disorder', '* between 40-70 years', 'healthy controls', 't2', 'inclusion', 'exclusion', 'global initiative', '6 months', 'possible other causes']"
NCT07403669,Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment,Acute MI,"Inclusion Criteria:

* Men and women over 18 years of age are included
* Eligible subjects must have one of the risk factor/ disease component of CKM:
* Diabetes with A1C of 7.5 or higher;
* or Heart disease with stent placement;
* or Coronary Artery Bypass Graft (CABG) in the last 12 months;
* or Chronic Kidney Disease (CKD) stage 2- 4
* and, in those with Heart failure, a recent hospitalization within one week of enrollment is required

Exclusion Criteria:

* Those subjects who are not willing to sign an informed consent",2,4,ALL,RECRUITING,"['component', 'age', 'stent placement', 'kidney', 'those subjects', 'stage', 'consent', 'eligible subjects', 'who', 'week', 'one week', 'disease', 'enrollment', 'artery', 'women', 'an informed consent', 'the last 12 months', 'ckd', 'inclusion', 'exclusion criteria', '* men', 'cabg', 'inclusion criteria', 'over 18 years', 'subjects', 'months', 'those', 'graft', 'placement', 'failure', 'heart', 'years', 'criteria', 'bypass', 'a recent hospitalization', 'risk', 'a1c', 'ckm', 'heart failure', 'artery bypass graft', 'hospitalization', 'exclusion', 'stent']"
NCT05835037,Effect of Zinc on Glucose Homeostasis,Prediabetic State,"Inclusion Criteria:

* Amish men or women who are 18 to 80 years old
* Prediabetes (HgbA1c = 5.7-6.4% or fasting glucose levels 100-125 mg/dL)

Exclusion Criteria:

* Pregnant
* Currently breastfeeding
* History of severe gastrointestinal disorders or upper gastrointestinal surgery
* Has hemochromatosis, cancer, liver disease, kidney disease, cardiovascular disease, or other coexisting malignancy
* Hemoglobin \< 12.5 g/dl (male) or \< 11 g/dl (female)
* Severe hypertension (blood pressure \> 160/95 mm Hg)
* Has a creatinine greater than 2.0 mg/dl, aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 2 times the upper limit of normal, hematocrit (Hct) less than 32%, or thyroid-stimulating hormone (TSH) less than 0.4 or greater than 5.5 milli-international units (mIU) per liter.
* At the discretion of the study physician or PI, taking medications that affect the outcomes of the study including, but not limited to, corticosteroids, anti-psychotic agents, protease in",18,80,ALL,RECRUITING,"['transaminase', 'disease', '11 g', '* severe hypertension', 'anti-psychotic agents', 'the study', ', aspartate aminotransferase', 'prediabetes', 'the outcomes', 'physician', 'years', 'hg', 'thyroid', 'alanine transaminase', '5.5 milli-international units', 'inclusion', 'corticosteroids', 'hgba1c', 'malignancy', 'units', 'history', 'kidney disease', 'creatinine', 'that', 'limit', 'a creatinine', 'women', '2.0 mg', 'outcomes', 'hemochromatosis', 'blood pressure', 'severe gastrointestinal disorders', 'hypertension', 'hct', 'fasting glucose levels', 'discretion', 'hemoglobin', 'exclusion', 'female', 'miu', 'pi', 'times', 'kidney', 'dl', 'the discretion', 'cardiovascular disease', 'who', '*', 'the study physician', '12.5 g/dl (male', 'cancer', 'inclusion criteria', 'medications', 'study', '-6.4%', 'agents', 'criteria', 'blood', 'surgery', 'other coexisting malignancy', 'ast', 'disorders', 'aspartate', 'alanine', 'alt', 'glucose', 'levels', '* amish men', 'liter', 'liver disease', 'liver', 'pressure', 'protease', 'male', 'tsh', 'hormone', 'upper gastrointestinal surgery']"
NCT07169422,Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care,Diabetic Kidney Disease,"Inclusion Criteria:

* Adults ≥18 years with T2D and DKD (eGFR≥ 30-60 ml/min/1.73m2 and/or UACR≥3 mg/mmol)
* Adults who do not have primary care provider,
* Adults who are eligible for initiation of treatment with RASi, SGLT2i or nsMRA

Exclusion Criteria:

* Hypotension
* Type 1 diabetes
* History of allergy or intolerance to either, renin angiotensin system inhibitor (RASi), SGLT2 inhibitor (SGLT2i) and nonsteroidal mineralocorticoid receptor antagonist (nsMRA).
* Already receiving all three medications: RASi, SGLT2i, and nsMRA .
* Exceed algorithm thresholds for potassium levels or eGFR less than 30 mL/min/1.73m²
* Limited life expectancy of less than 1 year
* Followed by a subspecialty physician (e.g., nephrologist or endocrinologist)
* Unable to give consent",18,100,ALL,NOT_YET_RECRUITING,"['history', 'initiation', 'consent', 'allergy', 'type', 'who', 'ml', 'inhibitor', 'sglt2', 'adults', 'year', 'a subspecialty physician', 'treatment', 'levels', 'mineralocorticoid receptor antagonist', 'potassium levels', 'dkd', 'inclusion criteria', 'system', 'potassium', 'medications', 'angiotensin', 'intolerance', '* adults', 'diabetes', 'life', 'physician', 'care', 'sglt2i', 'nsmra', 'years', 'criteria', 'provider', 'antagonist', 'uacr≥3 mg/mmol)\n* adults', 'hypotension', 'primary care provider', 'algorithm thresholds', 'receptor', 'rasi', 'subspecialty', 'sglt2 inhibitor', 'thresholds', 'less than 1 year', 'all three medications', 'inclusion', 'exclusion', 'expectancy']"
NCT07254572,Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes,Coronary Artery Disease,"Inclusion Criteria:

* Age 18 - 80
* Diagnosed coronary artery disease (coronary artery stenosis of at least 20% with a reference diameter of \>2.5 mm or status after percutaneous coronary revascularization procedure found on coronary CT scan)
* Coronary CT scan performed \<3 months after inclusion in the study, at least of good quality
* Pre-diabetic status defined as fasting blood glucose 100-125 mg% or Hba1c 5.70-6.49% (measurement documented at the screening/randomization appointment or within 30 days prior to the screening/randomization appointment) or documented, positive result of an oral glucose load test (fasting blood glucose 100-125 mg% and 140-199 mg% 2h after a 75 g oral glucose load) performed up to 30 days before the screening/randomization appointment
* Stable treatment and control of cardiovascular risk factors, including dietary and lifestyle management for at least 4 weeks
* Willing and able to give informed consent to participate in the study
* Willing and able, acc",18,80,ALL,RECRUITING,"['age', 'coronary artery stenosis', 'percutaneous coronary revascularization procedure', 'stable treatment', 'screening', 'days', 'quality', 'consent', 'status', 'result', 'disease', 'artery', 'glucose', 'treatment', 'informed consent', 'cardiovascular risk factors', 'diameter', '\\>2.5 mm', 'factors', 'the study', '100-125 mg%', 'at least 4 weeks', 'blood glucose', 'inclusion criteria', 'months', ', positive result', 'study', 'management', 'weeks', '6.49%', 'reference', 'measurement', '\\<3 months', '30 days', 'a reference diameter', 'coronary ct scan', 'control', 'appointment', 'hba1c', 'criteria', 'blood', 'stenosis', 'randomization', 'load', 'risk', '140-199 mg%', 'test', 'procedure', 'revascularization', 'the screening/randomization appointment', 'at least 20%', 'inclusion', 'lifestyle', 'dietary and lifestyle management']"
NCT06422975,Registry of Patients in Shock Treated With Vasopressin,Vasopressin Causing Adverse Effects in Therapeutic Use,"Inclusion Criteria:

* Any patient over 18 years of age who is in shock and requires the administration of vasoconstrictors, to whom vasopressin is administered in the operating theatre and/or critical care unit, according to best clinical practice.

Exclusion Criteria:

* Non-consent by patient/legal representatives",18,100,ALL,RECRUITING,"['whom', 'age', 'administration', 'practice', 'vasoconstrictors', 'theatre', 'patient/legal representatives', 'who', 'shock', 'vasopressin', '18 years', 'exclusion criteria', 'inclusion criteria', 'patient', 'care', 'the administration', 'unit', 'years', 'criteria', 'any patient', 'best clinical practice', 'representatives', 'inclusion', 'exclusion']"
NCT06338072,Impact of the Menstrual Cycle in Reproductive Aged Women With Type 1 Diabetes Using a Closed Loop System (DIABETEXX/1).,Type 1 Diabetes,"Inclusion Criteria:

* Diagnostic criteria for DM1 according to ADA
* Women and men treated with the Medtronic© MinimedTM 780G advanced closed loop system.
* Women presenting spontaneous regular menstrual cycles with a duration of 24 to 35 days, during the last year.
* Men under 50 years old.
* Acceptance of participation in the study and signing of the informed consent

Exclusion Criteria:

* Gestation
* Use of hormonal contraceptives (including intrauterine devices)
* Institutionalization, serious or terminal illness or renal replacement therapy.
* Refusal to participate in the study or to sign the informed consent",18,100,ALL,RECRUITING,"['illness', 'loop', 'devices', 'days', 'consent', 'contraceptives', '24 to 35 days', 'year', 'acceptance', 'dm1', 'women', 'duration', 'the study', 'serious or terminal illness', '* men', 'inclusion criteria', 'spontaneous regular menstrual cycles', 'system', 'therapy', 'study', 'the medtronic©', 'participation', '* refusal', 'replacement', 'refusal', 'cycles', '* diagnostic criteria', 'intrauterine devices', '* gestation\n* use', 'ada\n* women', '* acceptance', 'men', 'criteria', 'years', '* women', 'the informed consent', 'signing', 'gestation', 'institutionalization', 'the last year', 'a duration', 'hormonal contraceptives', 'renal replacement therapy', 'inclusion', 'exclusion']"
NCT05795439,The CARING Study: Creating and Restoring Health Through Nutrition Guidance,Type2diabetes,"Inclusion Criteria:

1. Blue Cross Blue Shield subscriber continuously enrolled for the prior 12 months
2. Male or female
3. Age at least 18 years
4. Have a diagnosis of type 2 diabetes
5. Ability and willingness to participate in all components of the study, including:

   1. Following a plant-based diet for the initial 16 weeks of the study;
   2. Attending weekly online classes for the initial 16 weeks of the study; and
   3. Keeping physical activity level consistent throughout the initial 16 weeks of the study.

Exclusion Criteria:

1. Diabetes mellitus type 1 or history of any endocrine condition that would affect body weight, such as a pituitary abnormality or Cushing's syndrome
2. Smoking during the past six months
3. Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use
4. Current or unresolved past drug abuse
5. Rec",18,100,ALL,RECRUITING,"['abuse', 'condition', 'weight', 'history', 'at least 18 years', 'a plant-based diet', 'weekly online classes', 'alcohol consumption', 'a pituitary abnormality', 'plant', 'level', 'more than 2 drinks', 'alcohol', 'type', 'that', 'consumption', 'a history', 'physical activity level', 'weekends', 'any current use', 'dependency', 'diet', 'the initial 16 weeks', 'abnormality', 'alcohol abuse', 'any endocrine condition', 'the study', 'ability', 'body weight', 'components', 'body', 'exclusion criteria', 'inclusion criteria', 'drinks', 'months', 'all components', 'study', 'weeks', 'syndrome', 'the past six months', 'diabetes', 'day', 'diagnosis', 'classes', 'years', 'criteria', 'the prior 12 months', 'willingness', 'cushing', 'subscriber', 'drug', 'a diagnosis', 'inclusion', 'endocrine', 'exclusion', 'drinking', 'activity', 'female']"
NCT05188014,Exercise and the Menstrual Cycle in Type 1 Diabetes,Type 1 Diabetes,"Inclusion Criteria:

* type 1 diabetes diagnosed for at least 1 year
* regular menses
* using monophasic oral contraceptives
* residing in Edmonton, Alberta and able to visit the lab at the University of Alberta

Exclusion Criteria:

* HbA1c \> 9.9%
* frequent and unpredictable hypoglycemia
* change in insulin management strategy within two months of the study
* use of an automated insulin delivery system
* blood pressure \> 140/95
* history of cardiovascular disease
* severe peripheral neuropathy
* active proliferative retinopathy
* use of medications (other than insulin) that would affect blood glucose levels
* any musculoskeletal condition that would contraindicate exercise (e.g. sprain, strain, joint injury, etc.)",18,100,FEMALE,RECRUITING,"['condition', 'history', 'delivery', 'blood glucose levels', '140/95\n* history', 'type', 'that', 'contraceptives', 'hypoglycemia', 'year', 'any musculoskeletal condition', 'strain', 'two months', 'monophasic oral contraceptives', 'menses', 'disease', 'glucose', '* use', 'levels', 'the study', 'edmonton', 'blood pressure', 'inclusion criteria', 'system', 'alberta\n\nexclusion criteria', 'medications', 'exercise', 'alberta', 'months', 'study', 'management', 'insulin management strategy', 'diabetes', '* type 1 diabetes', 'injury', 'pressure', 'change', 'criteria', 'the university', 'blood', 'joint injury', '9.9%', 'at least 1 year', 'insulin', 'inclusion', 'regular menses', 'strategy', 'exclusion', 'the lab']"
NCT07270016,Pilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes,"Diabetes Mellitus, Type 2","Inclusion criteria:

* Ages 16-24 years, any sex or gender
* Diagnosis of type 2 diabetes in childhood (younger than 18 years of age)
* English-speaking (app in English)
* Possession of personal smartphone that is compatible with FreeStyle Libre app

Exclusion Criteria:

• Cognitive impairment or severe psychiatric conditions that could interfere with participation in behavioral intervention for diabetes self-management",16,24,ALL,NOT_YET_RECRUITING,"['any sex', 'age', '16-24 years', '* ages', 'conditions', 'type', 'that', 'younger than 18 years', ')\n* possession', 'severe psychiatric conditions', 'childhood', 'self-management', 'gender', 'possession', 'inclusion criteria', '• cognitive impairment', 'management', 'diabetes', 'impairment', 'participation', '* english-speaking (app', 'diagnosis', 'years', 'criteria', 'freestyle', 'behavioral intervention', 'personal smartphone', 'self', 'english', 'inclusion', 'exclusion', 'smartphone', 'ages', 'intervention']"
NCT06694558,Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease,Chronic Kidney Disease(CKD),"Inclusion Criteria:

1. T1D CKD subjects:

   1. Adults, males or females diagnosed with T1D
   2. Age 18-65 years
   3. Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2)
   4. Diagnosed with albuminuria (UACR 30-500 mg/g)
   5. On insulin injections or pump
   6. On CGM

   Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0
2. Controls: T1D subjects without CKD

   1. Adults, males or females diagnosed with T1D
   2. Age 18-65 years
   3. No CKD (eGFR \>90 ml/min/1.73 m2)
   4. No albuminuria (UACR \<30 mg/g)
   5. On insulin injections or pump
   6. On CGM

Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0

Exclusion Criteria:

1. Hemoglobin \<9
2. On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors ",18,65,ALL,RECRUITING,"['tir\\>70%', 'metrics', 'age', '-90 ml/min/1.73 m2', 'sodium', 'the investigators', '30-500 mg', 'females', 'egfr \\>90 ml/min/1.73 m2', 'inhibitor', 'albuminuria', 'a1c 5.0-7.0\n\nexclusion criteria', 'inhibitors', 'adults', '/g', 'controls', 'dpp4 inhibitor', 'glucose', 'egfr', '-transporter-2 inhibitors', '\\<30', 'insulin injections', 'group', 'co', 'ckd', 'agonist', 'subjects', 'males', '18-65 years', 'cgm', 'g', 'tir\\<60%', '1. hemoglobin \\<9', 'injections', 'tir\\<60', 'ckd subjects', 'groups', 'years', 'criteria', 'sodium-glucose', 'transporter-2', 'investigators', 't1d', 'baseline cgm metrics', 'insulin', 'no ckd', '2 groups group', 'a (lower tir group', 'inclusion', 'hemoglobin', 'exclusion', 't1d subjects']"
NCT07185555,Vey Low-Energy Ketogenic Therapy in Adults With Type 1 Diabetes and Obesity on Intensive Insulin Therapy Using Advanded Hybrid Closed Loop System,Type 1 Diabetes (T1D),"Inclusion Criteria:

Age ≥ 18 years

Diagnosis of type 1 diabetes or autoimmune diabetes for ≥ 12 months

BMI ≥ 30 kg/m²

HbA1c \< 9%

Knowledge and use of carbohydrate counting

Use of an Advanced Hybrid Closed Loop (AHCL) system for ≥ 3 months and willingness to maintain it during the study

At least 1 diabetology follow-up visit in the last 12 months (including telemedicine)

Willingness to purchase meal replacements for the entire study duration

Exclusion Criteria:

Ketoacidosis, severe hypoglycemia with seizures/coma, or severe hyperglycemia requiring hospitalization in the last 6 months

Febrile illness within the last 2 weeks

Dietary restrictions or intolerances incompatible with study food supplies

Celiac disease, gastroparesis, food allergies

Intense physical exercise \>2 hours on \>3 days per week

History or risk of eating disorder, or other psychiatric disorders

Recreational drug use or excessive alcohol consumption

Chronic kidney disease (eGFR \<60 ml/min)

Gallstone",18,100,ALL,RECRUITING,"['visit', 'intolerances', 'seizures', 'illness', 'food', 'allergies', 'loop', 'history', 'age', 'restrictions', 'days', 'kidney', 'severe hypoglycemia', 'alcohol', 'type', 'week', 'febrile illness', 'hypoglycemia', 'replacements', 'disease', 'counting', '\\>2 hours', 'duration', 'consumption', 'severe hyperglycemia', '3 months', 'autoimmune diabetes', 'the study', 'intense physical exercise', 'the last 12 months', 'diabetology', 'hyperglycemia', 'meal replacements', '18 years\n\ndiagnosis', 'inclusion criteria', 'the last 6 months', 'gastroparesis', 'egfr \\<60 ml/min)\n\ngallstone', 'system', 'it', 'dietary restrictions', 'months', 'study', 'coma', 'weeks', 'exercise', 'diabetes', 'hours', 'use', 'diagnosis', 'carbohydrate counting\n\nuse', 'years', 'food allergies', 'criteria', '\\>3 days', 'willingness', 'supplies', 'disorders', 'drug', '≥', 'telemedicine', 'knowledge', 'gallstone', 'ketoacidosis', 'week\n\nhistory', 'carbohydrate', 'risk', 'disorder', 'the last 2 weeks', 'inclusion', 'hospitalization', 'exclusion', '/coma', 'meal']"
NCT06473584,Study of the Prevalence of Diabetes and Pre-diabetes in Réunion Island,Diabetes,"Inclusion Criteria:

* Have lived in Réunion island for at least one year
* Be aged between 18 and 75
* Affiliated to or benefiting from a social security scheme
* Free, informed and signed consent

Exclusion Criteria:

* No main residence on the island or fixed address for at least one year on the island
* Participation in experimental research
* Pregnant women
* Adults under guardianship or legal protection
* Not understanding French",18,100,ALL,RECRUITING,"['research', 'réunion', 'security', 'island', 'scheme', 'consent', 'legal protection', 'adults', 'year', 'protection', 'réunion island', 'women', 'no main residence', 'at least one year', 'inclusion criteria', 'the island', '* adults', 'address', 'participation', 'fixed address', 'experimental research', 'residence', 'criteria', '* pregnant women', 'guardianship', 'inclusion', 'exclusion']"
NCT06727838,Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Human,Diabetes,"Inclusion Criteria:

1. Voluntarily sign informed consent before the start of activities related to this experiment, be able to communicate well with the investigators, understand the procedures and methods of this experiment, and be willing to strictly follow the clinical trial protocol to complete this experiment;
2. Healthy male aged 18-50 years old (including both ends of the value, subject to the signing of the informed consent);
3. Weight ≥ 50 kg, and body mass index (BMI): 22\~26 kg/m2 (including both ends of the value);
4. Signed informed consent to have no birth plan for 6 months after the last dose, and agreed to take effective contraceptive measures.

Exclusion Criteria:

1. Have a history of drug or food allergy, or are allergic;
2. Inability to swallow, chronic diarrhea and intestinal obstruction, or the presence of multiple other factors affecting the administration and absorption of drugs;
3. QTcF \> 450 ms was detected by 12-lead electrocardiogram during screening or th",18,50,MALE,NOT_YET_RECRUITING,"['food', 'presence', 'multiple other factors', 'weight', 'history', 'screening', 'administration', 'birth', '3. qtcf', 'the investigators', 'consent', 'dose', 'both ends', 'allergy', 'absorption', 'obstruction', 'ends', 'a history', 'trial', '450 ms', 'methods', 'informed consent', 'activities', 'measures', 'factors', 'body', 'lead', 'inclusion', 'no birth plan', 'exclusion criteria', '50 kg', 'inclusion criteria', 'the last dose', 'the procedures', '2. healthy male', 'bmi', 'months', 'procedures', 'electrocardiogram', 'the signing', 'the start', 'plan', '3. weight ≥', 'protocol', 'the value', 'the administration', 'years', 'drug or food allergy', '22\\~26 kg/m2', 'criteria', 'mass', '12-lead electrocardiogram', 'investigators', 'index', 'drugs', 'drug', 'this experiment', 'the clinical trial protocol', 'the informed consent', 'male', 'diarrhea', 'inability', 'signing', '2. inability', 'effective contraceptive measures', 'start', 'body mass index', 'value', 'exclusion', '6 months', 'experiment']"
NCT07082114,A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus,Type 2 Diabetes,"Inclusion Criteria:

1. Male or female subjects between 18 and 75 years of age (inclusive).
2. Have been diagnosed with type 2 diabetes mellitus (T2DM) for at least 3 months based on the World Health Organization, and participants treated with a stable dose of metformin (with maintenance dose of at least 1500 mg/day or a maximally tolerated dose not less than 1000 mg) for at least 8 weeks prior to screening; and must be stable for at least 12 weeks prior to randomization.
3. HbA1c ≥7.5% and ≤11.0% at screening as assessed by the local laboratory, and HbA1c ≥7.5% and ≤11.0% prior to randomization as assessed by the specified central laboratory.
4. Having a body mass index (BMI) of 19.0 to 40.0 kg/m2, inclusive.
5. Female participants of childbearing potential and male participants must agree to use highly effective contraception method from the day of signing the ICF and until 30 days (female) or 90 days (male) after the final dose administration.
6. Able to understand and comply with p",18,75,ALL,RECRUITING,"['participants', 'the world health organization', 'age', 'mellitus', 'screening', 'administration', 'a stable dose', 'days', 'highly effective contraception method', 'dose', 'type', '(male', 'type 2 diabetes', 'maintenance', '18 and 75 years', 'the local laboratory', 'the specified central laboratory', '90 days', 'body', '≥7.5%', 'laboratory', 'world', 'maintenance dose', 'inclusion criteria', '5. female participants', 'subjects', 'at least 3 months', 'bmi', 'the day', 'months', 'inclusive', 'potential and male participants', 'weeks', 'diabetes', 'at least 1500 mg/day', '30 days', 'health', 'contraception', 'a maximally tolerated dose', 'hba1c', 'a body mass index', 'the icf', 'randomization', 'dm', 'criteria', 'years', 'mass', 'index', 'method', 'metformin', 'male', 'the final dose administration', 't2', 'inclusion', 'organization', '%', 'male or female subjects', 'female']"
NCT05844644,The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

1. Males and females between the age of 18-75 years, inclusive, at screening
2. BMI ≥25 kg/m2
3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening

   Or,

   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months prior to enrollment. Acceptable methods of birth control include:
   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
   * Double-barrier method
   * Intrauteri",18,75,ALL,RECRUITING,"['acceptable methods', 'the duration', 'complete endometrial ablation', 'oral contraceptives', 'ortho evra', 'screening', 'oophorectomy', 'potential', 'vaginal contraceptive ring', 'birth', 'females', 'contraceptives', 'who', '* hormonal contraceptives', 'child-bearing potential', 'all hormonal birth control', 'year', 'bilateral oophorectomy', 'barrier', 'enrollment', 'e.g. hysterectomy', 'hormone birth control patch', 'duration', 'bmi ≥25 kg/m2', 'depo-provera', 'hormone implant (norplant system', 'methods', '18-75 years', 'a medically approved method', 'the study', 'hysterectomy', 'pregnancy', 'provera', 'injectable contraceptives', 'urine', 'inclusion criteria', 'lunelle', 'ablation', 'contraceptive', 'norplant', 'depo', 'system', 'males', 'months', 'a minimum', 'study', 'intrauteri', 'those', 'the age', 'use', 'ligation', 'birth control', 'child', 'control', 'years', 'criteria', 'minimum', 'sterilization', 'individuals', 'baseline', 'bilateral tubal ligation', 'method', 'a sterilization procedure', 'ring', 'three months', 'test', 'double-barrier method\n   * intrauteri', 'procedure', 'inclusion', 'patch', 'hormone']"
NCT06959316,T1D Pregnancy & Me,"Diabetes Mellitus, Type 1","Inclusion Criteria:

1. Age ≥18 years
2. Clinical diagnosis of presumed T1D for at least 6 months duration
3. Less than 15 weeks gestation at time of enrollment based on due date from provider
4. Planned CGM use on a regular basis (e.g., ≥10 out of 14 days) and willing to continue using CGM regularly with no plans to discontinue CGM use during the study
5. Following intensive insulin therapy regimen defined as basal-bolus delivery via an insulin pump (including a closed loop system) or multiple daily injections (MDI)
6. Have access to technology that may be required to complete study questionnaires and share diabetes device data.
7. Resident of the United States and plans to reside in the U.S. for the duration of the study
8. Comprehends written and spoken English or Spanish
9. Willing and able to provide informed consent, complete surveys and provide the device data that are part of the protocol

Exclusion Criteria:

1. Multiple pregnancy
2. Current renal dialysis or plan to begin ren",18,100,FEMALE,RECRUITING,"['due date', 'planned cgm use', 'the duration', '14 days', 'presumed t1d', 'loop', 'device', 'delivery', '7. resident', 'mdi', 'days', 'multiple daily injections', 'consent', 'that', 'the united states', 'bolus', 'questionnaires', 'enrollment', 'resident', 'ren', 'duration', 'informed consent', 'basal-bolus delivery', 'current renal dialysis', 'surveys', 'dialysis', 'complete surveys', 'the study', 'pregnancy', 'pump', 'intensive insulin therapy regimen', 'the device data', 'inclusion criteria', 'clinical diagnosis', 'system', 'plans', 'therapy', 'device data', 'basis', 'months', 'cgm', 'weeks', 'study', 'regimen', 'data', 'injections', 'age ≥18 years', 'part', 'plan', 'no plans', 'a closed loop system', 'study questionnaires', 'diagnosis', 'an insulin pump', 'time', 'the u.s', 'provider', 'criteria', 'years', 'a regular basis', 'cgm use', 'access', 'comprehends', 'the protocol\n\nexclusion criteria', 'date', 'insulin', 'share', 'gestation', '.', 'inclusion', 'basal', '1. multiple pregnancy', 'exclusion', 'technology']"
NCT04789148,Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency,Vasopressin Deficiency,"Inclusion Criteria:

* Age 18 and above
* Arginine-vasopressin deficiency
* Normal FT4 or T4
* Normal serum/plasma sodium
* Stable hormone replacement

Exclusion Criteria:

* Active substance use disorder within the last 6 months
* History of psychosis
* Suicidal behavior and/or active suicidal ideation with plan and/or intent, e.g., suicidal ideation of type 4 or type 5 as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS), in the last month
* Medication changes within 4 weeks of enrollment or planned medication changes during the study
* History of chronic nasal obstruction or local pathology in nostril pathway which, in the opinion of the investigator, would prevent appropriate nasal administration of the study drug.
* History of cardiac disease, including arrhythmias, coronary heart disease, coronary artery spasms, valvular heart disease, hypertrophic cardiomyopathy (hypertension is not exclusionary)
* History of chronic kidney disease stage III and above
* History of ",18,100,ALL,RECRUITING,"['nasal', 'rating', 'age', 'stage', 'ideation', 'c-ssrs', 'disease', 'suicide', 'pathology', 'suicidal ideation', 'spasms', 'chronic kidney disease stage', 'plan', 'replacement', 'psychosis', 'heart', 'valvular heart disease', 'inclusion', 'scale', 'history', 'sodium', 'the investigator', 'substance', 'serum', '* history', 'psychosis\n* suicidal behavior', 'weeks', 'hypertension', 'severity', 'month', 'appropriate nasal administration', 'arginine-vasopressin deficiency', 'exclusion', 'nostril', '* normal serum/plasma sodium', 'pathway', 'kidney', '* medication changes', 't4', '* normal ft4', 'medication', 'enrollment', 'the study drug', 'changes', '4 weeks', 'inclusion criteria', 'nostril pathway', 'plasma', 'the opinion', 'study', 'opinion', 'cardiac disease', 'criteria', 'drug', 'hypertrophic cardiomyopathy (hypertension', 'disorder', 'local pathology', 'deficiency', 'intent', 'which', 'administration', 'type', 'obstruction', 'arginine', 'vasopressin', 'artery', 'the study\n* history', 'the last 6 months', 'months', 'investigator', 'active suicidal ideation', 'chronic nasal obstruction', 'coronary artery spasms', 'behavior', 'coronary heart disease', 'the last month', 'hormone']"
NCT06110143,Oral Health and Adverse Pregnancy Complications,Periodontal Diseases,"Inclusion Criteria:

* Pregnant women who are planned to give birth at either Holbaek or Nykoebing Falster hospital
* Pregnant women diagnosed with periodontitis (stage I-III) by the study dentist

Exclusion Criteria:

* Pregnant women without peridontitis
* Pregnant women with less than 20 healthy teeths
* Pregnant women with peridontitis and currently receiving treatment for peridontitis
* Pregnant women with peridontitis stage IV",18,100,FEMALE,RECRUITING,"['i', 'birth', 'iv', 'stage', 'who', 'peridontitis\n* pregnant women', 'either holbaek', 'treatment', 'women', 'teeths', 'inclusion criteria', 'study', 'peridontitis', 'criteria', '* pregnant women', 'hospital', 'peridontitis stage', 'pregnant women', 'holbaek', 'dentist', 'inclusion', 'periodontitis', 'exclusion']"
NCT05390892,PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes,Type2Diabetes,"Inclusion Criteria:

* Type 2 diabetes based on clinical diagnosis
* HbA1c ≥6% measured within 12 months prior to screening
* Secondary prevention cohort (at least 70% of cohort):

  * Age 40 to 80 years
  * Evidence of established atherosclerotic cardiovascular disease (ASCVD), as defined by one or more of the following
  * Coronary heart disease defined by at least one of the following: prior myocardial infarction, prior coronary percutaneous coronary intervention, ≥50% stenosis of a coronary artery documented by invasive or non-invasive imaging (including CT coronary angiography), positive stress test, or coronary artery calcium score \>400 Agatston units;
  * Cerebrovascular disease defined by at least one of the following: prior ischemic stroke, prior carotid revascularization procedure, carotid stenosis ≥ 50% documented by X-ray angiography, MR angiography, CT angiography, or Doppler ultrasound;
  * Symptomatic peripheral artery disease defined by at least one of the following: l",40,80,ALL,RECRUITING,"['infarction', 'prevention', 'units', 'age', '≥6%', '* secondary prevention cohort', 'doppler ultrasound', '* type 2 diabetes', 'a coronary artery', 'calcium', 'type', '12 months', 'x-ray angiography', 'at least 70%', 'established atherosclerotic cardiovascular disease', 'disease', 'doppler', 'artery', 'prior ischemic stroke', 'coronary artery calcium score', 'invasive or non-invasive imaging', 'mr angiography', '50%', 'imaging', 'inclusion', 'stroke', 'clinical diagnosis', 'inclusion criteria', 'carotid', 'months', 'l', '\\>400 agatston units', 'ct coronary angiography', '≥50% stenosis', 'diabetes', 'heart', 'diagnosis', 'stress', 'score', '* cerebrovascular disease', 'hba1c', 'criteria', '40 to 80 years', 'stenosis', 'years', 'angiography', 'prior carotid revascularization procedure', 'ct angiography', '* evidence', 'prior myocardial infarction', 'test', 'cohort', 'evidence', 'procedure', 'ascvd', 'revascularization', 'positive stress test', 'ultrasound', 'intervention']"
NCT06832787,Evaluation of Combinational Use of Negative Pressure Wound Therapy (NPWT) for Diabetic Foot Wounds,Diabetic Foot Ulcer,"Inclusion Criteria:

* Age 21-100
* First or last toe ray amputation
* Adequate perfusion (either \>50% stenosis on duplex ultrasound or undergone successful revascularization with \<30% residual stenosis)

Exclusion Criteria:

* Amputations not at first or last toe
* Venous ulcers
* Heel ulcers
* Osteomyelitis
* Active Infection
* Patients on imunosuppressant
* Patients with known allergy to fish
* Patients unable to give informed consent.",21,100,ALL,RECRUITING,"['consent', 'patients', 'allergy', 'duplex ultrasound', 'osteomyelitis', 'imunosuppressant\n* patients', '* patients', '* heel ulcers', 'active infection\n* patients', 'known allergy', 'informed consent', 'infection', '* osteomyelitis', 'inclusion criteria', 'ultrasound', 'undergone successful revascularization', 'criteria', 'amputation', 'stenosis', ')\n\nexclusion criteria', 'duplex', '* amputations', 'amputations', 'ulcers', 'either \\>50% stenosis', '\\<30% residual stenosis', 'perfusion', 'revascularization', 'inclusion', 'exclusion', 'toe ray amputation', '* venous ulcers', 'heel']"
NCT06739993,Effects of Autonomic Nervous System Modulation by Heart Rate Variability Biofeedback Training With Resonant Frequency Breathing on Glucose Metabolism in Individuals With Prediabetes,Prediabetes,"Inclusion Criteria:

* Presence of prediabetes Fasting glucose: 100-125 mg/dl (5.6-6.9 mmol/L) and/or HbA1c in %: 5.7-6.4 (39-47 mmol/mol Hb) and/or 2-hour value of the 75 g OGTT: 140-199 mg/dl (7.8-11.0 mmol/L)

  * This is checked using a 75 g OGTT in a screening visit.
* Age between 18 and 65 years
* BMI between 20 and 40 kg/m²

Exclusion Criteria:

* Diabetes mellitus
* Malignant diseases within the last 5 years before randomization
* History of gastrointestinal surgery
* Pancreatic diseases other than pancreatic lipomatosis
* Acute diseases or infections
* Regular intake of cardiac drugs that affect heart rate within the last 4 weeks before the first measurement (e.g. beta-receptor blockers, antiarrhythmics, etc.)
* Intake of centrally acting drugs
* Medical contraindications to a meaningful interpretation of the heart rate analysis (e.g. patients with pacemakers, atrial fibrillation or other arrhythmias)
* Chronic diseases (particularly metabolic diseases, heart diseases, blood d",18,65,ALL,RECRUITING,"['visit', '7.8-11.0 mmol/l', 'presence', 'fibrillation', 'the last 4 weeks', 'arrhythmias', '* presence', 'mol hb', 'history', 'antiarrhythmics', 'atrial fibrillation', 'screening', 'diseases', 'dl', 'interpretation', 'lipomatosis', 'analysis', '100-125 mg', 'heart rate', 'patients', 'that', 'the 75 g', 'hour', 'regular intake', 'glucose', '18 and 65 years', 'blockers', '* chronic diseases', 'prediabetes', '* age', 'the first measurement', 'the last 5 years', 'a screening visit', 'contraindications', 'rate', 'inclusion criteria', 'medical contraindications', 'other arrhythmias', '2-hour value', '(39-47 mmol', 'weeks', 'heart diseases', 'intake', 'measurement', 'heart', 'a meaningful interpretation', 'beta', 'metabolic', 'years', 'hba1c', 'blood', 'criteria', 'a 75 g ogtt', '(5.6-6.9 mmol/l', 'randomization', '* pancreatic diseases', 'infections', 'centrally acting drugs', 'this', 'ogtt', '* intake', 'surgery', 'drugs', 'mellitus\n* malignant diseases', 'pacemakers', 'receptor', 'the heart rate analysis', 'cardiac drugs', '(e.g. beta-receptor blockers', 'gastrointestinal surgery', 'inclusion', 'particularly metabolic diseases', 'value', '%', 'e.g. patients', 'exclusion']"
NCT05305287,Quantifying Hepatic Mitochondrial Fluxes in Humans,Non-Alcoholic Fatty Liver Disease,"T2D with NAFL

Inclusion Criteria:

* Confirmed T2D based on OGTT (2 h glucose ≥200 mg/dl).
* Treated with diet, metformin, and/or sulfonylurea and in good general health determined by medical history, physical exam, and routine blood chemistries;
* age = 18-80 years;
* BMI = 25-40 kg/m2;
* HbA1c = 7-10%; stable body weight (±4 pounds) over the preceding 3-months;
* not taking any medication known to affect glucose metabolism other than antidiabetic medications.
* Evidence of moderate/severe fatty liver (steatosis; grade S2/S3 on FibroScan corresponding to ≥10% fat on MRI-PDFF) and no/minimal hepatic fibrosis (grade F0/F1 on FibroScan).

Exclusion Criteria:

* Alcohol consumption \>14 units/week for women and \>21 units/week for men.
* Cirrhosis (fibrosis stage 4).
* Type 1 diabetes and/or GAD positive subjects.
* Subjects not drug naive or have been on metformin more than 3 months.
* Presence of proliferative retinopathy.
* Urine albumin excretion \> 300 mg/day.
* Evidence of other fo",18,80,ALL,RECRUITING,"['medical history', 'nafl\n\ninclusion criteria', 'weight', '* presence', 'positive subjects', 'stage', 'good general health', '≥200', 'diet', '25-40 kg/m2', 'body', 'exclusion criteria', 'urine', 'diabetes', 'health', '7-10%', 'years', 'moderate/severe fatty liver', 'metabolism', 'fibrosis', 'proliferative retinopathy', 'units', 'history', 'steatosis', 'women', 'the preceding 3-months', '/day', '* type', 'albumin excretion \\', 'men', 'ogtt', 'routine blood chemistries', 'no/minimal hepatic fibrosis', 'exclusion', 'any medication', 'mg', 'presence', 'glucose metabolism', 'dl', 'pounds', '±4 pounds', 'chemistries', 'medication', 'consumption', 'mri-pdff', '* cirrhosis', 'medications', 'subjects', '\\>21 units', ';\n* age', 'antidiabetic medications', 'criteria', 'blood', 'physical exam', 'metformin', 'grade s2/s3', 'stable body weight', '18-80 years', 'grade f0/f1', 'exam', 'grade', '≥10% fat', 'fibroscan', 'alcohol', 'type', '* urine', 'week', 'glucose', 't2d', 'cirrhosis', 'pdff', 'months', 'liver', 'hba1c', '* evidence', '* hba1c', '2 h glucose ≥200', 'sulfonylurea', 'evidence', 'more than 3 months']"
NCT06273657,Effects of Medisinstart for Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

* Extracted a new drug/active substance (A10A/A10B) for type 2 diabetes
* Age ≥ 18 years
* The drugs are administered by the patient/relatives
* Good command of Norwegian, both written and spoken

Exclusion Criteria:

* Inability to understand and/or complete consent forms, questionnaires and/or other patient-oriented materials
* Not able to attend physical appointments in the pharmacy
* Not given written consent to participate in the study
* Diabetes medication is administered by a healthcare professional
* Known pregnancy
* HbA1c is unsuitable as an average measure of blood glucose at baseline
* Received initiation of medication for type 2 diabetes within the last year
* Ongoing participation in other studies involving similar interventions to increase adherence and ensure correct medication use",18,100,ALL,RECRUITING,"['good command', 'physical appointments', 'the pharmacy', 'ongoing participation', 'relatives', 'an average measure', 'a new drug/active substance', 'initiation', 'consent', 'type', 'studies', 'a10b', 'substance', 'year', 'questionnaires', 'medication', 'glucose', 'similar interventions', '2 diabetes', '18 years', 'pregnancy', 'materials', 'both', 'exclusion criteria', 'blood glucose', 'inclusion criteria', 'the patient/relatives', '* inability', 'other patient-oriented materials', 'the drugs', 'study', 'patient', 'pharmacy', 'diabetes', 'participation', 'interventions', 'forms', 'correct medication use', 'command', 'other studies', 'hba1c', 'criteria', 'years', 'blood', 'complete consent forms', 'baseline', 'adherence', 'drugs', 'drug', '≥', 'written consent', 'measure', 'inability', 'a10a', 'norwegian', 'the last year', 'appointments', 'inclusion', 'exclusion']"
NCT07019012,Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.,T2DM,"Inclusion Criteria:

* Able to understand and voluntarily sign a written informed consent form.
* Male or female subjects aged 18 years and above .
* Meet the diagnostic criteria for Type 2 Diabetes Mellitus (T2DM).
* Have been on initial SGLT2i monotherapy (dapagliflozin) at a dose of 10 mg daily for at least 12 weeks.
* Have received metformin treatment for ≥12 weeks, with a stable dose maintained during the screening period (≥1500 mg/day if tolerable or at the maximum tolerated dose (\<1500 mg/day but ≥1000 mg/day), and no dosage adjustment).
* HbA1c levels within the range: 7.0% \< HbA1c ≤ 10.0%.
* Fasting plasma glucose (FPG) \< 15 mmol/L.
* Body Mass Index (BMI) ≤ 40 kg/m2.
* Estimated Glomerular Filtration Rate (eGFR) ≥ 60 ml/min/1.73m2.
* Agree to maintain the same diet and exercise habits throughout the trial period, willing and able to accurately use a home blood glucose meter for self-monitoring of blood glucose (SMBG) and keep records.

Exclusion Criteria:

* Type 1 Diabete",18,100,ALL,RECRUITING,"['mellitus', 'screening', 'hba1c ≤ 10.0%', 'dose', 'consent', 'the diagnostic criteria', '7.0%', 'diet', '1 diabete', 'body', 'fpg', 'dapagliflozin', 'blood glucose', 'exclusion criteria', 'diabetes', 'min/1.73m2', 'years', 'meter', 'self', 'inclusion', 'records', 'a stable dose', 'smbg', 'range', '60 ml', 'home', '40 kg/m2', 'exercise habits', 'exercise', 'bmi', 'weeks', '* type', 'the trial period', 'monitoring', 'index', '≥', 'form', 'self-monitoring', 'exclusion', 'metformin treatment', 'dosage', '/', 'adjustment', 'trial', 'egfr', 'treatment', 'no dosage adjustment', '\\<1500 mg', 'period', 'rate', 'inclusion criteria', '≤', 'plasma', 'subjects', '* hba1c levels', 'criteria', 'mass', 'blood', 'dm', 'at least 12 weeks', 'metformin', '≥12 weeks', 'habits', 't2', 'monotherapy', 'type', 'the range', 'the maximum tolerated dose', 'glucose', 'levels', '* fasting plasma glucose', 'initial sglt2i monotherapy', 'filtration', 'diabete', 'sglt2i', 'the same diet', 'the screening period', 'a dose']"
NCT06970834,Explore the Effect of Bitter Melon Peptides on Glycemic Control and Metabolic Indicators in Diabetic Patients,Diabetes,"Inclusion Criteria:Participants were diagnosed with type 2 DM based on criteria recommended by the American Diabetes Association and required to have fasting plasma glucose of ≥126 mg/dl or an HbA1c of

≥ 6.5%, as measured on two separate occasions

Exclusion Criteria:cancer, active liver disease, current pregnancy , acute illness and autoimmune thyroid disease.",18,100,ALL,NOT_YET_RECRUITING,"['participants', 'illness', 'active liver disease', 'an hba1c', 'type', 'association', 'disease', 'glucose', 'acute illness', '≥126 mg/dl', 'pregnancy', 'the american diabetes association', 'cancer', 'plasma', '2 dm', 'plasma glucose', 'liver', 'autoimmune thyroid disease', 'occasions', 'criteria', 'current pregnancy', 'thyroid', '≥126', '≥', 'inclusion', 'exclusion']"
NCT06945419,"A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes",Healthy,"Inclusion Criteria:

* Have no significant body weight change for the 3 months prior to screening

Part A and Part E:

* Are considered healthy
* Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening

Part B:

* Have a BMI of 27 to 45 kg/m2 at screening

Part C:

* Have a BMI of 25 to 45 kg/m2 at screening

Part D:

* Have type 2 diabetes
* Have hemoglobin A1C (HbA1c) ≥7.0% and ≤10.5% at screening
* Have a BMI of 27 to 45 kg/m2 at screening

Exclusion Criteria:

* Have had an acute cardiovascular condition within the past 6 months prior to screening
* Have liver disease or pancreatitis
* Have used medications for weight loss within the 3 months prior to screening

Parts A, B, C, E:

* Have any form of diabetes

Part D:

* Have type 1 diabetes",18,100,ALL,RECRUITING,"['the 3 months', 'weight loss', 'diabetes\n\npart', '27 to 45 kg', 'condition', 'an acute cardiovascular condition', 'weight', 'screening', 'any form', 'type', '*', 'disease', '2 diabetes', 'body', 'c', 'exclusion criteria', 'inclusion criteria', 'pancreatitis', 'medications', 'screening\n\npart', 'liver disease', 'bmi', 'a bmi', 'months', 'liver', 'loss', 'diabetes', 'part', 'the past 6 months', 'e', 'parts', 'change', 'hba1c', 'a body mass index', '22 to 35 kilograms', 'criteria', 'mass', 'index', '/m2', '25 to 45 kg', 'form', 'meter', 'a1c', '1 diabetes', 'kilograms', 'inclusion', 'hemoglobin', 'a', 'exclusion', 'square meter', '(kg/m2']"
NCT07209930,Inter- and Intraindividual Variability of the Acute Glucose Response to Exercise in Healthy Adults and People Living With Type 1 Diabetes: A Cross-over Replicate Trial,Exercise,"Inclusion Criteria:

(Healthy and T1D phases):

* age between 18 and 60 years old;
* being healthy individuals;
* engagement in physical activity at least once a week; (T1D phase):
* diagnosis of T1D for \>18 months;
* hypoglycaemia self awareness.

Exclusion Criteria:

(Healthy and T1D phases)

* presence of cardiovascular disease or contraindications to exercise;
* infectious or inflammatory conditions;
* chronic renal or liver disease;
* pregnancy;
* gestational diabetes;
* diagnosed eating disorders;
* any physical or mental condition preventing participation; (Healthy phase)
* diabetes mellitus (type 1 or type 2); (T1D phase)
* inability to self-manage diabetes.",18,60,ALL,RECRUITING,"['presence', 'condition', 'phase', '* presence', 'mellitus', '\\>18 months', 'phases', 'conditions', '* diagnosis', 'cardiovascular disease', 'renal', 'type', 'week', '* gestational diabetes', 'disease', 'engagement', '* diagnosed eating disorders', 'pregnancy', '* age', 'infectious or inflammatory conditions', 'healthy phase', 'exclusion criteria', 'inclusion criteria', 'awareness', 'months', 'liver', 'diabetes', 'participation', 'healthy individuals', 'diagnosis', 'hypoglycaemia', 'contraindications', 'criteria', 'years', '\\>18', 'individuals', '* diabetes', 'physical activity', 'disorders', 't1d', '(t1d phase', '* pregnancy', 'inability', 'self', 'inclusion', 'healthy and t1d phases', 'exclusion', 'activity', 'hypoglycaemia self awareness']"
NCT06867198,"Peanuts for Cardiometabolic, Brain, and Intestinal Health",Prediabetes,"Inclusion Criteria:

* men and women
* 20-59 years of age
* Prediabetes (fasting blood glucose levels 100-125 mg/dL and/or HbA1c between 5.7-6.4%)

Exclusion Criteria:

* Allergies to peanuts and peanut products
* Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs
* Active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological diseases or severe head injury
* Smoking
* Consumes greater than 2 alcoholic beverages per day
* Consumes antioxidant, probiotic, and prebiotic supplements
* Pregnant or Lactating
* Actively participating in a weight loss program",20,59,ALL,RECRUITING,"['allergies', 'antibiotics', 'program', 'weight', 'age', 'anti-inflammatory drugs', 'blood glucose levels', 'diseases', 'supplements', 'a weight loss program', 'head', 'glucose', 'women', 'levels', 'prediabetes', 'cancer', 'inclusion criteria', 'peanut', '20-59 years', 'loss', 'day', 'consumes', 'injury', 'active cancer', 'years', 'hba1c', 'men', 'criteria', 'blood', 'products', ')\n\nexclusion criteria', '-125 mg', 'antidiabetic', 'thyroid', 'drugs', 'beverages', 'insulin', 'peanut products', 'inclusion', 'smoking', 'peanuts', 'exclusion']"
NCT06501612,Pilot RCT Evaluating Clinical Outcomes of Using Undermyfork Mobile App With Dexcom G7,Type 2 Diabetes,"Inclusion Criteria:

* Have been diagnosed with type 2 diabetes
* Are on any pills or injectable glucose lowering medication regimen except bolus insulin
* Speak, read, and write in English
* Have A1c between 7.7% and 12.5% in the last 90 days
* Have a cell phone that can download the Dexcom G7 and Undermyfork app

Exclusion Criteria:

* Are on bolus insulin
* Are pregnant
* Are currently participating in another diabetes related study",18,100,ALL,RECRUITING,"['bolus insulin', 'days', 'pills', 'type', 'that', '*', 'type 2 diabetes', 'medication', 'glucose', 'dexcom', 'pregnant\n*', 'bolus insulin\n* speak', 'speak', 'study', 'medication regimen', 'the last 90 days', 'regimen', 'diabetes', 'cell', 'phone', 'the dexcom g7', 'criteria', 'a cell phone', 'injectable glucose', 'any pills', 'another diabetes related study', 'insulin', 'english', '12.5%', 'inclusion', 'exclusion']"
NCT06320600,Precision Medicine of Diabetes Program in China,Diabetes,"Inclusion Criteria:

* Patients diagnosed with diabetes according to WHO 1999 criteria

Exclusion Criteria:

* with duration more than 1 year; Diabetes has not been diagnosed by WHO standards in 1999; Absence of medical history data",18,100,ALL,RECRUITING,"['more than 1 year', 'criteria', 'year', 'medical history data', 'duration', 'standards', 'history', 'data', 'diabetes', 'absence', 'inclusion', 'patients', 'who', 'inclusion criteria', 'exclusion']"
NCT06753734,Early Prediction of Gestational Diabetes in High-risk Women Based on Breath Metabolomics,Gestational Diabetes,"Eligibility Criteria

* 18-55 years old
* 11-14 weeks of pregnancy
* at least one risk factor for GDM
* signed a written informed consent

Exclusion Criteria:

* Diabetes mellitus or abnormal glucose metabolism before pregnancy
* Hyperemesis gravidarum (urine ketone positive))
* Thyroid dysfunction
* Asthmatic patients
* Hypertensive diseases that are difficult to control
* Severe hepatic and renal insufficiency or severe electrolyte disturbance
* Malignant tumor
* Acute inflammation
* lung disease
* Patients with gastritis, duodenum and other digestive system diseases
* Those with upper respiratory or oral problems who cannot cooperate with expiratory collection
* smoker",18,55,FEMALE,ENROLLING_BY_INVITATION,"['metabolism', 'mellitus', 'diseases', 'collection', 'consent', 'problems', 'patients', 'digestive system diseases', 'who', 'that', 'disease', 'glucose', 'lung', 'pregnancy\n* hyperemesis gravidarum', 'pregnancy', 'dysfunction', 'insufficiency', 'disturbance', 'urine', 'system', 'gravidarum', 'weeks', 'eligibility criteria', 'expiratory', 'those', 'gastritis', '* acute inflammation', 'expiratory collection', 'hypertensive diseases', 'years', 'criteria', 'hyperemesis', 'factor', 'thyroid', 'tumor', 'inflammation', 'smoker', 'risk', '11-14 weeks', 'gdm', 'abnormal glucose metabolism', 'exclusion']"
NCT06471699,The Effect of Continuous Glucose Monitoring in Individuals With Newly Diagnosed Type 2 Diabetes,Diabetes Type 2,"Inclusion Criteria:

1. Type 2 diabetes
2. Adults 18 years or older
3. Written Informed Consent
4. HbA1c greater than or equal to 58 mmol/mol (7.5% DCCT standard) and less than 100 mmol/mol
5. Type 2 diabetes diagnosis \<4 weeks
6. Body mass index \> 25 kg/m2

Exclusion Criteria:

1. Pregnancy or planned pregnancy for the study duration
2. Type 1 diabetes
3. Judged to be in need of insulin
4. Severe cognitive dysfunction or other disease, which is judged by the physician to be not suitable for inclusion.
5. History of allergic reaction to chlorhexidine or alcohol anti-septic solution.
6. Abnormal skin at the anticipated glucose sensor attachment sites (excessive hair, burn, inflammation, infection, rash, and/or tattoo).
7. Participation in another study.
8. Other investigator-determined criteria unsuitable for patient participation.",18,100,ALL,NOT_YET_RECRUITING,"['skin', 'history', 'which', 'rash', 'excessive hair', 'standard', 'another study', 'consent', 'alcohol', 'type', 'adults', 'less than 100 mmol/mol', 'type 2 diabetes', 'burn', 'severe cognitive dysfunction', '5. history', 'dcct', 'need', 'duration', 'informed consent', '7. participation', 'glucose', '18 years', 'allergic reaction', 'body', 'pregnancy', 'other investigator-determined criteria', 'dysfunction', '25 kg/m2\n\nexclusion criteria', 'inclusion', 'infection', '58 mmol/mol', 'disease', 'inclusion criteria', 'patient participation', 'the physician', 'hair', 'planned pregnancy', 'reaction', 'weeks', 'other disease', 'study', 'solution', 'investigator', 'attachment', 'diabetes', 'physician', 'participation', 'diagnosis', '6. abnormal skin', 'criteria', '1. pregnancy', 'years', 'hba1c', '. type', 'inflammation', 'insulin', 'the study duration', 'sensor', 'sites', '7.5% dcct standard', 'exclusion', 'chlorhexidine']"
NCT05208164,My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria

* Self-identifies as African American or Black
* Diagnosis of type 2 diabetes
* Valid address in greater Chicagoland area
* Mobile phone with unlimited text-messaging
* Mobile device (smartphone, tablet, or computer) with the ability to connect to the internet if remote online delivery
* Availability to participate in mindfulness class either in-person or online
* Age 21-75

Exclusion Criteria

* Untreated obstructive sleep apnea (OSA)
* Severe insomnia, narcolepsy, or REM sleep related disorder
* Major cognitive impairments or psychiatric disorder
* Alcohol or drug abuse
* Limited English proficiency
* Inability to send/receive text messages
* Currently engaging in mindfulness practice",21,75,ALL,RECRUITING,"['insomnia', 'person', 'messages', 'abuse', 'sleep', 'device', 'delivery', 'computer', 'practice', 'proficiency', 'text', 'alcohol', 'the internet', 'type', 'internet', 'greater chicagoland area', 'tablet', 'mindfulness', 'apnea', 'ability', '* severe insomnia', 'chicagoland', 'impairments', 'inclusion criteria', 'self-identifies', 'mobile phone', 'osa', 'mindfulness practice', 'availability', 'class', 'diabetes', 'address', 'area', 'phone', 'identifies', 'diagnosis', '* valid address', 'criteria', 'drug', '* limited english proficiency', 'mindfulness class', 'disorder', 'inability', 'self', 'untreated obstructive sleep apnea', '-75\n\nexclusion criteria', 'text messages', 'inclusion', 'the ability', 'exclusion', 'smartphone']"
NCT06979401,"Effect of Sensory Training on Functional Performance, Balance, Gait in Type 2 Diabetic Individuals With Neuropathy",Diabetes,"Inclusion Criteria:

* Being 35-65 years old
* Being diagnosed with type 2 diabetes
* Having achieved glycemic control
* Having given less than 8 correct answers in the Semmes-Weinstein Monofilament test performed with a 5.07 monofilament
* Getting a Neuropathy Disability Score of 3 and above
* Being willing to participate in the study
* Being literate

Exclusion Criteria:

* Having a neurological or orthopedic comorbidity
* Having a respiratory disease such as uncontrolled COPD or asthma
* Having active lower extremity ulceration
* Using medications known to affect the postural control system such as benzodiazepines
* Having nephropathy, retinopathy and diabetic arthritis at a level that may affect mobility in addition to neuropathy
* Using a walking aid
* Body Mass Index \>30
* Having communication problems
* Not participating in at least 3 consecutive exercise sessions
* Not participating in more than 30% of each session",35,65,ALL,NOT_YET_RECRUITING,"['benzodiazepines', 'disability', 'answers', 'a walking aid', 'session', 'level', 'problems', 'addition', 'that', 'type', 'mobility', 'sessions', 'disease', 'a 5.07 monofilament', 'type 2 diabetes', 'active lower extremity ulceration', '* body mass index', 'arthritis', 'the semmes-weinstein monofilament test', 'copd', 'body', 'the study', 'a neuropathy disability score', 'communication problems', 'inclusion', 'inclusion criteria', 'system', 'medications', 'communication', 'exercise', 'a level', 'study', 'diabetes', 'extremity', 'control', 'score', 'years', 'criteria', 'semmes', 'glycemic control', 'index', 'more than 30%', 'monofilament', 'comorbidity', 'asthma', 'ulceration', 'test', 'each session', 'uncontrolled copd', 'literate\n\nexclusion criteria', 'the postural control system', 'exclusion', 'a respiratory disease']"
NCT05000021,Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes,Type 1 Diabetes,"Inclusion Criteria:

* Type 1 Diabetes (T1D) duration ≥6 months
* English or Spanish speaking
* At least moderate Diabetes Distress (DD) (score of ≥2 on T1D-Diabetes Distress Scale)
* Stable insulin treatment regimen (insulin prescription, use of pump, etc.) for at least 3 months prior to study enrollment

Exclusion Criteria:

* Comorbid psychiatric condition, including depression, anxiety, or suicidality, which may be independently associated with the main outcomes of DD or glycemic control. Comorbid psychiatric conditions listed above are being excluded because CBT-DD currently centers on mitigating specifically diabetes distress to improve glycemic outcomes
* In treatment for a psychological condition within the last 6 months or on a non-stable dose of psychiatric medication over the last 2 months
* Developmental or sensory disability interfering with participation
* Current pregnancy, as self-management and glycemic goals differ
* Participation in another behavioral intervention st",18,100,ALL,RECRUITING,"['condition', 'which', 'disability', 'prescription', 'conditions', 'intervention', 'dose', 'type', 'centers', 'cbt-dd currently centers', 'enrollment', 'medication', 'duration', 'dd', 'depression', '≥2', 'treatment', 'participation\n* current pregnancy', 'self-management', 'outcomes', 'pump', 'pregnancy', 't1d-diabetes distress scale', 'inclusion', 'st', 'inclusion criteria', 'the last 6 months', 'anxiety', 'another behavioral intervention', 'glycemic outcomes', 'months', 'regimen', 'management', 'diabetes', 'psychiatric medication', 'participation', '* type 1 diabetes', 'the main outcomes', 'use', 'a psychological condition', 'a non-stable dose', 'control', 'score', 'enrollment\n\nexclusion criteria', 'criteria', '* comorbid psychiatric condition', 'glycemic control', '≥6 months', 'insulin', 'distress', 'developmental or sensory disability', 'self', 'suicidality', 'glycemic goals', 'insulin prescription', 'goals', 'the last 2 months', 'scale', 'comorbid psychiatric conditions', 'exclusion']"
NCT06989216,Multi-modal Quantitative Imaging of the Skin,Skin Cancer,"Inclusion criteria:

* Adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation.
* Patients with signed informed consent

Exclusion criteria:

* Cognitive impairment
* Patients unable to understand the oral and written study information in Swedish or English
* Other severe disorder or terminal disease
* Patients unable to provide an informed consent
* Patients not able to keep balance, while standing up with closed eyes, without any aid
* Claustrophobic patients",18,100,ALL,RECRUITING,"['balance', 'flow', 'this investigation', 'consent', 'patients', 'that', 'eyes', 'disease', '* patients', 'claustrophobic patients', '* adult patients', 'an informed consent', 'closed eyes', 'inclusion criteria', 'study', 'patient', 'investigation', 'part', 'impairment', 'criteria', 'any aid', 'the investigational sites', 'information', 'healthcare', 'disorder', 'english', 'sites', 'inclusion', 'adult', 'exclusion']"
NCT07313384,Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy,Obesity Type 2 Diabetes Mellitus,"Inclusion Criteria:

* Adults aged 18 and older
* Recently has been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication
* Has regular access to a smartphone and internet to complete short surveys and food recalls online
* Willing to sign informed consent.

Exclusion Criteria:

* Already began the GLP-1 medication
* Have medical concerns making participation unsafe",18,100,ALL,RECRUITING,"['t2dm', 'food', 'concerns', 'a smartphone', 'consent', 'internet', 'glp-1', 'adults', 'medication', 'obesity', 'the treatment', 'informed consent', 'treatment', 'surveys', 'short surveys', 'regular access', 'exclusion criteria', 'inclusion criteria', 'therapy', 'the glp-1 medication', '* adults', 'participation', 'online', 'criteria', 'the medication', 'medical concerns', 'access', 'inclusion', 'exclusion', 'smartphone']"
NCT07285811,GLycaemic Outcomes With Whey Protein in ageING,Type 2 Diabetes,"* Male or female
* 75-90 years old
* Type 2 Diabetes (confirmed with glycated haemoglobin (HbA1c) \>6.5% in clinic or in SportExR)
* Stable body mass (body mass index (BMI) ≤40kg/m2)
* Generally healthy, assessed via a General Health Questionnaire (GHQ)
* Some residual beta-cell activity (confirmed with urine test on induction)
* Normal or moderately increased albuminuria (needs to be below 300mg/g)
* Normal, mildly or moderately decreased glomerular filtration rate (GFR) (needs to be above 45ml/min/1.732).
* Able and willing to attend SportExR a total of 5 times: 1 induction and 2 testing visits and 2 return check-up visits.

Exclusion Criteria:

* \<75 years old and over 90 years of age
* Currently on fast-acting insulin therapy (i.e., Humalog)
* Confirmed uncontrolled diabetes (HbA1C \>10% or 85mmol/mol).
* Currently on GLP-1 therapy
* Habitual smoker or vaper
* Veganism
* Lactose or dairy intolerance
* Coeliac or gluten intolerance
* History of gastrointestinal disease
* Experience",75,90,ALL,RECRUITING,"['clinic', '\\<75', 'intolerance\n* history', 'times', 'dairy', 'history', 'age', 'therapy\n* habitual smoker', 'haemoglobin', '5 times', 'type', 'check', 'albuminuria', 'coeliac', 'body mass index', 'total', '≤40kg/m2', 'disease', 'glycated haemoglobin', 'body', 'fast-acting insulin therapy', 'a total', '* stable body mass', 'return', 'exclusion criteria', 'urine', 'rate', 'ghq', '\\>6.5%', 'a general health questionnaire', 'hba1c \\>10%', 'bmi', '85mmol/mol', 'sportexr', '2 testing visits', 'filtration', 'therapy', 'intolerance', 'testing', 'lactose', '* confirmed uncontrolled diabetes', 'diabetes', 'glycated', 'cell', '2 return check-up visits', 'questionnaire', '300mg', 'health', 'gastrointestinal disease', 'beta', 'veganism', 'years', 'hba1c', 'mass', 'criteria', 'experience', 'min/1.732', 'index', 'induction', '300mg/g', 'smoker', '45ml/min/1.732', 'insulin', 'urine test', 'test', 'vaper', 'visits', 'some residual beta-cell activity', 'gfr', '45ml', 'activity', 'female', 'exclusion']"
NCT07121504,Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral Nutrition,Type 2 Diabetes,"Inclusion Criteria:

1. Age ≥18 years.
2. Diagnosis of T2DM requiring surgical procedures (duration ≥2 hours) with anticipated short-term total parenteral nutrition (TPN) during the perioperative period (expected hospitalization \>72 hours).
3. Glycemic control criteria (meeting any of the following):

   ①HbA1c ≥7.5% or random plasma glucose ≥13.9 mmol/L
   * Established T2DM with poor glycemic control (HbA1c ≥7.5%) despite combination therapy (≥2 oral antidiabetic drugs) ③Insulin-treated patients with suboptimal control (HbA1c ≥7.0%) after adequate dose adjustment.
4. Willing to sign the informed consent form.

Exclusion Criteria:

1. Patients with acute diabetic complications, including: diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), etc.
2. Patients with type 1 diabetes or other specific types of diabetes.
3. Patients with severe organ dysfunction, defined as:

   * Cardiac function ≥Class III (NYHA classification)

     * ALT/AST \>3× upper limit of normal (U",18,100,ALL,RECRUITING,"['t2dm', 'nutrition', 'diabetic ketoacidosis', '≥class', '③insulin-treated patients', '2. diagnosis', 'dose', 'combination', 'following', 'adjustment', 'patients', 'consent', 'type', 'hospitalization \\>72 hours', 'poor glycemic control', 'classification', 'dka', 'severe organ dysfunction', 'function', 'limit', 'adequate dose adjustment', 'organ', 'glucose', 'any', 'hba1c ≥7.0%', 'duration', 'state', 'dysfunction', 'hhs', 'the following', 'combination therapy', 'inclusion', 'term', '①hba1c', 'exclusion criteria', 'u', 'inclusion criteria', 'period', 'plasma', 'the informed consent form', 'therapy', 'types', '3. glycemic control criteria', 'procedures', '3. patients', '≥2 oral antidiabetic drugs', 'age ≥18 years', 'type 1 diabetes', 'diabetes', 'hours', 'the perioperative period', 'suboptimal control', 'hyperglycemic hyperosmolar state', 'diagnosis', 'control', 'years', 'hba1c', 'surgical procedures', 'other specific types', 'criteria', 'drugs', 'form', 'mmol', 'ketoacidosis', 'duration ≥2 hours', 'complications', 'acute diabetic complications', 'tpn', 'hospitalization', 'exclusion']"
NCT06231771,Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer,Diabetic Foot Ulcer,"Inclusion Criteria:

* Patients between 18-70 years old.
* Patients have type 2 diabetes mellitus
* Patients with HbA1c, less than or equal to 10%.
* Patients who were presented with an ulcer size between 8 to 12 cm2, have been diagnosed as full-thickness DFU.
* Adequate vascular perfusion (ABI ≥ 0.7 and \< 1.3)
* Patients who are able and willing to provide consent and agree to comply with study procedures and follow-up evaluations.

Exclusion Criteria:

* Patients who are not diabetic.
* Patients with 2 or more ulcers.
* Patients with a history of participating in another stem cells trial or therapy within 3 months.
* Patients who are unsuitable to participate the clinical trial as determined by Investigators.",18,70,ALL,NOT_YET_RECRUITING,"['10%', '2 or more ulcers', 'abi', 'history', 'ulcer', 'consent', 'patients', '* adequate vascular perfusion', 'type', 'who', 'a history', 'evaluations', 'trial', '* patients', '2 diabetes', 'thickness', 'mellitus\n* patients', '3 months', 'vascular', 'exclusion criteria', 'inclusion criteria', 'therapy', 'months', 'study', 'procedures', 'full-thickness dfu', 'diabetes', 'cells', 'size', 'years', 'hba1c', 'study procedures', 'criteria', 'investigators', '8 to 12 cm2', '≥', 'ulcers', 'stem', 'perfusion', 'an ulcer size', 'another stem cells trial', 'inclusion', 'follow-up evaluations', 'exclusion', 'the clinical trial']"
NCT05801614,Normalized Glucose Levels in Type 2 Diabetes With Carbohydrate or Caloric Restriction,Diabetes Mellitus Type 2 in Obese,"Inclusion Criteria:

* HbA1c \> 48 mmol/mol (with or without medical treatment);
* less than 6 years since the diagnosis of T2D
* BMI ≥ 27 kg/m2 (≥ 25 kg/m2 for Asians).

Exclusion Criteria:

* Insulin deficiency.
* HbA1c concentration of 12% or more (≥108 mmol/mol),
* treatment with sulphonyl urea or sodium-glucose-cotrasporter2-inhibitor (SGL2-i),
* myocardial infarction within the previous 6 months,
* severe or unstable heart failure
* other severe diseases including cancer, psychiatric/eating disorders, severe depression - substance abuse,
* conditions that may affect the ability of patients to participate in the study",18,100,ALL,RECRUITING,"['infarction', 'less than 6 years', 'deficiency', 'abuse', 'cotrasporter2', '* hba1c concentration', 'diseases', 'conditions', 'sulphonyl', 'sodium', 'patients', 'urea', '25 kg/m2', 'that', '27 kg/m2', 'inhibitor', 'substance', '* insulin deficiency', 'glucose', 'treatment', 'depression', 'medical treatment', 'the study', '48 mmol/mol', 'ability', 'inclusion', 'concentration', 'the diagnosis', 'other severe diseases', 'exclusion criteria', 'cancer', 'inclusion criteria', '* myocardial infarction', '≥108', 't2d\n* bmi', 'asians', 'months', 'study', '(≥108 mmol/mol', 'sgl2', 'failure', 'heart', 'diagnosis', 'years', 'criteria', 'sulphonyl urea', 'disorders', '≥', 'insulin', 'psychiatric/eating disorders', 'the previous 6 months', '12%', 'the ability', 'exclusion', 'sodium-glucose-cotrasporter2-inhibitor']"
NCT06716216,A Study of BGM0504 in Participants with Type 2 Diabetes,Type 2 Diabetes Mellitus (T2DM),"Inclusion Criteria:

* ■ Have been diagnosed with type 2 diabetes mellitus (T2DM);

  * Metformin is used in screening : 1) After used stable-dose metformin (≥1500 mg/day) or maximum tolerated (\< 1500mg but≥1000mg daily) for 8 weeks before screening； 2)Metformin treatment dose \<1500mg/day at Screening and have not reached the maximum tolerated dose ；3) Metformin combined with daily fixed-dose sulfonylureas (minimum therapeutic dose on the drug label) had been stable for ≥8 weeks when entering the induction period.
  * Have a BMI ≥23 kilograms per meter squared (kg/m²) at screening;
  * Be of stable weight (± 5%) for at least 3 months before screening;
  * Have HbA1c between ≥7.5% and ≤11.0%；

Exclusion Criteria:

* ■ Previous diagnosis of type 1 diabetes, special type diabetes;

  * There are malignant tumors within 5 years before screening, or patients are in latent of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical car",18,100,ALL,RECRUITING,"['carcinoma', 'skin', 'weight', 'mellitus', 'screening', '8 weeks', 'the induction period', '■ previous diagnosis', '5%', 'a bmi ≥23 kilograms', 'dose', 'sulfonylureas', 'patients', 'type', 'type 2 diabetes', 'latent', '；\n\nexclusion criteria', 'treatment', 'basal', 'period', 'stable weight', 'malignant tumors', 'kg/m²', 'stable-dose metformin', 'the drug label', 'weeks', 'months', 'tumors', '≥1500 mg/day', 'skin basal cell carcinoma', 'diabetes', 'type 1 diabetes', 'cell', '±', 'squamous cell carcinoma', 'diagnosis', ', special type diabetes', 'hba1c', '* metformin', 'criteria', 'years', 'dm', 'label', 'drug', 'induction', 'metformin', 'meter', 'kilograms', 't2', 'inclusion', '≥8 weeks', 'exclusion', 'clinical malignant tumors']"
NCT05182970,Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET),PreDiabetes,"Inclusion Criteria:

I. AMI

II. Swedish citizens with a personal ID number ≥18 years and ≤80 years

III. Newly diagnosed prediabetes:

1. HbA1c 42-47 mmol/mol or
2. Capillary or venous fasting plasma glucose concentration 6.1-6.9 mmol/L or
3. 2-hour post-load capillary glucose concentration 8.9-12.1 mmol/L or
4. 2-h post-load venous plasma glucose concentration 7.8-11.0 mmol/L
5. HbA1c \<48 mmol/mol and 2-hour post-load capillary glucose concentration \>12.1 mmol/L or 2-h post-load venous plasma glucose concentration \>11.0 mmol/L (thus elevated 2-hour glucose levels in the diabetes range but without HbA1c levels diagnostic for diabetes)

IV. Naïve to metformin and other glucose lowering therapy

V. Signed informed consent

Exclusion Criteria:

I. Type 1 diabetes

II. Known type 2 diabetes

III. Indication for glucose lowering treatment

IV. Acute condition with high risk for volume depletion, circulatory shock, hypoxia

V. Serious illness, other than cardiovascular, with short life e",18,100,ALL,RECRUITING,"['high risk', '6.1-6.9 mmol/l', 'illness', 'condition', 'other glucose', '8.9-12.1 mmol/l', '2-hour glucose levels', 'a personal id number', 'iv', 'consent', 'hba1c 42-47 mmol/mol', '≥18 years', 'range', 'type', 'i. ami\n\nii', 'hour', 'shock', 'number', 'glucose', 'treatment', '\\>11.0 mmol/l', 'levels', 'prediabetes', 'concentration', 'fasting plasma glucose concentration', 'mol', 'inclusion criteria', 'plasma', 'therapy', 'hba1c levels', '/l', 'hypoxia', 'diabetes', 'short life', 'life', 'citizens', 'indication', '≤80 years', 'depletion', 'volume depletion', 'criteria', 'hba1c \\<48 mmol', '. acute condition', 'years', 'volume', 'risk', 'serious illness', 'inclusion', 'circulatory shock', 'exclusion', 'the diabetes range']"
NCT07187531,SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes,Type 1 Diabetes,"Inclusion Criteria:

1. Participant and/or appropriate legal guardian must have given written informed consent and/or assent according to local, regional and/or country specific guidance before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
2. Males and females 15-40 years old at the time of randomisation in Part A. Males and females 5-40 years old\*, inclusive, at the time of randomisation in Part B.
3. Weight ≥16.0 kg at time of randomisation.
4. Participant has received a diagnosis of T1D according to American Diabetes Association criteria within 100 days of randomization. For participants who were initially misdiagnosed with Type 2 diabetes, time from misdiagnosis with Type 2 diabetes to randomization is 100 days. Note: The date of diagnosis is defined as the date of the first insulin dose or any other glucose lowering medication. An extension of no more than 14 days",15,40,ALL,RECRUITING,"['participants', 'adverse effects', 'purpose', 'weight', 'nature', 'days', 'assent', 'guidance', 'dose', 'consent', 'females', 'type', 'participant', 'who', 'association', 'american diabetes association criteria', 'trial', 'type 2 diabetes', 'medication', 'glucose', 'the time', 'activities', '4. participant', 'possible risks', 'effects', 'inclusion criteria', '5-40 years', 'any study-related activities', 'the trial', 'males', 'randomisation', 'misdiagnosis', 'part a. males', 'study', 'the date', '2. males', 'any other glucose', 'diabetes', 'part', 'diagnosis', 'an extension', 'the first insulin dose', 'time', 'years', 'criteria', 'randomization', 'the full nature', 'country', 'extension', 't1d', 'a diagnosis', 'guardian', 'date', 'insulin', '100 days', 'risks', 'weight ≥16.0 kg', 'inclusion']"
NCT05951283,Quantifying Artificial Pancreas-related Changes in Diabetic Neuropathy,Diabetes Complications,"Inclusion Criteria:

Type 1 diabetes aged 18-70 who falls into either of these three categories and has the ability to read and comprehend English:

Starting Artificial Pancreas therapy as determined for clinical need Starting insulin pump therapy as determined for clinical need On multiple daily injection therapy for insulin delivery

Exclusion Criteria:

* History of ocular disease that may affect the cornea.
* History of corneal trauma or surgery (NB cataract surgery does not preclude enrolment unless surgery occurred in the 3 months prior to enrolment date)
* Concurrent ocular disease, infection or inflammation.
* History of neuropathy due to alcoholism, renal impairment requiring renal replacement therapy, infectious disease (e.g., Lyme disease, HIV/AIDS, hepatitis B), liver failure, B12 deficiency
* Unable to read and comprehend English",18,100,ALL,NOT_YET_RECRUITING,"['the 3 months', 'enrolment date', 'deficiency', 'history', 'delivery', 'artificial pancreas therapy', 'these three categories', 'enrolment', 'liver failure', 'corneal trauma', 'type', 'that', 'ocular disease', 'who', 'neuropathy', 'disease', 'insulin pump therapy', 'need', 'injection', 'insulin delivery\n\nexclusion criteria', 'ability', 'pump', 'infection', 'inclusion', 'pancreas', 'infectious disease', 'trauma', 'inclusion criteria', 'the cornea', 'e.g., lyme disease', 'cornea', 'therapy', 'b12 deficiency', 'cataract', 'months', 'liver', 'diabetes', 'type 1 diabetes', 'alcoholism', 'impairment', 'replacement', 'failure', 'hepatitis b', 'multiple daily injection therapy', 'categories', 'criteria', 'surgery', 'inflammation', 'date', 'insulin', '* concurrent ocular disease', 'either', 'english', 'renal replacement therapy', 'nb cataract surgery', 'the ability', 'clinical need', 'hiv/aids', 'exclusion']"
NCT06573905,"Mapping Diabetes in Quebec: Validating Medico-administrative Algorithms for Type 1 Diabetes, Type 2 Diabetes and LADA","Diabetes Mellitus, Type 1","Inclusion Criteria:

* Individuals diagnosed with Type 1, Type 2, or Latent Autoimmune Diabetes in Adults (LADA) based on clinical or self-reported data.
* Participants diagnosed between 1997 and 2024.
* Residents of Quebec with available medico-administrative records from 1997 to 2024.

Exclusion Criteria:

* Non-residents of Quebec during the study period.",18,100,ALL,NOT_YET_RECRUITING,"['participants', '* residents', 'type', 'residents', 'clinical or self-reported data', 'adults', 'latent autoimmune diabetes', '* participants', 'the study period', 'period', 'exclusion criteria', 'inclusion criteria', 'lada', 'study', 'data', 'diabetes', 'quebec', 'criteria', 'available medico-administrative records', '-', 'individuals', 'self', 'inclusion', 'records', 'exclusion']"
NCT06921356,Groceries Plus Multi-Component Lifestyle Intervention for Adults With Hypertension and Type 2 Diabetes,Hypertension,"Inclusion Criteria:

* Age 18 years or older
* Diabetes Mellitus Type 2 defined by: self-reported type 2 diabetes diagnosis, or HbA1c\>=6.5%, or treatment of diabetes with diabetes medications(s)
* Baseline systolic BP 120-159 mmHg (with or without medications.)
* Serum potassium level \>3.0 and \<5 mmol/L,
* Estimated glomerular filtration rate (eGFR) \>=45 mL/min/1.73m2.
* Willing and able to complete required procedures in English.
* Living in Healthy Food Priority Area in Baltimore; the US Department of Agriculture (USDA) defined low income, low access areas, or census blocks with area deprivation index (ADI) 60 and above (State Decile\>=6.)

Exclusion Criteria:

* Hypoglycemia requiring hospitalization or the assistance of another person in the last 6 months
* Cardiovascular event within 6 months
* On diabetes or weight loss medications such as glucagon-like peptide 1 (GLP-1), GLP-1/glucose-dependent insulin-releasing peptide (GIP), insulin, or any combination of these medications",18,100,ALL,RECRUITING,"['census blocks', 'food', 'blocks', 'weight', 'age', 'agriculture', 'baseline systolic bp', 'peptide', '\\>3.0', 'weight loss medications', '* cardiovascular event', 'state decile\\>=6', 'required procedures', 'exclusion criteria', 'low income', 'procedures', 'diabetes', 'older\n* diabetes', 'the assistance', 'diagnosis', 'years', 'insulin', 'self', 'inclusion', 'hospitalization', '6 months', 'glucagon', '* hypoglycemia', 'the us department', '120-159 mmhg', 'level', 'event', 'serum', '18 years', '* serum potassium level', 'adi', 'usda', '\\<5 mmol/l', 'deprivation', 'another person', 'area', 'these medications', 'index', 'glucagon-like peptide', 'exclusion', 'mellitus type', 'healthy food priority area', 'glp-1', 'hypoglycemia', 'areas', 'treatment', 'glucose-dependent insulin-releasing peptide', 'rate', 'inclusion criteria', 'potassium', 'medications', 'any combination', 'criteria', 'baltimore', 'hba1c\\>=6.5%', 'english', 'person', 'gip', 'combination', 'type', 'ml/min/1.73m2', 'glucose', 'state', 'mmhg', 'income', 'the last 6 months', 'months', 'filtration', 'loss', 'census', 'area deprivation index', 'low access areas', 'access', 'priority', 'assistance']"
NCT03900286,Low Energy Diet and Familial Partial Lipodystrophy,Lipodystrophy,"Inclusion Criteria:

* Familial Partial Lipodystrophy
* Age \>= 18 yrs
* T2DM
* Willingness to check daily blood sugars
* HbA1c between 53mmol(7%)- 108 mmol(12%)
* Weight stable for 3 months
* Capacity to consent

Exclusion Criteria:

* Pregnancy
* Untreated thyroid dysfunction (patients who have been euthyroid on medication for at least 3 months can be included)
* Use of medication adversely that affects diabetes control (e.g. steroids/ immunosuppressants/ certain antipsychotics)
* Incapacity to give informed consent
* History of an eating disorder/ purging behaviour
* Previous gastric bypass/ banding
* Use of Leptin Therapy
* Untreated retinopathy",18,100,ALL,RECRUITING,"['behaviour', 'daily blood sugars', 'weight', 'history', 'capacity', 'leptin', 'consent', 'patients', 'antipsychotics', 'who', '53mmol(7%)- 108 mmol(12%', '* weight', 'medication', 'untreated retinopathy', '* use', '* incapacity', 'informed consent', '3 months', 'pregnancy', 'leptin therapy', 'dysfunction', '* t2dm\n* willingness', 'exclusion criteria', 'inclusion criteria', 'retinopathy', 'therapy', 'at least 3 months', '18 yrs', 'months', '* capacity', 'control', 'criteria', 'lipodystrophy', 'blood', 'willingness', 'thyroid', 'sugars', 'affects', 'incapacity', 'inclusion', 'exclusion']"
NCT07389005,"Exercise, Chronotype, and Prediabetes",Prediabetes,"Inclusion Criteria:

1. Able to provide signed and dated written informed consent prior to any study specific procedures
2. Adult men and women aged between more than 18 and ≤ 75 years
3. Body mass index (BMI) of 25 - 35 kg/m2
4. Stable weight (no weight loss or gain \> 3 kg in the past 3 months)
5. Pre-diabetes defined as an isolated impaired glucose tolerance or a combination of impaired glucose tolerance and impaired fasting glucose (values are based on the American Diabetes Association (ADA):

   1. impaired glucose tolerance (plasma glucose 140 mg/dL to 199 mg/dL, 120 minutes after consumption of 75g of glucose)
   2. impaired fasting glucose (fasting plasma glucose 100 mg/dL to 125 mg/dL)
6. Morning (Morningness-Eveningness Questionnaire \[MEQ\] score ≥ 59) or evening (MEQ score ≤ 41) chronotype

Exclusion Criteria:

1. Previously diagnosed with type 2 diabetes
2. Moderate to severe anemia (hemoglobin \< 10 g/L)
3. Uncontrolled hypertension
4. Abnormal electrocardiogram (ECG) at ",18,100,ALL,NOT_YET_RECRUITING,"['. body mass index', '199 mg', 'moderate to severe anemia', 'any study specific procedures', 'the past 3 months', 'weight', 'hemoglobin', 'dl', 'impaired glucose tolerance', 'consent', '75g', 'combination', 'ecg', 'type', '75 years', 'type 2 diabetes', 'glucose', 'ada', 'women', '120 minutes', 'consumption', '25 - 35 kg/m2', 'body', 'the american diabetes association', '(meq', 'no weight loss', 'written informed consent', 'stable weight', 'morning', '\\', 'inclusion criteria', 'fasting plasma glucose', 'score ≥', 'plasma', 'morningness', 'electrocardiogram', 'bmi', 'months', '6. morning', 'l', 'study', 'procedures', 'loss', 'hypertension', 'diabetes', 'questionnaire', 'abnormal electrocardiogram', 'impaired fasting glucose', 'years', '125 mg', 'criteria', 'fasting', 'score', 'uncontrolled hypertension', '3 kg', 'index', 'minutes', 'adult men', 'tolerance', 'anemia', 'evening', 'inclusion', 'adult', 'chronotype', 'a combination', 'exclusion', 'values']"
NCT06436794,"""Mantou"" Screening for GDM Before 20 Weeks of Gestation",GDM,"Inclusion Criteria:Singleton , before 20 weeks of gestation, aged 18-40 years old, able to understand the experimental requirements, willing and able to follow the experimental and follow-up procedures.

Exclusion Criteria: diabetes diagnosed before pregnancy, serious heart disease, blood disease, immune system disease and other unsuitable for pregnancy, twin or multiple pregnancy, age\<18 or\>40, fetal death in utero before 28 weeks, serious mental illness, and inability to communicate.",18,40,FEMALE,NOT_YET_RECRUITING,"['illness', 'the experimental requirements', 'disease', 'death', 'fetal death', 'or\\>40', 'pregnancy', 'serious heart disease', '28 weeks', 'exclusion criteria', 'inclusion criteria', 'system', 'serious mental illness', 'weeks', 'procedures', 'requirements', 'age\\<18 or\\>40', 'diabetes', 'age\\<18', 'heart', '20 weeks', 'years', 'criteria', 'blood', 'twin or multiple pregnancy', 'immune system disease', 'inability', 'gestation', 'blood disease', 'exclusion']"
NCT01702051,Extending Indication for Islet Autotransplantation in Pancreatic Surgery,Diabetes,"Inclusion Criteria:

* 18 years of age

  * ability to provide written informed consent
  * fasting glycaemia \<126 mg/dl without glucose-lowering medications.

Exclusion Criteria:

* Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial
* Diagnosis of intraductal papillary mucinous cancer, unless the absence of multifocal lesion is demonstrated by endoscopic US
* Presence of multifocal or residual disease at the pancreatic margin. If a malignat disease is the reason for the surgery, 1 cm of the pancreatic remnant in proximity to the pancreatic margin will be resected and sent for immediate pathologic analysis to confirm margin negativity and to rule out multifocal tumor",18,100,ALL,RECRUITING,"['presence', 'condition', '* presence', 'age', 'any medical condition', 'lesion', 'reason', 'dl', 'the safe completion', 'analysis', 'consent', 'the investigator', 'trial', 'disease', '* 18 years', 'completion', 'glucose', 'endoscopic us', 'intraductal papillary mucinous cancer', 'multifocal lesion', 'ability', 'proximity', 'absence', 'a malignat disease', 'remnant', 'exclusion criteria', 'cancer', 'inclusion criteria', 'medications', 'malignat', 'the opinion', '* ability', 'investigator', 'opinion', 'glycaemia', 'the absence', 'the pancreatic remnant', 'the pancreatic margin', 'the trial\n* diagnosis', 'diagnosis', 'margin', 'the surgery', 'criteria', 'years', 'negativity', 'surgery', 'margin negativity', 'tumor', '1 cm', 'immediate pathologic analysis', 'multifocal tumor', 'pathologic', 'glucose-lowering medications', 'multifocal or residual disease', 'inclusion', 'exclusion', 'the reason']"
NCT06217302,Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease,Diabetic Nephropathies,"Inclusion Criteria:

* Type1 diabetes (T1D) continuously treated with insulin within one year from diagnosis.
* Duration of T1D ≥ 8 years;
* eGFR based on serum creatinine and cystatin c (2021 serum creatinine-cystatin C CKD-EPI equation) between 20 and 60 ml/min/1.73 m2 at screening (with the option of a second eGFR measurement within 4 weeks from the first one if the eGFR was in the range of \>60 to ≤65 or ≥16 to \<20 ml/min/1.73 m2);
* a. First morning void urinary albumin creatinine ratio (UACR) ≥200 mg/g at Screening or on repeat measurement within 4 weeks from the first one, or b. First morning void urinary UACR ≥100 mg/g at Screening or on repeat measurement within 4 weeks and at least one uACR \>=30 in the previous 2 years while treated with RASB at a stable dose;
* HbA1c at screening \<10% (with the option of a second HbA1c measurement within 4 weeks from the first one if the HbA1c was ≤10.2%);
* Receiving standard of care, including renin angiotensin system blockers (RASB) at",18,100,ALL,RECRUITING,"['mg', '≤65', '* type1 diabetes', 'ratio', 'urinary uacr', 'the egfr', 'screening', 'a stable dose', 'standard', 'option', 'dose', 'a second hba1c measurement', 'creatinine', '≥200', 'type1', 'range', '8 years', 'a second egfr measurement', 'the range', 'year', 'repeat measurement', 'egfr', 'duration', 'repeat', '* duration', 'serum', 'blockers', 'renin angiotensin system blockers', 'inclusion', '4 weeks', 'inclusion criteria', 'morning', 'system', 'angiotensin', 'the hba1c', 'weeks', 'g', 'rasb', '\\>=30', 'diabetes', 'measurement', 'care', '* egfr', '\\>60', 'diagnosis', '\\<10%', 'one year', 'the previous 2 years', 'criteria', 'years', 'hba1c', '\\<20 ml/min/1.73 m2', 't1d', 'insulin', 't1d ≥', '* hba1c', 'uacr', 'the option', '≥16', 'serum creatinine', 'epi', '%', 'equation']"
NCT05294653,Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes,Atherosclerotic Cardiovascular Disease,"Inclusion Criteria:

1. Diagnosis of type 1 diabetes or type 2 diabetes
2. Age of onset: \<18y
3. Enrollment age: ≥18y
4. Gender: male or female
5. Diabetes duration ≥ 5 years

Exclusion Criteria:

1. Specific types of diabetes
2. Clinical diagnosis of diabetes is unknown, and it belongs to untyped diabetes
3. Pregnancy or lactation
4. Received glucocorticoids, immunosuppressants, non-glycemic biological agents, and cytotoxic drugs in the past 3 months; non-steroidal pain relievers or antibiotics used for more than 1 week continuously
5. Onset of acute complications of diabetes in the past 3 months
6. Major trauma and surgery history in the past 3 months",18,100,ALL,NOT_YET_RECRUITING,"['acute complications', '5 years\n\nexclusion criteria', 'antibiotics', 'pain', 'the past 3 months', 'more than 1 week', 'age', 'history', 'enrollment age', '5. onset', 'type', 'week', 'relievers', 'non-steroidal pain relievers', 'enrollment', 'major trauma', 'onset', 'duration', '2 diabetes', 'gender', 'non-glycemic biological agents', 'pregnancy', 'trauma', 'inclusion criteria', 'types', 'glucocorticoids', 'it', 'cytotoxic drugs', 'months', 'lactation', 'immunosuppressants', 'diabetes', 'agents', 'diagnosis', '\\<18y', 'years', 'criteria', 'surgery', 'drugs', '3. pregnancy', 'untyped diabetes', 'complications', 'inclusion', '1. specific types', 'surgery history', 'female', 'exclusion']"
NCT05203640,Effects of Resistance Exercise on Blood Glucose in Post-menopausal Women With Type 1 Diabetes,Type 1 Diabetes,"Inclusion Criteria:

* female
* type 1 diabetes diagnosed for at least 1 year
* at least 12 months since last menstrual period
* physically able and willing to perform resistance exercise
* HbA1c \< 10%
* residing near Edmonton, Alberta / able to attend laboratory based sessions at the University of Alberta

Exclusion Criteria:

* Individuals with HbA1c \>9.9%
* Frequent and unpredictable hypoglycaemia
* A change in insulin management strategy within two months of the study
* Blood pressure \> 144/95,
* Severe peripheral neuropathy,
* A history of cardiovascular disease
* Musculoskeletal injuries affecting the ability to perform resistance exercise.
* Individuals who are treated with medications (other than insulin) that affect glucose metabolism (e.g. atypical antipsychotics, corticosteroids)
* A body mass index \>30kg/m2,
* Smoking
* Moderate to high alcohol intake (\>2 drinks per day)",18,100,FEMALE,RECRUITING,"['metabolism', '10%', '\\> 144/95', 'resistance', 'history', 'glucose metabolism', 'cardiovascular disease', 'female', 'alcohol', 'type', 'that', 'who', 'antipsychotics', 'sessions', 'a history', '* individuals', 'high alcohol intake', 'year', 'resistance exercise', 'disease', 'two months', 'glucose', 'last menstrual period', 'injuries', 'strategy', 'body', 'ability', 'period', 'laboratory', 'edmonton', 'inclusion criteria', 'smoking', 'alberta\n\nexclusion criteria', 'medications', '(\\>2 drinks', 'exercise', 'drinks', 'alberta', 'months', 'study', 'management', 'insulin management strategy', 'musculoskeletal injuries', 'e.g. atypical antipsychotics', 'diabetes', 'day', 'intake', 'hypoglycaemia', 'pressure', 'change', 'criteria', 'the university', 'blood', 'mass', 'individuals', 'laboratory based sessions', 'a change', 'index', 'at least 1 year', 'insulin', 'at least 12 months', 'inclusion', 'the ability', 'exclusion', '* smoking', 'corticosteroids']"
NCT06888050,"Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study",New-onset Type 2 Diabetes,"Inclusion Criteria:

* Age between 18 and 75 years old.
* Diagnosed with type 2 diabetes according to WHO diagnostic criteria, with HbA1c between 7% and 9% at this examination, fasting venous blood glucose ≤ 11.1 mmol/L, and BMI ≥ 18.5 kg/m2; known disease duration ≤ 24 months.
* Voluntary participation in this study and signing of the informed consent form. If the subject is unable to read the informed consent form (e.g., illiterate subjects), a witness must be present to observe the informed consent process and sign the informed consent form on their behalf.
* No previous use of hypoglycemic drugs.

Exclusion Criteria:

* Type 1 diabetes.
* Participants who have participated in other clinical trials of diabetes treatment drugs before the start of this study.
* Those who have experienced diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar non-ketotic coma within the past six months and required hospitalization.
* Those who have experienced decompensated heart failure (NYHA",18,75,ALL,RECRUITING,"['participants', 'diabetic ketoacidosis', 'the informed consent process', '≥ 18.5 kg/m2', 'subject', 'consent', 'witness', 'decompensated heart failure', 'type', 'who', 'no previous use', 'disease', 'type 2 diabetes', 'trials', 'glucose', 'diabetes treatment drugs', 'duration', '* participants', 'treatment', 'examination', 'this examination', '* age', 'other clinical trials', 'exclusion criteria', 'inclusion criteria', 'coma', 'the informed consent form', 'subjects', 'bmi', 'months', 'study', 'those', 'the past six months', 'diabetes', 'the start', 'participation', '* type 1 diabetes', 'the subject', 'process', 'diabetic lactic acidosis', 'heart', '* those', 'failure', 'years', 'hba1c', 'criteria', 'blood', 'this study', 'a witness', '11.1 mmol/l', 'who diagnostic criteria', 'drugs', '* voluntary participation', 'form', 'ketoacidosis', 'behalf', 'hyperosmolar non-ketotic coma', 'signing', 'hypoglycemic drugs', 'e.g., illiterate subjects', 'start', 'acidosis', 'inclusion', 'hospitalization', 'exclusion', 'their behalf', 'known disease duration ≤']"
NCT05228860,Addressing Diabetes by Elevating Access to Nutrition,Diabetes,"Inclusion Criteria:

* For main study (index/intervention) participants:

  * Age at enrollment: 18+ years
  * Self-identified ethnicity: Hispanic, Latino, Chicano, or Spanish
  * Type 2 diabetes indicated in the electronic health record, e.g. as ICD-10 (International Classification of Diseases) diagnosis code or HbA1c value
  * Have indicated food insecurity according to the screening 2-item Hunger Vital Sign questionnaire
  * Have a Body Mass Index (BMI) =\> 25
  * Receiving care at our partnering community health centers (e.g., Clinica de la Raza)
  * Currently residing in Alameda or Contra Costa County and not expecting to relocate in the next 6-12 months
  * Have access to phone or computer, email, and some internet for access to remote intervention and completion of follow-up measures
* For household members:

  * Age at enrollment: 12+ years
  * Significantly involved in supporting nutrition in the home including food shopping, preparation, social support for healthy nutrition
 ",18,100,ALL,RECRUITING,"['participants', 'nutrition', 'food', 'contra costa county', 'computer', 'screening', 'diseases', 'code', 'household', 'shopping', 'type', 'household members', 'internet', 'centers', '(index/intervention', 'classification', 'food insecurity', 'completion', 'enrollment', 'members', 'measures', 'home', 'body', 'vital sign questionnaire', 'hba1c value', '* age', 'item', 'inclusion', 'community', 'the electronic health record', 'inclusion criteria', 'email', 'the home', 'hunger', 'follow-up measures', 'ethnicity', 'bmi', 'preparation', 'social support', 'study', 'value', 'months', 'support', 'record', 'icd-10', 'diabetes', 'chicano', 'alameda', 'phone', 'care', 'insecurity', 'health', 'questionnaire', 'diagnosis', 'years', 'criteria', 'a body mass index', 'mass', 'index', 'access', 'the screening 2-item hunger', 'sign', 'some internet', 'self', 'the next 6-12 months', 'hispanic, latino', 'remote intervention', '12+ years', 'food shopping', 'healthy nutrition', 'intervention']"
NCT05026723,Food as Medicine for HIV and Diabetes,"Diabetes Mellitus, Type 2","Inclusion Criteria

* Male or female
* Diagnosis of HIV
* Diagnosis of Type 2 Diabetes Mellitus or high risk for type 2 diabetes mellitus, defined as meeting CDC eligibility criteria for the diabetes prevention program. Specifically, an individual without a diagnosis of T2DM must 1) have had a blood test result in the prediabetes range within the past year (Hemoglobin A1C: 5.7-6.4% OR Fasting plasma glucose: 100-125 mg/dL OR Two-hour plasma glucose \[after a 75 g glucose load\]: 140-199 mg/dL), 2) Have been previously diagnosed with gestational diabetes, OR 3) have a high-risk result (score of 5 or higher) on the Prediabetes Risk Test (https://www.cdc.gov/prediabetes/pdf/Prediabetes-Risk-Test-Final.pdf)
* Experiencing food insecurity as indicated by 2-item Hunger Vital Sign
* English speaking
* Aged ≥18 years
* BMI ≥ 23 kg/m2
* No plans to move from the area for at least 1 year
* Free living to the extent that participant has control over dietary intake
* Willing and able to provide wr",18,100,ALL,RECRUITING,"['high risk', 't2dm', '2-item hunger vital sign', 'food', 'diabetes mellitus', 'prevention', 'program', 'mellitus', 'dl', 'load\\', 'individual', 'type', 'the prediabetes', 'participant', 'result', 'hour', 'food insecurity', 'year', 'gestational diabetes', 'glucose', '23 kg/m2', '5.7-6.4%', 'https://www.cdc.gov/prediabetes/pdf/prediabetes-risk-test-final.pdf', 'prediabetes', 'cdc eligibility criteria', 'item', 'the extent', 'the diabetes prevention program', 'inclusion criteria', '\\[after', 'an individual', 'dietary intake', 'plasma', 'hunger', 'plans', 'plasma glucose', 'extent', 'a blood test result', 'diabetes', 'speaking', 'area', 'intake', 'no plans', 'insecurity', 'diagnosis', 'the prediabetes risk test', 'control', 'score', 'years', 'criteria', 'blood', 'hiv', '140-199 mg', 'eligibility', '≥', 'a diagnosis', 'sign', 'the past year', 'a high-risk result', '* bmi', 'a1c', 'risk', 'test', 'living', 'that participant', 'the area', 'inclusion', 'hemoglobin']"
NCT07236723,"Vitamin D, Nerve Growth Factor and Nerve Conduction Studies in Adult Male Type 2 Diabetic Neuropathy Patients",Diabetic Neuropathy,"Inclusion Criteria:

* Adult male patients 40 -65 years' old who have type 2 diabetes mellitus on oral hypoglycemic , non-diabetic healthy subjects of matched age and type 2male diabetic neuropathy patients of matched age .

Exclusion Criteria:

* Cardiac patients.
* Patients who have transient ischemic attack or stroke.
* Patients with inflammatory rheumatic diseases.
* Patients with malignant diseases.
* Hyperparathyroidism.
* Hypothyroidism.
* Renal impairment with renal replacement therapy.
* Liver diseases.
* Patients on vitamin D supplementation.
* Patients on vitamin B12 supplementation.",40,65,MALE,NOT_YET_RECRUITING,"['mellitus', 'diseases', '* adult male patients', '* cardiac patients', 'patients', 'type', 'who', '* patients', '2 diabetes', '* hyperparathyroidism', 'inclusion', 'stroke', 'exclusion criteria', '* hypothyroidism', 'inclusion criteria', 'hypothyroidism', 'vitamin b12 supplementation', 'therapy', 'subjects', 'vitamin', 'liver', 'malignant diseases', 'inflammatory rheumatic diseases', 'diabetes', 'impairment', 'replacement', '* liver diseases', 'matched age', 'criteria', 'years', 'supplementation', 'transient ischemic attack', 'hyperparathyroidism', 'attack', 'renal replacement therapy', '* renal impairment', 'adult', 'exclusion', 'vitamin d supplementation']"
NCT06970886,Effects of Rhythm-Based Music on Pregnancies With Gestational Diabetes,Gestational Diabetes Mellitus in Pregnancy,"Inclusion Criteria:

* Voluntarily agree to participate in the study with informed written consent
* Diagnosed with Gestational Diabetes Mellitus (GDM) and currently hospitalised
* In the third trimester of pregnancy
* Over the age of 18
* Have a live, single fetus

Exclusion Criteria:

* Any condition preventing participation in rhythm-based music making and listening (e.g., hearing, vision, or speech impairments)
* Regular and routine music listening habits during pregnancy
* Physical limitations or restrictions
* Mental or cognitive disorders requiring medication
* Use of corticosteroids or medications containing corticosteroids
* Known fetal abnormalities
* Systemic diseases other than GDM (e.g., Hypertension, Type 1 or Type 2 Diabetes, Thyroid disorders, etc.)
* Body mass index (BMI) of 30 or higher
* Discharge from the hospital before the 3rd day of the intervention",18,100,FEMALE,NOT_YET_RECRUITING,"['speech', 'condition', '(e.g., hypertension', 'mellitus', 'hearing', 'informed written consent', 'diseases', 'listening', 'intervention', 'trimester', 'consent', 'the intervention', 'fetus', 'limitations', 'the third trimester', 'gestational diabetes', 'medication', '* body mass index', 'exclusion', 'rhythm', '* use', 'mental or cognitive disorders', '2 diabetes', 'body', 'the study', 'pregnancy', 'inclusion', 'abnormalities', 'impairments', 'inclusion criteria', 'restrictions', 'medications', 'discharge', '* discharge', 'bmi', 'the 3rd day', 'study', 'hypertension', 'diabetes', 'the age', 'participation', 'music', 'criteria', 'mass', 'thyroid', 'pregnancy\n* physical limitations', 'index', 'disorders', 'hospital', '(gdm', 'the hospital', 'habits', 'vision', 'thyroid disorders', 'gdm', 'corticosteroids']"
NCT07073170,A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes,"Inclusion Criteria:

* Are native Chinese
* Have type 2 diabetes for at least 6 months
* Have been treated with diet and exercise, with or without a stable dose of metformin for at least 3 months
* Have hemoglobin A1c (HbA1c) of at least 7% and no greater than 10%
* Have a body mass index (BMI) of at least 20 milligrams per square meter (kg/m2) and no greater than 40 kg/m2
* Have had a stable body weight for the 3 months prior to screening
* Women must not be of childbearing potential

Exclusion Criteria:

* Have type 1 diabetes or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization
* Have had an episode of severe hypoglycemia within 6 months or have a history of hypoglycemia unawareness
* Have a clinically significant gastric emptying abnormality
* Have or have a history of pancreatitis
* Have signs and symptoms of liver disease, with the exception of non-alcoholic fatty liver disease
* Have a personal or family history of multiple endocrine neoplasia s",18,100,ALL,RECRUITING,"['the 3 months', 'weight', 'history', 'hyperosmolar state', 'a stable dose', 'episode', 'severe hypoglycemia', 'dose', 'exception', 'native chinese', 'type', 'an episode', 'hospitalization', 'hypoglycemia', 'a history', '*', 'disease', 'a clinically significant gastric', 'non-alcoholic fatty liver disease', '2 diabetes', 'diet', 'women', 'abnormality', 'state', 'body', 'milligrams', 'hypoglycemia unawareness', 'a stable body weight', 'pancreatitis', 'signs', 'exercise', 'symptoms', 'at least 3 months', 'bmi', 'liver disease', 'months', 'liver', 'unawareness', 'diabetes', 'at least 6 months', 'family', 'hba1c', 'a body mass index', 'potential\n\nexclusion criteria', 'multiple endocrine', 'at least 20 milligrams', 'neoplasia', 'criteria', 'mass', 'index', '* women', 'the exception', 'metformin', 'ketoacidosis', 'meter', 'at least 7%', 'gastric', 'inclusion', 'hemoglobin', 'endocrine', 'exclusion', 'square meter', '6 months', '(kg/m2']"
NCT06405373,Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART,Diabetes type1,"Inclusion Criteria:

* Adults 30 years and older
* Type 1 diabetes OR latent autoimmune diabetes in adults (LADA) clinically managed as type 1 diabetes
* Elevated diabetes distress, defined as a score \>= 2.0 on the T1-DDAS core scale
* English speaking

Exclusion Criteria:

* Does not receive diabetes care at UNC Endocrinology at Eastowne
* Cannot commit to the pre-scheduled weekly, virtual sessions
* Diagnosis of any major medical or psychiatric condition that would preclude participation
* Diagnosis of dementia or other conditions that affect memory or information retention, such as cognitive impairment
* Visual or auditory impairment that would interfere with participation in a group intervention
* Receiving inpatient psychiatric treatment or history of a suicide attempt within the past 12 months at the time of enrollment",18,100,ALL,RECRUITING,"['condition', 'retention', 'history', 'core', 'conditions', 'memory', 'participation\n* diagnosis', 'type', 'that', 'sessions', 'attempt', 'adults', 'suicide', 'enrollment', 'latent autoimmune diabetes', 'the time', '30 years', 'virtual sessions\n* diagnosis', 'the pre-scheduled weekly', 'weekly', 'treatment', 'other conditions', 'inpatient psychiatric treatment', 'group', 'unc endocrinology', 'dementia', 'inclusion criteria', 'a score \\>=', 'lada', 'a suicide attempt', 'months', '* adults', 'diabetes', 'participation', 'impairment', 'diagnosis', 'score', 'years', 'the t1-ddas core scale', 'criteria', 'time', 'information retention', 'the past 12 months', 'information', '1 diabetes', 'distress', 'a group intervention', 'eastowne', 'endocrinology', 'inclusion', 'scale', 'exclusion', 'intervention']"
NCT07046273,Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes,Type 2 Diabetes (T2DM),"Inclusion Criteria:

* 1\) Voluntary signing of informed consent; 2) Aged 18-75 years (inclusive) at the time of signing the informed consent, male or female; 3) Diagnosed with type 2 diabetes according to the WHO diabetes diagnostic criteria; 4) Laboratory tests at the research center at screening: 7.5%≤HbA1c≤10.5%; 5) Before randomization, study participants received stable doses of metformin (≥1500mg/day or maximum tolerated dose: \<1500mg/day, but ≥1000mg/day) for at least 8 weeks (maximum tolerated dose must be supported by previous medical records); 6) Body mass index (BMI) ≥18.5kg/m2 and ≤35.0kg/m2 at screening; 7) Willing and able to undergo treatment and follow-up as required by the protocol.

Exclusion Criteria:

1. Type 1 diabetes, special type of diabetes;
2. Received hypoglycemic drugs other than metformin (including Chinese medicine) within 8 weeks before randomization;
3. Used non-diabetes treatment drugs that may have a significant impact on glucose metabolism for 1 wee",18,75,ALL,NOT_YET_RECRUITING,"['a significant impact', 'participants', 'at least 8 weeks', 'metabolism', 'impact', 'doses', 'center', 'screening', 'research', '* 1\\) voluntary signing', '8 weeks', 'glucose metabolism', 'dose', 'consent', 'type', 'that', 'who', 'non-diabetes treatment drugs', 'glucose', '≥1500mg/day', 'the time', 'informed consent', 'previous medical records', 'treatment', '1. type 1 diabetes', '≥18.5kg/m2', 'body', 'diagnostic criteria', 'laboratory', 'study participants', '7.5%≤hba1c≤10.5%', '1 wee', '4) laboratory tests', 'inclusion criteria', 'chinese medicine', 'follow-up', 'bmi', 'the research center', 'study', 'inclusive', 'weeks', 'diabetes', 'maximum tolerated dose', 'tests', 'protocol', '≤35.0kg/m2', 'special type', 'time', 'years', 'criteria', 'mass', 'randomization', 'index', 'the protocol', 'the', 'drugs', 'medicine', 'metformin', 'the informed consent', 'stable doses', 'signing', 'hypoglycemic drugs', 'inclusion', 'records', 'exclusion']"
NCT07243951,Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma,Combined Hepatocellular-cholangiocarcinoma,"Inclusion Criteria:

1. Age 18-75 years.
2. ECOG Performance Status ≤ 1.
3. Pathologically confirmed combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (cHCC/CCA), with R0 resection and classified as Stage IB, Stage II, Stage IIIA, Stage IIIB, or Stage IA (G3) according to AJCC TNM Staging System (8th Edition, 2017).
4. No extrahepatic metastasis.
5. Post-operative Child-Pugh liver function class A; ECOG PS score: 0-1.
6. For subjects with chronic HBV infection, HBV-DNA must be \<500 IU/mL. HBsAg-positive patients must receive antiviral therapy according to the ""Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2015)"". HCV-RNA positive patients must receive antiviral therapy according to the ""Guidelines for the Prevention and Treatment of Hepatitis C (2015)"" and have normal liver function.
7. Adequate organ function, defined as follows:

(1) Hematological tests (no blood transfusion or use of hematopoietic growth factors within 14 days prior to scre",18,75,ALL,NOT_YET_RECRUITING,"['carcinoma', '14 days', '1) hematological tests', 'prevention', 'age', '2. ecog performance status', 'iiia', 'days', 'stage', 'stage iiia', 'g3', 'antiviral therapy', 'the ""guidelines', 'patients', 'r0 resection', 'ml', 'status', 'function', 'pugh', 'no extrahepatic metastasis', 'organ', 'stage iiib', 'hbsag-positive patients', 'treatment', 'stage ia', '\\<500', 'ajcc tnm staging system', 'performance', '18-75 years', 'factors', 'hepatitis c', 'cholangiocarcinoma', 'the prevention', 'hematopoietic growth factors', 'infection', 'growth', 'resection', 'iiib', 'inclusion criteria', 'hcv-rna positive patients', 'system', 'therapy', 'subjects', 'combined hepatocellular carcinoma', 'liver', 'staging', 'edition', 'guidelines', 'stage ib, stage ii', 'chronic hepatitis b', 'class', 'scre', 'tests', 'use', 'child', 'score', 'years', 'criteria', 'ecog', 'blood', 'hbv-dna', '7. adequate organ function', 'normal liver function', '8th edition', 'metastasis', 'chcc/cca', 'transfusion', 'inclusion', 'intrahepatic cholangiocarcinoma', 'no blood transfusion', 'chcc', 'chronic hbv infection']"
NCT07064473,"EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease","Diabetes Mellitus, Type 2","Inclusion Criteria :

* At least 18 years old at time of consent
* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2).
* Participants with medical history of hypertension and on active pharmacological treatment
* Participants with medical history of type 2 diabetes mellitus (T2DM) and on active pharmacological treatment
* Established cardiovascular (CV) disease and on active pharmacological treatment
* At least one additional risk factor for developing heart failure (HF)

Exclusion Criteria:

* History of HF or hospitalization for HF or treatment of HF
* Atrial fibrillation or Atrial flutter with a resting heart rate \>110 beats per minute (bpm) documented by echocardiogram (ECG) at Visit 1 (screening)
* Advanced untreated conduction disease or untreated clinically relevant ventricular a",18,100,ALL,RECRUITING,"['visit', 'participants', 'medical history', 'hf\n* atrial fibrillation', 'fibrillation', 'diabetes mellitus', 'history', 'echocardiogram', 'bpm', 'screening', 'flutter', 'r2', 'birth', 'consent', 'ecg', 'type', 'trial', 'active pharmacological treatment', 'minute', 'disease', 'a resting heart rate', 'methods', 'beats', 'treatment', 'women', '* participants', 'ich-gcp and local legislation', 'ich m3', 'legislation', 'admission', '* history', 'written informed consent', 'conduction', 'cardiovascular (cv) disease', 'rate', 'inclusion criteria', 'the trial', '(wocbp', 'accordance', 'hypertension', 'diabetes', 'failure', 'heart', 'birth control', 'control', 'time', 'untreated clinically relevant ventricular', 'atrial flutter', 'criteria', 'years', 'dm', ')\n\nexclusion criteria', 'factor', '\\>110 beats', '* women', 'hf', 'highly effective methods', 'risk', 'heart failure', 't2', 'inclusion', 'hospitalization', 'exclusion', 'ventricular']"
NCT04192422,DiGESTnewborn Study,GDM,"Inclusion Criteria:

* mothers and their babies who have been enrolled in DiGest Trial and who have provided informed consent

Exclusion Criteria:

* none",18,100,ALL,RECRUITING,"['criteria', 'exclusion', 'their babies', 'digest trial', 'inclusion', 'babies', 'informed consent\n\nexclusion criteria', 'consent', '* mothers', 'mothers', 'none', 'who', 'inclusion criteria', 'trial']"
NCT06191094,Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy,Diabetic Retinopathy,"Inclusion Criteria:

Patients must meet the following criteria for study entry:

* Signed Informed Consent Form
* Age ≥ 18 years at time of signing Informed Consent Form
* Ability to comply with the study protocol, in the investigator's judgment
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined below:

  * Women must remain abstinent or use contraceptive methods with a failure rate of \<1% per year during the treatment period and for 3 months after the final dose of the study drug.
  * A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).
  * Examples of contracepti",18,100,ALL,ENROLLING_BY_INVITATION,"['entry', 'amenorrhea', 'heterosexual intercourse', 'ovaries', 'potential', 'e.g., müllerian agenesis', 'agreement', 'müllerian', ""the investigator's judgment"", 'another cause', 'contracepti', 'consent', 'dose', 'patients', 'a woman', 'no identified cause', 'the investigator', 'tubes', 'judgment', 'year', 'she', 'methods', 'women', 'the study drug', '12 continuous months', '(i.e., removal', 'treatment', 'state', '3 months', 'ability', 'period', 'a postmenopausal state', 'contraceptive methods', 'inclusion criteria', 'rate', 'uterus', 'intercourse', 'removal', 'the final dose', 'months', 'the study protocol', 'study', 'the treatment period', 'investigator', 'refrain', 'agenesis', 'failure', 'woman', 'study entry', 'contraception', 'protocol', 'time', 'the following criteria', 'criteria', 'years', 'a failure rate', 'surgery', 'examples', 'menopause', 'drug', '≥', 'form', 'fallopian tubes', 'cause', '* examples', 'inclusion', '\\<1%']"
NCT06613854,Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes,Type 2 Diabetes Mellitus (T2DM),"Inclusion Criteria:

* Diagnosed with type 2 diabetes for up to 2 years (prior to randomization);
* Aged between 18 and 70 years, both sexes, of any race or ethnicity;
* HbA1c ≤8.0% at randomization;
* Baseline treatment with metformin at a steady daily dose of ≥1500 mg;
* Signed informed consent to participate in the study.

Exclusion Criteria:

* Treatment at any time in the past with SGLT2i, GLP-1RA, or DPP-4 inhibitors;
* Insulin treatment for longer than 2 weeks in the past;
* Body Mass Index below 22 kg/m2 or BMI above 40 kg/m2;
* Chronic kidney disease stages 3-5 (eGFR below 60 ml/min or the presence of albuminuria (urine albumin-to-creatinine ratio above 34 g/mmol);
* Known cardiovascular disease (angina pectoris, history of myocardial infarction, ischemic heart disease, heart failure, known carotid atherosclerosis, objectively proven peripheral arterial disease, or other known atherosclerotic disease at other locations);
* Moderate or severe liver disease (Child-Pugh stage B o",3,5,ALL,RECRUITING,"['infarction', 'peripheral arterial disease', 'stage', 'dose', 'consent', 'inhibitors', 'pugh', 'longer than 2 weeks', 'disease', 'body', 'the study', 'exclusion criteria', 'locations', 'atherosclerosis', '≥1500 mg', 'diabetes', 'heart', 'years', 'race', 'randomization', '* insulin treatment', 'known carotid atherosclerosis', 'insulin', 'heart failure', 'inclusion', 'angina pectoris', 'a steady daily dose', 'history', 'any race', 'creatinine', '60 ml', 'albuminuria', 'past', 'informed consent', '40 kg/m2', 'weeks', '22 kg/m2', 'child', 'time', 'any time', 'index', 'exclusion', 'presence', 'up to 2 years', 'kidney', 'other known atherosclerotic disease', 'b', 'o', '* chronic kidney disease', '* body mass index', 'treatment', '18 and 70 years', 'inclusion criteria', 'ethnicity', 'study', 'failure', 'other locations', 'albumin', 'min', 'mass', 'criteria', 'myocardial infarction', '* known cardiovascular disease', 'metformin', 'ratio', 'child-pugh stage', 'both sexes', 'type', 'ischemic heart disease', 'stages', 'carotid', 'liver', 'dpp-4', '≤8.0%', 'hba1c', 'baseline', '34 g/mmol', '* baseline treatment', 'the past', 'dpp-4 inhibitors', 'sexes']"
NCT07255859,CRYSTALSIGHT Cohort 2.0,Maculopathy,"Inclusion Criteria:

1. Subjects in the age group ≥ 55 to 99 years old.
2. Both genders
3. Able to understand verbal spoken instructions in British/American English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation.
4. Able to turn on and connect the CRYSTALSIGHT device to a computer independently or with the help of family.
5. Subjects undergoing treatment for Wet-AMD without any signs and symptoms of recurrence of active AMD (AMD recurrence: choroidal neovascularisation, intraretinal or subretinal fluid is present) with OCT lesion fluid volume more than 2 mm2 or ILM height more than 300µm.
6. Ability to comply with the study protocol, in the investigator's judgment.
7. Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments.

Exclusion Criteria:

1. Unable to understand verbal spoken instructions and demonstrate device functionality and implementation.
2. Unable to t",55,99,ALL,RECRUITING,"['crystalsight', 'the help', 'any signs', 'device', 'computer', 'lesion', 'more than 300µm', ""the investigator's judgment"", 'consent', 'functionality', 'british/american english', 'height', 'judgment', 'neovascularisation', 'oct lesion fluid volume', 'more than 2 mm2', 'treatment', 'informed consent', 'ability', 'implementation', 'group', 'instructions', 'fluid', 'exclusion criteria', 'inclusion criteria', 'intraretinal or subretinal fluid', 'signs', 'verbal spoken instructions', 'symptoms', 'subjects', '5. subjects', 'active amd (amd recurrence', 'any study assessments', 'the study protocol', 'study', 'device functionality', 'investigator', 'assessments', 'genders', 'family', 'the age group', '7. subjects', 'a computer', 'bahasa melayu', 'years', 'criteria', 'wet-amd', 'protocol', 'volume', '≥', 'form', '2. both genders', 'the crystalsight device', 'choroidal neovascularisation', 'recurrence', 'help', 'inclusion', 'exclusion', '6. ability']"
NCT07144696,Study on the Improvement of Metabolic Indicators in Type 1 Diabetes Patients,Type 1 Diabetes Mellitus,"Inclusion Criteria:

* ≥ 18 years old;
* It meets the WHO diagnostic criteria for diabetes and is diagnosed as type 1 diabetes;
* Capable and willing to participate in a 12 hour structured education course training;
* Capable and willing to accept regular outpatient follow-up visits;
* Voluntarily participate in this study and sign informed consent.

Exclusion Criteria:

* Non adult type 1 diabetes, type 2 diabetes and other special types of diabetes;
* Severe microvascular complications: proliferative retinopathy; Urinary albumin/creatinine\&gt;300mg/g, or 24-hour urinary protein quantification\&gt;1g/d; Uncontrolled painful diabetes neuropathy and significant diabetes autonomic neuropathy;
* Individuals who have undergone vascular intervention or amputation due to acute cerebrovascular accidents, acute coronary syndrome, or peripheral arterial disease requiring hospitalization within the first 3 months of selection;
* Blood pressure remains above 180/110mmHg and cannot be controlled ",18,100,ALL,RECRUITING,"['accidents', 'acute coronary syndrome', 'peripheral arterial disease', 'consent', 'type', 'the who diagnostic criteria', 'who', 'vascular intervention', 'hour', '/g', 'disease', 'training', 'informed consent', '2 diabetes', 'course', '24-hour urinary protein', 'vascular', 'regular outpatient follow-up visits', 'protein', 'acute cerebrovascular accidents', 'uncontrolled painful diabetes', 'education', 'inclusion criteria', 'types', 'it', 'months', '* severe microvascular complications', 'study', 'syndrome', 'microvascular', 'diabetes', 'type 1 diabetes', 'adult', 'pressure', 'years', 'selection', 'criteria', 'blood', 'amputation', 'this study', 'outpatient', 'individuals', '* blood pressure', 'visits', 'complications', 'inclusion', 'hospitalization', 'other special types', 'exclusion', 'the first 3 months', 'intervention']"
NCT07227805,Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS),"Diabetes (Insulin-requiring, Type 1 or Type 2)","Inclusion Criteria:

1. Is aged ≥2 years old at time of screening.
2. Has a clinical diagnosis of Type 1 or Type 2 diabetes for ≥ 6 months prior to screening as determined via medical record by an individual qualified to make a medical diagnosis.
3. Is on MiniMed™ 780G with Simplera Sync sensor for at least 3 months before screening.
4. Has a glycosylated hemoglobin (HbA1c) \<11% (97 mmol/mol) at time of screening visit as processed at Point of Care (PoC) or local lab.
5. Must have a minimum daily insulin requirement (Total Daily Dose) of ≥ 6 units and a maximum of 250 units
6. Willing to switch to approved insulin per insulin pump labeling.
7. Investigator has confidence that the subject, parent(s)/legal guardian(s) can successfully operate all study devices and is capable of adhering to study visit schedule per protocol.
8. Subject, Parent(s)/legal guardian(s) is willing to participate in all training sessions as directed by study staff.
9. Subject, Parent(s)/legal guardian(s) is wil",18,100,ALL,NOT_YET_RECRUITING,"['simplera sync sensor', 'visit', 'sync', 'medical record', 'units', 'maximum', 'devices', 'screening', 'hemoglobin', 'approved insulin', '\\<11%', '(poc', 'dose', 'subject', 'individual', 'staff', 'type', 'sessions', '8. subject', 'all training sessions', 'point', '250 units', '9. subject', 'training', '2 diabetes', 'parent(s)/legal guardian(s', 'pump', '≥ 6 units', 'local lab', 'inclusion', 'inclusion criteria', 'wil', 'an individual', 'a glycosylated hemoglobin', 'months', 'study', 'simplera', 'investigator', 'record', 'diabetes', 'care', '7. investigator', 'the subject', 'protocol', 'diagnosis', 'time', 'years', 'hba1c', 'criteria', 'confidence', '97 mmol/mol', '≥', 'insulin', 'study staff', 'all study devices', 'a medical diagnosis', 'screening visit', 'visit schedule', 'sensor', 'a clinical diagnosis', '.', 'a maximum', 'schedule', 'requirement', 'total daily dose']"
NCT07374328,Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus,Type 2 Diabetes,"Inclusion Criteria:

* Patients with newly diagnosed type 2 diabetes.
* Age between 18 and 65 years old.
* HbA1c ≥ 9.0%.

Exclusion Criteria:

* Type 1 diabetes.
* Elevated creatinine or urinary albumin/creatinine.
* Combined with coronary heart disease, tumor or pregnancy.
* Receiving glucocorticoids.",18,65,ALL,RECRUITING,"['* elevated creatinine', 'creatinine', 'patients', 'type', 'disease', '* patients', 'pregnancy', '* age', 'inclusion criteria', 'glucocorticoids', 'diabetes', '* type 1 diabetes', 'heart', 'albumin', 'years', 'criteria', 'tumor', 'urinary albumin/creatinine', 'coronary heart disease', 'inclusion', '9.0%', 'exclusion']"
NCT06925334,A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus,Type 2 Diabetic Patients,"Inclusion Criteria:

1. Voluntarily sign the informed consent form;
2. Male and female between the ages of 18 and 75 (inclusive);
3. Diagnosed with type 2 diabetes mellitus according to WHO standards (1999) for more than 6 months;
4. Those who use premixed human insulin or insulin analogues with or without oral hypoglycemic drugs (which cannot contain secretagogues and DPP4 inhibitors) \>=3 months, and have poor blood sugar control;
5. Glycosylated hemoglobin \> 7.0% and \<=8.0% at screening;
6. Body mass index (BMI) \> 18 kg/m\^2 and \<=35 kg/m\^2;
7. Those who are willing and able to use the blood glucose meter for self-blood glucose monitoring according to the requirements of the program.

Exclusion Criteria:

1. People who are known to be allergic to Degu insulin or ingredients in its preparations;
2. Human glucagon-like peptide-1 (GLP-1) receptor agonist has been used within 3 months before screening;
3. Patients with hypoglycemic coma within 3 months before screening;
4. Patients",18,100,ALL,ENROLLING_BY_INVITATION,"['sugar', 'hypoglycemic coma', 'program', 'standards', 'mellitus', 'which', 'screening', 'the program', 'preparations', 'consent', 'patients', 'type', '6. body mass index', 'who', 'oral hypoglycemic drugs', 'glp-1', 'the requirements', 'inhibitors', 'type 2 diabetes', '18 and 75 (inclusive', 'glucose', 'the blood glucose meter', '\\<=35 kg/m\\^2', '3 months', 'more than 6 months', 'dpp4 inhibitors', 'degu insulin', 'body', 'agonist', 'the ages', 'exclusion criteria', 'inclusion criteria', 'coma', 'the informed consent form', 'bmi', 'months', 'people', 'its preparations', 'inclusive', 'those', 'requirements', 'hemoglobin \\', 'diabetes', 'control', 'monitoring', 'criteria', 'blood', 'ingredients', ') \\> 18 kg/m\\^2', 'index', 'drugs', 'analogues', 'form', 'secretagogues', 'receptor', 'self-blood glucose monitoring', 'insulin', 'meter', 'self', 'inclusion', 'exclusion', 'ages', 'poor blood sugar control']"
NCT06993064,Effect of Vitamin D on Inflammatory Markers in Type 2 Diabetes Mellitus in Mexico.,Type 2 Diabetes Melitus,"Inclusion Criteria:

* subjects with medically diagnosed type 2 diabetes mellitus
* controlled with diet and/or metformin
* less than 5 years of evolution
* children and grandchildren of Mexican origin

Exclusion Criteria:

* Subjects that do not complete the study
* Subjects that do not take the supplement",18,100,ALL,NOT_YET_RECRUITING,"['mexican origin\n\nexclusion criteria', '* subjects', 'mellitus', 'supplement', 'the supplement', 'type', 'that', 'evolution', 'grandchildren', 'origin', 'inclusion criteria', 'subjects', 'study', 'the study\n* subjects', 'diabetes', 'medically diagnosed type', 'years', 'criteria', 'evolution\n* children', 'children', 'inclusion', 'exclusion']"
NCT07292558,Achieving Health in Emerging Adults With Diabetes (AHEAD) Program: A Clinical Trial Designed to Understand if Participation in a Clinical Program Developed Specifically to Support Emerging Adults With Type 1 Diabetes Leads to Improved Diabetes Outcomes.,"Diabetes Mellitus, Type 1 Diabetes","Inclusion Criteria:

1. 16-19 years of age
2. Have had type 1 diabetes ≥ 12 months
3. Had a recent HbA1c ≥7.0%
4. Currently receive outpatient diabetes care at a Seattle Children's Hospital Diabetes Clinic located in Bellevue, Everett, Federal Way, or Seattle
5. Are able to complete written surveys
6. Will be able to receive clinical care in WA State for the next 2 years

Exclusion Criteria:

1. Have had a pilot program AHEAD clinic visit
2. Most recent Usual Care diabetes visit was with a current AHEAD provider",16,19,ALL,RECRUITING,"['written surveys', 'a pilot program', 'clinic', 'visit', 'program', 'age', 'type', 'clinical care', 'surveys', 'outpatient diabetes', 'state', 'wa state', '1. 16-19 years', 'bellevue, everett, federal way', 'inclusion criteria', 'months', 'diabetes', 'care', 'years', 'criteria', 'clinic visit', 'provider', 'outpatient', 'children', 'hospital', '≥', 'pilot', '1 diabetes', 'a current ahead provider', 'inclusion', 'exclusion']"
NCT06926855,Community Health Workers Reduce Social Barriers That Affect the Health of Patients With High Blood Pressure and Diabetes.,Uncontrolled Diabetes,"Inclusion Criteria

* 18 years or older
* People with Type 2 diabetes with their most recent hemoglobin A1c test result (a blood test that reflects average blood sugar levels over the past 2-3 months) is greater than or equal to 9%.
* People with essential hypertension with their last systolic blood pressure (BP) (the top number in a BP reading) is greater than or equal to 140 mmHg or diastolic BP (the bottom number in a BP reading) is greater than or equal to 90 mmHg.

Exclusion Criteria

* People who are less than 18 years old
* Pregnant people
* People who don't meet the Type 2 diabetes or hypertension criteria.",18,100,ALL,RECRUITING,"['a bp reading', 'sugar', 'essential hypertension', 'hypertension criteria', 'type', 'that', 'who', 'the past 2-3 months', '9%', 'number', '90 mmhg', 'average blood sugar levels', 'levels', 'a blood test', 'mmhg', 'the top number', 'their most recent hemoglobin', 'exclusion criteria', 'inclusion criteria', 'diastolic', '* people', 'people', 'the type 2 diabetes', 'months', 'hypertension', 'diabetes', 'diastolic bp', '140 mmhg', 'pressure', 'reading', 'years', 'criteria', 'blood', 'test', '(the bottom number', 'result', 'hemoglobin', 'bp', 'exclusion', 'test result']"
NCT05565248,"An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D",Diabetes Mellitus,"Inclusion Criteria:

* Diagnosis of T1D for a minimum of 5 years
* Stable diabetes regimen for at least 3 months prior to enrollment.

Exclusion Criteria:

* Medical history of islet cell, kidney, and/or pancreas transplant
* Occurrence of 2 or more severe, unexplained hypoglycemic events within 6 months prior to enrollment
* Known causes of diabetes other than T1D
* Immunosuppressant therapy in the previous 30 days and/or requirements for chronic immunosuppressive therapy during the study
* Prior treatment with gene therapy or edited product",18,100,ALL,RECRUITING,"['medical history', 'immunosuppressant', 'history', '* stable diabetes regimen', 'kidney', 'days', '* diagnosis', 'edited product', 'pancreas transplant', 'gene therapy', 'enrollment', 'treatment', 'prior treatment', 'events', 'the study', 'islet cell', 'pancreas', 'transplant', 'gene', 'exclusion criteria', 'chronic immunosuppressive therapy', 'inclusion criteria', 't1d\n* immunosuppressant therapy', 'therapy', 'months', 'a minimum', '5 years', 'requirements', 'regimen', 'study', 'diabetes', 'cell', '* occurrence', 'the previous 30 days', 'diagnosis', 'minimum', 'years', 'criteria', 'causes', 'enrollment\n* known causes', 't1d', 'islet', 'inclusion', 'product', 'exclusion', '6 months', 'occurrence']"
NCT07396155,Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial,Diabetic Nephropathy Type 2,"Inclusion Criteria:

* Diagnosed with Type 2 Diabetes Mellitus (T2DM)
* Aged between 40 and 65 years
* Diagnosed with chronic kidney disease (CKD) stage III or IV, defined as estimated GFR (eGFR) between 15-60 mL/min/1.73 m² (using CKD-EPI formula)
* Renal biopsy showing diabetic nephropathy type IIa-IV
* Presence of proteinuria, with urine albumin-to-creatinine ratio (UACR) between 30-3000 mg/g (spot morning urine sample)
* Controlled diabetes, defined as HbA1c \<10.0% during screening
* Blood pressure within the range of: Systolic 100-160 mmHg, Diastolic 60-100 mmHg
* On stable standard therapy for diabetic nephropathy (e.g. ACE inhibitors or ARBs) for at least 12 weeks prior to screening
* Willing to provide written informed consent and comply with all study procedures until completion

Exclusion Criteria:

* Active malignancy or history of cancer
* Active liver disease or abnormal liver function (ALT or AST ≥2× upper limit of normal)
* Hemoglobin \<8 g/dL or platelet count \<100,00",40,65,ALL,RECRUITING,"['\\<100,00', 'presence', 'malignancy', 'count', 'history', 'mellitus', 'all study procedures', 'ratio', 'iv', 'kidney', 'stage', 'systolic', 'formula', 'consent', 'biopsy', 'creatinine', 'type', 'range', 'nephropathy', 'inhibitors', 'function', 'limit', 'estimated gfr', 'the range', 'type 2 diabetes', 'platelet count \\<100,00', 'disease', 'completion', '15-60 ml/min/1.73 m²', '≥2× upper limit', 'written informed consent', 'inclusion', 'mmhg', 'blood pressure', 'urine', 'morning', 'inclusion criteria', 'ckd) stage iii', 'diastolic', 'cancer', 'therapy', 'active malignancy', 'weeks', 'study', 'procedures', 'liver', 'g', '40 and 65 years', 'diabetic nephropathy', 'arbs', 'diabetes', 'abnormal liver function', 'chronic kidney disease', 'spot', 'hba1c \\<10.0%', 'pressure', 'albumin', 'years', 'criteria', 'blood', 'proteinuria', 'dm', 'stable standard therapy', 'completion\n\nexclusion criteria', 'uacr', 'systolic 100-160 mmhg', '* controlled diabetes', 't2', 'renal biopsy', 'hemoglobin', 'epi', 'exclusion']"
NCT06043843,Effectiveness of Focused Tele-education in Reducing Diabetes Complications During Ramadan,Diabetes Mellitus,"Inclusion Criteria:

* Adults with diabetes planning to fast in Ramadan,

  1. Adults with type 2 diabetes aged at least 21 years old,
  2. Able to fast at least 15 days in Ramadan based on experience of fasting in previous year's Ramadan,
  3. Underlying type 2 diabetes treated with basal insulin and one or more doses of prandial insulin, or at least twice-daily premixed insulin
  4. Performed laboratory tests as per standard care - glycated haemoglobin (HbA1c), serum Low Density Lipoprotein- cholesterol, serum triglycerides, serum High Density Lipoprotein- cholesterol, serum Total cholesterol and serum creatinine
  5. Ability to give informed consent,
  6. Ability to perform self-monitoring blood glucose
  7. Have had diabetes-related clinic visits or hospitalization in the past 10 months.
  8. Have the capacity for video conferencing (internet connection with mobile phone or computer)

Exclusion Criteria:

1. Severe diabetes complications including end-stage renal failure
2. Severe ",21,100,ALL,RECRUITING,"['conferencing', 'clinic', 'video conferencing', 'internet connection', 'doses', 'prandial insulin', 'computer', 'haemoglobin', 'capacity', 'days', 'stage', 'consent', 'creatinine', 'type', 'internet', 'hospitalization', 'cholesterol', 'adults', 'year', 'type 2 diabetes', 'glucose', 'informed consent', 'serum', 'connection', 'ramadan', 'ability', 'inclusion', 'laboratory', 'exclusion criteria', 'laboratory tests', 'inclusion criteria', 'video', 'self-monitoring blood glucose', 'density', 'months', 'mobile phone', 'diabetes', '* adults', 'tests', 'serum total cholesterol', 'care', 'triglycerides', 'diabetes-related clinic visits', 'phone', 'failure', 'one or more doses', 'years', 'hba1c', 'criteria', 'blood', 'experience', 'basal insulin', 'the capacity', 'insulin', 'serum triglycerides', '1. severe diabetes complications', 'self', 'the past 10 months', 'at least 15 days', 'visits', 'serum creatinine', ""previous year's ramadan"", 'basal', 'end-stage renal failure', 'exclusion', 'complications', 'underlying type 2 diabetes']"
NCT06314048,4T Sustainability Program,Type1diabetes,"Inclusion Criteria:

Inclusion criteria includes all youth with new onset T1D seen in the Stanford/Lucile Packard Children's Hospital ages 6 months-21 years of age. The program will also be offered to pediatric patients with existing T1D who wear a CGM or want to start a CGM and receive RPM. We intend to include all possible patients with the goal of maximizing generalizability of the results and 4T program. (NOTE: We will include children and families who speak all languages using the Stanford interpreter services so as to have the greatest generalizability of the research. Questionnaires will only be given to English and Spanish speakers.)

* All individuals with a T1D diagnosis seen at the Stanford Children's Diabetes Clinic
* Individuals who plan to receive follow-up care at the Stanford Children's Diabetes Clinic
* Individuals who agree to wear a CGM that will connect to the RPM-care model
* Age: six months to \< 21 years of age
* Patient or guardian must own and operate a compati",18,100,ALL,ENROLLING_BY_INVITATION,"['the results', 'clinic', 'program', 'age', 'the program', 'existing t1d', 'research', 'all youth', 'ages', 'packard', 'the stanford interpreter services', 'the goal', 'that', 'who', 'a cgm', 'new onset', 'the rpm-care model', 'patients', 'interpreter', 'the research', 'questionnaires', 'onset', 'all individuals', 'a t1d diagnosis', 'follow-up care', 'a compati', '21 years', 'languages', 'compati', 'we', '* age', 'inclusion criteria', '\\', 'age\n* patient', 'model', 'rpm', 'months', 'all languages', 'youth', 'results', 'patient', 'families', 'diabetes', '4t program', 'english and spanish speakers', 'care', 'diagnosis', '6 months-21 years', 'criteria', 'years', 'the greatest generalizability', 'individuals', 'children', 'pediatric patients', 'hospital', 't1d', 'all possible patients', 'services', 'guardian', 'goal', 'speakers', 'inclusion', 'six months', 'generalizability']"
NCT06851858,"Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist",Endocrinology,"Inclusion Criteria:

1. Be 18 to 75 years old at the time of signing the informed consent.
2. Diagnosed with type 2 diabetes ≥ 180 days before screening.
3. HbA1c value at screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol).
4. On a stable maintenance dose of an injectable GLP-1 RA.
5. At Screening, have a BMI ≥ 27 kg/m2

Exclusion Criteria:

1. Has received treatment with prescription or non-prescription medication for weight loss within the last 3 months prior to screening (other than a GLP-1 RA).
2. Self-reported weight change of \> 5 % in the 3 months prior to screening.
3. Diabetes mellitus that is not clearly type 2 diabetes.
4. Use of insulin therapy for T2DM
5. Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
6. Significant hepatobiliary disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis)

8\. Impaired renal fu",18,75,ALL,RECRUITING,"['4. use', 'the 3 months', 'weight loss', '10%', 'weight', 'device', 'mellitus', 'screening', 'bariatric surgery', 'prescription', 'days', 'dose', 'consent', 'type', 'a stable maintenance dose', 'that', 'study period', 'barrier', 'type 2 diabetes', 'maintenance', 'ra', 'duodenal barrier', 'medication', 'disease', 'the time', 'treatment', 'steatohepatitis', '3. hba1c value', 'significant hepatobiliary disease', 'non-alcoholic steatohepatitis', 'portal hypertension', 'cirrhosis', 'period', 'inclusion criteria', '\\', '42 mmol/mol', 'nonalcoholic fatty liver disease', 'therapy', 'the last 3 months', 'months', '86 mmol/mol', 'study', 'liver', 'hypertension', 'loss', '8\\. impaired renal fu', 'diabetes', 'a glp-1 ra', '6.0%', 'a weight loss device', '5 %', 'time', 'years', 'criteria', 'change', 'surgery', '≥', 'non-prescription medication', 'balloon', 'the informed consent', 'fitting', 'insulin therapy', 'gastric balloon', 'insulin', 'self', 't2', 'inclusion', 'value', 'exclusion', '2. self-reported weight change']"
NCT06694155,Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals,Prediabetes / Type 2 Diabetes,"Inclusion Criteria:

1. Males and females ages 50-70 years.
2. Capable of providing informed consent.
3. COVID-19 negative and/or asymptomatic.
4. Willing to abstain from drinking alcohol or consuming marijuana and CBD products during the 7-day study meal period on two occasions.
5. HbA1c: 5.7-6.4% or 6.5% to 7.5%

Exclusion Criteria:

1. Subject who does not/will not eat dairy protein sources.
2. Subjects taking exogenous insulin injections or GLP /GIP injections or other appetite suppressants.
3. Unwilling to keep a detailed 7 day food journal on two occasions
4. Unwilling to wear a CGM for 7 days on two occasions and share the data with the research team.
5. Lactose intolerance.
6. Hemoglobin \<10g/dL at screening.
7. History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment.
8. History of gastrointestinal bypass/reduction surgery.
9. Pregnant or lactating individuals.
10. History of a chronic inflammatory disease (e.g. Lupus, Crohn's disease)
11. C",50,70,ALL,RECRUITING,"['(e.g. lupus', 'food', 'marijuana and cbd products', 'history', 'dairy protein sources', 'dairy', 'research', '2. subjects', '7 days', 'days', 'glp /gip injections', 'consent', 'alcohol', '7. history', 'a chronic inflammatory disease', 'who', 'a cgm', '. hemoglobin \\<10g', 'asymptomatic', 'suppressants', 'chemotherapy', 'disease', 'enrollment', 'informed consent', '5.7-6.4%', 'sources', 'two occasions', 'the research team', ""crohn's disease"", 'protein', 'period', 'radiation therapy', '5. lactose intolerance', 'gastrointestinal bypass/reduction surgery', '50-70 years', 'inclusion criteria', 'cancer', 'radiation', 'females ages', 'subjects', 'therapy', 'males', 'months', 'study', 'exogenous insulin injections', 'the data', 'data', 'injections', 'intolerance', 'reduction', 'occasions', 'years', 'criteria', 'products', 'team', 'individuals', 'bypass', 'surgery', 'other appetite suppressants', 'the 6 months', 'insulin', 'inclusion', 'journal', 'exclusion', 'appetite', 'ages', 'meal']"
NCT06251635,Effects of Antipsychotics on Brain Insulin Action in Females,Insulin Resistance,"Inclusion Criteria:

* Age: 18-35 years
* Body Mass Index (BMI) between 18.5 - 24.9 kg/m2
* Normal menstrual cycle (defined as cycle length ranging from 21 to 35 days over the past 6 months).

Exclusion Criteria:

* History of psychiatric illness (screened using the Mini International Neuropsychiatric Interview (MINI));
* Pre-diabetes or diabetes (fasting glucose ≥6.0 mmol/L, HbA1c\>6% or use of anti-diabetic drug);
* Evidence of impaired insulin sensitivity, assessed using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) ≥2.5;
* Family history of diabetes in a first degree relative (parent or sibling)
* Use of weight reducing agents;
* History of kidney or liver disease;
* Moderate-to-severe substance use;
* Irregular menstrual cycles (e.g., menstruation occurs less than 21 days or more than 35 days apart, or not having menstruated for three months (or 90 days), or conditions such as endometriosis or polycystic ovary syndrome (PCOS) or prior surgical interventions suc",18,35,FEMALE,RECRUITING,"['kidney or liver disease', 'illness', 'homa-ir) ≥2.5', 'cycle', 'hba1c\\>6%', 'weight', 'history', 'assessment', 'resistance', 'days', 'conditions', 'kidney', 'mini', 'the homeostatic model assessment', 'sibling', 'homa', 'length', 'disease', 'substance', '* body mass index', 'glucose', '* use', '90 days', 'body', '* age', '* history', 'inclusion', 'relative', 'exclusion criteria', 'insulin resistance', 'inclusion criteria', 'parent', 'model', 'bmi', 'months', 'liver', 'degree', 'endometriosis', 'syndrome', 'pcos', 'prior surgical interventions', 'diabetes', 'a first degree relative', 'hba1c\\>6', '* irregular menstrual cycles', 'the past 6 months', 'interventions', 'use', 'anti-diabetic drug', 'agents', 'menstruation', 'family', 'cycles', 'years', 'criteria', 'moderate-to-severe substance use', 'mass', 'sensitivity', 'cycle length', '21 to 35 days', 'index', 'drug', '* evidence', 'impaired insulin sensitivity', 'insulin', 'psychiatric illness', '18-35 years', 'three months', 'evidence', 'fasting glucose ≥6.0 mmol/l', '* family history', 'exclusion', 'neuropsychiatric']"
NCT06605508,Regenerative Injection of Stem Cells or Stem Cell-derived Exosomes for Erectile Dysfunction (RISE),Erectile Dysfunction,"Inclusion Criteria:

* Age: Adult males aged 30 to 75 years.
* Diagnosis: Confirmed diagnosis of erectile dysfunction (ED) of mild to moderate severity, as defined by an International Index of Erectile Function (IIEF) score.
* Treatment Response: Failure or suboptimal response to conventional ED treatments, such as PDE-5 inhibitors.
* General Health: Overall good health without contraindications to stem cell therapy.
* Informed Consent: Ability and willingness to provide written informed consent to participate in the study.

Exclusion Criteria:

* Severe Cardiovascular Disease: Presence of severe cardiovascular conditions, including uncontrolled hypertension or significant heart disease.
* Active Infections: Ongoing infections that could interfere with treatment or pose a risk to the participant.
* Malignancies: History of or current cancer, including malignancies that could affect safety or treatment outcomes.
* Contraindications to Stem Cell Therapy: Any medical conditions or treatme",30,75,MALE,RECRUITING,"['* severe cardiovascular disease', 'presence', 'ongoing infections', 'pde-5', '* general health', 'history', 'safety', 'severe cardiovascular conditions', 'cell therapy', 'conditions', '* diagnosis', 'consent', 'current cancer', 'that', 'participant', 'inhibitors', 'function', 'disease', 'any medical conditions', 'iief', 'confirmed diagnosis', '* active infections', 'treatment', 'suboptimal response', 'a risk', 'response', 'adult males', 'ability', 'the study', 'dysfunction', '* age', 'malignancies', 'written informed consent', 'ed', 'erectile', 'treatme', 'exclusion criteria', 'cancer', 'inclusion criteria', 'erectile dysfunction', 'mild to moderate severity', 'significant heart disease', 'therapy', 'males', 'an international index', 'overall good health', '* malignancies', 'study', 'hypertension', 'severity', 'safety or treatment outcomes', 'cell', 'failure', 'heart', 'health', 'adult', 'diagnosis', 'pde-5 inhibitors', 'contraindications', 'criteria', 'years', 'score', 'willingness', 'treatments', 'infections', 'uncontrolled hypertension', 'index', 'outcomes', 'risk', 'the participant', 'conventional ed treatments', 'inclusion', '* treatment response', '* contraindications', 'exclusion', '* informed consent']"
NCT07108985,"Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors","Diabetes Mellitus, Type 2","Inclusion Criteria:

1. Adults aged between 19 and 75 years at the time of providing written informed consent.
2. Diagnosed with type 2 diabetes mellitus and having an HbA1c level between 7.5% and 11.0%.
3. Receiving DPP4 inhibitor monotherapy or combination therapy with metformin and/or sulfonylurea for at least 8 weeks without dose adjustment.
4. Provided written informed consent voluntarily after receiving a full explanation of the study.
5. Considered capable of understanding the study procedures and cooperating throughout the study period until completion.

Exclusion Criteria:

1. Patients with diabetes other than type 2 diabetes, including type 1 diabetes or gestational diabetes.
2. Use of TZD or SGLT2 inhibitors within the past 8 weeks, or history of discontinuation due to serious adverse reactions.
3. Currently receiving four or more antidiabetic medications.
4. History of diabetic ketoacidosis (with or without coma) or acute/chronic metabolic acidosis within the past 24 weeks.",19,75,ALL,NOT_YET_RECRUITING,"['the past 24 weeks', 'at least 8 weeks', 'diabetic ketoacidosis', 'diabetes mellitus', 'history', 'mellitus', 'dose', 'consent', 'level', 'combination', 'patients', 'type', 'adjustment', 'inhibitor', 'an hba1c level', 'inhibitors', 'dose adjustment', 'sglt2', 'adults', 'between 7.5% and 11.0%', 'type 2 diabetes', 'completion', 'gestational diabetes', 'acute/chronic metabolic acidosis', 'serious adverse reactions', 'the time', 'reactions', 'chronic', 'a full explanation', 'the study', 'dpp4 inhibitor monotherapy', 'the study period', 'combination therapy', 'written informed consent', 'sglt2 inhibitors', 'period', 'the study procedures', 'discontinuation', 'inclusion criteria', 'coma', 'medications', 'therapy', 'weeks', 'study', 'procedures', 'diabetes', 'type 1 diabetes', '4. history', 'metabolic', 'time', 'years', 'criteria', '2. use', '19 and 75 years', 'metformin', 'ketoacidosis', 'the past 8 weeks', 'sulfonylurea', 'tzd', 'explanation', 'acidosis', 'inclusion', 'exclusion', 'monotherapy']"
NCT06904417,Effect of Feldenkrais Method in Enhancing Postural Control for Patients with Diabetic Polyneuropathy,Diabetic Polyneuropathy,"Inclusion Criteria:

* Individuals must have a diagnosis of Diabetic Polyneuropathy (DPN), confirmed by clinical examination and electrophysiological testing.
* Participants must have stable glycemic control for at least three months prior to enrollment.
* Individuals must be able to walk independently, with or without the use of an assistive device.

Exclusion Criteria:

* Individuals with severe visual or vestibular impairments are excluded from participation.
* Participants with significant musculoskeletal disorders affecting gait are not eligible.
* Individuals with severe cardiovascular or respiratory conditions are excluded.
* Participants with cognitive impairments that prevent active participation are not eligible.
* Individuals currently engaged in structured physical therapy or balance training programs are excluded.",18,100,ALL,ENROLLING_BY_INVITATION,"['participants', 'cognitive impairments', 'balance', 'an assistive device', 'device', 'structured physical therapy', 'at least three months', 'conditions', 'that', 'diabetic polyneuropathy (dpn', '* individuals', 'enrollment', 'training', 'balance training programs', '* participants', 'examination', 'active participation', 'clinical examination', 'exclusion criteria', 'significant musculoskeletal disorders', 'impairments', 'therapy', 'electrophysiological testing', 'months', 'stable glycemic control', 'participation', 'gait', 'diagnosis', 'control', 'criteria', 'individuals', 'disorders', 'the use', 'a diagnosis', 'programs', 'inclusion', 'testing', 'exclusion']"
NCT06376240,The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

* Diagnosis of type 2 diabetes,
* Generalized microvascular dysfunction, i.e.

  * eGFR 30-60 mL/min/1.73m2, and/or
  * Microalbuminuria albumin-creatinine ratio 3-30 mg/mmol, and/or
  * Retinopathy (not proliferative), and/or
  * Neuropathy (any).

Exclusion Criteria:

* Uncontrolled diabetes (i.e., hypoglycaemia \>2 times/week and/or unstable HbA1c \>9%),
* Use of \>12 Units long-acting insulin per day,
* Use of short-acting insulin,
* Intraocular pressure ≥30 mmHg,
* History of glaucoma,
* Diagnosis of proliferative diabetic retinopathy,
* Diagnosis of diabetic macula edema,
* Albumine-creatinine ratio \>30 mg/mmol,
* eGFR \<30 mL/min/1.73m2,
* Diagnosis of epilepsy,
* Active cardiovascular disease,
* Alcohol usage \>4 U/day,
* Drugs abuse,
* Use of systemic glucocorticosteroids,
* Higher grade hypertension
* Diagnosis of inflammatory disease,
* Use of an investigational product within the previous month,
* Unstable body weight,
* Pregnancy or lactation,
* Chang",18,100,ALL,RECRUITING,"['short-acting insulin', 'abuse', 'glucocorticosteroids', 'times', 'units', 'history', 'glaucoma', '30 mg/mmol', 'ratio', 'weight', '* diagnosis', 'proliferative diabetic retinopathy', 'alcohol', 'creatinine', 'type', 'week', 'neuropathy', 'macula', 'disease', 'type 2 diabetes', 'any', 'epilepsy', '* use', '* uncontrolled diabetes', 'alcohol usage', 'body', '* microalbuminuria albumin-creatinine ratio', 'pregnancy', 'dysfunction', 'mmhg', 'unstable body weight', 'drugs abuse,\n* use', 'exclusion criteria', 'inclusion criteria', 'retinopathy', '(i.e., hypoglycaemia', 'i.e.\n\n  * egfr', 'chang', 'lactation', 'hypertension', 'microvascular', 'an investigational product', 'diabetes', 'edema', 'day', 'month', 'the previous month', '* generalized microvascular dysfunction', 'systemic glucocorticosteroids', 'diagnosis', 'pressure', 'usage', 'criteria', 'active cardiovascular disease', 'drugs', 'product', '\\>12 units', 'insulin', 'long-acting insulin', '/min/1.73m2', 'albumine', 'grade', 'inclusion', 'egfr \\<30 ml/min/1.73m2', 'exclusion', 'inflammatory disease']"
NCT06603792,Neurofeedback for the Management of Neuropathic Pain in People with Diabetes,"Neuropathy, Painful Diabetic","Inclusion Criteria:

Age ≥18 and ≤82 years

* Diagnosed with 1) type 1 diabetes (for at least 5 years) or 2) type 2 diabetes
* The Toronto consensus criteria will be used for a case definition of DPN where patients have to have at least probable DPN (31). Diagnosis of DPN is confirmed with abnormal DPN Check. Painful DPN will be defined using the grading system for neuropathic pain (50) and will be in line with IASP's definition of neuropathic pain, i.e., ""pain caused by a lesion or disease of the somatosensory system"" (The Toronto consensus criteria).
* TCNS score \> 5
* Eligible patients with painful DPN must have a pain intensity of at least 4 on an 11-point numerical rating scale (NRS, 0-10) for at least 3 months on at least semi-daily basis and no severe pain other than pain due to neuropathy (the pain intensity will be based on the pain the patients experience while on current pain treatment, if any).
* Stable pain medication for \> 1 month prior to inclusion. Exclusion criteria
",5,100,ALL,RECRUITING,"['current pain treatment', 'pain', 'a lesion', 'rating', 'the somatosensory system', 'lesion', 'intensity', 'the toronto consensus criteria', '* stable pain medication', 'no severe pain', 'patients', 'type', 'at least 5 years', 'neuropathy', 'line', 'check', 'disease', '≤82', 'medication', 'point', 'abnormal dpn check', 'iasp', 'nrs', 'treatment', '(the toronto consensus criteria', 'age ≥18', 'definition', 'neuropathic pain', 'exclusion criteria', 'inclusion criteria', '\\', 'system', 'at least probable dpn', 'at least 3 months', 'the pain', 'months', 'basis', 'painful dpn', 'the patients', 'consensus', 'dpn', 'i.e., ""pain', 'diabetes', 'month', ""iasp's definition"", 'diagnosis', 'score', 'years', 'criteria', 'a case definition', 'the pain intensity', '* tcns', '5\n* eligible patients', 'experience', '2) type', 'a pain intensity', '1) type 1 diabetes', 'at least semi-daily basis', 'inclusion', 'the grading system', 'scale', 'exclusion', 'case']"
NCT04219709,Effects of Ketosis on Brain Function in Patients With T1DM,Type1diabetes,"Inclusion Criteria:

* Males and females with T1D for at least 1 year
* Age 18 to 40 years
* Tanner stage ≥ IV
* BMI 18.5-35 kg/m2
* Stable glycemic control (HbA1c 6.5-9%)
* Use of a continuous glucose monitor (CGM)
* Use of an insulin pump
* Attendance of at least 1 diabetes care visit over the past 12 months (including virtual)

Exclusion Criteria:

* Ketoacidosis or severe hypoglycemia with seizure or coma in the past 6 months
* Dietary restrictions or intolerances that are incompatible with the planned food deliveries, e.g. celiac disease, gastroparesis, certain food allergies
* Following a weight-loss or otherwise restrictive diet
* Vigorous exercise \>2 hours on \>3 days a week
* History of an eating disorder or at risk for eating disorder, assessed by the Eating Disorders Diagnostic Scale (EDDS)
* Major medical illness or use of medications other than insulin and metformin that could interfere with metabolic or glycemic variables
* Significant psychiatric illness
* Smoking, use ",18,40,ALL,RECRUITING,"['food', 'weight', 'monitor', 'age', 'stage', 'females', 'disease', '18 to 40 years', 'diet', '* tanner stage', 'a continuous glucose monitor', 'cgm', 'diabetes', 'use', 'years', 'edds', 'insulin', 'risk', 'inclusion', 'scale', 'attendance', 'intolerances', 'allergies', 'history', '* males', 'severe hypoglycemia', 'that', 'an eating disorder', '6.5-9%', 'certain food allergies', '\\>2 hours', 'gastroparesis', 'coma', 'exercise', 'the planned food deliveries', 'major medical illness', 'care', 'metabolic', '≥', 'exclusion', 'illness', 'celiac disease', 'hypoglycemia', 'inclusion criteria', 'seizure', 'restrictions', 'medications', 'dietary restrictions', 'males', 'criteria', '\\>3 days', 'disorders', 't1d', 'metformin', 'at least 1 year', 'disorder', 'variables', '* smoking', 'visit', 'tanner', 'days', '* attendance', 'week', 'year', 'glucose', '* significant psychiatric illness', '* use', 'pump', 'months', 'loss', 'hours', 'the past 6 months', 'virtual)\n\nexclusion criteria', 'an insulin pump', 'control', 'deliveries', 'the past 12 months', 'ketoacidosis', 'smoking']"
NCT05776563,Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM),"Diabetes Mellitus, Type 2","Inclusion Criteria:

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged 18-60
* medical history for Type 2 diabetes
* HbA1c \> 7.5%, BMI ≥18 kg/m2
* Be willing to adhere to the intensification of their diabetes regimen

Exclusion Criteria:

* Creatinine \> 1.5 mg/dL
* Hgb \< 10 mg/dL, hematocrit of 37 % for males participants and 33 % for female participants
* ALT \>3 x ULN
* untreated thyroid disease,
* uncontrolled hypertension
* known neurological disorders
* untreated psychiatric disorders
* malignancy
* bleeding disorders
* current or recent steroid use in last 3 months
* illicit drug use
* for women: pregnancy, actively seeking pregnancy, or breastfeeding
* inability to enter MRI/MRS (as per standard MRI safety guidelines).",18,100,ALL,RECRUITING,"['participants', 'the duration', 'malignancy', '33 %', 'history', 'all study procedures', 'safety', 'dl', 'consent', 'creatinine', 'the study\n* male', 'female participants', 'type', '* provision', '* known neurological disorders', '7.5%', '* untreated psychiatric disorders', 'disease', 'standard mri safety guidelines', 'women', 'duration', 'pregnancy', 'intensification', 'inclusion criteria', '37 %', 'males participants', 'males', 'months', 'study', 'bmi ≥18 kg/m2', 'last 3 months', 'provision', 'procedures', 'availability', 'regimen', 'hypertension', 'diabetes', 'the intensification', 'guidelines', 'hematocrit', 'criteria', 'willingness', 'thyroid', 'uncontrolled hypertension', 'disorders', 'drug', 'mri/mrs', 'form', 'male', 'inability', 'steroid', 'inclusion', '18-60\n* medical history', 'exclusion']"
NCT07296484,Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D),Type 2 Diabetes,"Inclusion Criteria:

* From Screening 1

  * Age at least 18 years.
  * HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current \[as of Screening 1\] regimen).
  * Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).
  * Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.
  * Use of insulin pumps or insulin brand changes (e.g., due to insurance change o",18,100,ALL,RECRUITING,"['the 3 months', 'the historical hba1c value', 'units', 'doses', 'insulin dose', 'injectable or oral adms', 'an adm', 'dose', 'kg', 'an adm dose', 'pumps', 'treatment', '* use', '≥2', 'changes', '3 months', 'stable and adequate doses', '≥7.5%', 'less than half-maximal dose', 'the current \\[as', '/day', 'inclusion', 'inclusion criteria', 'brand', 'the dose', 'it', 'the maximal labelled dose', 'insurance change', 'months', 'tolerability', 'regimen', 'mm', 'day', 'change', '* treatment', 'hba1c', 'at least 2 months', 'adjustments', 'insulin brand changes', 'at least 0.3 units', 'criteria', 'years', 'insulin', 'adms', '1\\] regimen', '1\n\n  * age', 'value', 'insulin pumps', 'insurance']"
NCT06674980,Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs,Pathologic Processes,"Inclusion Criteria for DFU:

1. At least 18 years of age or older.
2. Must have diagnosis of type 1 or 2 Diabetes mellitus.
3. At enrollment, subject must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the imaging device.
4. Must have a target ulcer that has been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care, prior to screening visit.
5. Target ulcer located on the foot with at least 50% of the ulcer below the malleolus.
6. Target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.
7. Subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:

   1. ABI between 0.7 and \<= 1",18,100,ALL,RECRUITING,"['visit', 'target', 'diabetes mellitus', 'maximum', 'vascular assessment', 'age', 'a target ulcer', 'the ulcer', 'at least 18 years', 'mellitus', 'ulcer', 'standard', 'device', 'screening', 'subject', 'aspect', 'tendon', 'type', 'that', 'wagner', 'the foot', 'the muscle', 'dfu', '5. target ulcer', 'enrollment', 'any', 'methods', '\\<=', 'surface', 'debridement', '3 months', 'limb', 'vascular', 'the malleolus', '6. target ulcer', 'inclusion', '4 weeks', 'inclusion criteria', 'it', 'weeks', 'a minimum', 'months', 'assessment', 'a maximum surface area', 'dermis', 'diabetes', ""7. subject's affected limb"", 'area', 'care', '0.7 cm2', 'diagnosis', 'exposed tendon', 'years', 'the first screening visit', 'criteria', 'minimum', 'a minimum surface area', 'the imaging device', 'at least 50%', '1. abi', 'the following methods', 'muscle', 'perfusion', 'tissue', '52 weeks', 'post', 'foot', 'screening visit', 'grade', 'the medial aspect', 'adequate perfusion', 'bone', 'malleolus']"
NCT06047262,Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia,"Diabetes Mellitus, Type 2","Inclusion Criteria:

* Diagnosis of type 2, Diabetes mellitus as defined by the criteria of the American Diabetes Association (ADA) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (see Appendix 1) and recognized by the World Health Organization (WHO, 2019), for at least 3 months prior to the Baseline Visit/Day 1
* HbA1c value of ≥ 7.7% to ≤ 11.0% at the Screening Visit.
* High-sensitivity C-reactive protein (hsCRP) ≥ 1.5 mg/L at the Screening Visit.
* Body mass index (BMI) ≥18 to ≤ 40 kg/m2 at the Screening Visit
* Acceptable overall medical condition to safely participate in the study and complete all study procedures (particularly with regard to cardiovascular, renal, and hepatic conditions), in the opinion of the Investigator

Exclusion Criteria:

* Diagnosis of type 1 diabetes mellitus
* HbA1c value of ≤ 7.5% or ≥ 10.5% at the Baseline Visit/Day 1, as determined at point of care (local laboratory)
* Use of thiazolidinediones (glitazones), pramlintide, or s",18,100,ALL,RECRUITING,"['visit', 'the world health organization', 'the screening visit', 'hscrp', 'the investigator\n\nexclusion criteria', 'condition', 'mellitus', 'all study procedures', 'pramlintide', 'screening', '1\n* hba1c value', 'conditions', '* diagnosis', 'thiazolidinediones', '≤ 7.5%', 'type', 'expert', 'who', 'classification', 'point', 'local laboratory', '7.7%', 'body', 'the study', '* high-sensitivity c-reactive protein', '40 kg/m2', 'hba1c value', 'protein', 'laboratory', 'the diagnosis', 'inclusion criteria', 'glitazones', 's', 'reactive', 'the opinion', 'bmi', 'months', 'study', 'procedures', 'committee', 'investigator', 'opinion', '/l', 'diabetes', '11.0%', 'care', 'health', 'the baseline visit', 'diagnosis', 'sensitivity', 'criteria', 'hba1c', 'mass', 'baseline', 'index', '≥', 'appendix', '1.5 mg', 'regard', 'organization', 'inclusion', 'value', 'the criteria', 'exclusion']"
NCT02166372,Taiwan Diabesity Study:Comparison With Mild Obese T2DM Patients Who Under Metabolic Surgery,Diabetes,"Inclusion Criteria:

* Diabetic Mellitus Type 2 medically controlled at Diabetes Center for at least six months
* BMI over 25
* age between 20 and 67

Exclusion Criteria:

* Diagnosed with cancer within past five years
* HIV positive
* Active TB patients
* CV events in past six months
* serum cretinine over 2.0 mg/dl
* C-peptide bellow 1.0 ng/ml in past three months
* Diabetic retinopathy; vision bellow 0.1
* Cushing's syndrome
* History of organ transplant
* History of bariatric surgery
* History of alcohol or drug dependency in past five years
* Psychological problems likely to interfere with adherence to protocol",18,100,ALL,RECRUITING,"['alcohol or drug dependency', 'organ transplant', 'history', 'center', 'five years', 'diabetic retinopathy', 'dl', 'bariatric surgery', 'problems', 'alcohol', 'patients', 'type', 'at least six months', 'ml', '25\n* age', 'peptide', 'organ', 'serum', 'dependency', 'events', '2.0 mg', 'transplant', '* psychological problems', 'cancer', '* diabetic mellitus type', 'retinopathy', 'months', 'syndrome', 'diabetes', 'bellow', 'cretinine', 'protocol', 'years', 'criteria', 'cushing', 'adherence', 'hiv', 'surgery', 'drug', '* bmi', 'three months', '* c-peptide bellow', 'vision', 'inclusion', 'exclusion', 'six months']"
NCT06292871,The Use of Social Media Platform to Continuously Support Pregnant Women With Gestational Diabetes Mellitus,Gestational Diabetes,"Inclusion Criteria:

* Diagnosed with GDM as confirmed by the Oral Glucose Tolerance Test during pregnancy
* Age ≥ 21 and ≤ 45 years
* Attended first (baseline) session of GDM diet counselling session
* Able to read and comprehend English
* Have a digital device accessible to social media platform
* Have SingPass access
* Able to provide informed consent

Exclusion Criteria:

* With known Type 1 or Type 2 diabetes
* Have multiple pregnancy",18,100,FEMALE,RECRUITING,"['device', 'platform', 'session', 'consent', 'type', 'multiple pregnancy', 'singpass', '*', 'counselling', 'glucose', 'known type', '2 diabetes', 'diet', 'pregnancy', 'a digital device', 'inclusion criteria', 'gdm diet counselling session', 'singpass access', 'media', 'diabetes', 'informed consent\n\nexclusion criteria', 'years', 'criteria', 'access', 'first (baseline) session', '≥', 'test', 'tolerance', 'english', 'inclusion', 'pregnancy\n* age', 'gdm', 'social media platform', 'exclusion']"
NCT05909046,A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE,Pre-Gestational Diabetes,"DIP - Inclusion Criteria:

* Immediately postpartum individuals during their delivery hospital admission
* ≥ 18 years old with the ability to give informed consent.
* Diagnosed with GDM during pregnancy by:

  * Elevated one-hour 50-gram glucose challenge test any time during pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis OR
  * Two elevated values on a 3-hour 100-gram glucose tolerance test any time in pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis
* English or Spanish speaking
* Receiving prenatal and postpartum care at OSU

DIP- Exclusion Criteria:

* Individuals who cannot tolerate a 2-hour oral glucose tolerance test (OGTT) (i.e. history of gastric bypass)
* Not English or Spanish speaking

PP CARE Inclusion criteria: Enrolled DIP participants who are English speaking will be eligible for PP CARE follow up if they are between 12 and 24 months postpartum.

PP CARE Exclusion c",18,100,FEMALE,RECRUITING,"['participants', 'history', 'delivery', 'pp care', 'pregnancy and provider documentation', 'consent', 'dip participants', 'who', 'dip - inclusion criteria', 'challenge', 'their delivery hospital admission', 'hour', 'pp care inclusion criteria', 'gestational diabetes', 'glucose', 'not pregestational diabetes) diagnosis', 'informed consent', 'pregestational diabetes) diagnosis', 'pregnancy', 'ability', 'admission', 'prenatal and postpartum care', 'months', '* immediately postpartum individuals', 'diabetes', 'speaking', 'gram', 'care', 'postpartum', 'diagnosis', '(i.e. history', 'time', 'years', 'they', 'two elevated values', 'gastric bypass', 'criteria', 'ogtt', 'individuals', 'provider', 'bypass', 'hospital', '≥', 'osu\n\ndip- exclusion criteria', 'test', 'tolerance', 'inclusion', 'english speaking', 'the ability', 'gdm', 'documentation', 'values', 'exclusion']"
NCT05758545,Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers,Diabetic Foot Ulcer,"Inclusion Criteria:

1. Subjects are male or female, ≥22 and ≤90 years of age
2. Female subjects of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence) starting at screening and throughout the duration of their study participation.
3. The participant (or LAR if applicable) must be able to understand and sign the informed consent form (ICF) and comply with requirements set in the protocol including trial visits, trial treatment and dressing regimens and compliance with required offloading device (if applicable)
4. Type 1 or Type 2 diabetes mellitus
5. Presence of one full-thickness DFU located at or below the malleoli (If the subject has more than one DFU that meets eligibility criteria, the investigator will designate one DFU as the target DFU to be treated in the trial)
6. Wagner Grade 1 or 2 (without bone exposure)
7. There is a minimum 2 cm margin between the target DFU and any other ulcer on that same foot",18,100,ALL,RECRUITING,"['acceptable methods', 'the duration', 'presence', 'that same foot', 'target', 'abstinence', 'device', 'age', 'screening', 'required offloading device', 'mellitus', 'potential', 'birth', 'childbearing potential', 'pills', 'exposure', 'subject', 'consent', 'type', 'that', 'the investigator', 'one full-thickness dfu', 'bone exposure', 'participant', 'their study participation', 'trial', 'regimens', 'trial visits', 'ulcer', 'methods', 'compliance', '2 diabetes', 'duration', 'treatment', 'thickness', 'wagner grade', 'dressing', 'inclusion', 'barriers', 'inclusion criteria', 'more than one dfu', 'the informed consent form', 'subjects', 'dressing regimens', 'one dfu', 'the trial', 'study', 'eligibility criteria', 'requirements', 'birth control pills', 'female subjects', 'the target dfu', 'investigator', 'the malleoli', 'diabetes', 'participation', 'malleoli', 'the subject', 'contraception', 'protocol', 'control', 'margin', 'years', 'criteria', 'icf', 'the protocol', '. type', 'form', 'trial treatment', 'wagner', 'foot', 'visits', 'grade', '3. the participant', 'bone', 'any other ulcer']"
NCT04874012,"Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes","Diabetes Mellitus, Type 2","Inclusion criteria

* Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;
* Age over 30 years;
* BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months;
* HbA1c between 7.5% and 10.5%.

Exclusion criteria

* Use of herbal supplements, antioxidants, and multivitamins in the last 3 months;
* Pregnancy or lactation;
* Chronic renal failure with glomerular filtration rate calculated by MDRD \< 30 mL/h;
* Myocardial infarction in the last than 6 months
* Current neoplasia;
* Chronic use of glucocorticoids;
* Bariatric surgery.",18,100,ALL,RECRUITING,"['infarction', 'weight', 'female and male individuals', '* bariatric surgery', 'dm2', '* chronic use', 'supplements', 'bmc', '* current neoplasia', '7.5%', 'mdrd \\', '30 years', '* use', 'h', 'pregnancy', '* chronic renal failure', '* age', 'glomerular filtration rate', '10.5%', 'exclusion criteria', 'rate', 'clinical diagnosis', 'inclusion criteria', '* myocardial infarction', 'glucocorticoids', 'the last 3 months', 'months', 'lactation', 'filtration', '30 ml', 'failure', 'at least 6 months', 'diagnosis', 'antioxidants', 'multivitamins', 'change', 'years', 'criteria', 'neoplasia', 'individuals', 'surgery', 'weight change', 'herbal supplements', 'inclusion', '18.5 kg/m2', 'exclusion']"
NCT06408311,Safety of ENC-201-CED ENCRT,"Diabetes Mellitus, Type 1","Inclusion Criteria:

* Candidates must satisfy site's eligibility for standard of care islet infusion.

Exclusion Criteria:

* Candidates are excluded based on the site's criteria for standard of care islet infusion.",18,100,ALL,RECRUITING,"['care islet infusion', 'criteria', 'eligibility', 'islet', ""the site's criteria"", 'candidates', 'site', 'standard', 'care', 'infusion', 'inclusion', ""site's eligibility"", 'exclusion criteria', 'inclusion criteria', 'exclusion']"
NCT05764200,Acute Microbial Switch,Insulin Sensitivity,"Inclusion Criteria:

* Lean normoglycemic individuals:
* Lean (BMI ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2 );
* Normal fasting glucose (plasma glucose \< 5.6 mmol/L) and a HOMA-IR\< 2.2

Individuals with overweight/obesity and prediabetes/insulin resistance:

* Overweight/obesity (BMI ≥ 28 kg/m2 and ≤ 40 kg/m2 );
* insulin resistance (HOMA-IR\>2.2) and/or impaired fasting glucose (IFG: plasma glucose ≥ 5.6 mmol/l)

For both subject groups:

* Aged 30 - 75 years;
* Normal blood pressure (systolic blood pressure 100-150mmHg, diastolic blood pressure 60-100 mmHg);
* Weight stable for at least 3 months (± 2 kg)

Exclusion Criteria:

* T2DM (defined as fasting plasma glucose ≥ 7.0 mmol/L)
* Gastroenterological diseases
* Abdominal surgery affecting the GI tract;
* Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life expectancy shorter than five years;
* Abuse of products;

  * Alcohol (\> 15 standard units per week)
  * Drugs
  * Excessive nicotine use defined as \>20 cig",30,75,ALL,RECRUITING,"['* overweight/obesity', 'normal blood pressure', 'abuse', 'weight', 'diseases', '* drugs', 'disease', 'obesity', 'the gi tract', 'prediabetes', 'systolic blood pressure', 'nicotine', '* cardiovascular diseases', 'fasting', 'years', 'products', '5.6 mmol/l', 'insulin', '(bmi', '≤ 24.9 kg/m2', 'inclusion', 'cig', 'units', 'resistance', '60-100 mmhg', '* abuse', 'overweight/obesity and prediabetes/insulin resistance', 'homa', 'a homa-ir\\< 2.2\n\nindividuals', 'tract', '* insulin resistance', '40 kg/m2', 'diastolic', 'plasma glucose', 'life', 'groups', 'impaired fasting glucose', 'plasma glucose \\', 'individuals', ')\n\nexclusion criteria', '≥', 'diastolic blood pressure', 'exclusion', 'expectancy', 'kidney', '* weight', '* lean normoglycemic individuals', 'abdominal surgery', '* excessive nicotine use', 'cancer', 'inclusion criteria', '≤', 'plasma', 'at least 3 months', 'both subject groups', 'a life expectancy', 'malfunction', '28 kg/m2', '±', 'criteria', 'blood', '* gastroenterological diseases', '\\> 15 standard units', 'surgery', '(ifg', '* normal fasting glucose', '\\>20', '* t2dm', 'five years', 'alcohol', 'homa-ir\\>2.2', 'week', '100-150mmhg', 'glucose', 'mmhg', 'kidney malfunction', 'months', 'liver', 'pressure', 'drugs', '7.0 mmol/l']"
NCT06796322,Clinical Evaluation of Non-invasive Blood Glucose Meter,Diabetes Mellitus,"Inclusion Criteria:

Inclusion Criteria for healthy subjects:

* Male or female, aged \>=18 years.
* Fully understand the nature, significance, possible benefits, possible inconveniences or potential risks of this research, and should also understand the research procedures, be willing to complete the entire research process, and provide written consent form.

Inclusion Criteria for patients with type 2 diabetes:

* Male or female, aged \>=18 years.
* Previously diagnosed type 2 diabetes according to WHO criteria of 1999.
* Fully understand the nature, significance, possible benefits, possible inconveniences or potential risks of this research, and should also understand the research procedures, be willing to complete the entire research process, and provide written consent form.

Exclusion Criteria:

Exclusion Criteria for healthy subjects:

* There are injuries, scars, obvious pigmentation and other factors that interfere with the detection of the palm skin to be tested.
* Allergy to",18,100,ALL,RECRUITING,"['skin', 'research', 'nature', 'benefits', 'written consent form', 'the detection', 'consent', 'patients', 'type', 'that', 'who', 'the entire research process', 'allergy', 'type 2 diabetes', 'scars', '\\>=18', 'possible inconveniences', 'injuries', 'factors', 'healthy subjects', 'exclusion criteria', 'possible benefits', 'inclusion criteria', '* allergy', 'subjects', 'potential risks', 'pigmentation', 'procedures', 'other factors', 'diabetes', 'significance', 'process', 'this research', 'palm', 'years', 'criteria', 'the research procedures', 'inconveniences', 'form', 'detection', '* previously diagnosed type', 'the palm skin', 'risks', 'obvious pigmentation', 'inclusion', 'exclusion', 'the nature']"
NCT06572345,Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study,Pediatric Obesity,"Inclusion criteria

LED intervention

* Diagnosis of T2DM (defined as an HbA1C ≥48mmol/mol, in the absence of features of type 1 or monogenic/syndromic diabetes).
* Current HbA1C ≥48 (or ≥42 on antidiabetic medication) and ≤ 80 mmol/mol.
* Aged 12 to 17 years old.
* BMI ≥98th centile (+2 SD) for age and sex (UK90 growth reference data).
* Informed consent:

  * Received from the young person (age 16-17) OR
  * Received from young person's parent/carer, with patient assent (age 12-15).
* Willing to engage in and commit to low energy diet, FR and weight management phases including follow-up and attending study visits.

LED Intervention Interviews

The same interview inclusion criteria for LED intervention, with the following additional requirements:

Patients:

* Informed consent:

  * Received from the young person (age 16-17) OR
  * Received from young person's parent/carer, with patient assent (age 12-15).
* Willing to take part in a qualitative interview alongside a parent/carer.

Re",12,17,ALL,RECRUITING,"['t2dm', '* informed consent', 'centile', 'person', 'study visits', 'weight', 'age', 'low energy diet', 'phases', 'interviews', 'assent', 'consent', 'patients', '* bmi ≥98th centile', 'type', 'medication', 'an hba1c ≥48mmol/mol', '≥42', 'patient assent', 'the young person', 'diet', '+2 sd', 'led intervention', 'intervention interviews', 'absence', 'parent', 'interview', 'inclusion criteria', 'fr and weight management', '≤', 'follow-up', 'study', 'a qualitative interview', 'management', 'sex', ""young person's parent/carer"", 'data', 'requirements', 'a parent/carer', '80 mmol/mol', 'part', 'diabetes', 'reference', 'the absence', 'the following additional requirements', 'diagnosis', 'intervention\n\n* diagnosis', 'criteria', 'years', 'carer', 'antidiabetic medication', 'uk90 growth reference data', 'energy', 'visits', 'inclusion', 'growth', '* current hba1c ≥48', 'features', 'intervention']"
NCT02037867,Nottingham Community Liver Biomarkers Cohort,Chronic Liver Disease,"Inclusion Criteria:

* Adult patients aged 18 years or over (male or female) with primary risk factor for liver disease:

  * Hazardous alcohol use (\>14 units/week for women, \>21 units/week for men)
  * Type 2 Diabetes
  * Obesity
  * Persistently elevated ALT with normal liver serology

Exclusion Criteria:

* Active malignancy at study enrolment
* Inability to provide informed consent for study enrolment
* Known presence of histologically proven liver disease prior to pilot pathway participation",18,100,ALL,RECRUITING,"['presence', 'malignancy', 'units', 'pathway', 'histologically proven liver disease', 'enrolment', 'consent', 'alcohol', 'patients', 'type', 'week', '\\>14 units', 'disease', '* adult patients', 'women', 'obesity', 'informed consent', 'persistently elevated alt', 'serology', 'inclusion criteria', 'active malignancy', 'liver disease', 'study enrolment\n* inability', '* hazardous alcohol use', 'liver', 'study', '\\>21 units', 'primary risk factor', 'diabetes', 'pilot pathway participation', 'participation', 'years', 'men', 'criteria', 'factor', 'pilot', 'risk', 'inability', 'inclusion', 'adult', 'exclusion', 'female']"
NCT06989164,Post Prandial Individual Responses to Different Foods,PreDiabetes,"Inclusion Criteria:

* BMI (body mass index) \>19 kg/m2 but \< 45 kg/m2
* HbA1c \< or equal to 7.0% while not on antihyperglycemic medications
* Be willing to provide written informed consent for all study procedures.
* Able to commute to Stanford campus for on-site visits

Exclusion Criteria:

* recent (\<6mos) CVD (cardiovascular disease) event
* active malignancy
* kidney/liver disease
* pregnancy/lactation
* chronic inflammatory disease
* eating disorder
* bariatric surgery
* history of acute pancreatitis
* current use of antihyperglycemic, diabetogenic, or weight loss medications
* heavy alcohol use
* physical activity \>2 hours/day
* inability to come to Stanford CTRU (Clinical and Translational Research Unit) for metabolic testing",18,100,ALL,RECRUITING,"['malignancy', 'activity', '* kidney/liver disease', 'weight', 'history', 'all study procedures', 'research', '* bariatric surgery', 'kidney', 'consent', 'event', 'alcohol', 'disease', '7.0%', 'site', 'metabolic testing', 'stanford campus', 'body', 'pregnancy', 'written informed consent', 'inclusion', 'inclusion criteria', '\\', 'pancreatitis', 'medications', 'active malignancy', 'study', 'procedures', 'liver', 'lactation', 'loss', 'testing', 'hours', 'antihyperglycemic medications', '\\>19 kg/m2', '(cardiovascular disease', 'metabolic', 'unit', 'criteria', 'hba1c', 'surgery', 'index', 'campus', '* bmi', 'disorder', 'inability', 'visits', 'body mass index', '45 kg/m2', '\\>2 hours/day\n* inability', 'exclusion']"
NCT06959277,Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems,Peripheral Neuropathies,"Inclusion Criteria:

* Able to understand and provide informed consent for him or herself
* Age 55 and older, male or female
* Able to complete all functional outcome measures without the use of an assistive device
* Clinical diagnosis of peripheral neuropathy prior to participating in the study as documented in the participant's medical record or by physician's note. Individuals with chemo-induced peripheral neuropathy must be at least one-year post-chemotherapy, indicating that their PN has become a chronic condition.
* Self-reported gait and balance problems
* Foot size that allows the Walkasins to function appropriately
* Willing to use the Walkasins device as recommended

Exclusion Criteria:

* Ability to stand on one leg for at least 30 seconds (If the person can stand for at least 30 seconds, he/she is excluded because his/her balance is likely not impaired enough to benefit from Walkasins.)
* Self-reported acute thrombophlebitis, including deep vein thrombosis
* Self-reported s",18,100,ALL,RECRUITING,"['balance', 'person', 'as recommended\n\nexclusion criteria', 'foot size', 'him', 'condition', 'an assistive device', 'peripheral neuropathy', 'device', 'thrombophlebitis', 'self-reported s', 'chemo', 'deep vein thrombosis', 'herself\n* age', '* self-reported acute thrombophlebitis', 'consent', 'problems', 'outcome', 'that', 'walkasins', 'neuropathy', 'participant', 'chemotherapy', 'year', 'she', 'informed consent', ""the participant's medical record"", 'measures', 'the study', 'ability', 'the person', '* clinical diagnosis', 'inclusion criteria', 'he', 'one leg', 'study', '* ability', 'record', 'thrombosis', 'physician', 'gait', 'seconds', 'at least 30 seconds', 'diagnosis', 'size', 'criteria', '-', 'individuals', 'the walkasins device', 'the use', 'his/her balance', 'a chronic condition', ""physician's note"", 'chemo-induced peripheral neuropathy', 'all functional outcome measures', 'their pn', 'the walkasins', 'note', 'post', 'self', 'foot', 'inclusion', 'exclusion', 'at least one-year post', 'female']"
NCT05441267,A Study of Cardiovascular Events iN Diabetes Plus,"Diabetes Mellitus, Type 2","Inclusion Criteria:

* Adults aged at least 55 years at the time of the Screening assessment
* Type 2 Diabetes Mellitus (based on self-reported medical history)

Exclusion criteria:

* Myocardial Infarction
* Stroke
* Current or planned treatment with a GLP-1 RA
* Previous hypersensitivity to or intolerance of GLP-1 RA therapy
* Severe hypoglycaemia within the last six months or during run-in
* Symptomatic hypoglycaemia within the last month
* Currently under consideration to commence insulin
* Severe heart failure (NYHA class 4)
* Current or planned renal replacement therapy
* Unwilling to complete regular follow-up assessments
* Ongoing treatment for cancer or diagnosis with cancer (excluding non-melanoma skin cancer) in the last 2 years
* Type 1 or other type of diabetes (e.g. MODY)
* History of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
* Currently breastfeeding or pregnant, or planning a pregnancy
* Any serious illness which is likely to limit survival or a",55,100,ALL,RECRUITING,"['infarction', 'illness', 'skin', 'other type', 'assessment', 'history', 'mellitus', 'any serious illness', 'which', 'screening', 'a pregnancy', 'medullary', 'type', 'the last six months', '(e.g. mody', 'adults', 'exclusion', 'ra', 'the time', 'self-reported medical history', 'treatment', 'ra therapy', 'multiple endocrine neoplasia type', 'mody', 'pregnancy', '* history', 'non-melanoma skin cancer', 'stroke', 'cancer', 'inclusion criteria', '* severe hypoglycaemia', 'therapy', 'assessments', 'months', '* type', 'ongoing treatment', 'class', 'intolerance', '* adults', 'regular follow-up assessments', 'diabetes', 'run-in\n* symptomatic hypoglycaemia', 'month', 'commence', 'heart', 'failure', 'diagnosis', 'hypoglycaemia', 'replacement', 'time', 'years', 'criteria', 'hypersensitivity', ')\n\nexclusion criteria', 'medullary thyroid carcinoma', 'thyroid', 'insulin', 'consideration', 'self', 'survival', 'inclusion', 'endocrine', 'the last month', 'the last 2 years']"
NCT04303364,CARdiomyopathy in Type 2 DIAbetes Mellitus,"Cardiomyopathy, Diabetic","Inclusion criteria

* Female or male, aged between ≥ 40 and ≤80 years
* Normal LVEF AND absence of akinetic segment assessed by echocardiography (i.e. LVEF≥50%)
* Patients diagnosed according to the specific diagnostic criteria of each disease (Cf. table below (definition criteria)). For each group, the diagnosis will be based on current accepted criteria:

  * HFpEF: left ventricular ejection fraction (LVEF) LVEF≥50% AND presence/or history of symptoms (e.g. breathlessness, ankle swelling and fatigue) or signs (e.g. elevated jugular venous pressure, pulmonary crackles and peripheral oedema) of heart failure AND significant diastolic dysfunction (left atrial volume index \>34 mL/m2 or a LVMI ≥115 g/m2 for males and ≥95 g/m2 for female, E/e' ≥13 and e' \<9 cm/s) OR NT-proBNP \>125 pg/Ml
  * No HFpEF: LVEF≥50% AND absence of symptoms (e.g. breathlessness, ankle swelling and fatigue) or signs (e.g. elevated jugular venous pressure, pulmonary crackles and peripheral oedema) of heart failur",18,100,ALL,RECRUITING,"['no hfpef', 'presence', 'significant diastolic dysfunction', 'each group', 'history', 'echocardiography', 'the specific diagnostic criteria', '* hfpef', 'table', 'female', 'patients', 'lvmi', '≥115', 'akinetic segment', 'ml', 'disease', 'hfpef', 'dysfunction', 'group', 'segment', 'absence', 'definition', 'fraction', 'the diagnosis', 'swelling', 'lvef≥50%', 'ejection', 'inclusion criteria', 'signs', 'diastolic', 'symptoms', 'a lvmi', '≥95 g/m2', 'failur', 'cf. table', 'males', 'oedema', 'g', 'ankle swelling', 'failure', 'nt-probnp \\>125', 'heart failur', 'heart', 'diagnosis', 'pg', '(definition criteria', 'pressure', 'fatigue', 'criteria', 'years', 'lvef≥50', 'index', '/m2', 'volume', 'lvef', '(i.e. lvef≥50%', 'male', 'crackles', 'ankle', 'heart failure', 'inclusion', 'current accepted criteria', 'ventricular ejection fraction', 'each disease']"
NCT05326204,1 Versus 2 Hours Post Meal Glucose Monitoring in Gestational Diabetes on Treatment,Gestational Diabetes,"Inclusion Criteria:

* Gestational diabetes diagnosed based on National Institute for Health and Care Excellence guideline
* requiring treatment either with metformin alone or combined with insulin

Exclusion Criteria:

* type 1 and 2 diabetes
* bad obstetrics history
* underlying medical disorders such as Systemic Lupus Erythematosus
* fetal anomaly
* delivery elsewhere",18,100,FEMALE,RECRUITING,"['history', 'delivery', 'type', '* gestational diabetes', 'treatment', 'obstetrics', 'guideline', 'bad obstetrics history', 'inclusion criteria', '* type', 'lupus', 'diabetes', 'care', 'health', 'insulin\n\nexclusion criteria', 'criteria', 'national institute', 'disorders', 'metformin', 'insulin', 'care excellence guideline', 'inclusion', 'exclusion']"
NCT07296952,Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE),Diabetic Retinopathy (DR),"Inclusion Criteria:

* Established patient
* Medicaid insurance
* History of diabetic retinopathy
* Lives within 25 miles of the clinic
* English speaking",18,100,ALL,NOT_YET_RECRUITING,"['medicaid insurance', 'lives', 'the clinic', 'clinic', '* established patient', '* lives', 'history', '25 miles', '* english', 'patient', 'speaking', 'miles', 'inclusion', 'criteria', 'inclusion criteria', 'insurance']"
NCT06641765,Continuous Glucose Monitoring in Dialysis Patients With Diabetes,"Diabetes Mellitus, Type 2","Inclusion Criteria:

* Written informed consent obtained before any trial-related procedures are performed
* Diabetes, one of the following groups: Type 1 diabetes OR Type 2 diabetes receiving glucose-lowering therapy OR Type 2 diabetes managed with lifestyle changes with an HbA1c ≥ 50 mmol/mol
* Maintenance haemodialysis or peritoneal dialysis (minimum of two weeks)
* Subject must be willing and able to comply with trial protocol and be fluent in Danish or English

Exclusion Criteria:

* Major allergy to tape/adhesives
* Women who are pregnant or planning pregnancy
* Ongoing use of CGM
* Ongoing use of insulin pump",18,100,ALL,RECRUITING,"['haemodialysis', 'peritoneal dialysis', 'trial protocol', 'tape/adhesives', 'two weeks', 'subject', 'consent', 'glucose-lowering therapy', 'type', 'who', 'allergy', '* major allergy', 'trial', 'lifestyle changes', 'type 2 diabetes', 'maintenance', 'glucose', 'tape', 'women', '2 diabetes', 'adhesives', 'dialysis', 'changes', 'pregnancy', 'pump', '* written informed consent', 'cgm\n* ongoing use', 'inclusion criteria', 'any trial-related procedures', 'therapy', 'weeks', 'procedures', 'the following groups', 'diabetes', '* subject', 'groups', 'protocol', 'minimum', 'criteria', 'insulin', '1 diabetes', 'inclusion', 'lifestyle', 'insulin pump', 'exclusion']"
NCT06141434,PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life,Type 1 Diabetes,"Inclusion Criteria:

* Pregnant women and their offspring where the offspring has a first degree relative (mother, biological father, full sibling) with type 1 diabetes
* Mother is 18 or older
* Mother is both gestational and biological mother
* Gestation up to 24 weeks at enrollment

Exclusion Criteria:

* Parents do not agree to inclusion of the offspring in the study and genetic risk testing
* Greater than singleton pregnancy",18,100,ALL,RECRUITING,"['sibling', 'type', 'singleton', 'enrollment', 'singleton pregnancy', 'women', 'parents', 'the study', 'father', 'pregnancy', 'up to 24 weeks', 'inclusion criteria', 'full sibling', '* gestation', 'weeks', 'degree', 'study', 'testing', 'the offspring', 'type 1 diabetes', 'diabetes', '* mother', 'gestational and biological mother', 'enrollment\n\nexclusion criteria', 'criteria', 'genetic risk testing', 'pregnant women', 'offspring', 'risk', 'gestation', 'mother', 'a first degree', 'biological father', 'inclusion', 'exclusion', 'their offspring']"
NCT06693934,Jockey Club Precision Prevention Programme on Young Onset Diabetes,Diabetes,"Inclusion Criteria:

* Aged between 18 and 44 years old
* With at least one risk factor for diabetes

Exclusion Criteria:

* Known history of Diabetes
* With conditions considered not suitable by the project team (including illiteracy)

The risk factors for diabetes include central or general obesity, family history of diabetes, smoking history, history of hypertension/ high blood glucose level/ abnormal lipid level/ vascular disease/ fatty liver, history of gestational diabetes/ polycystic ovary syndrome/ delivery of baby≥ 4kg (for women only), and less than 150mins of physical activity every week.",18,44,ALL,RECRUITING,"['history', 'diabetes\n\nexclusion criteria', 'delivery', 'central or general obesity', 'conditions', 'week', 'ovary', 'glucose', 'women', 'obesity', 'factors', 'vascular', 'the risk factors', '4kg', 'inclusion criteria', 'liver', 'lipid', 'diabetes', 'baby≥', '150mins', 'the project team', 'family', 'years', 'criteria', 'team', 'blood', 'family history', 'illiteracy', 'factor', 'physical activity', 'risk', '* known history', 'project', 'inclusion', 'exclusion', 'activity']"
NCT06774014,"Heart Failure in Patients With Diabetes: Cells, Crosstalk and Consequences",Diabetes Mellitus Type 2,"Inclusion Criteria:

* Age \>18 years
* Ability to provide written informed consent
* Persons who are legally competent and mentally able to follow the instructions of the study staff

Exclusion Criteria:

* Anaemia Hb \<8 mg/dl
* Patients with acute infectious diseases (e.g. pneumonia)
* Patients with heart failure due to sepsis
* People with acute myocardial ischemia, which is manifested, for example, by angina pectoris or ECG changes under stress
* Patients with acute liver or kidney failure or severe COPD (FEV1\<1.0)
* Pregnant and breastfeeding women
* People who are institutionalized on official or court orders
* People who are dependent or employed by the sponsor or investigator
* Taking study medication (of an investigational drug) 30 days before the start of the study",18,100,ALL,RECRUITING,"['mg', '* anaemia', 'acute liver', 'the instructions', 'which', 'diseases', 'kidney', 'dl', 'days', 'consent', '* age \\>18 years', 'acute myocardial ischemia', 'staff', 'patients', 'who', 'court', 'pneumonia', '* patients', 'medication', 'women', 'copd', 'changes', 'sepsis', 'the study', 'ability', 'e.g. pneumonia', 'study medication', 'instructions', 'inclusion', 'orders', 'inclusion criteria', 'kidney failure', 'people', 'study', '* ability', 'investigator', 'anaemia', 'ischemia', 'liver', 'sponsor', 'sepsis\n* people', 'the sponsor', 'the start', 'failure', 'persons', 'heart', 'example', 'severe copd', 'stress', 'years', 'criteria', '\\>18', 'drug', 'an investigational drug', 'heart failure', 'start', 'angina pectoris', 'official or court orders', 'acute infectious diseases', 'fev1\\<1.0', 'exclusion']"
NCT06046833,Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes,"Diabetes Mellitus, Type 2","Inclusion Criteria:

* Over the age of 18 years.
* Hemoglobin A1c ≤11% within the last 6 months.
* Patients with diagnosis of type 1 Diabetes or type 2 Diabetes for at least one year.
* Normal thyroid-stimulating hormone (TSH) within the last year.
* No episodes of diabetic ketoacidosis (DKA), Hyperosmolar Hyperglycemic Status (HHS), or hypoglycemia in the past 2 weeks requiring ER visit or hospitalization.
* Symptoms of gastroparesis have been present for at least the past 3 months, in patients with gastroparesis.
* In patients with gastroparesis, documented delayed gastric emptying on scintigraphy and/or wireless motility capsule (Smart Pill) as defined by greater than 10% retention at 4 hours or greater than 4-hour gastric transit time (GTT) in the past five years.
* Patients using a Smartphone (iPhone or Android) compatible with LibreView App.

Exclusion Criteria:

* Hemoglobin A1c of \>11% at enrollment.
* Advanced chronic kidney disease (serum creatinine of \>2 mg/dL or estimated",18,100,ALL,RECRUITING,"['visit', 'diabetic ketoacidosis', 'retention', '* hemoglobin a1c', 'episodes', 'transit', 'hemoglobin', 'kidney', 'a smartphone', 'the past 2 weeks', 'patients', 'type', 'pill', 'creatinine', 'hypoglycemia', 'status', 'dka', 'hour', 'year', '* patients', 'disease', 'enrollment', '* hemoglobin', '* normal thyroid-stimulating hormone', 'er visit', '2 diabetes', 'serum', '18 years', '4 hours', 'at least one year', 'hhs', 'inclusion', 'a1c ≤11%', 'the past five years', '4-hour', 'gastroparesis', 'inclusion criteria', 'the last 6 months', 'exclusion criteria', 'symptoms', 'scintigraphy', 'libreview app', 'months', 'weeks', 'capsule', '(gtt', 'diabetes', 'the age', 'hours', 'smart pill', 'smartphone', 'diagnosis', 'time', 'years', 'criteria', 'greater than 10% retention', '\\>2 mg', 'thyroid', 'motility', 'no episodes', 'hyperosmolar hyperglycemic status', 'ketoacidosis', 'wireless motility capsule', '\\>11%', 'the last year', 'tsh', 'serum creatinine', 'hospitalization', 'exclusion', 'hormone', 'iphone']"
NCT07318207,Time-restricted Eating for Patients With Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

* Diagnosis of Type 2 Diabetes

Exclusion Criteria:

* Pregnant or breastfeeding
* Diagnosed eating disorder
* Night shift worker
* Taking drugs which induce hypoglycemia
* Unable or unwilling to participate in the time-restricted eating intervention",18,100,ALL,RECRUITING,"['which', '* diagnosis', 'type', 'hypoglycemia', 'the time-restricted eating intervention', 'inclusion criteria', 'night', '* night shift worker', 'diabetes', 'worker', 'diagnosis', 'time', 'shift', 'criteria', 'drugs', 'disorder', 'inclusion', 'diagnosed eating disorder', 'exclusion', 'intervention']"
NCT03323216,BIO-2-HEART: Identification of Biomarkers in T2DM and Heart Failure,Heart Failure,"Inclusion Criteria:

1. guideline-appropriate clinical indication for CRT implantation/electrophysiologial examination/pulmonary vein ablation
2. age of majority
3. written declaration of consent
4. persons who are able to work and mentally able to follow the instructions of the study staff
5. free access routes

Exclusion Criteria:

1. anemia Hb \<8 mg / dl
2. patients with acute infectious disease (e.g. pneumonia)
3. non-intubatable coronary sinus
4. patients who do not have access to the subclavian vein (e.g. thrombosis of the subclavian vein or superior vena cava)
5. patients with idiopathic hypertrophic, restrictive or constrictive cardiomyopathy, or heart failure due to a known inflammatory or infiltrating disease (e.g. amyloidosis, sarcoidosis) or a constrictive disease
6. patients with heart failure by sepsis
7. persons with acute myocardial ischaemia, e.g. by angina pectoris or ECG changes under load
8. patients with acute coronary syndrome are not implanted in the past 3 mont",18,100,ALL,RECRUITING,"['e.g. amyloidosis', 'sarcoidosis', 'age', 'the instructions', 'superior vena cava', 'acute coronary syndrome', 'written declaration', 'sinus', 'consent', 'angina pectoris', 'patients', 'staff', 'who', 'inflammatory', 'the past 3 mont', 'acute myocardial ischaemia', 'majority', 'disease', 'pneumonia', 'acute infectious disease', 'the subclavian vein', 'guideline', 'changes', 'examination', 'sepsis', 'amyloidosis', 'routes', 'e.g. pneumonia', 'instructions', 'a constrictive disease', 'inclusion', 'inclusion criteria', 'ablation', 'mont', 'non-intubatable coronary sinus', 'declaration', 'study', 'syndrome', 'thrombosis', 'failure', 'persons', 'the study staff', 'heart', 'indication', 'criteria', 'load', 'implantation', 'access', '(e.g. thrombosis', 'guideline-appropriate clinical indication', 'anemia', 'heart failure', 'a known inflammatory', 'mg / dl', 'exclusion', 'infiltrating disease']"
NCT05740514,Healthy Outcomes for Muscle with Exercise in T1D,"Diabetes Mellitus, Type 1","Inclusion Criteria:

* Age of 18-30 or 45-65
* Sedentary or recreationally active, as defined by self-reported activity levels below the recommended 150-minute minimum of moderate-to-vigorous intensity physical activity per week

Exclusion Criteria:

* Chronic use of anti-inflammatory, glucocorticoid, or other pain-relief medication
* History of daily cannabis, tobacco, or nicotine use within six months of study initiation
* BMI \>30kg/m2
* Prediabetes
* Type 2 diabetes
* Health conditions that put the subject at risk to participate in exercise during this study
* Atypical or Grade 2b diabetic sensorimotor polyneuropathy
* More than one lifetime event of hospitalization for diabetic ketoacidosis",18,100,ALL,RECRUITING,"['moderate-to-vigorous intensity physical activity', 'diabetic ketoacidosis', 'pain', 'self-reported activity levels', 'history', 'intensity', 'initiation', '* chronic use', 'conditions', 'subject', 'event', 'type', 'that', 'week', 'health conditions', 'sensorimotor', 'minute', 'medication', 'week\n\nexclusion criteria', 'levels', 'prediabetes', '* age', 'tobacco', 'inclusion criteria', 'exercise', 'months', 'other pain-relief medication', 'relief', 'study', 'diabetes', 'the subject', 'health', 'nicotine', 'cannabis', 'minimum', 'criteria', 'ketoacidosis', 'risk', 'self', 'grade', 'lifetime', 'inclusion', 'hospitalization', 'study initiation', 'exclusion', 'the recommended 150-minute minimum', 'activity', 'six months']"
NCT07206875,Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders,Diabetes,"Inclusion Criteria:

* Age ≥18 years
* Outpatient Diabetes Unit patient
* Ability to give informed consent

Diagnosis of at least one of the following:

* Metabolic disease, defined as BMI ≥25 Kg/m2
* Type 1 or type 2 diabetes mellitus
* Gestational diabetes
* Monogenic diabetes (MODY)
* Other types of diabetes or dysglycemia
* Dyslipidemia
* Arterial hypertension
* Steatosis liver disease (SLD)

Exclusion Criteria:

* Age \<18 years
* Deny participation at the study
* Recruitment in an interventional protocol
* Patients with missing significant data",18,100,ALL,NOT_YET_RECRUITING,"['missing significant data', '\\<18', 'informed consent\n\ndiagnosis', 'recruitment', 'consent', 'following', 'steatosis', 'patients', 'type', '* gestational diabetes', 'disease', 'arterial hypertension', '* metabolic disease', 'mody', 'ability', 'the study\n* recruitment', '* age \\<18 years', 'the following', 'inclusion criteria', 'types', 'liver', 'hypertension', '* ability', 'study', 'patient', 'data', 'diabetes', 'participation', 'other types', 'diagnosis', 'protocol', 'metabolic', 'unit', 'years', 'criteria', ')\n\nexclusion criteria', 'outpatient', '* steatosis liver disease', 'inclusion', 'exclusion', 'sld']"
NCT07332416,Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening,Gestational Diabetes,"Inclusion Criteria:

* 12-16 weeks postpartum
* Gestational diabetes Mellitus (GDM) diagnosis in most recent pregnancy
* Oral Glucose Tolerance Test (OGTT) order placed in the medical record

Exclusion Criteria:

* Pre-gestational diabetes
* Non-English language",18,100,FEMALE,NOT_YET_RECRUITING,"['order', 'exclusion', 'weeks', 'glucose', '* non-english language', 'record', 'language', 'diabetes', 'test', 'tolerance', 'pregnancy', 'postpartum', 'diagnosis', 'inclusion', '* pre-gestational diabetes', 'criteria', 'inclusion criteria', 'ogtt']"
NCT06272565,Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage,Diabetic Retinopathy,"Inclusion Criteria:

1. Patients \> 40 years old.
2. CON (non diabetes control group)：patients undergoing phacoemulsification surgery.
3. NDR (non diabetes retinopathy diabetes patients): patients with diabetes history and undergoing phacoemulsification surgery.
4. NPDR (non proliferative diabetes retinopathy): patients with history of diabetes, fundus microangiopathy shown by fundus fluorescein angiography, including microangioma, hard exudation, wadding exudation and other non proliferative diabetes retinopathy signs, and did not receive invasive ophthalmic treatment within 3 months.
5. PDR (proliferative diabetes retinopathy): patients with a history of diabetes, fundus neovascular lesions shown by fundus fluorescein angiography, and did not receive invasive ophthalmic treatment within 3 months.
6. Patients voluntarily signed informed consent.

Exclusion Criteria:

1. CON (non diabetes control group)：patients with a history of other ophthalmic operations.
2. NDR (non diabetes retino",18,100,ALL,NOT_YET_RECRUITING,"['lesions', '2. con', 'fluorescein angiography', 'history', 'hard exudation', 'operations', 'npdr', 'wadding exudation', 'consent', 'patients', 'proliferative diabetes', 'non', '2. ndr', 'a history', 'invasive ophthalmic treatment', 'fundus fluorescein angiography', 'phacoemulsification', 'treatment', 'informed consent', '3 months', 'exclusion criteria', 'inclusion criteria', '\\', 'signs', 'other ophthalmic operations', 'months', 'diabetes retinopathy signs', 'diabetes', 'microangioma', 'group)：patients', 'years', 'criteria', '5. pdr', 'retino', 'surgery', 'angiography', 'ndr', 'exudation', 'phacoemulsification surgery', 'inclusion', 'neovascular lesions', 'exclusion', 'con']"
NCT05754567,CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes,Neurocognitive Disorders,"Inclusion Criteria:

* Children of women who participated in the CONCEPTT trial at selected recruiting sites

Exclusion Criteria:

* NA",18,100,ALL,RECRUITING,"['criteria', 'children', 'exclusion', 'women', 'the conceptt trial', '* children', 'conceptt', 'sites', 'inclusion', 'recruiting', 'who', 'inclusion criteria', 'trial']"
NCT07239700,Buzzy and TickleFlex in Reducing Insulin Injection Pain and Fear,Diabete Type 1,"Inclusion Criteria:

* Children aged 6 to 12 years.
* Diagnosed with Type 1 Diabetes Mellitus (T1DM) for at least 6 months.
* Receiving daily subcutaneous insulin injections as part of routine diabetes management.
* Able to understand and communicate pain and fear levels using the Wong-Baker -FACES Pain Rating Scale and the Children's Fear Scale.
* Accompanied by a parent or legal guardian who can provide informed consent.
* Willingness of both the child and parent to participate in the study.
* No visual, auditory, or cognitive impairments that would interfere with data collection.

Exclusion Criteria:

* Presence of neurological, sensory, or cognitive disorders that may affect pain or fear perception.
* Peripheral neuropathy or other diabetic complications influencing pain sensation.
* Use of analgesics, sedatives, or anxiolytic medications within 24 hours prior to data collection.
* Local skin lesions, infections, or allergies at or near the insulin injection site.
* History of need",6,12,ALL,ENROLLING_BY_INVITATION,"['lesions', 'the insulin injection site', '24 hours', 'allergies', 'presence', 'daily subcutaneous insulin injections', 'pain', 'skin', 'rating', '* presence', 'history', 'collection', 'both the child', 'consent', 'type', 'that', ""the children's fear scale"", 'who', 'neuropathy', 'pain sensation', 'legal guardian', 'need', 'informed consent', '* use', 'a parent', 'levels', 'injection', 'routine diabetes management', 'site', 'the study', '* history', 'parent', 'exclusion criteria', 'inclusion criteria', 'fear', 'impairments', 'perception', 'medications', 't1', 'other diabetic complications', 'months', 'study', 'management', 'sensation', '* children', 'injections', 'data collection', 'diabetes', 'part', 'sedatives', 'data', 'hours', '* local skin lesions', 'at least 6 months', 'child', 'pain or fear perception', 'anxiolytic medications', 'years', 'criteria', 'willingness', 'infections', 'children', 'disorders', 'pain and fear levels', 'guardian', 'insulin', 'type 1 diabetes mellitus', 'complications', 'inclusion', 'scale', '* peripheral neuropathy', 'analgesics', '* willingness', 'exclusion']"
NCT06526936,The Effect of Foot Care Training Given to Diabetic Hemodialysis Patients on Foot Care Behavior,Diabetic Foot,"Inclusion Criteria:

* Being over 18 years old
* Having a diagnosis of diabetes
* Volunteering to participate in the study
* Good communication skills and the patient's ability to receive training himself

Exclusion Criteria:

* Not willing to participate in conflict",18,100,ALL,RECRUITING,"['communication', 'study', 'a diagnosis', 'conflict', 'skills', 'patient', 'diabetes', 'himself\n\nexclusion criteria', 'ability', 'diagnosis', 'inclusion', ""the patient's ability"", 'years', 'criteria', 'inclusion criteria', 'exclusion']"
NCT06883344,Automated Insulin for Management of Intrapartum Glycemia,Type 1 Diabetes (T1D),"Inclusion Criteria:

* Currently pregnant at ≥ 34 weeks
* Known diagnosis of type 1 diabetes ≥ 1 year
* Use of commercially available AID system since at least 28 weeks gestation
* Singleton pregnancy
* English- or Spanish-speaking

Exclusion Criteria:

* Multifetal gestation
* Planned cesarean delivery
* Use of medications known to interfere with glucose metabolism
* Intrauterine fetal demise
* Physical or psychological disease likely to interfere with the conduct of the study and/or the ability to participate in own healthcare",18,100,FEMALE,RECRUITING,"['metabolism', 'delivery', 'type', '* singleton pregnancy', 'demise', 'year', 'singleton', 'disease', 'glucose', 'the study', 'pregnancy', 'ability', 'system', 'inclusion criteria', 'medications', 'the conduct', 'weeks', 'study', 'diabetes', 'own healthcare', 'diagnosis', 'commercially available aid system', 'criteria', '1 year\n* use', '≥', 'healthcare', 'gestation', 'inclusion', 'conduct', 'the ability', 'exclusion']"
NCT06783309,CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D),Type 1 Diabetes Mellitus,"Inclusion Criteria:

1. Participants who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.
2. Men and non-pregnant, non-breast-feeding women ages 12-35 years inclusive.
3. Documented diagnosis of T1D within 180 days prior to study enrollment according to at least 1 of the American Diabetes Association \[ADA\] criteria.
4. Participants must be on standard of care diabetes management (e.g., insulin therapy, a nutrition plan, regular exercise, or other relevant specialty care).
5. Participants with a peak stimulated C-peptide of \>0.2 nmol/L measured from a mixed meal tolerance test (MMTT). Note: this test result may be obtained from an MMTT conducted within 1 month of planned first dose.
6. Participants with an episode of diabetic ketoacidosis (DKA) must have a MMTT performed no sooner than 2 weeks and up to 4 weeks after resolution of the DKA event to have a qualifying C-peptide reading.
7",12,35,ALL,RECRUITING,"['participants', 'nutrition', 'diabetic ketoacidosis', 'non-pregnant, non-breast-feeding women', '\\>0.2 nmol/l', 'planned first dose', '180 days', 'this test result', '(e.g., insulin therapy', 'standard', 'institutional review board', 'privacy', 'days', 'consent', 'dose', 'episode', 'event', 'who', 'an episode', 'dka', 'result', 'peptide', 'qualifying', 'enrollment', 'women', 'an mmtt', 'language', 'a qualifying c-peptide reading', 'c', 'privacy language', 'a mmtt', 'care diabetes management', 'written informed consent', 'review', 'national regulations', 'specialty', 'inclusion criteria', '3. documented diagnosis', '1 month', 'the dka event', 'therapy', 'exercise', 'peak', 'meal', 'a nutrition plan', 'board', 'mmtt', '2. men', 'management', 'weeks', 'resolution', 'diabetes', 'regular exercise', 'plan', 'other relevant specialty care', 'care', 'month', 'diagnosis', 'reading', 'years', 'criteria', 't1d', 'ketoacidosis', 'insulin', 'note', 'a peak', 'tolerance', 'test', 'regulations', 'inclusion', 'irb']"
NCT06278207,An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions,Chronic Kidney Disease,"Inclusion Criteria:

* A minimum of 12 months of continuous enrolment in the databases with medical and pharmacy coverage measured as continuously receiving medical care from health providers contributing to the EHR or claims system, depending on the database used
* No recorded prescription for finerenone in the 12 months prior to the index date
* Age of 18 years or older as of the index date
* Evidence of T2D at any point before (and including) the index date.
* CKD stages 2-4 related to eligibility will be defined according to the presence of the following criteria at any point before (and including) the index date:

  * A diagnosis code indicating CKD stage 2, 3, 4 or stage unspecified
  * two UACR tests results ≥ 30 mg/g separated by at least 90 days and by not more than 540 days
  * two different eGFR test results ≥ 15 mL/min/1.73 m2 AND \< 60 mL/min/1.73 m2 separated by at least 90 days and by not more than 540 days

Exclusion Criteria:

\- Kidney failure defined as follows:

* T",2,4,ALL,RECRUITING,"['any point', 'mg', 'presence', 'medical and pharmacy coverage', 'code', 'prescription', 'days', 'stage', 'kidney', 'enrolment', 'providers', '12 months', 'database', '/g', 'the presence', '15 ml/min/1.73 m2', 'point', 'continuous enrolment', 'egfr', 'stages', 'health providers', '18 years', 't2d', '60 ml/min/1.73 m2', 'no recorded prescription', 'medical care', '* age', 'inclusion criteria', 'kidney failure', 'databases', 'system', 'at least 90 days', 'finerenone', 'the index date', '* t', 'months', 'a minimum', 'the database', 'results', 'pharmacy', 'tests', 'failure', 'care', 'health', 'diagnosis', 'claims', 'the following criteria', 'minimum', 'criteria', 'years', 'indicating', 'coverage', 'index', 'eligibility', '* evidence', '≥', 'date', 'test', 'evidence', 'the 12 months', 'a diagnosis code indicating', 'inclusion', 'the databases', 'exclusion']"
NCT06816303,Patients With Diabetes Mellitus on Drug Treatment on the List or Already Undergoing Orthotopic Liver Transplantation,Diabetes Mellitus Type 2,"Inclusion Criteria:

* type 2 diabetes mellitus
* presence on the list for OLT for at least 3 months or have already been submitted to OLT for at least 3 months
* age ≥ 18 years
* signature of written informed consent to participate in the observational study, either by the participant or legal guardian

Exclusion Criteria:

\- Pregnancy or breastfeeding",18,100,ALL,RECRUITING,"['presence', 'age', 'mellitus', 'mellitus\n* presence', '* type 2 diabetes', 'signature', 'consent', 'type', 'participant', 'legal guardian\n\nexclusion criteria', 'pregnancy', 'written informed consent', 'inclusion criteria', 'at least 3 months', 'months', 'study', 'diabetes', 'the list', '* signature', 'years', 'criteria', '\\- pregnancy', '≥', 'list', 'the observational study', 'guardian', 'olt', 'the participant', 'inclusion', 'exclusion']"
NCT06813170,Diet With or Without Metarecod® in Obese Subjects With Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

1. Signed Informed consent at study entry;
2. Age: 30-70 years;
3. T2DM diagnosis according to the American Diabetes Association criteria since ≥6 months;
4. Stable metabolic control as indicated by levels of glycated hemoglobin (HbA1c) \<7.5% on two consecutive measurements before study enrollment;
5. Body mass index (BMI) level ≥30 Kg/m2 during the 3 months preceding randomization.

Exclusion Criteria:

1. Chronic treatment with corticosteroids and/or chronic treatment with non-steroidal inflammatory drugs, defined as ≥3 times/week with the rationale that these drugs independently impact on the whole inflammatory state;
2. Clear indication for dual antiplatelet therapy and/or anticoagulant therapy (full dose);
3. Active cancer or cancer in complete remission from less than one year, except for treated early-stage squamous or basal cell skin carcinomas;
4. For women with childbearing potential, pregnancy.",30,70,ALL,NOT_YET_RECRUITING,"['entry', 'the 3 months', 'control', 'anticoagulant', 'skin', 'times', 'potential', 'stage', 'dose', 'consent', 'level', 'glycated hemoglobin', '≥3 times', 'that', 'childbearing potential, pregnancy', 'association', 'chronic treatment', 'less than one year', 'week', 'indication', 'year', 'full dose', 'enrollment', 'women', 'informed consent', 'treatment', 'levels', 'basal', 'state', 'body', 'pregnancy', '\\<7.5%', 'exclusion criteria', 'cancer', 'inclusion criteria', 'complete remission', 'measurements', 'therapy', 'months', 'study', 'corticosteroids and/or chronic treatment', 'diabetes', 'glycated', 'these drugs', 'cell', 'study entry', 'stable metabolic control', 'study enrollment', 'active cancer', '30-70 years', 'diagnosis', 'dual antiplatelet therapy', 'hba1c', 'criteria', 'two consecutive measurements', 'randomization', 'years', 'dm diagnosis', 'the rationale', 'index', 'antiplatelet', 'drugs', '≥6 months', 'remission', 'non-steroidal inflammatory drugs', 'clear indication', 'anticoagulant therapy', '2. age', 'rationale', 'inclusion', 'hemoglobin', 'the whole inflammatory state', 'exclusion', 'corticosteroids']"
NCT06368817,A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma,Basal Ganglia Germinoma,"Inclusion Criteria:

* Patients must be ≥ 3 years and \< 30 years at the time of study enrollment
* Patients must be newly-diagnosed primary localized germinoma of the suprasellar and/or pineal region by pathology and/or serum and/or CSF hCGbeta 5-50 mIU/mL AND institutional normal AFP (or ≤ 10 ng/mL if no institutional normal exists), including tumors with contiguous ventricular or unifocal parenchymal extension. No histologic confirmation required
* Patients with EITHER (A) bifocal (pineal + suprasellar) involvement OR (B) pineal lesion with diabetes insipidus (DI) AND hCGbeta ≤ 100 mIU/mL in serum and/or CSF AND institutional normal AFP (or ≤ 10 ng/mL if no institutional normal exists) in both serum and CSF. No histologic confirmation required
* Patients with hCGbeta 51-100 mIU/mL in serum and/or CSF and institutional normal AFP (or ≤ 10 ng/mL if no institutional normal exists) in both serum and CSF. Histologic confirmation of germinoma IS required
* Patients with germinoma of the b",3,17,ALL,RECRUITING,"['no histologic confirmation', 'both serum', 'lesion', 'pineal', 'hcgbeta 51-100 miu/ml', 'patients', 'di', 'ml', 'region', 'csf', 'the b', 'exists', 'the time', '30 years', 'serum', 'inclusion criteria', '≤', 'tumors', 'insipidus', 'study', '(b) pineal lesion', 'histologic confirmation', 'diabetes', 'study enrollment', 'time', 'institutional normal afp', 'criteria', 'years', 'involvement', 'extension', '≥', 'newly-diagnosed primary localized germinoma', 'confirmation', 'germinoma', 'inclusion']"
NCT07187479,Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus,Chronic Kidney Disease (Stages 4 and 5),"Inclusion Criteria:

* Is age 18 or older (male or female)
* Have a documented diagnosis of CKD stage 3b, 4, or 5 and T2DM of 6 months or greater prior to screening. Patients may have treatment regimens associated with T2DM that include diabetic oral and/or injectable medications including insulin and/or GLP-1 receptor agonists.
* In the opinion of the Investigator, has been on an appropriate, stable regimen for management of any complications present for the past six (6) months.
* In the opinion of the Investigator, is able to do all of the following:

  * Provide valid informed consent.
  * Understand and comply with study procedures as presented in the consent process.
  * Has the capacity or support to attend all required visits.
* If female, the subject must meet either of the following sets of conditions:

  o Is of non-childbearing potential, defined as meeting either of the following criteria:
* Age ≥50 years and post-menopausal for at least one (1) year
* Surgically sterile du",18,100,ALL,RECRUITING,"['t2dm', 'a documented diagnosis', 'the following sets', 'du', 'the consent process', 'age', 'screening', 'capacity', 'potential', 'stage 3b', 'conditions', 'all', 'stage', 'subject', 'consent', 'o', 'patients', 'that', 'the investigator', 'regimens', 'non-childbearing potential', 'year', '* age ≥50 years', 'treatment', 'treatment regimens', 'all required visits', 'ckd', 'valid informed consent', 'medications', 'the opinion', 'any complications', 'months', 'study', 'procedures', 'management', 'investigator', 'support', 'opinion', 'regimen', 'the subject', 'process', 'diagnosis', 'the following criteria', 'sets', 'criteria', 'study procedures', 'years', 'dm', 'agonists', 'receptor', 'the capacity', 'insulin', 'an appropriate, stable regimen', 'visits', 'complications', 't2', 'inclusion', '6 months', 'female']"
NCT05000996,Gut Microbiota in Metabolic Surgery,Bariatric Surgery Candidate,"Inclusion Criteria:

* Be approved and scheduled for metabolic surgery at the Vanderbilt University Medical Center
* Have a history of type 2 diabetes, hypertension, or dyslipidemia
* Be able and willing to provide personal information and biological samples needed for the study

Exclusion Criteria:

* Prior gastric operations
* A history of coronary artery disease, stroke, heart failure, HIV infection, or untreated viral hepatitis
* Chemotherapy or radiotherapy for cancer within 2 years
* Current inflammatory bowel disease or celiac disease
* Vomiting, constipation, or diarrhea within 7 days or use of antibiotics within 2 months",18,100,ALL,RECRUITING,"['the study\n\nexclusion criteria', 'antibiotics', 'radiotherapy', 'center', 'history', '2 months', 'constipation', 'operations', 'metabolic surgery', '7 days', 'days', 'celiac disease', 'samples', 'type', 'coronary artery disease', 'a history', 'chemotherapy', 'disease', 'type 2 diabetes', 'artery', 'vomiting', 'infection', 'stroke', 'cancer', 'inclusion criteria', 'biological samples', 'months', 'study', 'hypertension', 'bowel', 'hiv infection', 'diabetes', 'viral hepatitis\n* chemotherapy', 'failure', 'heart', 'use', 'personal information', 'years', 'criteria', 'current inflammatory bowel disease', 'surgery', 'hepatitis', 'university', '2 years', 'diarrhea', 'information', 'heart failure', '* prior gastric operations', 'inclusion', 'exclusion']"
NCT06732362,To Observe the Clinical Effect of Femoral Nerve Block With Low Concentration of Ropivacaine Based on DPN Grading,"Diabetes Mellitus, Type 2","Inclusion Criteria:All patients met the 1999 WHO diagnostic criteria for diabetes.

\-

Exclusion Criteria:(1) Type 1 diabetes; (2) Peripheral neuropathy obviously caused by other reasons; (3) Patients with neuropathy caused by diabetic foot ulcers and gangrene, as well as known history of bone and joint trauma or surgery of the lower limbs; (4) Contraindications to peripheral nerve block (such as local anesthetic allergy, coagulation dysfunction, peripheral infection, etc.) (5) Contraindications to drug components of postoperative analgesic pumps; (6) Existing opioid therapy.

\-",18,100,ALL,NOT_YET_RECRUITING,"['limbs', 'coagulation dysfunction', 'known history', 'postoperative analgesic pumps', 'history', 'nerve', '\\-', 'peripheral infection', 'patients', 'type', 'allergy', 'pumps', 'neuropathy', 'local anesthetic allergy', 'drug components', 'components', 'the lower limbs', '(3) patients', 'joint trauma', 'dysfunction', 'reasons', '(5) contraindications', 'infection', 'other reasons', 'exclusion criteria:(1', 'trauma', '(2) peripheral neuropathy', 'coagulation', 'therapy', '(4) contraindications', 'criteria:(1', 'block', 'diabetes', 'diabetic foot ulcers', '(6) existing opioid therapy', 'contraindications', 'criteria', 'surgery', 'peripheral nerve block', 'drug', 'ulcers', 'foot', 'gangrene', 'inclusion', 'bone', 'exclusion', 'all patients']"
NCT07275086,Therapeutic Outcomes of Using Complementary Hand-based Treatment in Diabetes,"Diabetes Mellitus, Type 1","Inclusion Criteria:

* Adults (≥18 years) with type 1 diabetes ≥ 1 year
* Able to attend two assessment visits at Vrinnevi Hospital
* Uses CGM or equivalent system
* Able to communicate in Swedish and provide consent

Exclusion Criteria:

* Severe diabetes complications (e.g., advanced neuropathy)
* Acute psychiatric disorder requiring treatment
* Contraindications to massage (e.g., thrombosis, fever, infection, recent surgery)",18,100,ALL,NOT_YET_RECRUITING,"['* severe diabetes complications', 'assessment', 'vrinnevi hospital', 'fever', 'consent', 'type', '≥18 years', 'adults', 'year', 'treatment', 'two assessment visits', 'infection', 'inclusion criteria', 'system', 'thrombosis', '* adults', 'type 1 diabetes', 'diabetes', 'years', 'criteria', 'contraindications', 'surgery', 'hospital', '≥', 'cgm or equivalent system', 'disorder', 'consent\n\nexclusion criteria', 'visits', 'complications', 'inclusion', '* contraindications', 'exclusion']"
NCT07149142,Pediatric Artificial Intelligence for Retinopathy Screening in Children With Type 1 Diabetes,Type 1 Diabetes Mellitus,"Inclusion Criteria:

* Type 1 diabetes diagnosed according to the ADA criteria
* Age over 11.0 years or duration of diabetes over 2 years
* Signed written informed consent by both the CwD and their parent/caregiver

Exclusion Criteria:

* Unwillingness to sign a written informed consent by both the CwD and their parent/caregiver",18,100,ALL,NOT_YET_RECRUITING,"['their parent/caregiver', 'consent', 'type', 'both the cwd', 'duration', 'informed consent', 'a written informed consent', 'unwillingness', '* age', 'parent', 'inclusion criteria', 'diabetes', 'caregiver', '* type 1 diabetes', 'years', 'criteria', '11.0 years', 'the ada criteria', '* unwillingness', 'their parent/caregiver\n\nexclusion criteria', 'inclusion', 'exclusion']"
NCT07322380,Feasibility and Adoption of a Screening Program for T1D Relatives in Canada,Type 1 Diabetes (T1D),"Inclusion Criteria:

* Males and females ≥18 years old living in the Québec province
* Having a FDR living with T1D (parents, siblings or offspring)
* Willing to adhere to follow-up care if screened positive

Exclusion Criteria:

* Having a diagnosis of T1D
* Pregnancy (ongoing or current attempt to become pregnant)
* Current or future expected use of glucocorticoid medication (except low stable dose and inhaled steroids and stable adrenal insufficiency treatment e.g., Cortef®) or any systemic immunosuppressive agents
* Planned or recent (\< 6 weeks) monoclonal antibodies treatment, immunoglobulin perfusions or plasmapheresis.
* Other serious medical illness likely to interfere with study participation or with the ability to complete the study by the judgment of the investigator",18,100,ALL,NOT_YET_RECRUITING,"['illness', 'stable adrenal insufficiency treatment', 'ongoing or current attempt', 'study participation', 'the québec province', 'steroids', 'dose', 'females', 'the investigator', 'attempt', 'judgment', 'medication', 'treatment', 'follow-up care', 'parents', 'the study', 'plasmapheresis', 'pregnancy', 'insufficiency', 'ability', 'inclusion criteria', 'males', 'weeks', 'study', 'investigator', 'the judgment', 'participation', 'glucocorticoid medication', 'immunoglobulin perfusions', 'care', 'agents', 'diagnosis', 'low stable dose', 'siblings', 'years', 't1d\n* pregnancy', 'criteria', 'perfusions', 'monoclonal', 'a diagnosis', 'offspring', 'immunoglobulin', 'inclusion', 'the ability', 'exclusion', 'province', 't1d (parents']"
NCT06557317,In-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes,"Behavior, Adolescent","Inclusion Criteria for adolescent participants:

* 12-18 years of age
* self-identify as Black or African American
* have obesity (\>=95th percentile BMI)

Exclusion Criteria for adolescent participants:

* pregnant or within 3 months postpartum.
* participated in a formal weight management program within 6 months prior to study.
* currently taking medications or diagnosed with a condition known to influence metabolism, physical activity ability, or cognitive function.
* have previously undergone bariatric surgery.
* have type 2 diabetes.
* unable to speak English or have developmental conditions that interfere with ability to communicate.

Inclusion Criteria for caregiver participants:

* 18 years or older.
* proficiency in speaking English.
* live in the same household as the adolescent who will also be enrolled.
* prepares the majority (\>50%) of meals in the household.

Exclusion Criteria for caregiver participants:

* pregnant or within 3 months postpartum.
* unable to speak Engli",12,18,FEMALE,RECRUITING,"['the adolescent', 'participants', 'metabolism', 'adolescent', 'condition', 'program', 'weight', 'age', 'cognitive function', 'bariatric surgery', 'proficiency', 'conditions', 'household', '* 12-18 years', 'type', 'that', 'who', 'the majority', 'function', 'majority', 'obesity', '2 diabetes', 'a condition', '* have type', '18 years', 'the same household', 'ability', 'the household', 'exclusion criteria', 'inclusion criteria', '\\>50', 'medications', 'engli', 'months', 'management', '3 months postpartum', 'diabetes', 'caregiver participants', 'caregiver', '* proficiency', 'physical activity ability', 'postpartum', 'years', 'criteria', 'surgery', '\\>=95th percentile bmi', 'meals', 'black or african american', 'self', 'english', 'developmental conditions', 'inclusion', '%', 'adolescent participants', 'activity', 'exclusion']"
NCT06767774,Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus,ASCVD,"Inclusion Criteria:

* Age Requirement:

  * Patients aged 18 years or older.

Glycemic Status:

* Patients who are not taking oral hypoglycemic agents (OHAs) and meet all of the following criteria:

  * Fasting glucose less than 126 mg/dL.\*
  * HbA1c less than 6.5%.
  * Plasma glucose less than 200 mg/dL after 2 hours during a 75 g oral glucose tolerance test (OGTT).\*Note: For fasting glucose, two measurements of 126 mg/dL or greater within 3 months are required for a diagnosis of diabetes.

Cardiovascular Disease:

* Patients with established atherosclerotic cardiovascular disease, defined as having at least one of the following:

  * Coronary Heart Disease (CHD):

    * Documented history of myocardial infarction (MI).
    * History of coronary revascularization.

      * 50% stenosis of a major epicardial coronary artery confirmed by cardiac catheterization, computed tomography (CT), or coronary angiography.
  * Cerebrovascular Disease:

    \>History of stroke of atherosclerotic",18,100,ALL,RECRUITING,"['infarction', 'fasting glucose', 'glycemic status', 'less than 126 mg', 'history', 'all', 'cardiac catheterization', 'cardiovascular disease', 'patients', 'who', 'status', 'two measurements', '126 mg', 'established atherosclerotic cardiovascular disease', 'disease', '* patients', 'glucose', 'artery', '* 50% stenosis', '18 years', '3 months', '* history', 'oral hypoglycemic agents', 'dl.\\', 'coronary angiography', 'stroke', '* plasma glucose', 'inclusion criteria', 'measurements', 'plasma', '2 hours', 'months', '* coronary heart disease', 'tomography', '\\>history', 'diabetes', 'hours', 'documented history', 'heart', 'agents', 'ohas', 'diagnosis', 'the following criteria', '* cerebrovascular disease', '* age requirement', 'hba1c', 'criteria', 'years', 'stenosis', 'catheterization', 'angiography', 'myocardial infarction', 'chd', 'mi', 'a diagnosis', 'coronary revascularization', 'less than 200 mg', 'ct', 'test', 'tolerance', 'computed tomography', 'revascularization', 'inclusion', 'requirement']"
NCT07300982,Studies of Insulin and Glucagon Action in the Liver,Diabetes (DM),"Inclusion Criteria:

* Healthy adults age 18-45 years
* Body Mass Index (BMI) \< 27.0 kg/m²
* Fasting plasma glucose ≤ 95 mg/dL or HbA1c ≤ 5.8% as measured at screening visit

Exclusion Criteria:

* Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders
* No personal history of diabetes or pancreatitis
* No personal history of cardiac, gastrointestinal, renal or liver disease
* No history of diabetes among any first-degree family members
* Renal insufficiency (eGFR \< 60 mL/kg/min)
* Anemia (hematocrit \< 34%) as measured at screening visit
* Pregnant females
* Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)",18,45,ALL,NOT_YET_RECRUITING,"['visit', 'metabolism', 'history', '* active medical disease', 'screening', 'glucose metabolism', 'dl', 'no history', 'psychotropics', 'females', 'that', 'screening visit\n\nexclusion criteria', 'function', 'renal insufficiency', 'gi function', 'adults', '* body mass index', 'disease', 'glucose', 'members', 'consumption', 'body', '95 mg', 'insufficiency', 'metoclopramide', 'any first-degree family members', 'inclusion criteria', 'pancreatitis', 'plasma', '18-45 years', 'glucocorticoids', 'medications', 'bmi', '/kg/min', 'liver', 'degree', 'diabetes', 'health', 'family', 'hematocrit', 'years', 'criteria', 'mass', 'no personal history', 'hba1c ≤', 'index', 'disorders', '34%', 'anemia', 'narcotics', 'daily medications', 'inclusion', '* healthy adults', 'exclusion', '* consumption']"
NCT06771024,Community Physical Exercise Program in Chronic Disease,Osteoarthritis Pain,"Inclusion Criteria:

* Adults aged ≥50 years;
* At least 2 of the following: Prior cardiovascular disease (\>12 months); High cardiovascular risk (SCORE2 or SCORE2 O.P.); Post-stroke (ischemic or hemorrhagic) with treated etiology; Type 2 Diabetes (\> 6 months, ADA); Osteoarthristis (clinical signs/symptoms, NICE); Overweight/Obesity (BMI ≥ 27 kg/m2).
* Autonomous walking.
* Able to provide informed consent.
* Stable medications for ≥ 3 months (related to diagnoses of interest).
* Physical activity below WHO recommendations.
* No contraindications to exercise (cardiovascular, cerebrovascular, respiratory, musculoskeletal) according to ACSS.

Exclusion Criteria:

* Moderate to severe cognitive impairment - Montreal Cognitive Assessment (MoCA).
* Type 2 Myocardial Infarction.
* Class III or IV angina (Canadian Cardiovascular Society).
* Class III or IV angina (New York Heart Association).
* Uncontrolled CVD: symptomatic arrhythmias with hemodynamic compromise; severe symptomatic aortic v",18,100,ALL,NOT_YET_RECRUITING,"['infarction', 'prior cardiovascular disease', 'arrhythmias', 'activity', 'assessment', 'diagnoses', 'walking', 'treated etiology', 'moca', 'consent', 'no contraindications', 'type', 'who', 'adults', 'high cardiovascular risk', 'type 2 diabetes', 'aged ≥50 years', 'overweight/obesity', 'disease', 'ada', 'interest', 'obesity', 'informed consent', 'clinical signs', 'iv angina', '3 months', 'exclusion criteria', 'compromise', 'inclusion criteria', '* autonomous walking', 'signs', 'symptoms', '* stable medications', 'medications', 'bmi', 'months', '\\>12 months', 'acss', 'class iii', 'symptomatic arrhythmias', 'hemodynamic compromise', 'class', '* adults', 'diabetes', 'impairment', 'years', 'criteria', '-', 'contraindications', '* physical activity', '* uncontrolled cvd', 'society', '≥', 'risk', 'post', 'osteoarthristis', 'etiology', '.', 'inclusion', 'exclusion', '6 months']"
NCT06440486,Assessment of Probiotics on Inflammation and Metabolism in Type 2 Diabetes.,Type 2 Diabetes,"Inclusion Criteria:

1. Signed an informed consent form before the study and has a thorough understanding of the content, process, and possible adverse reactions of the study;
2. Age 18 (inclusive) and above, gender not limited;
3. Diagnosed with type 2 diabetes mellitus;
4. Not diagnosed with cardiovascular, kidney, or any other diabetic complications.

Exclusion Criteria:

1. Age over 75 years old;
2. Use of exogenous insulin or patients with cardiovascular disease and other complications;
3. Patients who are currently using α-glucosidase inhibitors;
4. Patients who have a habit of taking probiotics or are currently taking probiotics;
5. Pregnant or lactating women;
6. Subjects deemed unsuitable for participation in this clinical study by the investigators due to other reasons.",18,100,ALL,NOT_YET_RECRUITING,"['a thorough understanding', 'age', 'mellitus', 'kidney', 'the investigators', 'cardiovascular disease', 'consent', 'glucosidase', 'patients', 'type', 'age 18 (inclusive', 'who', 'inhibitors', 'type 2 diabetes mellitus', 'disease', 'other complications', 'reactions', 'women', 'α-glucosidase inhibitors', 'the study', 'gender', 'exogenous insulin', 'reasons', 'other reasons', 'exclusion criteria', 'inclusion criteria', 'understanding', 'subjects', 'study', 'inclusive', 'this clinical study', 'diabetes', 'participation', 'process', 'use', 'an informed consent form', 'years', 'criteria', 'habit', 'investigators', 'a habit', 'form', 'content', 'insulin', 'probiotics', 'complications', 'inclusion', 'exclusion']"
NCT06329037,The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study,Healthy,"Inclusion Criteria:

Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.

Normal or corrected-normal version

Exclusion Criteria:

* History of neuropsychiatric diseases.
* History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
* History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
* History of renal diseases, including renal stones or renal failure.
* History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
* Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
* Infections such as COVID-19 or influenza, or unexplained fever.
* Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
* His",18,100,ALL,RECRUITING,"['biliary obstructive disease', 'food', '* subjects', 'history', 'cholestasis', 'mellitus', 'bp ≤ 90/60mmhg', 'fever', 'diseases', 'sodium', 'consent', 'renal failure', 'who', 'influenza', 'hyponatremia(serum sodium \\<135mmol/l', 'hyperkalemia', 'disease', 'medication', 'severe liver dysfunction', 'unexplained loss', 'allergic reaction', 'bp ≥130/80mmhg', 'dysfunction', 'healthy subjects', '* history', 'written informed consent', 'inclusion', 'hepatic diseases', 'inclusion criteria', 'renal stones', 'subjects', 'reaction', 'aortic stenosis', 'hypertension', 'study', '* infections', 'loss', 'liver', 'diabetes', 'syncope', 'failure', 'consciousness', 'heart', 'cardiac disease', 'strong allergic reaction', 'insipidus\n* known hypersensitivity', 'criteria', 'covid-19', 'stones', 'this study', 'stenosis', 'hypotension', 'serum potassium\\>5.5mmol/l', 'hypersensitivity', 'infections', 'renal diseases', 'unexplained fever', 'version', 'his', 'neuropsychiatric diseases', 'congestive heart failure', 'exclusion', 'hormone', 'any medication']"
NCT07341373,"A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500",Type 1 Diabetes,"Inclusion Criteria:

* Subjects who meet all the following criteria at Screening will be included in the study:

  1. Subjects ≥18 to ≤60 years of age at the time of signing the informed consent.
  2. Subjects diagnosed with T1DM for at least 12 months.
  3. Subjects who have been using an approved insulin pump or use MDI with basal and bolus insulin (stable use for 3 months).
  4. Fasting C-peptide concentration of ≤0.3 nmol/L (0.9061 ng/ml), assessed at a plasma glucose concentration \>90 mg/dL. (If necessary, the subject may consume carbohydrates to raise BG over 90 mg/dL as measured by YSI (glucose analyzer) prior to drawing blood for C-peptide. This may be repeated as needed to ensure C-peptide is assessed when plasma glucose concentration is \>90 mg/dL).
  5. HbA1c concentration of ≤8.5%.
  6. Body mass index (BMI) within the range ≥18.5 to ≤30.0 kg/m2.
  7. Weight ≥ 50 kg.
  8. Female subjects must be non-pregnant and non-lactating and postmenopausal (no menses \>12 months); pos",18,100,ALL,RECRUITING,"['(stable use', '8. female subjects', '* subjects', 'weight', 'bolus insulin', 'age', 'screening', '2. subjects', 'mdi', 'dl', 'subject', 'all the following criteria', '≤60 years', 'consent', '≤30.0 kg/m2', 'carbohydrates', 'who', '6. body mass index', 'range', 'the range', 'peptide', 'glucose', 'menses', 'the time', '3 months', 'the study', '/ml', 'over 90 mg', '≤0.3 nmol/l', '\\>90 mg', 'pump', 'an approved insulin pump', 'concentration', 'body', '50 kg', 'ysi', 'plasma', '≤8.5', '0.9061 ng', 'bmi', 'plasma glucose concentration', 'subjects', '3. subjects', '\\>12 months', 'study', 'months', 'the subject', 'a plasma glucose concentration', 'c-peptide', 't1dm', 'time', '(glucose analyzer', 'criteria', 'blood', 'years', 'postmenopausal', 'index', 'this', 'the informed consent', '5. hba1c concentration', 'insulin', 'at least 12 months', 'c-peptide concentration', '7. weight ≥', 'inclusion', 'basal', '%', '≥18', 'no menses']"
NCT07303803,A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus,MASH - Metabolic Dysfunction-Associated Steatohepatitis,"Inclusion Criteria:

1. Men and women aged at least 18 years and under 75 years (inclusive) at the time of obtaining consent.
2. Participants must be diagnosed as T2DM and HbA1c ≤ 9.5% at time of screening.
3. Participants must take Fibroscan examination with the result of CAP ≥ 238 dB/m and LSM\>8.5 kPa.
4. Diagnosis of MASH by liver biopsy, with NAFLD Activity Score (NAS) ≥4 with ≥1 point for each component, and fibrosis stage 1 or more over according to the NASH Clinical Research Network (CRN) scoring system. (or liver biopsy not more than 6 months prior to screening)
5. Stable body weight (≤10% body weight change) for at least 3 months.
6. Possess good understanding and behavior and be able to take the medication daily as required by the trial.
7. Willing to sign the informed consent.

Exclusion Criteria:

1. Alcohol consumption \>20g ethyl alcohol/day for women and \>40g ethyl alcohol/day for men.
2. Evidence of other forms of chronic liver disease:

   1. Alcoholic liver disease,",18,100,ALL,NOT_YET_RECRUITING,"['t2dm', 'participants', '4. diagnosis', 'scoring', 'fibrosis', 'activity', 'component', 'nafld activity score', 'weight', 'screening', 'good understanding', '5. stable body weight', 'research', 'other forms', 'stage', 'alcohol consumption \\>20', 'consent', 'alcohol', 'biopsy', '≥1 point', '(or liver biopsy', 'm', 'cap', 'result', '75 years', 'trial', 'disease', 'liver biopsy', 'point', 'medication', 'women', 'the time', 'lsm\\>8.5 kpa', 'consumption', 'examination', 'body', 'network', '\\>40', 'exclusion criteria', 'inclusion criteria', 'system', 'db', 'fibroscan examination', 'understanding', 'at least 3 months', 'the trial', 'months', 'liver', 'inclusive', 'chronic liver disease', 'fibrosis stage', 'forms', '2. evidence', 'diagnosis', 'time', 'years', 'men', 'the medication', 'criteria', 'nafld', 'score', 'change', 'hba1c ≤', '≤10% body weight change', 'behavior', '≥', 'the informed consent', 'the result', 'alcoholic liver disease', 'evidence', 'each component', 'inclusion', 'mash', 'exclusion', '(crn) scoring system']"
NCT01316783,"Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations",Diabetes,"* INCLUSION CRITERIA:

Subjects will include unrelated persons who self-identify as white or African American, Afro-Caribbean or migrant from sub-Saharan Africa. Adults of African ancestry are prioritized for this study because of the paucity of genetics studies investigating the association of risk alleles contributing to the prevalence of T2D, CVD, obesity and other common conditions in this population. A small proportion of whites (less than 10%) will be included in this study, as they are in Dr. Sumner s ongoing projects; they will have the same clinical measurements obtained in the same laboratory to serve as a comparison group. This study only includes adults because these phenotypes are more commonly present in adults. In summary, inclusion criteria include:

* Persons who self-identify as either

  * African American
  * Afro-Caribbean
  * A migrant from sub-Saharan Africa
  * White
* Persons \>= 18 years
* Participation in a protocol with Dr. Anne Sumner, NIDDK/NIH

EXCLUSION ",18,100,ALL,ENROLLING_BY_INVITATION,"['a protocol', 'ancestry', 'nih\n\nexclusion', 'this population', 'comparison', 'conditions', 'a small proportion', 'the prevalence', 'studies', 'who', 'sub-saharan africa', 'less than 10%', 'association', 'alleles', 'dr. anne sumner', 'adults', 'population', 'obesity', 'phenotypes', 'the association', 't2d', 'these phenotypes', 'group', 'laboratory', 'projects', 'measurements', 'inclusion criteria', 'persons \\>=', 'subjects', 'summary', 'the same clinical measurements', 'study', 'the same laboratory', 'risk alleles', 'niddk', 'participation', 'persons', 'protocol', 'years', 'they', 'unrelated persons', '18 years\n* participation', 'this study', 'a migrant', 'whites', 'other common conditions', 'african american', 'criteria', 'proportion', 'african ancestry', 'migrant', 'a comparison group', 'paucity', 'risk', 'cvd', 'prevalence', 'self', 'genetics', 'the paucity', 'inclusion', 'exclusion', 'genetics studies']"
NCT06297980,Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes,Type 1 Diabetes,"Inclusion Criteria:

* Women 18-45 who have had type 1 diabetes for at least 12 months
* Premenopausal with either menstrual cycles or currently using oral contraceptives

Exclusion Criteria:

* Women who are postmenopausal, pregnant, trying to become pregnant, or have had a hysterectomy",18,100,FEMALE,RECRUITING,"['criteria', 'premenopausal', 'months', 'women', 'diabetes', 'at least 12 months', '* premenopausal', 'oral contraceptives\n\nexclusion criteria', 'hysterectomy', 'a hysterectomy', 'cycles', 'inclusion', 'contraceptives', 'type', 'who', 'inclusion criteria', 'either menstrual cycles', 'exclusion']"
NCT06388603,RCT on Bioactive Glass S53P4 in Diabetic Foot Osteomyelitis in the Forefoot (DFORCT),Osteomyelitis - Foot,"Inclusion Criteria:

1. Written informed consent obtained.
2. Male or female patients \>= of 18 years old.
3. They should have type I since at least 5 years or type II DM
4. They should have a diagnosis - confirmed by imaging and culture - of OM localized in the forefoot not responding for at least 2 up to 6 weeks to systemic antibiotic therapy and/or associated with soft tissue infection, abscess, phlegmon, necrosis, and for which a surgical debridement is indicated.
5. They should have palpable pulses on TP or DP at the ankle in the affected limb, and/or ABPI \>0.7 and \<1.2 and /or TcPO2 at dorsum of the foot ≥36 mmHg.
6. They should be able to accomplish with the procedures and prescriptions indicated by the Study protocol, particularly with the offloading prescription, as well as they should be willing and able to attend and respect the program of control visits and medications.
7. Anatomical area: forefoot.

Exclusion Criteria:

1. They should not have metabolic decompensation as",5,100,ALL,RECRUITING,"['systemic antibiotic therapy', 'program', 'i', '\\<1.2', 'control visits', 'which', 'the program', 'prescription', 'consent', 'patients', 'type', 'at least 5 years', 'decompensation', 'a surgical debridement', 'abscess', 'the offloading prescription', 'debridement', 'limb', 'mmhg', 'imaging', 'written informed consent', 'infection', 'the ankle', 'exclusion criteria', 'inclusion criteria', 'abpi \\>0.7', 'medications', 'prescriptions', 'the procedures', 'necrosis', 'dorsum', '7. anatomical area', 'the study protocol', 'metabolic decompensation', 'weeks', 'therapy', 'culture', 'pulses', 'procedures', 'study', 'area', 'om', 'diagnosis', 'protocol', 'control', 'years', 'they', 'palpable pulses', 'criteria', 'the affected limb', '/or', 'tcpo2', 'soft tissue infection', 'the foot ≥36 mmhg', 'tissue', 'ankle', 'forefoot', 'the forefoot', 'foot', 'visits', 'inclusion', 'tp', 'dp', 'exclusion']"
NCT05965869,Healthy Communities Through CHW Initiatives,"Diabetes Mellitus, Type 2","Inclusion Criteria:

* Spanish-speaking Latino(a)s adults

Exclusion Criteria:

* pregnant state or anticipated state in the next 6 months
* Type 1 diabetes diagnosis
* Not geographically located to reach church site/attend classes
* Not Spanish-speaking, and
* Self-disclosed diagnosis of schizophrenia, psychotic/delusional disorder, or severe Alzheimer's disease.",18,100,ALL,RECRUITING,"['alzheimer', 'the next 6 months', 'type', 'church', 'adults', 'disease', 'attend classes', 'state', 'site', 'church site', 'inclusion criteria', 'months', 'spanish', 'diabetes diagnosis', 'diabetes', 'schizophrenia', 'diagnosis', 'psychotic/delusional disorder', 'classes', 'criteria', 'disorder', 'self', ""severe alzheimer's disease"", 'inclusion', 'exclusion']"
NCT05596773,Community-Based Chronic Disease Care in Rural Lesotho,Non-communicable Diseases (NCDs),"Inclusion Criteria village level:

* Village size of 40 to 100 households
* Village consent obtained from village chief
* Possibility to identify or recruit a CC-VHW from the village population meeting the following requirements which are largely in line with the criteria of the Lesotho VHW Program Policy:

  o Criteria of the Lesotho Village Health Program Policy:
* Having primary residence in the village (according to village chief)
* Having a proven record of trustworthiness in the resident village
* Having proven ability to maintain confidentiality on public matters
* Being aged between 20 and 50 years
* Being able to provide written reports and being able to do basic mathematical calculations
* Having at least educational level equivalent to high school leaving certificate (Junior Certificate)

  o Additional ComBaCaL criteria:
* Having the ability and willingness to work with a tablet-based eHealth tool
* Having good social and communication skills
* Having the ability and willin",20,50,ALL,RECRUITING,"['trustworthiness', 'policy', 'school', 'program', 'village chief\n* possibility', '* village size', 'which', 'the resident village', 'willin', '* village consent', 'level', '40 to 100 households', 'basic mathematical calculations', 'consent', 'village chief', 'high school leaving certificate', 'chief', 'possibility', 'line', 'population', 'having proven ability', 'tablet', 'skills', 'tool', 'additional combacal criteria', 'the village population', 'village', 'ability', 'at least educational level', 'the following requirements', 'junior certificate', 'communication', 'a tablet-based ehealth tool', 'requirements', 'record', 'inclusion criteria village level', 'primary residence', 'health', '20 and 50 years', 'size', 'the village', 'residence', 'criteria', '-', 'a cc', 'willingness', 'a proven record', 'o criteria', 'years', 'vhw', 'certificate', 'matters', 'reports', 'public matters', 'calculations', 'households', 'the ability', 'the criteria', 'written reports', 'confidentiality']"
NCT05902156,Electronic Patient Decision Support System for Patients with Type 2 Diabetes (DiaPaDeSS),Mobile Health,"Inclusion Criteria:

* Patients with type 2 diabetes who had been followed up and treated at the Endocrinology and Metabolic Diseases Polyclinic
* Aged between 18-65 years
* Patients who know their diagnosis and can verbally express it
* Have been diagnosed with type 2 diabetes for at least six months
* Who are literate
* Who have internet access at home, who have one of the tools such as a computer, tablet or smartphone and can use these tools
* Consented to participate in the study
* Had no other psychiatric or mental barriers to answering the questions, language or cognitive difficulties, and barriers to verbal or written communication

Exclusion Criteria:

* Diagnosed with myocardial infarction, stroke or diabetic foot in the last six months
* Diagnosed with type 1 diabetes or gestational diabetes
* Diagnosed with terminal illness
* Using steroid therapy
* Had pregnant
* Having dementia and cognitive deficits
* Having retinopathy or advanced neuropathy
* Patients whose information ",18,65,ALL,NOT_YET_RECRUITING,"['infarction', 'illness', 'difficulties', 'the questions', 'computer', 'diseases', 'patients', 'type', 'internet access', 'at least six months', 'who', 'internet', 'the last six months', 'type 2 diabetes', '* patients', 'gestational diabetes', 'tablet', 'language', 'home', 'cognitive deficits', 'the study', 'dementia', 'stroke', 'barriers', 'inclusion criteria', 'terminal illness', 'communication', 'therapy', 'it', 'months', '18-65 years', 'study', 'steroid therapy', 'diabetes', 'type 1 diabetes', 'questions', 'diagnosis', 'their diagnosis', 'a computer', 'metabolic', 'criteria', 'years', 'myocardial infarction', 'access', 'tools', 'information', 'these tools', 'foot', 'endocrinology', 'deficits', 'steroid', 'diabetic foot', 'inclusion', 'exclusion', 'smartphone', 'the tools']"
NCT05994937,Cleaner Air for Lower Cardiometabolic Risk,PreDiabetes,"Inclusion Criteria:

* Participant is ≥18 years old
* Participant and members of household are reported to be non-smokers (defined as no household members are currently known to smoke cigarettes or use other tobacco products including e-cigarettes)
* Participant is to understand/speak English or Spanish
* Participant can understand study procedures and give informed consent
* Participant has prediabetes, defined as the absence of diabetes and any of the following: fasting plasma glucose 100-125 mg/dL, 2 hour plasma glucose of 140-199 mg/dL after 75 g oral glucose tolerance test, or A1c 5.7- 6.4%.
* Able to wear CGM for 2 two-week periods
* Able to participate in telephone or video conference for home equipment setup if needed
* Able to visit clinic for blood draws before and after the study period
* Do not intend to sleep anywhere outside of primary bedroom for more than 48 consecutive hours or a total of 7 days during the study period.
* Ability to lift, or access to assistance with l",18,100,ALL,RECRUITING,"['conference', 'clinic', 'bedroom', 'spanish\n* participant', '2 two-week periods', '7 days', 'days', 'household', 'dl', 'consent', 'participant', 'week', 'hour', 'members', 'glucose', 'any', 'home', 'ability', 'prediabetes', 'a total', 'the study period', 'tobacco', 'absence', 'period', 'other tobacco products', 'fasting plasma glucose', 'plasma', 'video', 'smokers', 'a1c 5.7- 6.4%', 'cgm', 'l', '* ability', 'study', 'procedures', 'telephone', 'diabetes', 'hours', 'equipment', 'the absence', 'e', 'primary bedroom', 'years', 'criteria', 'study procedures', 'cigarettes', '-', 'blood', 'products', '-125 mg', '140-199 mg', 'access', 'informed consent\n* participant', 'home equipment setup', 'setup', 'no household members', '* participant', 'telephone or video conference', 'tolerance', 'test', 'english', 'periods', 'inclusion', 'assistance', 'total']"
NCT07135531,Continuous Glucose Monitoring (CGM) in an Underserved Population,Diabetes,"Inclusion Criteria:

* Age 18-75 years
* Type 2 diabetes mellitus
* HbA1C ≥ 7.5%
* At least on 1 insulin injection therapy daily
* Patients established with primary care clinic or endocrinology clinic or diabetes clinics in the New Orleans and surrounding areas
* Patients with Medicaid or free care or uninsured
* Patients must be able to speak and understand English and be capable of providing informed consent to participate in the study

Exclusion Criteria:

* Type 1 diabetes mellitus
* Currently on CGM or using insulin pump
* Advanced renal disease or Estimated Glomerular Filtration Rate (eGFR) \<40
* Serious co-morbidities which in the investigator's opinion, will make it challenging for patients to participate
* The patient has been diagnosed with end-stage renal disease, is on dialysis, or has had a kidney transplant, Hemoglobinopathies, iron therapy or other condition that interferes with HbA1c measurement
* Pregnant",18,75,ALL,NOT_YET_RECRUITING,"['other condition', 'the study\n\nexclusion criteria', 'iron therapy', 'clinic', 'condition', 'age', 'mellitus', 'which', 'kidney', 'stage', 'consent', 'serious co', 'patients', 'endocrinology clinic', 'type', 'hemoglobinopathies', 'that', '7.5%', 'disease', 'egfr', 'areas', 'informed consent', 'dialysis', 'injection', '18-75 years', 'morbidities', 'end-stage renal disease', 'pump', 'estimated glomerular filtration rate', 'transplant', 'rate', 'inclusion criteria', 'therapy', 'clinics', 'it', '* type', 'cgm', 'study', 'filtration', 'surrounding areas', 'investigator', 'opinion', 'patient', 'diabetes', 'measurement', 'care', 'years', 'the new orleans', '-', 'criteria', 'primary care clinic', '\\<40', ""the investigator's opinion"", 'hba1c measurement', 'insulin', 'english', 'a kidney transplant', 'endocrinology', 'iron', 'inclusion', 'medicaid or free care', 'exclusion', 'the patient']"
NCT03552562,Measurement of Total Retinal Blood Flow and Oxygen Extraction in Patients With Diabetes and Healthy Subjects,Retinal Blood Flow,"Inclusion Criteria for healthy subjects:

* Men and women aged over 18 years
* Non-smokers
* Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
* Normal ophthalmic findings, ametropy \< 6 Dpt.

Inclusion criteria for patients with diabetes

* Men and women aged over 18 years
* Non-smokers
* Previously diagnosed type II diabetes
* No, mild, moderate or severe non-proliferative diabetic retinopathy
* Normal ophthalmic findings except mild diabetic retinopathy, ametropy \< 6 Dpt.

Exclusion Criteria for healthy subjects:

* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Presence or history of a severe medical condition as judged by the clinical investigator
* Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study (except oral contraceptive)
* untreated arterial hypertension (defined as either systolic blood pressure ",18,100,ALL,RECRUITING,"['a severe medical condition', 'illness', 'abuse', 'presence', 'condition', 'the 3 weeks', 'history', '* symptoms', 'patients', 'type', 'the investigator', 'non', 'trial', 'medication', 'alcoholic beverages', '* untreated arterial hypertension', 'women', 'either systolic blood pressure', 'abnormality', 'the clinical investigator', 'the study', 'smokers\n* normal findings', 'healthy subjects', 'the medical history', '* men', 'inclusion criteria', 'over 18 years', 'a clinical trial', 'symptoms', 'smokers', 'subjects', 'oral contraceptive', 'weeks', 'study', 'contraceptive', 'hypertension', 'investigator', 'diabetes', 'participation', 'pressure', 'findings', 'years', 'men', '-', 'criteria', 'blood', 'beverages', 'an abnormality', 'regular use', 'a clinically relevant illness', 'inclusion', 'exclusion']"
NCT07377266,"The Impact of Changing to a New Child- and Family-centered Outpatient Diabetes Clinic Focusing on Early Involvement of the Child With Diabetes, Training in Calmness Around Diabetes Management, Healthy Lifestyle, and Creating Peer-to-peer Networks",Diabetes,"Inclusion of children and their families

Inclusion Criteria:

* Age 3-10 years
* Followed at Steno Diabetes Center Copenhagen

Exclusion Criteria:

* Severe psychiatric disease
* Language barriers (Children not speaking Danish, Parents not speaking Danish or English)",3,10,ALL,ENROLLING_BY_INVITATION,"['children', '3-10 years', 'disease', 'steno', 'center', 'copenhagen', 'language', 'families', 'diabetes', 'parents', 'danish', 'their families\n\ninclusion criteria', '* age', 'inclusion', 'years', 'criteria', 'barriers', 'exclusion']"
NCT07255222,Effects of a Multimodal Exercise Program on Physical Performance and Muscle Function in Middle-aged Patients With T2DM,Type 2 Diabetes Mellitus (T2DM),"Inclusion Criteria:

* Diagnosed with Type 2 Diabetes Mellitus and on stable oral hypoglycemic medication.

Middle-aged adults between 45 and 64 years old.

Able to communicate in Mandarin or Taiwanese.

Willing to provide informed consent or have informed consent obtained from a proxy

Exclusion Criteria:

* Limited limb or joint function (e.g., fractures or dislocations).
* Communication or emotional issues, such as depression or mental illness.
* Severe cognitive impairment, such as dementia.
* End-stage renal disease.
* Major comorbidities or complications, including diabetic foot, amputation, myocardial infarction, autonomic neuropathy, and a history of stroke within the last 3 years.",45,64,ALL,RECRUITING,"['infarction', 'mandarin', 'illness', 'the last 3 years', 'history', 'mellitus', 'fractures', 'stage', 'consent', 'issues', 'type', '* major comorbidities', 'a history', 'function', 'adults', 'disease', 'medication', 'mental illness', '* severe cognitive impairment', 'informed consent', 'depression', '* end-stage renal disease', 'limb', 'inclusion', 'dementia', 'stroke', 'stable oral hypoglycemic medication', 'inclusion criteria', 'middle-aged adults', 'communication', 'diabetes', 'impairment', 'dislocations', 'proxy', 'years', 'criteria', 'amputation', 'a proxy\n\nexclusion criteria', 'myocardial infarction', 'comorbidities', 'foot', 'complications', 'diabetic foot', 'taiwanese', 'exclusion']"
NCT07372872,"Feasibility Testing of the ""MyGlucoCare"" Smartphone App for Women With Gestational Diabetes",Gestational Diabetes Mellitus (GDM),"Inclusion Criteria:

* Pregnant women diagnosed with Gestational Diabetes Mellitus (GDM) via a 75g Oral Glucose Tolerance Test (OGTT), conducted between 24 and 28 weeks of gestation (Hong Kong College of Obstetricians and Gynaecologists, 2016).
* Aged 18 years or older.
* Own a smartphone with reliable internet access.
* Able to read and understand Chinese.

Exclusion Criteria:

* Pre-existing diagnosis of Type 1 or Type 2 diabetes mellitus.
* Known major fetal anomaly.
* Concurrent enrollment in any other structured GDM self-management intervention.
* Severe mental health conditions.",18,100,FEMALE,NOT_YET_RECRUITING,"['* concurrent enrollment', '2 diabetes mellitus', 'mellitus', 'conditions', 'a smartphone', 'hong kong college', 'type', 'internet', 'enrollment', 'glucose', 'gestational diabetes mellitus', 'women', 'chinese', 'exclusion criteria', 'inclusion criteria', 'aged 18 years', '24 and 28 weeks', 'weeks', 'management', 'gynaecologists', 'diabetes', '* pre-existing diagnosis', 'health', 'diagnosis', 'years', 'criteria', 'ogtt', 'access', 'pregnant women', '(gdm', 'obstetricians', 'reliable internet access', 'test', 'gestation', 'tolerance', 'self', 'inclusion', 'exclusion', 'smartphone', 'intervention']"
NCT04706481,Archival of Human Biological Samples in CU-Med Biobank,Healthy,"Inclusion Criteria:

* Enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed.

Exclusion Criteria:

* Subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.",18,100,ALL,RECRUITING,"['criteria', 'subjects', 'exclusion', '* subjects', 'de-identified data', 'data', '* enrolled subjects', 'signed informed consent', 'consent', 'inclusion', 'specimens', 'the specimens', 'that', 'exclusion criteria', 'inclusion criteria', 'signed consent']"
NCT06557005,Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions,Hypertension,"Inclusion Criteria

* Receiving obstetric care at an MGH-affiliated obstetrics practice (except for the MGH HOPE Clinic, which has a unique care model that provides prenatal and postnatal care for individuals with substance use disorder, including the provision of primary care through 2+ years postpartum)
* Pregnant with a live fetus or delivered a live-born neonate ≥24 weeks of gestation, based on the clinical estimate of gestational age
* If postpartum, has a neonate that is currently living at the time of enrollment
* Has one or more of the following conditions listed in the ""Problem List,"" ""Medical History,"" or clinical notes during prenatal, intrapartum, or postpartum encounters in the EHR (or in the case of BMI, the patient's anthropometric measurements):

  * Chronic or essential hypertension
  * Hypertensive disorders related to pregnancy (e.g., pre-eclampsia)
  * Type 1 or 2 diabetes (i.e., pre-existing diabetes)
  * Gestational diabetes
  * Class II Obesity (pre-pregnancy bod",18,100,FEMALE,RECRUITING,"['gestational age', 'history', 'which', 'practice', 'notes', 'conditions', 'the mgh hope clinic', 'a unique care model', 'the clinical estimate', 'type', 'a neonate', 'that', 'hypertensive disorders', 'bod', 'the provision', 'fetus', 'substance', 'prenatal and postnatal care', 'the case', 'enrollment', 'the time', 'obstetrics', 'obesity', 'intrapartum', 'pregnancy', 'eclampsia', 'measurements', 'primary care', 'inclusion criteria', 'clinical notes', 'model', 'the ""problem list', 'bmi', '* type', 'hypertension', 'hope', 'provision', 'weeks', 'patient', '1 or 2 diabetes', 'neonate', 'diabetes', 'care', 'a live fetus', 'postpartum', 'an mgh-affiliated obstetrics practice', 'if postpartum', 'time', 'years', 'criteria', '-', 'individuals', '2+ years postpartum', 'substance use disorder', 'disorders', 'list', 'the following conditions', 'obstetric care', 'disorder', 'gestation', 'problem', 'estimate', 'inclusion', 'the ehr', 'case', '(i.e., pre-existing diabetes']"
NCT07069166,Para-Probiotic Oral Care in Periodontal Patients With Type 2 Diabetes,Periodontitis,"Inclusion Criteria:

* Age between 18 and 70 years
* Diagnosis of periodontitis (Stage II or III; Grade B or C)
* Presence of at least one periodontal pocket per side of the mouth, with a maximum of 20 teeth presenting pathological probing depths
* Presence of both single- and multi-rooted teeth
* Type 2 diabetes mellitus diagnosed at least one year prior to enrollment
* Good general health status and ability to comply with study protocol
* Written informed consent provided

Exclusion Criteria:

* Presence of cardiac pacemakers
* History of neurological disorders
* History of psychiatric disorders
* Current pregnancy or breastfeeding
* Steroid-induced diabetes mellitus
* Inability or unwillingness to attend follow-up visits or adhere to home oral care instructions",18,70,ALL,RECRUITING,"['cardiac pacemakers', 'grade b', 'presence', 'maximum', '* presence', 'mellitus', 'history', 'probing', 'mouth', '* diagnosis', 'consent', 'type', 'teeth', 'status', 'neurological disorders', 'year', 'enrollment', 'steroid-induced diabetes', 'home', 'pathological probing depths', 'unwillingness', 'c', 'ability', 'follow-up visits', 'side', '* age', 'multi-rooted teeth', 'pocket', 'pregnancy', 'instructions', '18 and 70 years', 'exclusion criteria', 'the mouth', 'inclusion criteria', 'stage ii', 'study', 'diabetes', 'mellitus\n* inability', 'care', 'health', 'diagnosis', 'years', 'criteria', 'current pregnancy', 'psychiatric disorders', 'disorders', 'pacemakers', 'iii', 'inability', 'steroid', 'depths', 'visits', 'inclusion', 'home oral care instructions', 'periodontitis', 'exclusion']"
NCT07212075,Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups,Diabetes (DM),"Inclusion Criteria:

* 18 to 80 years of age
* Diagnosis of type 1 diabetes or type 2 diabetes or other specific type of diabetes
* Diabetes duration ≥ 1 year
* Sufficient German language skills
* Informed consent

Exclusion Criteria:

* Inability to consent
* Significant cognitive impairment (e.g. dementia)
* Severe disorder or condition impacting the person's ability to participate in the study or likely to confound results (e.g. treated cancer, heart disease ≥ NYHA III, schizophrenia/psychotic disorder)
* Terminal illness
* Being bedridden",18,80,ALL,RECRUITING,"['person', 'illness', 'condition', '* terminal illness', 'diabetes duration', 'severe disorder', 'consent', 'type', 'iii, schizophrenia/psychotic disorder', 'year', 'disease', 'duration', '2 diabetes', 'terminal', 'language', 'the study', 'ability', 'dementia', '* significant cognitive impairment', 'cancer', 'inclusion criteria', '* inability', 'study', ""the person's ability"", 'results', 'diabetes', 'impairment', 'other specific type', 'heart', 'schizophrenia', 'e.g. treated cancer', 'heart disease', 'diagnosis', 'age\n* diagnosis', 'criteria', 'years', '≥', 'disorder', 'inability', '(e.g. dementia', 'inclusion', 'exclusion']"
NCT07404657,Preliminary Assessment of an Automated Tool for Diabetic Retinopathy Screening,Diabetic Retinopathy (DR),"Inclusion Criteria:

* 22 years old or older
* diabetes or diabetic retinopathy
* understand the study information and able to sign a consent form

Exclusion Criteria:

* cannot tolerate eye imaging tests
* laser treatment or injections
* eye surgery, except for simple cataract surgery
* currently involved in another study
* pregnant
* cannot or do not want to have your eyes dilated
* photodynamic therapy within the last 90 days",18,100,ALL,NOT_YET_RECRUITING,"['photodynamic', 'eye imaging tests', 'laser', 'days', 'another study', 'consent', 'eyes', '*', 'laser treatment', 'treatment', 'imaging', 'inclusion criteria', 'retinopathy', 'eye surgery', 'therapy', 'cataract', 'study', 'the last 90 days', 'injections', 'diabetes', '* photodynamic therapy', 'tests', 'simple cataract surgery', 'the study information', 'years', 'criteria', 'your eyes', 'surgery', 'form', 'information', 'inclusion', 'exclusion']"
NCT06752772,WeArable teChnology daTa driVen digitAl healTh cOachINg (ACTIVATION)- A Mixed-methods Study,Elevated Blood Pressure,"Inclusion Criteria:

* 21-75 years old
* Patients who are at risk of any of the following:

  1. Elevated blood pressure
  2. Overweight (BMI\>=23kg/m2)
  3. Pre-diabetes, OR
* Patients who have one or more of the following (HOLD) conditions:

  1. Hypertension
  2. Obesity (BMI\>=27.5kg/m2)
  3. HyperLipidemia
  4. Type 2 Diabetes Mellitus
* Patients who own a smartphone
* Patients who are willing to wear a smartwatch during the intervention period.

Exclusion Criteria:

* Patients who have a medical condition that prevented participation in physical activity
* Patients who have current diagnosis or history of eating disorder, depression
* Patients who are currently pregnant or planning to become pregnant in the next 6 months
* Patients who are currently participating in a weight loss programme (commercial, medically supervised, or research study)
* Patients who are on weight loss medications (over-the-counter or prescription)
* Patients who are not mentally-, physically- or technolog",21,75,ALL,RECRUITING,"['smartwatch', 'a smartwatch', 'activity', 'condition', 'weight', 'history', 'the-counter', 'the next 6 months', 'research', 'prescription', 'conditions', 'patients', 'type', 'that', 'who', 'a weight loss programme', 'programme', 'physical activity\n* patients', '* patients', 'weight loss medications', 'any', 'obesity', 'depression', 'technolog', 'mellitus\n* patients', 'hyperlipidemia', 'period', 'exclusion criteria', 'research study', 'inclusion criteria', 'medications', 'the following (hold) conditions', 'the intervention period', 'months', 'hypertension', 'current diagnosis', 'a smartphone\n* patients', 'loss', 'a medical condition', 'study', 'diabetes', 'participation', 'diagnosis', 'pressure', 'years', 'criteria', 'blood', 'counter', 'bmi\\>=27.5kg/m2', 'hold', 'risk', 'disorder', 'bmi\\>=23kg/m2', 'inclusion', 'physically-', 'exclusion', 'smartphone', 'intervention']"
NCT06764719,Cryopreserved Hair Follicles for Disease and Cell Replacement,Diabetes Mellitus,"Inclusion Criteria:

* Gender: Male or Female.
* Age: ≥18 and ≤80 years.
* Language proficiency: Able to read and understand English.
* Informed consent: Willing to provide written, informed consent to participate in all study activities.

Exclusion Criteria:

* Scalp/Hair Disorders: Subjects diagnosed with active scalp infections or inflammatory skin conditions.
* Systemic Conditions: Subjects with chronic illnesses, such as autoimmune diseases or diabetes, that may impact scalp health or wound healing.
* Medications: Subjects on immunosuppressants, steroids, or other medications associated with hair loss.",18,100,ALL,RECRUITING,"['written, informed consent', 'skin', 'diseases', 'proficiency', 'conditions', 'illnesses', 'healing', 'steroids', 'consent', 'that', 'wound', '* medications', 'other medications', 'chronic illnesses', 'hair loss', 'activities', 'language', 'inflammatory skin conditions', 'gender', 'scalp', '* age', 'exclusion criteria', 'hair', 'inclusion criteria', 'all study activities', 'medications', 'subjects', '* scalp/hair disorders', 'study', 'active scalp infections', 'immunosuppressants', 'loss', '* language proficiency', 'diabetes', 'health', 'autoimmune diseases', 'years', 'scalp health', 'criteria', 'infections', '≥18 and ≤80 years', 'disorders', '* gender', 'male', 'english', 'inclusion', 'exclusion', '* informed consent']"
NCT07384728,Ramadan Experience of Individuals With Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

Individuals ≥18 years of age

Able to give informed consent

Diagnosed with type 2 diabetes

Planning to fast during Ramadan

Exclusion Criteria:

Presence of psychiatric illness

Presence of cognitive impairment

Receiving additional treatments that significantly affect glucose levels (e.g., ongoing steroid therapy)

Individuals who have decided not to fast during Ramadan

Individuals who have stopped fasting during Ramadan",18,100,ALL,NOT_YET_RECRUITING,"['presence', 'additional treatments', 'illness', 'age', 'consent', 'cognitive impairment', '≥18 years', 'that', 'type', 'who', 'glucose', 'informed consent', 'levels', 'ramadan', 'psychiatric illness\n\npresence', 'inclusion criteria', 'therapy', 'ramadan\n\nindividuals', 'diabetes', 'impairment', 'years', 'criteria', 'treatments', 'individuals', 'e.g., ongoing steroid therapy', 'ramadan\n\nexclusion criteria', 'glucose levels', 'steroid', 'inclusion', 'exclusion']"
NCT07198516,The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver:,NAFLD,"Inclusion Criteria:

* (1) Type 2 diabetes diagnosed according to WHO diagnostic criteria, age ≥ 18 years old, ≤ 70 years old, gender unlimited (2) Diagnosed with NAFLD according to the criteria of the ""Guidelines for the Prevention and Treatment of Non alcoholic Fatty Liver Disease (2018 Updated Edition)"" (3) Before screening, patients with type 2 diabetes who were treated with single or combined drugs of stable dose (except TZDs, SGLT2i, GLP-1RA, insulin and GKAs) for ≥ 8 weeks and had poor blood glucose control, 7% ≤ HbA1c ≤ 10% (4)BMI≥24 kg/m2 (5) Can understand the content and methods of this study and voluntarily sign an informed consent form

Exclusion Criteria:

* (1) Patients with diabetes other than type 2 diabetes, including type 1 diabetes and gestational diabetes (2) Acute diabetes complications such as diabetes ketosis or ketoacidosis, diabetes hypertonic state, diabetes lactic acidosis or serious chronic diabetes complications (3) Individuals with a history of recurrent ",18,100,ALL,NOT_YET_RECRUITING,"['lactic acidosis', '10%', 'ketosis', 'prevention', 'history', 'single or combined drugs', '4)bmi≥24 kg/m2', 'the ""guidelines', 'dose', 'consent', 'patients', 'type', 'who', '7% ≤ hba1c ≤', 'a history', 'hypertonic state', 'disease', 'type 2 diabetes', 'glucose', 'methods', 'treatment', 'state', 'gender', 'the prevention', 'stable dose', '* (1) patients', 'the content', 'weeks', 'liver', 'guidelines', 'edition', 'gkas', 'study', 'diabetes', '2) acute', 'diabetes complications', 'control', 'years', 'criteria', 'blood', 'nafld', 'this study', 'diabetes ketosis', 'individuals', 'who diagnostic criteria', 'drugs', '≥', 'content', 'form', 'ketoacidosis', 'insulin', '3) individuals', '2018 updated edition', 'acute', 'recurrent', 'complications', 'acidosis', 'inclusion', 'the criteria', 'poor blood glucose control', 'exclusion']"
NCT06446531,"Prevention of Progression of Prediabetes, Obesity and CV Risk",Pre-Diabetes,"Inclusion Criteria:

1. Patients will have an established diagnosis of pre-Diabetes Mellitus (DM) before the screening visit, documented by an acceptable modality in the last 6 months.
2. Age ≥ 18 years old
3. Body Mass Index (BMI)=25-40 kg/m2
4. Glycated Hemoglobin (HbA1c) = 5.7-6.4%
5. Blood Pressure (BP) \<160/100
6. Estimated Glomerular Filtration Rate (eGFR) ≥30 ml/min•1.73m2
7. Body weight must be stable (±5 pounds) over the last 3 months.
8. Oral diuretics, if prescribed to the patient according to local guidelines and discretion of the investigator, should be stable for at least 1 week prior to randomization.
9. Hispanic ethic group
10. Willing to adhere to medication regimen for up to 6 months.
11. Male or female, if female, met these criteria:

    1. Not pregnant or breast-feeding
    2. Negative pregnancy test result at visit 1 (screening)
    3. During the entire study, women of childbearing potential (WOCBP) including peri-menopausal women who have a menstrual period with",18,100,ALL,RECRUITING,"['visit', '8. oral diuretics', 'the screening visit', 'the patient', 'the entire study', 'weight', 'study', 'screening', 'an established diagnosis', 'modality', 'pounds', 'glycated hemoglobin', 'patients', 'female', 'the investigator', 'ml', 'who', 'week', '-40 kg/m2', 'stable (±5 pounds', 'breast', 'result', '≥30', 'medication', 'women', '5.7-6.4%', 'body weight', '9. hispanic ethic group', 'body', 'group', 'pregnancy', 'menopausal', 'estimated glomerular filtration rate', 'feeding', 'period', 'blood pressure', 'bmi)=25', 'inclusion criteria', 'the last 6 months', 'rate', 'wocbp', '(wocbp', 'the last 3 months', 'months', 'if female', 'medication regimen', 'filtration', 'up to 6 months', 'guidelines', 'these criteria', 'a menstrual period', 'patient', 'investigator', 'peri-menopausal women', 'regimen', 'diuretics', 'diagnosis', 'pressure', 'years', 'hba1c', 'criteria', 'blood', 'randomization', 'dm', 'peri', 'discretion', 'index', 'local guidelines', 'test', 'an acceptable modality', 'inclusion', 'hemoglobin', 'bp', '/min•1.73m2', 'pre-diabetes mellitus']"
NCT06932601,Evaluation of a Novel Self-Sampling Earwax Tool for Chronic Disease Biomarkers [TREARS STUDIES II],Metabolic Syndrome,"Inclusion Criteria:

\- i.People older than 35 years old ii.First-degree relative \[parents or siblings\] with diabetes. iii.Latin \[Chilean\] nationality iv.Women with a previous history of gestational diabetes or delivering a macrosomic (\>9lb) baby v.Overweight or obese \[BMI greater than or equal to 25 kg/m2\] vi.Physical inactivity (no work-, transport-, or recreation-related physical activity in a typical week) vii.BP ≥130 and/or ≥80 mm Hg or use of antihypertensive medication viii.Self-reported diagnosis of prediabetes IFG, IGT or borderline diabetes. ix.Self-reported history of CVD: myocardial infarction, coronary heart disease, or stroke.

x.HDL-cholesterol \< 35 mg/dL, triglycerides \> 250 mg/dL, or lipid-lowering medication use xi.Women with polycystic ovarian syndrome xii.People with conditions associated with insulin resistance, such as acanthosis nigricansxiii.

Have non-alcoholic fatty liver disease.

Exclusion Criteria:

1. Participants with any ear disease, including e",3,5,ALL,NOT_YET_RECRUITING,"['25 kg/m2\\] vi.physical inactivity', 'participants', 'recreation', 'infarction', 'a typical week', 'history', 'work-', 'resistance', 'borderline', 'dl', 'conditions', 'acanthosis nigricansxiii', '≥130', '35 mg', 'week', 'disease', 'gestational diabetes', 'lipid-lowering medication use', 'medication', 'exclusion', 'non-alcoholic fatty liver disease', 'prediabetes', 'siblings\\', 'vii.bp ≥130', 'stroke', 'insulin resistance', 'inclusion criteria', '\\', 'exclusion criteria', 'ix.self-reported history', '\\[parents', 'x.hdl', 'acanthosis', 'nationality iv.women', '\\[bmi', 'polycystic ovarian syndrome', 'degree', 'lipid', 'syndrome', 'liver', 'diabetes', 'any ear disease', 'heart', 'use', 'e', 'diagnosis', '\\[chilean\\', 'prediabetes ifg', 'a previous history', 'criteria', 'years', 'iii.latin \\[chilean\\', '\\- i.people', 'myocardial infarction', 'xii.people', 'baby', 'insulin', 'nationality', 'cvd', '≥80 mm hg', 'iv.women', 'coronary heart disease', 'v.overweight', 'inclusion', 'cholesterol', 'antihypertensive medication viii.self-reported diagnosis', 'nigricansxiii', 'inactivity', 'activity', 'xi.women']"
NCT05061030,Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents,Type1diabetes,"Inclusion Criteria:

1. Written informed consent for participation of the study (for subjects below 18 years of age also from both caregivers), given before undergoing any study-specific procedures
2. Clinical history compatible with type 1 diabetes diagnosed less than 6 months before enrolment
3. In the first part of the study, six subjects, three between 7-11 and three between 12-18 years of age (both groups inclusive at both ends), will be included. The sixty subjects in the second part of the study are stratified by age (12-21 and 7-11 years, respectively) and randomized to one of two treatment arms (active or placebo), with a 6-month safety delay for the younger stratum.
4. Mentally stable and, in the opinion of the investigator, able to comply with the procedures of the study protocol.
5. Fasting plasma C-peptide concentration \>0.12 nmol/L.
6. Subjects of child-bearing potential must agree to using adequate contraception until one year after the administration of WJMSC/Placebo. ",12,18,ALL,RECRUITING,"['the younger stratum', 'the second part', 'the first part', '12-21 and 7-11 years', 'age', 'history', 'placebo', 'safety', 'stratum', 'two treatment arms', 'potential', 'administration', 'wjmsc', 'enrolment', 'consent', 'both ends', 'type', 'wjmsc/placebo', 'a 6-month safety delay', 'the investigator', 'ends', 'child-bearing potential', 'both groups', 'clinical history', 'peptide', 'nmol/l.', 'year', 'treatment', 'informed consent', '18 years', 'the study', 'concentration', 'inclusion criteria', 'plasma', 'subjects', 'the opinion', 'the procedures', 'months', 'the study protocol', 'study', 'procedures', 'investigator', 'opinion', 'diabetes', 'type 1 diabetes', 'participation', 'part', 'month', 'arms', 'contraception', 'groups', 'protocol', 'the sixty subjects', 'six subjects', 'the administration', 'one year', 'criteria', 'years', 'delay', 'child', 'any study-specific procedures', 'both caregivers', 'caregivers', 'c-peptide concentration', 'inclusion', 'adequate contraception']"
NCT06999551,Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.,Diabetes Mellitus,"Inclusion Criteria:

* Age≥ 18 and \<70
* Type 2 diabetic patients, with a duration of NPH between 5 and 10 years.
* Patients treated with a double dose of NPH insulin with a stable dose of insulin and a stable dose of ADO (oral antidiabetic drugs) for at least 2 months prior to the start of the study.
* An HbA1c level between 7% and 10%
* Ability to use a continuous glucose monitoring (CGM) system and cycle blood glucose with the meter.
* Written informed consent obtained prior to participation in the study.

Exclusion Criteria:

* Pregnant and breastfeeding women
* Patients with active proliferative and/or complicated diabetic retinopathy, treated by photocoagulation or surgically, within 6 months prior to study entry or any other rapidly progressing unstable retinopathy that may require photocoagulation or surgery during the study (plan to perform fundus prior to inclusion).
* History of insulin glargine hypersensitivity
* Treatment with systemic, neuroleptic, immunosuppressive and ",5,10,ALL,NOT_YET_RECRUITING,"['entry', 'fundus', 'unstable retinopathy', '\\<70', 'cycle', 'history', '(plan', '* age≥', 'a stable dose', 'a continuous glucose monitoring', 'dose', 'level', 'consent', 'the meter', 'patients', 'type', 'that', '2 diabetic patients', 'glargine', '* patients', 'glucose', 'women', 'insulin glargine hypersensitivity', 'treatment', 'duration', 'the study', 'ability', '* history', '* written informed consent', 'exclusion criteria', 'system', 'inclusion criteria', 'retinopathy', 'nph insulin', 'cycle blood glucose', 'months', 'cgm', 'photocoagulation', 'study', 'ado', 'the start', 'participation', 'plan', 'years', 'criteria', 'monitoring', 'blood', 'a double dose', 'surgery', 'hypersensitivity', 'drugs', 'insulin', 'meter', 'a duration', 'start', 'inclusion', 'oral antidiabetic drugs', 'exclusion']"
NCT07109700,A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin,Type 2 Diabetes,"Inclusion Criteria:

* Confirmed as Type 2 Diabetes Mellitus (T2DM) for at least 24 weeks;
* Hemoglobin A1c (HbA1c) ≥7.5% and ≤10.5%
* Body Mass Index (BMI within the range of 22.5 \~ 40.0 kg/m2

Exclusion Criteria:

* Other types of diabetes besides T2DM
* Acute complications of diabetes (such as diabetic ketoacidosis, diabetic lactic acidosis, or hyperosmolar non-ketotic coma) occurred within 24 weeks prior to signing the Informed Consent Form (ICF)
* History of a level 3 hypoglycemic episode or a history of asymptomatic hyp oglycemic episodes within 24 weeks prior to signing the ICF
* History or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2)
* History of acute or chronic pancreatitis; or presence of risk factors for pancreatitis; or history of symptomatic gallbladder disease within 24 weeks prior to signing the ICF
* Investigator determines that the subject has a condition or disease affecting gastric em",18,100,ALL,RECRUITING,"['mtc', 'the icf\n* investigator', 'carcinoma', 'diabetic ketoacidosis', 'presence', 'condition', 'history', 'episodes', 'episode', 'subject', 'consent', 'the icf\n* history', 'level', '24 weeks', 'type', 'range', 'hyperplasia', 'type 2 diabetes mellitus', 'a history', 'the range', 'disease', '* body mass index', 'symptomatic gallbladder disease', '* hemoglobin', '* other types', 'a condition', 'factors', 'multiple endocrine neoplasia type', 'body', 'c-cell hyperplasia', '≥7.5%', '* history', 'at least 24 weeks', 'risk factors', 'gastric em', 'inclusion criteria', 'pancreatitis', 'coma', 'types', 'the informed consent form', 'endocrine', 't2dm\n* acute complications', 'weeks', 'investigator', 'asymptomatic hyp oglycemic episodes', 'diabetes', 'cell', 'the subject', 'family', 'diabetic lactic acidosis', 'gallbladder', 'hba1c', 'icf', 'criteria', 'mass', 'dm', 'family history', 'medullary thyroid carcinoma', 'index', 'thyroid', 'form', 'ketoacidosis', 'acute or chronic pancreatitis', 'men2', 'risk', 'hyperosmolar non-ketotic coma', 'complications', 't2', 'inclusion', 'hemoglobin', 'acidosis', '%', 'exclusion']"
NCT06929507,Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients,Renal Function Disorder,"Inclusion Criteria:

* Patients with diabetes
* Patients with DME or nAMD or macular edema secondary to retinal vein occlusion
* Patients already receiving nephroprotective drugs

Exclusion Criteria:

* Patients with end stage renal disease
* Pregnancy
* Patients with other retinal disorders
* Previous renal transplantation Patients under hemodialysis",18,100,ALL,RECRUITING,"['nephroprotective drugs\n\nexclusion criteria', 'stage', 'patients', 'hemodialysis', 'disease', '* patients', 'transplantation', 'occlusion', 'pregnancy', 'inclusion criteria', 'other retinal disorders', 'dme', 'retinal vein occlusion', 'diabetes', 'edema', 'namd or macular edema', 'criteria', 'disorders', 'drugs', '* pregnancy', 'inclusion', 'exclusion']"
NCT06234332,Peking University Birth Cohort in Weifang (PKUBC-WF),Health Problems in Pregnancy,"Inclusion Criteria:

* Pregnant woman

  1. Pregnant women, 6-13\^+6 gestational weeks
  2. Resided in Weifang in the past half years and have no plan to move out after delivery
  3. Pregnant women who plan to have antenatal care and delivery in Weifang maternal\&Child Hospital.
  4. Pregnant women who is willing to participate in this study with informed consent
* Pregnant woman's husband

  1. His wife was eligible for enrollment
  2. He is the biological father of the child (his wife's current pregnancy)
  3. Pregnant women's husband who is willing to participate in this study with informed consent
* Offspring 4. Children born to pregnant women who met the inclusion criteria after enrolling in this study.

  5\. Before the age of 8 years, his/her mother provided written informed consent. 6. After 8 years old, he/she agreed to continue this study and signed the informed consent.

Exclusion Criteria:

* Participants who cannot communicate normally.",18,100,ALL,RECRUITING,"['the biological father', 'participants', 'his wife', 'the inclusion criteria', 'delivery', 'informed consent\n* offspring', 'consent', 'who', '6-13\\^+6 gestational weeks', '8 years', 'the child', 'enrollment', '* pregnant woman', 'she', 'women', ""pregnant women's husband"", 'informed consent', '* participants', 'the past half years', 'weifang maternal\\&child hospital', 'father', 'pregnancy', 'exclusion criteria', 'inclusion criteria', 'weifang', 'he', 'weeks', 'study', 'wife', 'antenatal care', 'the age', 'woman', 'plan', 'care', 'his/her mother', 'child', 'years', 'criteria', 'husband', 'this study', 'children', '4. pregnant women', 'hospital', 'pregnant women', ""his wife's current pregnancy"", 'the informed consent', 'offspring', 'mother', 'no plan', 'inclusion', 'exclusion']"
NCT05071898,Pharmacogenetics of Response to GLP1R Agonists,Obesity,"Inclusion Criteria:

* BMI greater than or equal to 27 kg/m2
* Of Amish Descent

Exclusion Criteria:

* Woman of childbearing age who is sexually active
* History of diabetes (HbA1c \> 6.5% or random glucose \>200 mg/dL)
* Known allergy to semaglutide
* Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study
* eGFR \< 60 mL/min/1.73 sq. m.
* Hematocrit \< 35%
* TSH \< 0.4 o4 \> 5.5
* AST or ALT in excess of 2X the upper limit of normal
* Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide
* Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2",18,100,ALL,RECRUITING,"['carcinoma', 'the upper limit', ')\n* known allergy', 'medullary carcinoma', 'history', 'which', 'research', 'supplement', 'descent', 'random glucose', 'issues', 'allergy', 'who', 'the research physician', 'judgment', 'limit', 'glucose', 'egfr', '0.4 o4 \\', '5.5\n* ast', 'response', 'the study', '* history', 'pis', 'inclusion criteria', 'the thyroid', 'vitamin', 'the response', 'amish descent\n\nexclusion criteria', 'study', 'diabetes', '6.5%', 'the judgment', 'participation', '* medical issues', 'sq. m.', 'woman', 'physician', 'hematocrit', 'family', 'normal\n*', 'multiple endocrine neoplasia', 'nutritional supplement', '\\>200 mg/dl', '* woman', '60 ml/min/1.73', '35%', 'criteria', 'thyroid', 'neoplasia', 'drug', 'the risk', 'risk', 'childbearing age', 'personal or family history', 'tsh', 'inclusion', 'excess', 'childbearing', 'endocrine', 'exclusion', 'a drug']"
NCT06671587,iGlarLixi CGM Study in Chinese T2D Individuals After OADs,Type 2 Diabetes (T2D),"Inclusion Criteria:

* Participants who are diagnosed as T2D of at least 1 year before screening visit
* Participants who are treated at least 3 months prior to screening visit with a stable dose of metformin alone or in combination with a second OAD
* Inadequate control
* Body mass index (BMI) within the range 20-40 kg/m2 (inclusive)
* Is willing and able to wear the CGM device continuously
* Is willing to discontinue daily (oral) SU, glinide, alpha-GI, and DPP-4i
* Not using another CGM device during the study

Exclusion Criteria:

* Participants with severe renal dysfunction
* Participants with short life expectancy
* Participants with conditions/concomitant diseases making them non evaluable for the efficacy endpoints
* Participants with conditions/concomitant diseases precluding their safe participation in this study
* An episode of severe hypoglycemia requiring the assistance of a third party within 3 months before screening visit
* History of clinically significant pancreatitis ",18,100,ALL,RECRUITING,"['visit', 'the study\n\nexclusion criteria', 'participants', 'device', 'history', 'screening', 'diseases', 'a stable dose', 'conditions/concomitant diseases', 'their safe participation', 'severe hypoglycemia', 'a third party', 'combination', 'short life expectancy', 'dpp-4i', 'clinically significant pancreatitis', 'dose', 'range', 'who', 'an episode', 'hypoglycemia', 'episode', 'the range', 'year', '20-40 kg/m2', '* participants', '3 months', 'body', 'dysfunction', '* history', 'alpha', '(oral) su, glinide', 'inclusion criteria', 'pancreatitis', 'bmi', 'months', 'study', 'inclusive', 'life', 'efficacy', 'the assistance', 'participation', 'severe renal dysfunction', 'control', 'criteria', 'alpha-gi', 'mass', 'a second oad', 'this study', 'the cgm device', 'index', 'them', 'metformin', 'screening visit\n* participants', 'screening visit', 'conditions', 'inclusion', 'party', 'assistance', 'another cgm device', 'expectancy', 'exclusion']"
NCT07223892,Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds,Chronic Wounds,"Inclusion Criteria:

* Facilities and centers with the capacity to follow strict treatment and care guidelines for patients.
* Adults aged 18 years or older.
* Presence of a chronic wound (defined as a wound that has not shown significant improvement in 4 weeks) of any of the following etiologies: Diabetic foot ulcers, Venous leg ulcers, Arterial ulcers, Pressure ulcers, Burns, Trauma, Surgical
* Wound size greater than 1 cm²
* Ability to provide informed consent

Exclusion Criteria:

* Presence of active osteomyelitis
* Untreated malignancy in the wound area
* Known allergy to components of ATPs
* Pregnant or breastfeeding women
* Patients receiving immunosuppressive therapy
* Patients with a life expectancy of less than 12 weeks",18,100,ALL,NOT_YET_RECRUITING,"['presence', 'malignancy', '* presence', 'improvement', 'capacity', 'consent', 'patients', 'allergy', 'that', 'centers', 'a chronic wound', 'osteomyelitis', 'adults', 'wound', 'any', 'women', 'pressure ulcers', 'known allergy', 'immunosuppressive therapy', 'treatment', 'components', 'a wound', 'ability', 'trauma', 'significant improvement', '4 weeks', 'inclusion criteria', 'greater than 1 cm²', 'arterial ulcers', 'therapy', 'the wound area', 'weeks', 'guidelines', '* ability', 'surgical\n* wound size', 'a life expectancy', '* adults', 'life', 'area', 'care', 'informed consent\n\nexclusion criteria', 'venous leg ulcers', 'pressure', 'the following etiologies', 'diabetic foot ulcers', 'less than 12 weeks', 'criteria', 'facilities', 'years', 'size', '* facilities', 'burns', 'ulcers', 'the capacity', 'foot', 'inclusion', 'etiologies', 'expectancy', 'exclusion']"
NCT07313787,Effects of Meal Macronutrients on Postprandial Lipids,Nephrotic Syndrome,"* INCLUSION CRITERIA:

Common inclusion criteria (all groups):

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Age \>= 18 years
2. Average alcohol intake in the past 6 months \< 30 g/day (male) or \<20 g/day (female)

Healthy control specific inclusion criteria:

1. In good general health with no known active medical conditions as evidenced by medical history
2. Fasting glucose \<100 mg/dL
3. HbA1c \<5.7%
4. Fasting triglycerides \<150 mg/dL
5. ALT and AST within normal limits
6. BMI \>=18.5 to \<25 kg/m\^2 (or \<23 kg/m\^2 in participants of Asian descent)
7. Not taking any medications or supplements that, in the opinion of the investigator, would interfere with interpretation of study data.

Metabolic syndrome specific inclusion criteria

1\. Obesity defined as either

1. BMI \>30 kg/m\^2 (or \>=27 kg/m\^2 in participants of Asian descent), OR
2. Elevated waist circumference as defined below:

   * Country/Ethnic group",18,100,ALL,NOT_YET_RECRUITING,"['* country/ethnic group', 'participants', 'medical history', 'elevated waist circumference', 'average alcohol intake', 'any medications', 'history', 'interpretation', 'dl', 'all', 'bmi \\>=18.5', 'conditions', '* inclusion criteria', 'good general health', 'kg', 'supplements', '1\\. obesity', 'that', 'the investigator', '/m\\^2', 'individual', 'bmi \\>30 kg', '(male', 'alcohol', 'glucose', 'obesity', 'descent', '18 years', 'limits', '\\<23', 'group', 'an individual', '\\<5.7', 'the opinion', 'medications', 'months', 'study', 'investigator', 'opinion', 'data', '30 g', 'normal limits', 'day', '\\<23 kg/m\\^2', 'the past 6 months', 'intake', 'health', 'groups', 'triglycerides', 'control', 'the following criteria', 'years', 'criteria', 'all groups', 'this study', '\\>=27 kg/m\\^2', 'circumference', 'order', 'country', 'age \\>=', 'common inclusion criteria', 'waist', 'study data', 'asian descent', 'male', 'inclusion', 'female', '\\<5.7%\n4. fasting triglycerides']"
NCT07310849,Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity,Type2Diabetes,"Inclusion Criteria:

1. Age and Consent: Individuals aged 50 years or older who are willing to provide written informed consent.
2. Language and Literacy: Participants must be literate and able to communicate in Mandarin or Taiwanese.
3. Medical Diagnosis: Participants must have a physician-confirmed diagnosis of type 2 diabetes mellitus (T2DM) and at least one comorbid chronic disease (e.g., hypertension, hyperlipidemia, chronic kidney disease, or heart disease).
4. Technology Use: Participants must own a smartphone and be willing to use the LINE messaging app and web-based health education links.
5. Residence: Participants must reside within one of the four participating communities and have no plans to move away during the study intervention period.

Exclusion Criteria:

* (1)Those with severe diabetes-related complications, such as renal failure, cerebrovascular disease, diabetic foot, or retinopathy.

  (2)Individuals with psychiatric disorders, undergoing active cancer treatment,",18,100,ALL,ENROLLING_BY_INVITATION,"['participants', 'mandarin', '2. language', 'severe diabetes-related complications', '3. medical diagnosis', '2)individuals', 'age', 'mellitus', 'the study intervention period', 'kidney', 'a smartphone', 'consent', 'type', 'renal failure', 'who', '(2)individuals', 'line', 'communities', 'disease', 'treatment', 'language', 'the line', 'hyperlipidemia', 'literacy', 'written informed consent', 'inclusion', 'education', 'period', 'exclusion criteria', 'cancer', 'inclusion criteria', 'plans', 'cerebrovascular disease', 'study', 'hypertension', 'diabetes', 'physician', 'failure', 'no plans', 'chronic kidney disease', 'heart', 'health', 'diagnosis', 'heart disease', 'a physician-confirmed diagnosis', 'links', 'years', 'criteria', 'residence', 'dm', 'individuals', 'active cancer treatment', 'psychiatric disorders', 'disorders', 'the four participating communities', 'foot', 'complications', 't2', 'taiwanese', 'diabetic foot', 'exclusion', 'smartphone', 'technology', 'intervention']"
NCT06858787,Validating CGM for GDM,Gestational Diabetes Mellitus (GDM),"Inclusion Criteria:

* Ages 18-50
* Singleton pregnancy between 24-32 weeks gestational age
* Prenatal care and delivery at Mount Sinai Hospital

Exclusion Criteria:

* Multiple fetal gestation
* Preexisting diabetes
* Concurrent use of steroids
* Anomalous fetus
* Insufficient prenatal care (identified as missing half the recommended visits or establishing care after 20 weeks gestation)
* Unable to tolerate oral glucose test",18,50,FEMALE,RECRUITING,"['delivery', '24-32 weeks', '* ages', 'steroids', '20 weeks gestation', 'prenatal care', 'fetus', 'singleton', 'glucose', 'insufficient prenatal care', 'pregnancy', 'inclusion criteria', 'weeks', 'diabetes', 'care', 'criteria', '18-50\n* singleton pregnancy', 'half the recommended visits', 'hospital', '* anomalous fetus', 'test', 'gestation', 'visits', 'inclusion', 'oral glucose test', 'exclusion', 'ages']"
NCT05309850,Primary Prevention With the Lifestyle Tool,Cardiovascular Diseases,"Inclusion Criteria:

* informed consent
* Age above 35 years

Exclusion Criteria:

* type 1 diabetes, MODY or secondary diabetes
* conditions or treatments that in the judgement of the Investigator could affect the study evaluation
* connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.",18,100,ALL,RECRUITING,"['universities', 'the study team', 'bodies', 'such a way', 'conditions', 'consent', 'type', 'the investigator', 'the judgement', 'specific interests', 'authorities', 'connection', 'mody', 'outcomes', '* age', 'inclusion criteria', 'interests', 'study', 'judgement', 'investigator', 'evaluation', 'diabetes', '* type 1 diabetes', '35 years\n\nexclusion criteria', 'years', 'criteria', 'funders', 'treatments', 'team', 'the study outcomes', 'inclusion', 'exclusion']"
NCT05708859,Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT,Type II Diabetes,"Inclusion Criteria:

1. Male or female 40 years to 80 years of age at signing of informed consent
2. Type 2 DM of minimum 5 years duration with HbA1c ≥7.0% to ≤10.5%
3. Body mass index (BMI) ≥25 kilograms per meter squared (kg/m²)
4. Presence of two discrete coronary artery plaques with visual diameter stenosis \>20% on CCTA
5. At the baseline visit, participants must be on a stable (\>4 weeks) regiment of diabetes medications.
6. Patients using oral hormonal contraceptives must switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation

Exclusion Criteria:

1. Have had a major cardiovascular event within the last 60 days
2. Have type 1 diabetes mellitus
3. Current use of GLP1-RA
4. Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months
5. Are currently planning treatment for diabetic retinopathy and/or macular edema
6. Have history of, or currently p",5,100,ALL,RECRUITING,"['diabetes medications', 'participants', 'visit', '80 years', 'presence', 'history', 'age', 'mellitus', '≥25 kilograms', 'days', 'initiation', 'escalation', 'dose', 'consent', 'event', 'patients', 'type', 'ccta', 'minimum 5 years duration', 'a stable (\\>4 weeks', 'contraceptives', 'hypoglycemia', 'a history', 'barrier', 'regiment', 'glp1-ra', 'hba1c ≥7.0%', 'artery', 'treatment', 'informed consent', 'duration', 'diameter', 'body', 'a barrier method', 'visual diameter stenosis', '4 weeks', 'inclusion criteria', 'a major cardiovascular event', 'the last 6 months', 'medications', '2 dm', 'bmi', 'the last 60 days', 'weeks', 'months', 'unawareness', 'diabetes', 'edema', 'contraception', 'the baseline visit', 'minimum', 'years', 'criteria', 'stenosis', 'baseline', 'oral hormonal contraceptives', 'method', 'index', 'a non-oral contraceptive method', 'meter', 'signing', 'kilograms', '3. body mass index', 'current use', 'inclusion', '%', 'plaques', 'exclusion']"
NCT05910840,Support-t Online Training in Youth Living With Type 1 Diabetes Transitioning to Adult Care,Diabetes Mellitus,"Inclusion Criteria:

* Adolescents with a clinical diagnosis of T1D
* 14-16 years of age
* Receiving diabetes care at one of 4 university teaching hospital-based pediatric diabetes clinics in Quebec: Montreal Children's Hospital-McGill University Health Centre, Centre hospitalier universitaire de Sherbrooke, Le Copain-Hôpital de Gatineau, Centre Hospitalier Universitaire de Québec
* Having access to internet
* Having an active email address
* Fluent in English or French

Exclusion Criteria:

* Severe neurocognitive disabilities
* Patients with conditions associated with shortened erythrocyte survival, such as hemolytic anemia or other conditions associated with inaccurate HbA1c",14,16,ALL,RECRUITING,"['receiving diabetes', '* adolescents', 'teaching', 'centre', 'age', 't1d\n* 14-16 years', 'conditions', 'patients', 'internet', 'inaccurate hba1c', 'de québec', '* patients', 'universitaire', 'centre hospitalier universitaire', 'other conditions', 'copain', 'hemolytic anemia', 'inclusion criteria', 'email', 'clinics', 'de sherbrooke', 'adolescents', 'diabetes', 'address', 'an active email address', 'hôpital', 'quebec', 'health', 'diagnosis', 'disabilities', 'years', 'criteria', '* severe neurocognitive disabilities', 'children', 'access', 'hospital', 'university', 'anemia', 'a clinical diagnosis', 'inclusion', 'shortened erythrocyte survival', 'survival', 'exclusion', 'le copain-hôpital de gatineau']"
NCT07254689,The Food for Health Study,Type 2 Diabetes,"Inclusion Criteria:

* Adults aged 55 years or older
* Live on the Flathead Reservation
* Self-identify as Native American (NA)
* Food insecurity, as determined using Hunger Vital Sign™, a two question screener asked by providers.
* Pre-diabetic, based on HbA1c lab results of (5.7-6.4%) or scores 5+ on the National Diabetes Prevention Programs screener based on health and history.

Exclusion Criteria:

* Individuals with prevalent diabetes
* Individuals with end-stage renal disease
* Their health provider states they should not participate
* If a participant is unable to communicate due to severe hearing loss or speech disorder, or severe visual impairment precluding them from completing assessment.",18,100,ALL,NOT_YET_RECRUITING,"['speech', 'food', 'assessment', 'prevention', 'history', 'hearing', 'stage', 'hunger vital sign™', '* food insecurity', 'providers', 'speech disorder', 'native american', 'participant', 'their health provider', '* individuals', 'adults', 'disease', 'a two question screener', '5.7-6.4%', 'severe hearing loss', 'screener', 'states', 'end-stage renal disease', 'severe visual impairment', 'scores', 'inclusion criteria', 'hunger', 'prevalent diabetes', 'hba1c lab results', 'results', 'loss', '* adults', 'question', 'diabetes', 'impairment', 'insecurity', 'health', 'the flathead reservation', 'reservation', 'years', 'they', 'criteria', 'provider', 'individuals', 'a participant', 'sign', 'disorder', 'programs', 'self', 'inclusion', 'them', 'exclusion']"
NCT06851962,Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes Clinical Trial,Diabetes Mellitus Type 2,"Inclusion Criteria:

1. Age 40-70 years old, included.
2. Body Mass Index (BMI) between 25-40 kg/m².
3. Diagnosis of Type 2 Diabetes (T2D) according to the American Diabetes Association (ADA) criteria.
4. Patients with T2D insufficiently controlled (Hemoglobin A1c (HbA1c) 7-9.5%) with current (≥6 months) ""standard of care"" treatment, excluding the use of insulin.
5. The subject has provided written informed consent prior to any study-specific procedure.
6. Able and willing to comply with requested study visits and procedures.
7. Contraceptive measures, only for female participants:

   * A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
   * Is a woman of non-childbearing potential (WONCBP) OR
   * Is a woman of childbearing potential (WOCBP) and agrees to use a contraceptive method that is highly effective, with a failure rate of \<1%, during the study intervention period (to be effective before starti",40,70,ALL,NOT_YET_RECRUITING,"['participants', 'age', 't2d insufficiently controlled (hemoglobin', 'requested study visits', 'the study intervention period', 'potential', 'intervention', 'standard', 'conditions', 'subject', 'consent', 'any study-specific procedure', 'a woman', 'type', 'female participants', 'that', 'patients', '7. contraceptive measures', 'participant', 'non-childbearing potential', 'ada) criteria', 'current (≥6 months', 'type 2 diabetes', 'she', '-9.5%', 'treatment', 'measures', '4. patients', 'a female participant', 'woncbp', 'body', 'the american diabetes association', 'written informed consent', 'period', '25-40 kg/m²', 'a contraceptive method', '2. body mass index', 'rate', 'inclusion criteria', 'wocbp', 'bmi', 'months', 'procedures', 'study', 'diabetes', 'woman', 'failure', 'care', 'the subject', 'diagnosis', 'years', 'hba1c', 'criteria', 'a failure rate', '3. diagnosis', 'method', 'index', 'the use', 'insulin', 'the following conditions', 'starti', 'procedure', 'visits', 'inclusion', 'hemoglobin', '\\<1%']"
NCT06423274,Comparing Artificial Intelligence for Assisted Diagnosis of Diabetic Retinopathy,Diabetic Retinopathy,"Inclusion Criteria:

1. Diagnostic for diabetes: Type 1 diabetes of a lest 5 years of evolution; or Type 2 diabetes;
2. Obtaining informed consent;
3. Patient age 18 or above.

Exclusion Criteria:

1. Patients under 18 years of age;
2. Failure to Obtain informed consent;
3. Presence of other retinal diseases;
4. A patient who has already undergone the treatment.",18,100,ALL,NOT_YET_RECRUITING,"['presence', 'a lest 5 years', 'age', 'diseases', 'consent', 'a patient', 'type', 'lest', 'who', 'patients', 'evolution', 'other retinal diseases', 'the treatment', '2 diabetes', 'informed consent', 'treatment', '18 years', 'exclusion criteria', '3. presence', 'inclusion criteria', 'patient', 'diabetes', 'type 1 diabetes', 'failure', 'years', 'criteria', 'inclusion', '3. patient age', 'exclusion']"
NCT06345118,Evaluate the Results of Fall Prevention in Older Adults With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2","Inclusion Criteria:

For the first objective (Cross-sectional study):

* Type 2 diabetic patients diagnosed using American Diabetes Association 2022 criteria
* HbA1c ≥ 7.0 and ≤ 9%
* Age ≥ 60 and ≤ 80

For the second objective (Longitudinal study):

* All patients recruited from the first objective are at moderate or high risk of falls according to the criteria of World Guidelines for Falls Prevention and Management for Older Adults - British Geriatric Society.

Exclusion Criteria:

* Acute diabetic complications
* Patients are in the acute phase of musculoskeletal disorders: acute gout, progressing low-grade arthritis, acute joint pain due to joint degeneration, sciatic pain, and infectious arthritis.
* Patients suffer from conditions significantly affecting cognition and mobility: sequelae of stroke (with weakness, limb paralysis), muscular weakness, limb disabilities, severe heart failure, severe cognitive decline, and psychiatric disorders.
* Patients have been bedridden due to ill",18,100,ALL,RECRUITING,"['sciatic pain', 'falls', 'pain', 'weakness', 'prevention', 'phase', 'age', 'limb paralysis', 'conditions', 'sequelae', 'degeneration', 'falls prevention', 'patients', 'acute joint pain', 'type', '* acute diabetic complications', 'association', 'mobility', 'paralysis', 'longitudinal study', '9%', 'adults', 'severe cognitive decline', 'arthritis', 'moderate or high risk', 'world guidelines', 'limb', 'inclusion', 'world', 'exclusion criteria', 'stroke', 'inclusion criteria', 'objective', 'cross-sectional study', 'study', 'type 2 diabetic patients', 'the second objective', 'management', 'severe heart failure', 'guidelines', 'gout', 'failure', 'heart', 'disabilities', 'the acute phase', 'criteria', 'infectious arthritis', 'limb disabilities', 'muscular weakness', 'decline', 'society', 'the first objective', 'psychiatric disorders', 'disorders', '≥', 'low-grade arthritis', 'cognition', 'musculoskeletal disorders', 'acute gout', 'joint degeneration', 'risk', 'grade', 'complications', 'hba1c ≥', 'the criteria', 'all patients', 'exclusion']"
NCT04181996,Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine,Cardiovascular Diseases,"Inclusion Criteria:

Patients who have:

1. Type 2 Diabetes (on diet, oral hypo-glycemic agents and/or insulin) or pre-diabetes (defined by Diabetes Canada as HbA1C=6.0-6.45% or increased fasting blood sugar (FBS) (6.1-6.9 mmol/L) or impaired glucose tolerance);
2. suffered a recent cardiovascular event (≤120 days post ACS (i.e. STEMI or nonSTEMI) or TIA/stroke with associated large vessel atherosclerotic disease confirmed on US, CT or MRI;
3. stable symptoms and hemodynamics;
4. age ≥18 years;
5. given informed consent. Standard definitions will be used for STEMI, NSTEMI, and for ischemic stroke confirmed by CT or MRI and TIA confirmed by a neurologist.

Exclusion Criteria:

Patients who have

1. planned revascularization of infarct or stroke related artery more than 120 days after the qualifying/index event;
2. a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;
3. recent CV event likely to have been secondary to myocardial infarction with",18,100,ALL,RECRUITING,"['infarction', 'stroke related artery', 'sugar', 'fasting blood sugar', '≤120 days', '1. type 2 diabetes', 'hemodynamics', 'days', 'the qualifying/index event', 'impaired glucose tolerance', 'event', 'consent', 'neurologist', 'mri', 'patients', 'nstemi', 'fbs', 'who', 'type', 'disease', 'qualifying', 'glucose', 'artery', 'informed consent', 'diet', 'a recent cv event', 'a recent cardiovascular event', 'tia', 'exclusion criteria', 'stroke', 'inclusion criteria', 'vessel', 'planned revascularization', 'hba1c=6.0-6.45%', 'the opinion', 'symptoms', 'acs', 'diabetes canada', '3. stable symptoms', 'opinion', 'diabetes', 'age ≥18 years', 'stemi', 'recent cv event', 'agents', 'ischemic stroke', 'years', 'criteria', 'blood', 'index', 'standard definitions', 'myocardial infarction', 'the neurologist', 'us', 'a neurologist', 'infarct', 'insulin', 'ct', 'tolerance', 'definitions', 'revascularization', 'inclusion', 'oral hypo-glycemic agents', 'exclusion']"
NCT06152588,Restricted Eating Time in the Treatment of Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

* Age: ≥18 years
* Overweight or obesity (BMI ≥25 kg/m2)
* T2D with HbA1c\>53 mmol/mol
* Habitual eating window ≥12 h/day (incl. foods/snacks and energy-containing beverages)

Exclusion Criteria:

* Bariatric surgery or planned bariatric surgery within study duration
* Use of fast acting insulin and combination insulin products
* Habitual CGM use
* A wish to adhere to Ramadan
* For women: current/planned pregnancy or lactation
* Alcohol or drug abuse (judged by investigator) or treatment with disulfiram
* Severe hypoglycaemia within last year (Severe hypoglycaemia, as defined by the American Diabetes Association (ADA), denotes severe cognitive impairment requiring external assistance for recovery)
* Inability to understand written and oral information in Danish
* Unable or unwilling to adhere to TRE; for instance, due to competing medical conditions.
* Medical condition which, based on investigators assessment, challenges participation including but not limited to ",18,100,ALL,RECRUITING,"['* overweight', 'tre', 'competing medical conditions', 'abuse', 'condition', 'assessment', 'severe hypoglycaemia', 'study duration', 'which', 'bariatric surgery', '(bmi ≥25 kg/m2', 'conditions', 'combination', 'alcohol', 'year', 'alcohol or drug abuse', 'ada', 'severe cognitive impairment', 'obesity', '* use', 'women', 'treatment', 'duration', 'ramadan', 'external assistance', 'recovery', 'pregnancy', '* age', 'the american diabetes association', 'a wish', 'hba1c\\>53 mmol/mol', 'exclusion criteria', 'disulfiram', 'inclusion criteria', 'disulfiram\n* severe hypoglycaemia', 'instance', 'study', 'lactation', 'last year', 'investigator', 'written and oral information', 'overweight', 'impairment', 'current/planned pregnancy', 'participation', 'investigators assessment', 'wish', 'danish\n*', 'hypoglycaemia', 'years', 'criteria', 'products', 'assistance', 'planned bariatric surgery', 'surgery', 'investigators', 'beverages', 'drug', 'information', 'incl', 'insulin', 'energy-containing beverages', 'window', 'inability', '* medical condition', 'foods', 'energy', 'inclusion', 'snacks', 'exclusion']"
NCT04011020,Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes,Type 1 Diabetes,"Inclusion Criteria:

1. Adult patients ( 14 years)
2. Must have a diagnosis of type 1 diabetes mellitus based on the 2015 American Diabetes Association criteria for the Clarification and Diagnosis of diabetes.
3. Must have a blood test confirming the presence of at least one autoantibody to pancreatic islet Cells (IAA, IA2, GAD 65, ZnT8).
4. Fasting C-peptide level \> 0.3 ng/ml
5. HbA1C \< 10% at enrollment
6. Recent diagnosis (within two years of enrollment)
7. Adequate venous access for apheresis
8. Must be equipped with a continuous glucose monitoring system (CGMS)
9. Ability to provide informed consent
10. For female patients only, willingness to use FDA-recommended birth control (http://www.fda.gov/downloads/ForConsumers/ByAudience/ForWomen/FreePublications/UCM356451.pdf) until 6 months post treatment.
11. Must agree to comply with all study requirements and be willing to complete all study visits

Exclusion Criteria:

1. AST or ALT 2 \> x upper limit of normal.
2. Abnormal biliru",18,100,ALL,RECRUITING,"['10%', 'presence', 'c-peptide level', 'mellitus', 'fda-recommended birth control', 'birth', 'adequate venous access', 'clarification', 'level', 'consent', 'cgms', 'type', 'patients', 'association', 'limit', 'http://www.fda.gov/downloads/forconsumers/byaudience/forwomen/freepublications/ucm356451.pdf', 'the presence', 'peptide', 'enrollment', 'glucose', 'treatment', 'informed consent', 'a blood test', 'ability', '9. ability', 'adult patients', 'the clarification', 'system', 'apheresis', '14 years', 'months', 'study', 'all study requirements', 'requirements', 'diabetes', 'cells', 'female patients', 'diagnosis', 'control', 'gad', 'criteria', 'years', 'blood', 'hba1c', 'monitoring', 'willingness', 'biliru', 'access', '2. abnormal biliru', 'islet', 'a diagnosis', 'pancreatic islet cells', 'test', 'two years', 'visits', 'inclusion', 'adult', 'exclusion', '6 months']"
NCT06796582,Reliability of Multiple-Repetition-Maximum Tests in Patients with Cardiovascular Disease or Risk Factors,Heart Failure,"Inclusion Criteria:

* Age ≥ 50 years
* At least one of the following cardiovascular diseases / risk factors:
* Heart failure
* Coronary heart disease
* Atrial fibrillation
* Arterial hypertension
* Type 2 diabetes mellitus
* Clinically stable for ≥ 4 weeks
* Medical clearance to perform resistance training / strength testing
* Signed written informed consent

Exclusion Criteria:

* Pregnancy
* Acute infection
* Chronic joint inflammation
* Knee, hip, ankle, wrist, elbow or shoulder pain
* Known osteoporosis (T-value ≤ -2.5)
* Uncontrolled hypertension (≥160 mmHG systolic / ≥100 mmHG diastolic)
* Known cerebral or thoracic aneurysm",18,100,ALL,NOT_YET_RECRUITING,"['wrist', 'fibrillation', 'pain', 'diabetes mellitus', 'elbow', 'resistance', 'age', 'mellitus', 'diseases', '* medical clearance', 'consent', 'type', 'disease', 'strength', 'training', 'factors', 'pregnancy', 'mmhg', 'infection', 'clearance', 'shoulder', 'known osteoporosis', 'inclusion criteria', 'weeks', 'hypertension', 'knee', 'osteoporosis', 'hip', 'diabetes', 'aneurysm', 'failure', 'heart', 'years', 'criteria', '* knee', 'inflammation', '≥160', 'risk', 'ankle', 'shoulder pain', '50 years', '≥100', 'inclusion', 'value', 'testing', 'exclusion']"
NCT07090824,Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1","Inclusion Criteria:

To be eligible for the study, a subject must meet all of the following criteria:

1. 18-60 years of age
2. Clinical diagnosis of type 1 diabetes
3. On insulin pump therapy and continuous glucose monitor for at least 3 months
4. For females of childbearing potential, a negative pregnancy test and not attempting to conceive.
5. Understanding and willingness to follow the protocol and sign informed consent
6. Ability to speak, read and write English

Exclusion Criteria:

The presence of any of the following is an exclusion for the study:

1. Diabetic ketoacidosis within 3 months
2. Severe hypoglycemia resulting in seizure or loss of consciousness within 3 months prior to enrollment
3. Have donated blood within 8 weeks
4. Have a known clinically significant history of anemia
5. Pregnant or lactating
6. Active infection
7. Any medical condition that, in the investigator's opinion, might interfere with study completion or participant safety.
8. Known seizure disorder
9. ",18,60,ALL,RECRUITING,"['presence', 'condition', 'monitor', 'age', 'any medical condition', 'an exclusion', '8 weeks', 'potential', 'history', 'childbearing potential', 'all', 'severe hypoglycemia', 'subject', 'consent', 'following', 'females', 'type', 'hypoglycemia', 'a negative pregnancy test', 'the presence', 'a subject', 'insulin pump therapy', 'enrollment', 'any', 'glucose', 'completion', 'informed consent', '3 months', 'the study', 'pregnancy', 'pump', 'ability', 'the following', 'infection', 'clinical diagnosis', 'inclusion criteria', 'seizure', 'study completion', 'continuous glucose monitor', 'therapy', 'at least 3 months', 'understanding', 'months', 'study', 'weeks', 'english\n\nexclusion criteria', 'loss', 'investigator', 'known seizure disorder', 'opinion', 'diabetes', 'consciousness', 'diagnosis', '1. 18-60 years', 'participant safety', 'the following criteria', 'years', 'criteria', 'blood', 'protocol', 'willingness', 'the protocol', 'active infection', ""the investigator's opinion"", '5. understanding', 'ketoacidosis', 'insulin', 'safety', 'disorder', 'test', 'anemia', 'inclusion', 'exclusion', '6. ability', '1. diabetic ketoacidosis']"
NCT07063524,Transcutaneous Electrical Stimulation and Controlled Heat in People With and Without Diabetes,Diabetes,"Inclusion Criteria:

* Male or Female aged between 45-75 years old
* Clinical diagnosis of Type I or Type II diabetes
* Controlled diabetes mellitus (HbA1c ≤ 7%)

Exclusion Criteria:

* Pregnancy
* Current smoker
* Diagnosed neuropathy
* Uncontrolled hypertension (HTN)
* Allergy to tape or electrodes
* Diagnosis of dementia
* History of knee joint replacement
* Significant joint pain (e.g., back, hip, or ankle) that may limit the ability to wear a boot for 60 minutes
* Contraindications to TENS, including:

  * Presence of pacemakers
  * Dermatological conditions
  * Abnormal sensation in the knees
* Severe medical or neurological conditions, including:

  * Chronic obstructive pulmonary disease
  * Cardiovascular disease
  * Arteriosclerosis obliterans
  * Cerebrovascular accident
  * Lumbar disc disorders (e.g., herniation)
  * Rheumatoid arthritis
* Fear of electrical stimulation",45,75,ALL,RECRUITING,"['* current smoker', 'tens', 'presence', 'herniation', 'pain', 'history', '* presence', '* fear', 'conditions', 'knees', 'chronic obstructive pulmonary disease', 'arteriosclerosis obliterans', 'type', 'that', '60 minutes', '(e.g., herniation', 'allergy', 'disease', 'arthritis', 'tape', 'arteriosclerosis', 'type i', 'pregnancy', 'ability', 'dementia', 'boot', 'obliterans', 'inclusion criteria', 'fear', '7%', '* allergy', 'hypertension', 'knee', 'lumbar disc disorders', 'sensation', 'diabetes', 'significant joint pain', 'accident', 'replacement', 'type ii', 'diagnosis', '* dermatological conditions', 'htn', 'years', 'criteria', 'contraindications', 'disc', 'hba1c ≤', 'knee joint replacement', 'disorders', 'electrical stimulation', 'minutes', 'rheumatoid', '* pregnancy', 'pacemakers', 'smoker', 'stimulation', 'rheumatoid arthritis', 'ankle', '* cardiovascular disease', 'lumbar', 'inclusion', 'the ability', '* contraindications', '* cerebrovascular accident', 'a boot', 'exclusion']"
NCT07400588,Aleniglipron Phase 2 in Type 2 Diabetes Mellitus,Obese,"Inclusion Criteria:

* Signed Informed Consent
* A diagnosis of T2DM of ≥6 months,
* Hemoglobin A1c (HbA1c) ≥6.5% to ≤10% at Screening
* Have a BMI ≥27.0 kg/m2

Exclusion Criteria:

* Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema. All participants must have a photo fundoscopy, optical coherence tomography, or slit lamp assessment prior to randomization and within the last 12 months to confirm the absence or stable status of diabetic retinopathy and/or macular edema.
* Present or planned use of any drug that could interfere with glucose levels
* Self-reported change in body weight \>5 kg (11 pounds) within 3 months before screening
* Have prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to Screening)
* Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to Screening, including, but not ",18,100,ALL,RECRUITING,"['t2dm', 'participants', 'stable status', 'lamp', 'assessment', 'weight', 'device', 'screening', 'consent', 'endoscopic and/or device-based therapy', 'pounds', 'that', 'status', 'year', 'fundoscopy', 'exclusion', 'glucose', 'treatment', 'obesity', 'levels', 'body', 'slit lamp assessment', 'the last 12 months', 'absence', 'self-reported change', 'inclusion criteria', 'the last 6 months', 'removal', 'therapy', 'months', 'tomography', 'edema', 'coherence', 'all participants', 'a photo fundoscopy', 'the absence', 'diagnosis', 'change', 'any drug', 'hba1c', 'criteria', 'randomization', 'endoscopic', 'photo', '≥6 months', 'drug', 'a diagnosis', 'liposuction', '11 pounds', 'device removal', 'self', 'glucose levels', 'abdominoplasty', 'inclusion', 'hemoglobin', 'optical coherence tomography', '%', 'body weight \\>5 kg', '≤10']"
NCT06660940,Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy,Diabetic Kidney Disease,"Inclusion Criteria:

* Age: 18-75 years old, either sex;
* Meeting the diagnostic criteria for type 2 diabetes mellitus and DKD;
* The target eye met the diagnostic criteria for type 2 DR and the fundus showed moderate or severe NPDR;
* Have been treated with an adequate dose of RAASIs for more than 4 weeks;
* The 24h UTP between 0.5g and 3.5g (results of two tests);
* The eGFR ≥30ml/min/1.73m2；
* Blood pressure (BP) ≤ 140/90mmHg;
* Hemoglobin A1c (HbA1c) \< 9%;
* Voluntarily sign the informed consent form.

Exclusion Criteria:

* Patients with a known or suspected history of allergy to the test drug and its excipients;
* Various primary kidney diseases or non-diabetic kidney disease as judged by the investigator;
* Heat-toxin syndrome: swelling and pain the throat , redness, swelling, and pain in the eyes, mouth and tongue sores, swollen and painful gums, cough with yellow phlegm, stool stem nod, deep colored urine, red tongue with yellow coating; cold-dampness syndrome: poor appetite",18,75,ALL,NOT_YET_RECRUITING,"['fundus', 'poor appetite', 'mellitus', 'diseases', 'mouth', 'dose', 'consent', 'the diagnostic criteria', 'allergy', 'eyes', 'disease', 'the 24h utp', 'exclusion criteria', 'urine', 'the informed consent form', 'sores', 'cold-dampness syndrome', 'diabetes', 'years', 'the target eye', 'stem', 'stool stem nod', 'its excipients', 'inclusion', 'target', 'history', 'npdr', 'phlegm', 'non-diabetic kidney disease', 'the investigator', 'throat', 'dampness', 'the throat', 'weeks', 'toxin', 'excipients', 'either sex', 'tests', 'more than 4 weeks', 'the test drug', 'form', 'test', 'deep colored urine', 'hemoglobin', 'exclusion', 'appetite', 'yellow phlegm', 'pain', 'kidney', '9%', '*', '* patients', '* hemoglobin', 'various primary kidney diseases', 'coating', 'dkd', 'inclusion criteria', 'syndrome', 'heat', 'moderate or severe npdr', 'criteria', 'blood', 'an adequate dose', 'drug', 'yellow coating', 'patients', 'bp) ≤ 140/90mmhg', 'type', '* heat-toxin syndrome', 'gums', 'tongue', '2 dr', 'swelling', 'results', 'investigator', 'the fundus', 'pressure', 'hba1c', 'redness', 'two tests', 'red tongue', 'raasis', '(results', 'the eyes']"
NCT07139535,A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone,T2DM,"Inclusion Criteria:

1. Have been diagnosed with type 2 diabetes mellitus (T2DM)
2. Having received only dietary and exercise therapy and never taken any antihyperglycemic medications before screening; OR Having taken no antihyperglycemic medications within the 12 weeks before screening and, prior to that, having received only oral antihyperglycemic drugs in a regimen of no more than two concomitant agents.
3. Have a body mass index (BMI) ≥20 kilograms per meter squared (kg/m²) at screening
4. Be of stable weight (±5%) for at least 12 weeks before screening

Exclusion Criteria:

1. Have type 1 diabetes mellitus
2. Presence of severe chronic diabetic complications at screening, including but not limited to: proliferative diabetic retinopathy, diabetic macular edema, and severe non-proliferative diabetic retinopathy requiring acute treatment;
3. History of diabetic ketoacidosis or hyperosmolar hyperglycemic state within 24 weeks prior to randomization;
4. Occurrence of a Grade 3 hypoglyc",18,100,ALL,NOT_YET_RECRUITING,"['diabetic ketoacidosis', 'presence', 'weight', 'history', 'mellitus', 'screening', 'severe chronic diabetic complications', '24 weeks', 'any antihyperglycemic medications', 'that', 'type', 'the 12 weeks', 'type 2 diabetes', 'no antihyperglycemic medications', 'acute treatment', 'treatment', 'state', 'body', 'only oral antihyperglycemic drugs', 'stable weight', 'exclusion criteria', 'inclusion criteria', 'kg/m²', 'retinopathy', 'medications', 'therapy', 'bmi', 'weeks', 'regimen', 'diabetes', 'edema', '±5', 'agents', 'a grade 3 hypoglyc', 'criteria', 'a body mass index', 'mass', 'a regimen', 'dm', 'randomization', 'hyperosmolar hyperglycemic state', 'index', 'hypoglyc', 'drugs', 'severe non-proliferative diabetic retinopathy', 'ketoacidosis', 'meter', 'kilograms', 'grade', 'complications', 't2', 'inclusion', '%', 'exclusion', 'occurrence']"
NCT07216508,Liver Transplant CGM,Liver Transplant,"Inclusion Criteria:

• inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL

Exclusion Criteria:

* having a planned discharge to a rehabilitation or nursing facility,
* a contraindication to sensor placement,
* if discharge is anticipated to be \>30 days post-transplant, or
* if recent transplant also included a kidney or pancreas transplant",18,100,ALL,RECRUITING,"['180mg/dl\n\nexclusion criteria', 'participants', 'days', 'kidney', '\\>30 days', 'recent transplant', 'who', 'sensor placement', 'glucose', 'nursing', 'facility', 'transplant', 'pancreas', 'inclusion criteria', 'discharge', 'liver', 'placement', 'rehabilitation', 'a contraindication', 'criteria', 'a planned discharge', 'sensor', 'inclusion', 'exclusion', 'contraindication', 'an inpatient glucose']"
NCT02169518,Paraoxonase and HDL Qualities in Glycaemia and Inflammation,Diabetes Mellitus,"Inclusion Criteria:

* Patients with Type 1 diabetes who are not receiving lipid-lowering drugs, omega fatty acid supplements or thiazolidinediones and without clinical and/or ECG evidence of CHD.

Type 2 diabetic patients who are not receiving omega fatty acid supplements or thiazolidinediones and without clinical and/or ECG evidence of CHD.

Patients with impaired fasting glucose undergoing oral glucose tolerance test. Patients scheduled for bariatric surgery. Healthy controls who have no major acute or chronic illness, are not receiving regular medication and not taking omega fatty acid supplements, do not have clinically overt ischaemic heart disease.

Subjects (male and female) aged between 20 and 75. Subjects who have capacity and understanding for informed consent process.

Exclusion Criteria:

* Type 1 diabetics using lipid lowering therapy, thiazolidinediones, omega fatty acid supplements. History and/or ECG evidence of ST segment changes indicative of CHD.

Type 2 diabetics r",18,100,ALL,RECRUITING,"['illness', 'history', 'capacity', 'bariatric surgery', 'lipid lowering therapy', 'thiazolidinediones', 'supplements', 'consent', 'patients', 'lipid-lowering drugs', 'type', '2 diabetic patients', 'who', 'disease', '* patients', 'omega', 'controls', 'glucose', 'medication', 'informed consent process', 'acid', 'segment', 'exclusion criteria', 'diabetics', 'regular medication', 'inclusion criteria', 'oral glucose tolerance test', 'understanding', 'subjects', 'therapy', '* type', 'lipid', '2 diabetics', 'diabetes', 'type 1 diabetes', 'fatty', 'heart', 'process', 'history and/or ecg evidence', 'impaired fasting glucose', 'fasting', 'criteria', 'clinical and/or ecg evidence', 'surgery', 'chd', '1 diabetics', 'drugs', 'test', 'tolerance', 'evidence', 'healthy controls', '.', 'inclusion', 'exclusion', 'female', 'omega fatty acid supplements']"
NCT06480123,Stem Cell Derived Exome for Treatment of Diabetic Foot,Diabetic Foot,"Inclusion Criteria:

1. Clinical diagnosis of diabetic foot.
2. Signed informed consent before recruiting.
3. Age above 18 years or less than 90 years.
4. ECOG score \< 4
5. Tolerable coagulation function or reversible coagulation disorders
6. Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR \< 2.3 or PT \< 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin \> 28 g/L；Total bilirubin \< 51 μmol/L
7. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.

Exclusion Criteria:

1. Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks;
2. Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding;
3. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;
4. Patients have poor compliance.
5. Al",18,100,ALL,NOT_YET_RECRUITING,"['hb≥90g/l； plt', 'impact', 'bilirubin', 'which', '7 days', 'days', 'hepatic encephalopathy', 'consent', 'patients', '51 μmol/l', 'reversible coagulation disorders', 'function', 'laboratory examination test', 'trials', 'disease', 'treatment', 'informed consent', 'compliance', '18 years', '4. ecog', 'examination', 'prognosis', 'al', 'μmol', 'control；cr', 'laboratory', 'less than 90 years', 'tolerable coagulation function', 'exclusion criteria', 'laboratory tests', 'clinical diagnosis', 'inclusion criteria', '≤', '4 weeks', 'esophageal and gastric varices', 'coagulation', 'weeks', 'l；inr \\', 'clinical trials', 'diabetes', 'tests', 'plan', 'equipment', 'wbc≥3.0×10e9', 'seconds', 'heart', 'treatment plan', 'heart disease', 'diagnosis', 'score', 'the prognosis', 'criteria', 'years', 'encephalopathy', 'scheduled visits', 'psychiatric disorders', 'drugs', 'disorders', 'inadequately controlled diabetes', 'varices', 'ascites', '3. age', 'test', 'poor compliance', 'foot', 'procedure', 'an unknown, impact', 'hb≥90g', 'diabetic foot', 'inclusion', 'visits', 'pt \\', 'exclusion', 'wbc≥3.0×10e9/l']"
NCT05766735,Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification,Type 2 Diabetes,"Inclusion Criteria

1. Clinical diagnosis, based on investigator assessment, of type 2 diabetes within the past 24 months
2. Age ≥30.0 and ≤80 years
3. Hemoglobin A1c = ≥6.5-≤11% (medical record value \<6 month-old is acceptable)
4. Access to smartphone throughout the study
5. Diabetes management visit with medical provider within 12 months of screening date
6. If on weight altering medications (e.g., GLP-1, GIP), on a stable dose for about four weeks

Exclusion Criteria:

1. Medications that impede weight loss within the last 3 months, per study physicians' discretion
2. Any psychotropic medication that could raise blood glucose, per study physicians' opinion
3. Conditions that preclude participating in the study (e.g., severe mental disease like manic depressive illness, severe depression, active substance abuse)
4. Conditions that preclude increasing physical activity (e.g., severe neuropathy, cardiovascular disease, COPD/emphysema, severe osteoarthritis, stroke)
5. Conditions that ",18,100,ALL,RECRUITING,"['visit', 'weight loss', 'severe depression', 'illness', 'abuse', 'activity', 'assessment', 'weight', 'a stable dose', 'conditions', 'dose', 'type', 'that', 'glp-1', 'management visit', '12 months', 'substance', 'physicians', ""study physicians' opinion"", 'type 2 diabetes', 'disease', 'active substance abuse', 'investigator assessment', 'medication', 'glucose', 'depression', 'copd', ""study physicians' discretion"", 'the study', 'age ≥30.0', 'blood glucose', 'stroke', 'clinical diagnosis', 'medications', 'the last 3 months', 'months', 'study', 'medical record value', '≥30.0', 'investigator', 'management', 'record', 'weeks', 'loss', 'diabetes', 'opinion', 'month', 'altering', 'manic depressive illness', 'diagnosis', '≤80 years', 'years', 'criteria', 'provider', 'blood', 'osteoarthritis', '≥6.5-≤11%', 'discretion', 'access', 'severe osteoarthritis', 'increasing physical activity', 'date', 'the past 24 months', 'copd/emphysema', 'any psychotropic medication', 'medical provider', 'weight altering medications', 'inclusion', 'hemoglobin', 'value', 'exclusion', 'smartphone']"
NCT07124208,A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes,Type 2 Diabetes,"Inclusion Criteria:

* Willing and able to give informed consent for participation in the trial.
* Is able and willing to comply with all trial requirements.
* Male or female aged 18-70 years old without major diseases.
* An adult clinically diagnosed with DM2
* Participants must not be heavy users of Tesla BioHealing devices; enrollment will be determined by the clinical team based on an evaluation of the participant's prior device usage.
* Must be fluent in English.

Exclusion Criteria:

* Untreated psychiatric disturbances that would affect trial participation as judged by research medical professionals.
* Is participating in another investigational drug or device trial",18,70,ALL,RECRUITING,"['participants', 'biohealing', 'major diseases', 'devices', 'device', 'research', 'diseases', 'consent', 'that', 'participant', 'trial', 'dm2\n* participants', 'enrollment', 'all trial requirements', 'tesla', 'informed consent', 'professionals', '* untreated psychiatric disturbances', 'trial participation', 'exclusion criteria', 'inclusion criteria', 'the trial', 'an evaluation', 'requirements', 'evaluation', 'participation', 'tesla biohealing devices', 'an adult', 'usage', 'users', 'heavy users', 'criteria', 'years', 'team', 'drug', 'research medical professionals', 'english', 'inclusion', 'adult', 'disturbances', 'exclusion', 'the clinical team']"
NCT07347613,Long-term Follow-up of Diabetic Patients From the GLUTADIAB Study,Diabetes,"Inclusion Criteria:

* Person previously enroled in the GLUTADIAB study in group 1 or 2 (cf appendix 1 for GLUTADIAB inclusion criteria)

Exclusion Criteria:

* Pregnant or breastfeeding woman
* Absence of free and informed consent
* Subject deprived of freedom, subject under a legal protective measure",18,100,ALL,NOT_YET_RECRUITING,"['person', 'glutadiab inclusion criteria', '(cf appendix', 'subject', 'consent', 'the glutadiab study', '* person', 'pregnant or breastfeeding woman', 'group', 'absence', 'inclusion criteria', 'study', 'woman', 'criteria', 'appendix', 'freedom', 'measure', '* absence', 'inclusion', 'glutadiab', 'a legal protective measure', 'exclusion']"
